Hercules Capital - 10-Q quarterly report FY

00012807842026Q112-31falseone0.0465631.3333.3333.3333xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURiso4217:GBPhtgc:firmhtgc:segmenthtgc:portfolioCompanyhtgc:equityInvestmenthtgc:creditFacilityhtgc:votePerSharehtgc:quarterlyDistribution00012807842026-01-012026-03-310001280784htgc:CommonStockParValueZeroPointZeroZeroOnePerShareMember2026-01-012026-03-310001280784htgc:SixPointTwoFiveNotesDueTwoThousandThirtyThreeMember2026-01-012026-03-3100012807842026-04-280001280784us-gaap:InvestmentUnaffiliatedIssuerMember2026-03-310001280784us-gaap:InvestmentUnaffiliatedIssuerMember2025-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-3100012807842026-03-3100012807842025-12-310001280784us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2026-03-310001280784us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-12-310001280784us-gaap:InvestmentUnaffiliatedIssuerMember2026-01-012026-03-310001280784us-gaap:InvestmentUnaffiliatedIssuerMember2025-01-012025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-3100012807842025-01-012025-03-310001280784us-gaap:CommonStockMember2025-12-310001280784us-gaap:AdditionalPaidInCapitalMember2025-12-310001280784us-gaap:RetainedEarningsMember2025-12-310001280784us-gaap:RetainedEarningsMember2026-01-012026-03-310001280784us-gaap:CommonStockMember2026-01-012026-03-310001280784us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001280784us-gaap:CommonStockMember2026-03-310001280784us-gaap:AdditionalPaidInCapitalMember2026-03-310001280784us-gaap:RetainedEarningsMember2026-03-310001280784us-gaap:CommonStockMember2024-12-310001280784us-gaap:AdditionalPaidInCapitalMember2024-12-310001280784us-gaap:RetainedEarningsMember2024-12-3100012807842024-12-310001280784us-gaap:RetainedEarningsMember2025-01-012025-03-310001280784us-gaap:CommonStockMember2025-01-012025-03-310001280784us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001280784us-gaap:CommonStockMember2025-03-310001280784us-gaap:AdditionalPaidInCapitalMember2025-03-310001280784us-gaap:RetainedEarningsMember2025-03-3100012807842025-03-310001280784htgc:AdvisorFundsMember2026-01-012026-03-310001280784htgc:AdvisorFundsMember2025-01-012025-03-310001280784Debt Investments, Application Software, Alchemer LLC, Senior Secured, May 2028, 1-month SOFR + 8.14%, Floor rate 9.14%2026-03-310001280784Debt Investments, Application Software, AlphaSense, Inc., Senior Secured, June 2029, 3-month SOFR + 6.25%, Floor rate 8.25%2026-03-310001280784Debt Investments, Application Software, Annex Cloud, Senior Secured, June 2028, PIK Interest 3-month SOFR + 9.99%, Floor rate 10.99%2026-03-310001280784Debt Investments, Application Software, Annex Cloud, Senior Secured, December 2025, PIK Interest 3-month SOFR + 9.99%, Floor rate 10.99%2026-03-310001280784Debt Investments, Application Software, Annex Cloud, Senior Secured, June 2028, PIK Interest 3-month SOFR + 5.73%, Floor rate 6.73%2026-03-310001280784Debt Investments, Application Software, Total Annex Cloud2026-03-310001280784Debt Investments, Application Software, Babel Street, Senior Secured, December 2027, 3-month SOFR + 8.01%, Floor rate 9.01%2026-03-310001280784Debt Investments, Application Software, Behavox Limited, Senior Secured, September 2027, Prime - 0.55%, Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee2026-03-310001280784Debt Investments, Application Software, Brain Corporation, Senior Secured, September 2028, Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee2026-03-310001280784Debt Investments, Application Software, Ceros, Inc., Senior Secured, June 2027, 3-month SOFR + 8.99%, Floor rate 9.89%2026-03-310001280784Debt Investments, Application Software, Chainalysis, Inc., Senior Secured, June 2029, Prime + 2.95%, Floor rate 10.45%2026-03-310001280784Debt Investments, Application Software, Dashlane, Inc., Senior Secured, December 2027, Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee2026-03-310001280784Debt Investments, Application Software, Dispatch Technologies, Inc., Senior Secured, April 2028, 3-month SOFR + 7.86%, Floor rate 8.61%2026-03-310001280784Debt Investments, Application Software, Distributed Creation Inc., Senior Secured, April 2029, Prime + 3.00%, Floor rate 10.25%, 4.50% Exit Fee2026-03-310001280784Debt Investments, Application Software, DocPlanner, Senior Secured, January 2030, Prime + 2.75%, Floor rate 9.75%, 4.25% Exit Fee2026-03-310001280784Debt Investments, Application Software, Earnix, Inc., Senior Secured, June 2029, Prime - 1.15%, Floor rate 5.35%, PIK Interest 4.45%2026-03-310001280784Debt Investments, Application Software, Elation Health, Inc., Senior Secured, April 2029, Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.30%, 3.95% Exit Fee2026-03-310001280784Debt Investments, Application Software, Funnel Holding AB (publ), Senior Secured, October 2029, Prime + 0.60%, Floor rate 7.10%, Cap rate 8.60%, PIK Interest 3.00%, 2.25% Exit Fee2026-03-310001280784Debt Investments, Application Software, Imagen Technologies, Inc., Senior Secured, November 2028, Prime + 1.55%, Floor rate 9.05%, PIK Interest 1.00%, 3.95% Exit Fee2026-03-310001280784Debt Investments, Application Software, Intercom, Inc., Senior Secured, February 2031, Prime + 2.00%, Floor rate 8.50%, Cap rate 9.25%, PIK Interest 1.00%, 3.95% Exit Fee2026-03-310001280784Debt Investments, Application Software, iSpot.tv, Inc., Senior Secured, January 2029, Prime + 2.25%, Floor rate 9.00%, PIK Interest 1.00%, 5.70% Exit Fee2026-03-310001280784Debt Investments, Application Software, iSpot.tv, Inc., Senior Secured, January 2029, Prime + 1.40%, Floor rate 8.15%, PIK Interest 0.75%, 4.50% Exit Fee2026-03-310001280784Debt Investments, Application Software, Total iSpot.tv, Inc.2026-03-310001280784Debt Investments, Application Software, Khoros, LLC, Senior Secured, May 2030 , FIXED 10.00%2026-03-310001280784Debt Investments, Application Software, LinenMaster, LLC, Senior Secured, August 2029, 1-month SOFR + 8.28%, Floor rate 9.28%2026-03-310001280784Debt Investments, Application Software, Loftware, Inc., Senior Secured, March 2028, 3-month SOFR + 7.75%, Floor rate 8.75%2026-03-310001280784Debt Investments, Application Software, LogicSource, Senior Secured, July 2027, 3-month SOFR + 8.68%, Floor rate 9.68%2026-03-310001280784Debt Investments, Application Software, Mango Technologies, Inc., Senior Secured, August 2030, Prime + 2.25%, Floor rate 8.25%, 2.00% Exit Fee2026-03-310001280784Debt Investments, Application Software, Marigold Group, Inc., Senior Secured, April 2028, 6-month SOFR + 4.75%, Floor rate 5.75%, PIK Interest 5.25%2026-03-310001280784Debt Investments, Application Software, Microblink LLC, Senior Secured, August 2027, 3-month SOFR + 7.84%, Floor rate 8.84%2026-03-310001280784Debt Investments, Application Software, Omeda Holdings, LLC, Senior Secured, July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%2026-03-310001280784Debt Investments, Application Software, Pindrop Security, Inc., Senior Secured, June 2029, Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee2026-03-310001280784Debt Investments, Application Software, Proven Optics, LLC, Senior Secured, December 2030, 3-month SOFR + 7.30%, Floor rate 8.30%2026-03-310001280784Debt Investments, Application Software, Remodel Health Holdco, LLC, Senior Secured, December 2028, Prime + 2.35%, Floor rate 10.35%, 6.50% Exit Fee2026-03-310001280784Debt Investments, Application Software, Reveleer, Senior Secured, February 2027, Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee2026-03-310001280784Debt Investments, Application Software, ShadowDragon, LLC, Senior Secured, December 2026, 3-month SOFR + 8.79%, Floor rate 9.69%2026-03-310001280784Debt Investments, Application Software, Simon Data, Inc., Senior Secured, March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 3.59% Exit Fee2026-03-310001280784Debt Investments, Application Software, Sisense Ltd., Senior Secured, July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee2026-03-310001280784Debt Investments, Application Software, Smartsheet Inc., Senior Secured, January 2031, 3-month SOFR + 5.25%, Floor rate 6.00%2026-03-310001280784Debt Investments, Application Software, Snappt, Inc., Senior Secured, April 2029, Prime + 2.35%, Floor rate 8.85%, PIK Interest 1.00%, 4.25% Exit Fee2026-03-310001280784Debt Investments, Application Software, Streamline Healthcare Solutions, Senior Secured, June 2030, 3-month SOFR + 7.30%, Floor rate 8.30%2026-03-310001280784Debt Investments, Application Software, Suzy, Inc., Senior Secured, August 2027, Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee2026-03-310001280784Debt Investments, Application Software, TaxCalc, Senior Secured, November 2029, Daily SONIA + 8.17%, Floor rate 8.67%2026-03-310001280784Debt Investments, Application Software, Tipalti Solutions Ltd., Senior Secured, April 2029, Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%2026-03-310001280784Debt Investments, Application Software, Tipalti Solutions Ltd., Senior Secured, April 2029, Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%, 3.75% Exit Fee2026-03-310001280784Debt Investments, Application Software, Total Tipalti Solutions Ltd.2026-03-310001280784Debt Investments, Application Software, Ushur, Inc., Senior Secured, June 2028, Prime + 2.20%, Floor rate 9.20%, 3.95% Exit Fee2026-03-310001280784Debt Investments, Application Software, Zappi, Inc., Senior Secured, December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%2026-03-310001280784Debt Investments, Application Software, ZeroEyes, Inc., Senior Secured, May 2030, Prime + 2.00%, Floor rate 9.50%, PIK Interest 2.00%, 1.50% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:ApplicationSoftwareMember2026-03-310001280784Debt Investments, Biotechnology Tools, Antheia, Inc., Senior Secured, August 2029, Prime + 2.85%, Floor rate 10.35%, 5.55% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:BiotechnologyToolsMember2026-03-310001280784Debt Investments, Communications & Networking, Aryaka Networks, Inc., Senior Secured, December 2028, Prime + 1.80%, Floor rate 9.30%, PIK Interest 1.25%, 6.73% Exit Fee2026-03-310001280784Debt Investments, Communications & Networking, Tarana Wireless, Inc., Senior Secured, March 2030, Prime + 4.00%, Floor rate 10.75%, 3.95% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:CommunicationsNetworkingMember2026-03-310001280784Debt Investments, Consumer & Business Products, Tonal Systems, Inc., Senior Secured, March 2029, Prime + 4.25%, Floor rate 11.00%, 4.25% Exit Fee2026-03-310001280784Debt Investments, Consumer & Business Products, Weee! Inc., Senior Secured, April 2028, Prime + 2.25%, Floor rate 9.75%, 2.50% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:ConsumerBusinessProductsMember2026-03-310001280784Debt Investments, Consumer & Business Services, Andesa Services, Inc., Senior Secured, March 2031, 1-month SOFR + 7.80%, Floor rate 8.80%2026-03-310001280784Debt Investments, Consumer & Business Services, AppDirect, Inc., Senior Secured, September 2029, Prime + 2.05%, Floor rate 8.55%, PIK Interest 1.00%, 4.70% Exit Fee2026-03-310001280784Debt Investments, Consumer & Business Services, Carwow LTD, Senior Secured, December 2027, Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee2026-03-310001280784Debt Investments, Consumer & Business Services, CollectiveHealth, Inc., Senior Secured, February 2030, Prime + 3.50%, Floor rate 10.25%, 3.95% Exit Fee2026-03-310001280784Debt Investments, Consumer & Business Services, Finix Payments, Inc., Senior Secured, December 2029, Prime + 2.50%, Floor rate 9.25%, 4.25% Exit Fee2026-03-310001280784Debt Investments, Consumer & Business Services, GoEuro Travel GmbH, Senior Secured, November 2029, Prime + 3.45%, Floor rate 10.45%, 4.50% Exit Fee2026-03-310001280784Debt Investments, Consumer & Business Services, Houzz, Inc., Convertible Debt, May 2028, PIK Interest 12.00%2026-03-310001280784Debt Investments, Consumer & Business Services, Jobandtalent USA, Inc., Senior Secured, October 2028, 1-month SOFR + 3.50%, Floor rate 4.50%, PIK Interest 3.25%, 6.83% Exit Fee2026-03-310001280784Debt Investments, Consumer & Business Services, Nerdy Inc., Senior Secured, November 2029, Prime + 3.50%, Floor rate 10.75%, 7.50% Exit Fee2026-03-310001280784Debt Investment, Consumer & Business Services, Peek Travel, Inc., Senior Secured, October 2028, Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.00%, 4.95% Exit Fee2026-03-310001280784Debt Investment, Consumer & Business Services, Plentific Ltd, Senior Secured, October 2026, Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee2026-03-310001280784Debt Investment, Consumer & Business Services, Provi, Senior Secured, December 2027, Prime + 4.40%, Floor rate 10.65%, 1.00% Exit Fee2026-03-310001280784Debt Investment, Consumer & Business Services, Riviera Partners LLC, Senior Secured, March 2028, 3-month SOFR + 8.28%, Floor rate 9.28%2026-03-310001280784Debt Investment, Consumer & Business Services, RVShare, LLC, Senior Secured, December 2026, 3-month SOFR + 9.50%, Floor rate 10.50%2026-03-310001280784Debt Investment, Consumer & Business Services, SeatGeek, Inc., Senior Secured, May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.50% Exit Fee2026-03-310001280784Debt Investment, Consumer & Business Services, SeatGeek, Inc., Senior Secured, July 2026, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.50% Exit Fee2026-03-310001280784Debt Investment, Consumer & Business Services, Total SeatGeek, Inc.2026-03-310001280784Debt Investment, Consumer & Business Services, Skyword, Inc., Senior Secured, November 2027, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 5.50% Exit Fee2026-03-310001280784Debt Investment, Consumer & Business Services, Tectura Corporation, Senior Secured, January 2027, FIXED 8.25%2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:ConsumerBusinessServicesMember2026-03-310001280784Debt Investments, Defense Technologies, Hermeus Corporation, Senior Secured, March 2030, Prime + 2.75%, Floor rate 10.00%, PIK Interest 1.00%, 4.50% Exit Fee2026-03-310001280784Debt Investments, Defense Technologies, Saronic Technologies, Inc., Senior Secured, June 2030, Prime + 2.50%, Floor rate 9.00%, 2.00% Exit Fee2026-03-310001280784Debt Investments, Defense Technologies, Shield AI, Inc., Senior Secured, February 2029, Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:DefenseTechnologiesMember2026-03-310001280784Debt Investments, Diversified Financial Services, Gibraltar Acquisition LLC, Unsecured, July 2029, FIXED 11.50%2026-03-310001280784Debt Investments, Diversified Financial Services, Gibraltar Acquisition LLC, Unsecured, July 2029, FIXED 11.95%2026-03-310001280784Debt Investments, Diversified Financial Services, Total Gibraltar Acquisition LLC2026-03-310001280784Debt Investments, Diversified Financial Services, Hercules Adviser LLC, Unsecured, March 2027, FIXED 6.75%2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:DiversifiedFinancialServicesMember2026-03-310001280784Debt Investments, Drug Discovery & Development, Aldeyra Therapeutics, Inc., Senior Secured, April 2026, Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Alector, Inc., Senior Secured, December 2028, Prime + 1.05%, Floor rate 8.05%, 4.75% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Altimmune, Inc., Senior Secured, June 2029, Prime + 2.45%, Floor rate 9.70%, 6.25% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Arcus Biosciences, Inc., Senior Secured, September 2030, Prime - 0.05%, Floor rate 8.45%, PIK Interest 2.20%, 9.00% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Beren Therapeutics P.B.C., Senior Secured, October 2029, Prime + 2.45%, Floor rate 9.95%, 5.25% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Braeburn, Inc., Senior Secured, October 2028, Prime + 3.00%, Floor rate 10.50%, PIK Interest 0.25%, 5.45% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, COMPASS Pathways plc, Senior Secured, January 2031, Prime + 2.75%, Floor rate 9.75%, 7.75% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Corium, Inc., Senior Secured, September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Disc Medicine, Inc., Senior Secured, December 2029, Prime + 1.75%, Floor rate 8.25%, 6.75% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Dyne Therapeutics, Inc., Senior Secured, July 2030, Prime + 2.45%, Floor rate 9.95%, 5.50% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, enGene, Inc., Senior Secured, January 2030, Prime + 2.25%, Floor rate 9.25%, Cap rate 10.25%, 5.95% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Genetix Biotherapeutics Inc., Senior Secured, April 2029, Prime + 2.45%, Floor rate 9.45%, 6.45% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Heron Therapeutics, Inc., Senior Secured, September 2030, Prime + 1.95%, Floor rate 9.45%, PIK Interest 1.00%, 6.50% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Kura Oncology, Inc., Senior Secured, November 2027, Prime + 2.40%, Floor rate 8.65%, 6.05% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Maze Therapeutics, Inc., Senior Secured, February 2031, Prime + 0.95%, Floor rate 7.95%, 6.45% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, MoonLake Immunotherapeutics, Senior Secured, April 2030, Prime + 1.45%, Floor rate 8.45%, 6.95% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, NorthSea Therapeutics, Convertible Debt, December 2026, FIXED 6.00%2026-03-310001280784Debt Investments, Drug Discovery & Development, Phathom Pharmaceuticals, Inc., Senior Secured, February 2029, Prime + 3.10%, Floor rate 9.85%, 2.00% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Replimune Group, Inc., Senior Secured, October 2027, Prime + 1.75%, Floor rate 8.50%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Savara, Inc., Senior Secured, April 2030, Prime + 1.45%, Floor rate 7.45%, 6.95% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, SynOx Therapeutics Limited, Senior Secured, May 2027, Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Tenpoint Therapeutics Limited, Senior Secured, October 2029, Prime + 2.90%, Floor rate 10.40%, 6.65% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, uniQure B.V., Senior Secured, October 2030, Prime + 2.45%, Floor rate 9.45%, 5.50% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, Viridian Therapeutics, Inc., Senior Secured, October 2030, Prime + 1.45%, Floor rate 8.95%, Cap rate 9.45%, 6.00% Exit Fee2026-03-310001280784Debt Investments, Drug Discovery & Development, X4 Pharmaceuticals, Inc., Senior Secured, July 2027, Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:DrugDiscoveryDevelopmentMember2026-03-310001280784Debt Investments, Electronics & Computer Hardware, Locus Robotics Corp., Senior Secured, December 2028, Prime + 3.00%, Floor rate 9.50%, 4.00% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:ElectronicsComputerHardwareMember2026-03-310001280784Debt Investments, Healthcare Services, Other, Belong Health, Inc., Senior Secured, November 2029, Prime + 2.25%, Floor rate 9.75%, 5.45% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Blue Sprig Pediatrics, Inc., Senior Secured, November 2026, 1-month SOFR + 5.11%, Floor rate 6.00%, PIK Interest 4.45%2026-03-310001280784Debt Investments, Healthcare Services, Other, ChenMed, LLC, Senior Secured, May 2030, Prime + 2.45%, Floor rate 9.45%, 3.75% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Curana Health Holdings, LLC, Senior Secured, January 2028, Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Ennoble Care LLC, Senior Secured, February 2030, Prime + 2.60%, Floor rate 10.35%, 7.95% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Equality Health, LLC, Senior Secured, February 2028, Prime + 5.85%, Floor rate 9.50%, PIK Interest 1.95%2026-03-310001280784Debt Investments, Healthcare Services, Other, Main Street Rural, Inc., Senior Secured, July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Marathon Health, LLC, Senior Secured, February 2029, Prime + 0.75%, Floor rate 8.75%, PIK Interest 2.25%, 3.00% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Marathon Health, LLC, Senior Secured, February 2029, Prime + 3.00%, Floor rate 11.00%2026-03-310001280784Debt Investments, Healthcare Services, Other, Total Marathon Health, LLC2026-03-310001280784Debt Investments, Healthcare Services, Other, Modern Life, Inc., Senior Secured, February 2029, Prime + 2.75%, Floor rate 10.25%, 5.00% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, NeueHealth, Inc., Senior Secured, June 2028, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Octave Health Group, Inc., Senior Secured, October 2029, Prime + 2.70%, Floor rate 9.95%, 5.35% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Strive Health Holdings, LLC, Senior Secured, August 2029, Prime + 1.05%, Floor rate 9.55%, 5.95% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, The Recovery Company, Inc. (p.k.a. Recover Together, Inc.), Senior Secured, July 2027, Prime + 1.90%, Floor rate 9.90%, 7.50% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Tungsten Health Holdings, LLC, Senior Secured, December 2029, Prime + 1.00%, Floor rate 8.50%, Cap rate 9.00%, PIK Interest 1.25%, 8.35% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Vida Health, Inc., Senior Secured, January 2028, Prime - 2.75%, Floor rate 6.75%, PIK Interest 4.35%2026-03-310001280784Debt Investments, Healthcare Services, Other, Vida Health, Inc., Senior Secured, January 2028, Prime - 2.75%, Floor rate 6.75%, PIK Interest 4.35%, 10.00% Exit Fee2026-03-310001280784Debt Investments, Healthcare Services, Other, Total Vida Health, Inc.2026-03-310001280784Debt Investments, Healthcare Services, Other, WellBe Senior Medical, LLC, Senior Secured, May 2029, Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:HealthcareServicesOtherMember2026-03-310001280784Debt Investments, Information Services, Saama Technologies, LLC, Senior Secured, July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 3.45% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:InformationServicesMember2026-03-310001280784Debt Investments, Manufacturing Technology, VulcanForms Inc., Senior Secured, January 2028, Prime + 4.25%, Floor rate 11.25%, 4.25% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:ManufacturingTechnologyMember2026-03-310001280784Debt Investments, Medical Devices & Equipment, Cognito Therapeutics Group, Inc., Senior Secured, January 2030, Prime + 2.70%, Floor rate 9.95%, 5.75% Exit Fee2026-03-310001280784Debt Investments, Medical Devices & Equipment, Orchestra BioMed Holdings, Inc., Senior Secured, November 2028, Prime + 2.00%, Floor rate 9.50%, 6.35% Exit Fee2026-03-310001280784Debt Investments, Medical Devices & Equipment, Senseonics Holdings, Inc., Senior Secured, August 2029, Prime + 2.40%, Floor rate 9.90%, 13.40% Exit Fee2026-03-310001280784Debt Investments, Medical Devices & Equipment, Sight Sciences, Inc., Senior Secured, July 2028, Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:MedicalDevicesEquipmentMember2026-03-310001280784Debt Investments, Space Technologies, HawkEye 360, Inc., Senior Secured, December 2028, Prime + 2.10%, Floor rate 9.35%, PIK Interest 1.50%, 1.95% Exit Fee2026-03-310001280784Debt Investments, Space Technologies, Loft Orbital Solutions Inc., Senior Secured, December 2029, Prime + 1.75%, Floor rate 8.75%, PIK Interest 1.00%, 3.45% Exit Fee2026-03-310001280784Debt Investments, Space Technologies, Stoke Space Technologies, Inc., Senior Secured, May 2029, Prime + 1.00%, Floor rate 7.50%, PIK Interest 2.00%, 5.25% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:SpaceTechnologiesMember2026-03-310001280784Debt Investments, Sustainable and Renewable Technology, Electric Hydrogen Co., Senior Secured, May 2028, Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.25% Exit Fee2026-03-310001280784Debt Investments, Sustainable and Renewable Technology, Electric Hydrogen Co., Senior Secured, May 2028, Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 5.95% Exit Fee2026-03-310001280784Debt Investments, Sustainable and Renewable Technology, Total Electric Hydrogen Co.2026-03-310001280784Debt Investments, Sustainable and Renewable Technology, Tidal Vision Products, Inc., Senior Secured, October 2028, Prime + 2.45%, Floor rate 9.70%, 3.45% Exit Fee2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:SustainableAndRenewableTechnologyMember2026-03-310001280784Debt Investments, System Software, Akeyless Security Ltd., Senior Secured, August 2028, Prime + 4.00%, Floor rate 11.00%, 2.95% Exit Fee2026-03-310001280784Debt Investments, System Software, Armis, Inc., Senior Secured, March 2028, Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee2026-03-310001280784Debt Investments, System Software, Armis, Inc., Senior Secured, March 2028, Prime + 1.25%, Floor rate 8.75%, PIK Interest 2.00%, 2.25% Exit Fee2026-03-310001280784Debt Investments, System Software, Total Armis, Inc.2026-03-310001280784Debt Investments, System Software, ControlUp, Inc., Senior Secured, January 2031, Prime + 0.25%, Floor rate 6.75%, PIK Interest 2.00%, 3.00% Exit Fee2026-03-310001280784Debt Investments, System Software, CoreView USA, Inc., Senior Secured, January 2029, Prime + 2.75%, Floor rate 9.25%, 4.95% Exit Fee2026-03-310001280784Debt Investments, System Software, Coronet Cyber Security Ltd., Senior Secured, October 2028, Prime - 2.95%, Floor rate 3.55%, PIK Interest 5.85%2026-03-310001280784Debt Investments, System Software, DNSFilter, Inc., Senior Secured, October 2028, Prime + 2.15%, Floor rate 8.65%, PIK Interest 0.75%, 4.95% Exit Fee2026-03-310001280784Debt Investments, System Software, Expel, Inc., Senior Secured, April 2029, Prime + 3.90%, Floor rate 10.65%, 2.00% Exit Fee2026-03-310001280784Debt Investments, System Software, Harness, Inc., Senior Secured, March 2029, Prime - 2.25%, Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee2026-03-310001280784Debt Investments, System Software, LogRhythm, Inc., Senior Secured, July 2029, 3-month SOFR + 7.50%, Floor rate 8.50%2026-03-310001280784Debt Investments, System Software, Morphisec Information Security 2014 Ltd., Senior Secured, October 2027, Prime + 3.45%, Floor rate 11.70%, 5.95% Exit Fee2026-03-310001280784Debt Investments, System Software, Neo4j, Inc., Senior Secured, April 2030, Prime + 2.60%, Floor rate 9.10%, 3.50% Exit Fee2026-03-310001280784Debt Investments, System Software, New Relic, Inc., Senior Secured, November 2030, 3-month SOFR + 6.75%, Floor rate 7.75%2026-03-310001280784Debt Investments, System Software, PayIt, LLC, Senior Secured, December 2028, Prime + 1.45%, Floor rate 7.95%, PIK Interest 1.50%, 5.00% Exit Fee2026-03-310001280784Debt Investments, System Software, Scylla DB Ltd., Senior Secured, July 2029, Prime + 3.00%, Floor rate 10.50%, 0.75% Exit Fee2026-03-310001280784Debt Investments, System Software, Semperis Technologies Inc., Senior Secured, April 2028, Prime - 1.75%, Floor rate 6.75%, PIK Interest 3.25%2026-03-310001280784Debt Investments, System Software, Semperis Technologies Inc., Senior Secured, April 2028, Prime - 0.50%, Floor rate 8.00%, PIK Interest 3.85%2026-03-310001280784Debt Investments, System Software, Semperis Technologies Inc., Senior Secured, April 2028, Prime + 2.50%, Floor rate 9.00%, PIK Interest 1.50%2026-03-310001280784Debt Investments, System Software, Total Semperis Technologies Inc.2026-03-310001280784Debt Investments, System Software, Sumo Logic, Inc., Senior Secured, May 2030, 3-month SOFR + 6.50%, Floor rate 7.50%2026-03-310001280784Debt Investments, System Software, Zimperium, Inc., Senior Secured, May 2027, 3-month SOFR + 8.84%, Floor rate 9.84%2026-03-310001280784Debt Investments, System Software, Zimperium, Inc., Senior Secured, May 2027, 6-month SOFR + 8.84%, Floor rate 9.84%2026-03-310001280784Debt Investments, System Software, Zimperium, Inc., Senior Secured, May 2027, 1-month SOFR + 5.46%, Floor rate 6.64%2026-03-310001280784Debt Investments, System Software, Total Zimperium, Inc.2026-03-310001280784us-gaap:DebtSecuritiesMemberhtgc:SystemSoftwareMember2026-03-310001280784us-gaap:DebtSecuritiesMember2026-03-310001280784Equity Investments, Application Software, Black Crow AI, Inc. affiliates, Equity, 3/24/2021, Preferred Note2026-01-012026-03-310001280784Equity Investments, Application Software, Black Crow AI, Inc. affiliates, Equity, 3/24/2021, Preferred Note2026-03-310001280784Equity Investments, Application Software, CapLinked, Inc., Equity, 10/26/2012, Preferred Series A-32026-01-012026-03-310001280784Equity Investments, Application Software, CapLinked, Inc., Equity, 10/26/2012, Preferred Series A-32026-03-310001280784Equity Investments, Application Software, DNAnexus, Inc., Equity, 3/21/2014, Preferred Series C2026-01-012026-03-310001280784Equity Investments, Application Software, DNAnexus, Inc., Equity, 3/21/2014, Preferred Series C2026-03-310001280784Equity Investments, Application Software, HighRoads, Inc., Equity, 1/18/2013, Common Stock2026-01-012026-03-310001280784Equity Investments, Application Software, HighRoads, Inc., Equity, 1/18/2013, Common Stock2026-03-310001280784Equity Investments, Application Software, Hypercore Inc., Equity, 1/22/2026, Preferred Series A-II2026-01-012026-03-310001280784Equity Investments, Application Software, Hypercore Inc., Equity, 1/22/2026, Preferred Series A-II2026-03-310001280784Equity Investments, Application Software, Khoros, LLC, Equity, 5/23/2025, Earnout Interest2026-01-012026-03-310001280784Equity Investments, Application Software, Khoros, LLC, Equity, 5/23/2025, Earnout Interest2026-03-310001280784Equity Investments, Application Software, Leapwork ApS, Equity, 8/25/2023, Preferred Series B22026-01-012026-03-310001280784Equity Investments, Application Software, Leapwork ApS, Equity, 8/25/2023, Preferred Series B22026-03-310001280784Equity Investments, Application Software, Nextdoor.com, Inc., Equity, 8/1/2018, Common Stock2026-01-012026-03-310001280784Equity Investments, Application Software, Nextdoor.com, Inc., Equity, 8/1/2018, Common Stock2026-03-310001280784Equity Investments, Application Software, Verana Health, Inc., Equity, 7/8/2021, Common Stock2026-01-012026-03-310001280784Equity Investments, Application Software, Verana Health, Inc., Equity, 7/8/2021, Common Stock2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:ApplicationSoftwareMember2026-03-310001280784Equity Investments, Biotechnology Tools, Alamar Biosciences, Inc., Equity, 2/21/2024, Preferred Series C2026-01-012026-03-310001280784Equity Investments, Biotechnology Tools, Alamar Biosciences, Inc., Equity, 2/21/2024, Preferred Series C2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:BiotechnologyToolsMember2026-03-310001280784Equity Investments, Consumer & Business Products, Fabletics, Inc., Equity, 4/30/2010, Common Stock2026-01-012026-03-310001280784Equity Investments, Consumer & Business Products, Fabletics, Inc., Equity, 4/30/2010, Common Stock2026-03-310001280784Equity Investments, Consumer & Business Products, Fabletics, Inc., Equity, 7/16/2013, Preferred Series B2026-01-012026-03-310001280784Equity Investments, Consumer & Business Products, Fabletics, Inc., Equity, 7/16/2013, Preferred Series B2026-03-310001280784Equity Investments, Consumer & Business Products, Total Fabletics, Inc.2026-03-310001280784Equity Investments, Consumer & Business Products, Grove Collaborative, Inc., Equity, 4/30/2021, Common Stock2026-01-012026-03-310001280784Equity Investments, Consumer & Business Products, Grove Collaborative, Inc., Equity, 4/30/2021, Common Stock2026-03-310001280784Equity Investments, Consumer & Business Products, Savage X Holding, LLC, Equity, 4/30/2010, Class A Units2026-01-012026-03-310001280784Equity Investments, Consumer & Business Products, Savage X Holding, LLC, Equity, 4/30/2010, Class A Units2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:ConsumerBusinessProductsMember2026-03-310001280784Equity Investments, Consumer & Business Services, Carwow LTD, Equity, 12/15/2021, Preferred Series D-42026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Carwow LTD, Equity, 12/15/2021, Preferred Series D-42026-03-310001280784Equity Investments, Consumer & Business Services, Jobandtalent USA, Inc., Equity, 2/11/2025, Preferred Series F2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Jobandtalent USA, Inc., Equity, 2/11/2025, Preferred Series F2026-03-310001280784Equity Investments, Consumer & Business Services, Lyft, Inc., Equity, 12/26/2018, Common Stock2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Lyft, Inc., Equity, 12/26/2018, Common Stock2026-03-310001280784Equity Investments, Consumer & Business Services, Nerdy Inc., Equity, 9/17/2021, Common Stock2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Nerdy Inc., Equity, 9/17/2021, Common Stock2026-03-310001280784Equity Investments, Consumer & Business Services, OfferUp, Inc., Equity, 10/25/2016, Preferred Series A2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, OfferUp, Inc., Equity, 10/25/2016, Preferred Series A2026-03-310001280784Equity Investments, Consumer & Business Services, OfferUp, Inc., Equity, 10/25/2016, Preferred Series A-12026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, OfferUp, Inc., Equity, 10/25/2016, Preferred Series A-12026-03-310001280784Equity Investments, Consumer & Business Services, Total OfferUp, Inc.2026-03-310001280784Equity Investments, Consumer & Business Services, Oportun, Equity, 6/28/2013, Common Stock2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Oportun, Equity, 6/28/2013, Common Stock2026-03-310001280784Equity Investments, Consumer & Business Services, Reischling Press, Inc., Equity, 7/31/2020, Common Stock2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Reischling Press, Inc., Equity, 7/31/2020, Common Stock2026-03-310001280784Equity Investments, Consumer & Business Services, Rhino Labs, Inc., Equity, 1/24/2022, Common Stock2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Rhino Labs, Inc., Equity, 1/24/2022, Common Stock2026-03-310001280784Equity Investments, Consumer & Business Services, Tectura Corporation, Equity, 5/23/2018, Common Stock2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Tectura Corporation, Equity, 5/23/2018, Common Stock2026-03-310001280784Equity Investments, Consumer & Business Services, Tectura Corporation, Equity, 6/6/2016, Preferred Series BB2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Tectura Corporation, Equity, 6/6/2016, Preferred Series BB2026-03-310001280784Equity Investments, Consumer & Business Services, Tectura Corporation, Equity, 12/29/2023, Preferred Series C2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Tectura Corporation, Equity, 12/29/2023, Preferred Series C2026-03-310001280784Equity Investments, Consumer & Business Services, Total Tectura Corporation2026-03-310001280784Equity Investments, Consumer & Business Services, Worldremit Group Limited, Equity, 6/24/2024, Preferred Series X2026-01-012026-03-310001280784Equity Investments, Consumer & Business Services, Worldremit Group Limited, Equity, 6/24/2024, Preferred Series X2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:ConsumerBusinessServicesMember2026-03-310001280784Equity Investments, Defense Technologies, Saronic Technologies, Inc., Equity, 3/27/2026, Preferred Series D2026-01-012026-03-310001280784Equity Investments, Defense Technologies, Saronic Technologies, Inc., Equity, 3/27/2026, Preferred Series D2026-03-310001280784Equity Investments, Defense Technologies, Shield AI, Inc., Equity, 2/7/2025, Preferred Series F12026-01-012026-03-310001280784Equity Investments, Defense Technologies, Shield AI, Inc., Equity, 2/7/2025, Preferred Series F12026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:DefenseTechnologiesMember2026-03-310001280784Equity Investments, Diversified Financial Services, Gibraltar Acquisition LLC, Equity, 3/1/2018, Member Units2026-01-012026-03-310001280784Equity Investments, Diversified Financial Services, Gibraltar Acquisition LLC, Equity, 3/1/2018, Member Units2026-03-310001280784Equity Investments, Diversified Financial Services, Hercules Adviser LLC, Equity, 3/26/2021, Member Units2026-01-012026-03-310001280784Equity Investments, Diversified Financial Services, Hercules Adviser LLC, Equity, 3/26/2021, Member Units2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:DiversifiedFinancialServicesMember2026-03-310001280784Equity Investments, Drug Delivery, Aytu BioScience, Inc., Equity, 3/28/2014, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Delivery, Aytu BioScience, Inc., Equity, 3/28/2014, Common Stock2026-03-310001280784Equity Investments, Drug Delivery, BioQ Pharma Incorporated, Equity, 12/8/2015, Preferred Series D2026-01-012026-03-310001280784Equity Investments, Drug Delivery, BioQ Pharma Incorporated, Equity, 12/8/2015, Preferred Series D2026-03-310001280784Equity Investments, Drug Delivery, PDS Biotechnology Corporation, Equity, 4/6/2015, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Delivery, PDS Biotechnology Corporation, Equity, 4/6/2015, Common Stock2026-03-310001280784Equity Investments, Drug Delivery, Talphera, Inc., Equity, 12/10/2018, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Delivery, Talphera, Inc., Equity, 12/10/2018, Common Stock2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:DrugDeliveryMember2026-03-310001280784Equity Investments, Drug Discovery & Development, Arcus Biosciences, Inc., Equity, 2/19/2025, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Arcus Biosciences, Inc., Equity, 2/19/2025, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Avalo Therapeutics, Inc., Equity, 8/19/2014, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Avalo Therapeutics, Inc., Equity, 8/19/2014, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Bicycle Therapeutics PLC, Equity, 10/5/2020, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Bicycle Therapeutics PLC, Equity, 10/5/2020, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Daré Bioscience, Inc., Equity, 1/8/2015, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Daré Bioscience, Inc., Equity, 1/8/2015, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Dyne Therapeutics, Inc., Equity, 7/2/2025, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Dyne Therapeutics, Inc., Equity, 7/2/2025, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Heron Therapeutics, Inc., Equity, 7/25/2023, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Heron Therapeutics, Inc., Equity, 7/25/2023, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Hibercell, Inc., Equity, 5/7/2021, Preferred Series B2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Hibercell, Inc., Equity, 5/7/2021, Preferred Series B2026-03-310001280784Equity Investments, Drug Discovery & Development, Kura Oncology, Inc., Equity, 6/16/2023, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Kura Oncology, Inc., Equity, 6/16/2023, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, MoonLake Immunotherapeutics, Equity, 11/6/2025, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, MoonLake Immunotherapeutics, Equity, 11/6/2025, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, NorthSea Therapeutics, Equity, 12/15/2021, Preferred Series C2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, NorthSea Therapeutics, Equity, 12/15/2021, Preferred Series C2026-03-310001280784Equity Investments, Drug Discovery & Development, Phathom Pharmaceuticals, Inc., Equity, 6/9/2023, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Phathom Pharmaceuticals, Inc., Equity, 6/9/2023, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Rafael Holdings, Inc., Equity, 4/6/2021, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Rafael Holdings, Inc., Equity, 4/6/2021, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Rocket Pharmaceuticals, Ltd., Equity, 8/22/2007, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Rocket Pharmaceuticals, Ltd., Equity, 8/22/2007, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Savara, Inc., Equity, 8/11/2015, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Savara, Inc., Equity, 8/11/2015, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, uniQure B.V., Equity, 1/31/2019, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, uniQure B.V., Equity, 1/31/2019, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, Valo Health, LLC, Equity, 12/11/2020, Preferred Series B2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Valo Health, LLC, Equity, 12/11/2020, Preferred Series B2026-03-310001280784Equity Investments, Drug Discovery & Development, Valo Health, LLC, Equity, 10/31/2022, Preferred Series C2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Valo Health, LLC, Equity, 10/31/2022, Preferred Series C2026-03-310001280784Equity Investments, Drug Discovery & Development, Total Valo Health, LLC2026-03-310001280784Equity Investments, Drug Discovery & Development, Verge Analytics, Inc., Equity, 9/6/2023, Preferred Series C2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Verge Analytics, Inc., Equity, 9/6/2023, Preferred Series C2026-03-310001280784Equity Investments, Drug Discovery & Development, Verge Analytics, Inc., Equity, 7/2/2025, SAFE2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Verge Analytics, Inc., Equity, 7/2/2025, SAFE2026-03-310001280784Equity Investments, Drug Discovery & Development, Total Verge Analytics, Inc.2026-03-310001280784Equity Investments, Drug Discovery & Development, Viridian Therapeutics, Inc., Equity, 11/6/2023, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, Viridian Therapeutics, Inc., Equity, 11/6/2023, Common Stock2026-03-310001280784Equity Investments, Drug Discovery & Development, X4 Pharmaceuticals, Inc., Equity, 11/26/2019, Common Stock2026-01-012026-03-310001280784Equity Investments, Drug Discovery & Development, X4 Pharmaceuticals, Inc., Equity, 11/26/2019, Common Stock2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:DrugDiscoveryDevelopmentMember2026-03-310001280784Equity Investments, Electronics & Computer Hardware, Locus Robotics Corp., Equity, 11/17/2022, Preferred Series F2026-01-012026-03-310001280784Equity Investments, Electronics & Computer Hardware, Locus Robotics Corp., Equity, 11/17/2022, Preferred Series F2026-03-310001280784Equity Investments, Electronics & Computer Hardware, Skydio, Inc., Equity, 3/8/2022, Preferred Series E2026-01-012026-03-310001280784Equity Investments, Electronics & Computer Hardware, Skydio, Inc., Equity, 3/8/2022, Preferred Series E2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:ElectronicsComputerHardwareMember2026-03-310001280784Equity Investments, Healthcare Services, Other, Click Therapeutics, Inc., Equity, 5/20/2024, Common Stock2026-01-012026-03-310001280784Equity Investments, Healthcare Services, Other, Click Therapeutics, Inc., Equity, 5/20/2024, Common Stock2026-03-310001280784Equity Investments, Healthcare Services, Other, Curana Health Holdings, LLC, Equity, 5/13/2024, Class B Voting Common Units2026-01-012026-03-310001280784Equity Investments, Healthcare Services, Other, Curana Health Holdings, LLC, Equity, 5/13/2024, Class B Voting Common Units2026-03-310001280784Equity Investments, Healthcare Services, Other, Curana Health Holdings, LLC, Equity, 3/26/2026, Class C Non Voting Common Units2026-01-012026-03-310001280784Equity Investments, Healthcare Services, Other, Curana Health Holdings, LLC, Equity, 3/26/2026, Class C Non Voting Common Units2026-03-310001280784Equity Investments, Healthcare Services, Other, Total Curana Health Holdings, LLC2026-03-310001280784Equity Investments, Healthcare Services, Other, Main Street Rural, Inc., Equity, 10/28/2024, Preferred Series D2026-01-012026-03-310001280784Equity Investments, Healthcare Services, Other, Main Street Rural, Inc., Equity, 10/28/2024, Preferred Series D2026-03-310001280784Equity Investments, Healthcare Services, Other, NH Holdings 2025 SPV, L.P., Equity, 6/21/2024, Common Units2026-01-012026-03-310001280784Equity Investments, Healthcare Services, Other, NH Holdings 2025 SPV, L.P., Equity, 6/21/2024, Common Units2026-03-310001280784Equity Investments, Healthcare Services, Other, Strive Health Holdings, LLC, Equity, 6/27/2025, Common Units2026-01-012026-03-310001280784Equity Investments, Healthcare Services, Other, Strive Health Holdings, LLC, Equity, 6/27/2025, Common Units2026-03-310001280784Equity Investments, Healthcare Services, Other, WellBe Senior Medical, LLC, Equity, 6/10/2024, Common Units2026-01-012026-03-310001280784Equity Investments, Healthcare Services, Other, WellBe Senior Medical, LLC, Equity, 6/10/2024, Common Units2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:HealthcareServicesOtherMember2026-03-310001280784Equity Investments, Information Services, Yipit, LLC, Equity, 12/30/2021, Preferred Series E2026-01-012026-03-310001280784Equity Investments, Information Services, Yipit, LLC, Equity, 12/30/2021, Preferred Series E2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:InformationServicesMember2026-03-310001280784Equity Investments, Medical Devices & Equipment, Coronado Aesthetics, LLC, Equity, 10/15/2021, Common Units2026-01-012026-03-310001280784Equity Investments, Medical Devices & Equipment, Coronado Aesthetics, LLC, Equity, 10/15/2021, Common Units2026-03-310001280784Equity Investments, Medical Devices & Equipment, Coronado Aesthetics, LLC, Equity, 10/15/2021, Preferred Series A-22026-01-012026-03-310001280784Equity Investments, Medical Devices & Equipment, Coronado Aesthetics, LLC, Equity, 10/15/2021, Preferred Series A-22026-03-310001280784Equity Investments, Medical Devices & Equipment, Total Coronado Aesthetics, LLC2026-03-310001280784Equity Investments, Medical Devices & Equipment, Orchestra BioMed Holdings, Inc., Equity, 8/4/2025, Common Stock2026-01-012026-03-310001280784Equity Investments, Medical Devices & Equipment, Orchestra BioMed Holdings, Inc., Equity, 8/4/2025, Common Stock2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:MedicalDevicesEquipmentMember2026-03-310001280784Equity Investments, Semiconductors, Achronix Semiconductor Corporation, Equity, 7/1/2011, Preferred Series C2026-01-012026-03-310001280784Equity Investments, Semiconductors, Achronix Semiconductor Corporation, Equity, 7/1/2011, Preferred Series C2026-03-310001280784Equity Investments, Semiconductors, Achronix Semiconductor Corporation, Equity, 6/26/2015, Preferred Series D-22026-01-012026-03-310001280784Equity Investments, Semiconductors, Achronix Semiconductor Corporation, Equity, 6/26/2015, Preferred Series D-22026-03-310001280784Equity Investments, Semiconductors, Total Achronix Semiconductor Corporation2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:SemiconductorsMember2026-03-310001280784Equity Investments, Space Technologies, Planet Labs PBC, Equity, 1/13/2026, Common Stock2026-01-012026-03-310001280784Equity Investments, Space Technologies, Planet Labs PBC, Equity, 1/13/2026, Common Stock2026-03-310001280784Equity Investments, Space Technologies, Stoke Space Technologies, Inc., Equity, 9/23/2025, Preferred Series D2026-01-012026-03-310001280784Equity Investments, Space Technologies, Stoke Space Technologies, Inc., Equity, 9/23/2025, Preferred Series D2026-03-310001280784Equity Investments, Space Technologies, Stoke Space Technologies, Inc., Equity, 2/6/2026, Preferred Series D-22026-01-012026-03-310001280784Equity Investments, Space Technologies, Stoke Space Technologies, Inc., Equity, 2/6/2026, Preferred Series D-22026-03-310001280784Equity Investments, Space Technologies, Total Stoke Space Technologies, Inc.2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:SpaceTechnologiesMember2026-03-310001280784Equity Investments, Sustainable and Renewable Technology, Impossible Foods, Inc., Equity, 5/10/2019, Preferred Series E-12026-01-012026-03-310001280784Equity Investments, Sustainable and Renewable Technology, Impossible Foods, Inc., Equity, 5/10/2019, Preferred Series E-12026-03-310001280784Equity Investments, Sustainable and Renewable Technology, Modumetal, Inc., Equity, 6/1/2015, Common Stock2026-01-012026-03-310001280784Equity Investments, Sustainable and Renewable Technology, Modumetal, Inc., Equity, 6/1/2015, Common Stock2026-03-310001280784Equity Investments, Sustainable and Renewable Technology, Pivot Bio, Inc., Equity, 6/28/2021, Preferred Series D2026-01-012026-03-310001280784Equity Investments, Sustainable and Renewable Technology, Pivot Bio, Inc., Equity, 6/28/2021, Preferred Series D2026-03-310001280784Equity Investments, Sustainable and Renewable Technology, SUNation Energy, Inc., Equity, 12/10/2020, Common Stock2026-01-012026-03-310001280784Equity Investments, Sustainable and Renewable Technology, SUNation Energy, Inc., Equity, 12/10/2020, Common Stock2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:SustainableAndRenewableTechnologyMember2026-03-310001280784Equity Investments, System Software, Armis, Inc., Equity, 10/18/2024, Preferred Series D2026-01-012026-03-310001280784Equity Investments, System Software, Armis, Inc., Equity, 10/18/2024, Preferred Series D2026-03-310001280784Equity Investments, System Software, Contentful Global, Inc., Equity, 12/22/2020, Preferred Series C2026-01-012026-03-310001280784Equity Investments, System Software, Contentful Global, Inc., Equity, 12/22/2020, Preferred Series C2026-03-310001280784Equity Investments, System Software, Contentful Global, Inc., Equity, 11/20/2018, Preferred Series D2026-01-012026-03-310001280784Equity Investments, System Software, Contentful Global, Inc., Equity, 11/20/2018, Preferred Series D2026-03-310001280784Equity Investments, System Software, Total Contentful Global, Inc.2026-03-310001280784Equity Investments, System Software, Docker, Inc., Equity, 11/29/2018, Common Stock2026-01-012026-03-310001280784Equity Investments, System Software, Docker, Inc., Equity, 11/29/2018, Common Stock2026-03-310001280784Equity Investments, System Software, Druva Holdings, Inc., Equity, 10/22/2015, Preferred Series 22026-01-012026-03-310001280784Equity Investments, System Software, Druva Holdings, Inc., Equity, 10/22/2015, Preferred Series 22026-03-310001280784Equity Investments, System Software, Druva Holdings, Inc., Equity, 8/24/2017, Preferred Series 32026-01-012026-03-310001280784Equity Investments, System Software, Druva Holdings, Inc., Equity, 8/24/2017, Preferred Series 32026-03-310001280784Equity Investments, System Software, Total Druva Holdings, Inc.2026-03-310001280784Equity Investments, System Software, Lightbend, Inc., Equity, 12/4/2020, Common Stock2026-01-012026-03-310001280784Equity Investments, System Software, Lightbend, Inc., Equity, 12/4/2020, Common Stock2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:SystemSoftwareMember2026-03-310001280784us-gaap:EquitySecuritiesMember2026-03-310001280784Warrant Investments, Application Software, Annex Cloud, Warrant, 6/5/2025, Common Units2026-01-012026-03-310001280784Warrant Investments, Application Software, Annex Cloud, Warrant, 6/5/2025, Common Units2026-03-310001280784Warrant Investments, Application Software, Automation Anywhere, Inc., Warrant, 9/23/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Automation Anywhere, Inc., Warrant, 9/23/2022, Common Stock2026-03-310001280784Warrant Investments, Application Software, Bitsight Technologies, Inc., Warrant, 11/18/2020, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Bitsight Technologies, Inc., Warrant, 11/18/2020, Common Stock2026-03-310001280784Warrant Investments, Application Software, Brain Corporation, Warrant, 10/4/2021, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Brain Corporation, Warrant, 10/4/2021, Common Stock2026-03-310001280784Warrant Investments, Application Software, Carbyne, Inc., Warrant, 2/24/2025, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, Application Software, Carbyne, Inc., Warrant, 2/24/2025, Ordinary Shares2026-03-310001280784Warrant Investments, Application Software, Cloudpay, Inc., Warrant, 4/10/2018, Preferred Series B2026-01-012026-03-310001280784Warrant Investments, Application Software, Cloudpay, Inc., Warrant, 4/10/2018, Preferred Series B2026-03-310001280784Warrant Investments, Application Software, Cutover, Inc., Warrant, 9/21/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Cutover, Inc., Warrant, 9/21/2022, Common Stock2026-03-310001280784Warrant Investments, Application Software, Dashlane, Inc., Warrant, 3/11/2019, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Dashlane, Inc., Warrant, 3/11/2019, Common Stock2026-03-310001280784Warrant Investments, Application Software, Demandbase, Inc., Warrant, 8/2/2021, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Demandbase, Inc., Warrant, 8/2/2021, Common Stock2026-03-310001280784Warrant Investments, Application Software, Distributed Creation Inc., Warrant, 4/21/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Distributed Creation Inc., Warrant, 4/21/2025, Common Stock2026-03-310001280784Warrant Investments, Application Software, DroneDeploy, Inc., Warrant, 6/30/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, DroneDeploy, Inc., Warrant, 6/30/2022, Common Stock2026-03-310001280784Warrant Investments, Application Software, Earnix, Inc., Warrant, 6/6/2024, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Earnix, Inc., Warrant, 6/6/2024, Common Stock2026-03-310001280784Warrant Investments, Application Software, Elation Health, Inc., Warrant, 9/12/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Elation Health, Inc., Warrant, 9/12/2022, Common Stock2026-03-310001280784Warrant Investments, Application Software, First Insight, Inc., Warrant, 5/10/2018, Preferred Series B2026-01-012026-03-310001280784Warrant Investments, Application Software, First Insight, Inc., Warrant, 5/10/2018, Preferred Series B2026-03-310001280784Warrant Investments, Application Software, Fulfil Solutions, Inc., Warrant, 7/29/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Fulfil Solutions, Inc., Warrant, 7/29/2022, Common Stock2026-03-310001280784Warrant Investments, Application Software, Funnel Holding AB (publ), Warrant, 10/24/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Funnel Holding AB (publ), Warrant, 10/24/2025, Common Stock2026-03-310001280784Warrant Investments, Application Software, Imagen Technologies, Inc., Warrant, 11/26/2025, Preferred Series C-3-VI2026-01-012026-03-310001280784Warrant Investments, Application Software, Imagen Technologies, Inc., Warrant, 11/26/2025, Preferred Series C-3-VI2026-03-310001280784Warrant Investments, Application Software, Kore.ai, Inc., Warrant, 3/31/2023, Preferred Series C2026-01-012026-03-310001280784Warrant Investments, Application Software, Kore.ai, Inc., Warrant, 3/31/2023, Preferred Series C2026-03-310001280784Warrant Investments, Application Software, Leapwork ApS, Warrant, 1/23/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Leapwork ApS, Warrant, 1/23/2023, Common Stock2026-03-310001280784Warrant Investments, Application Software, Mango Technologies, Inc., Warrant, 8/15/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Mango Technologies, Inc., Warrant, 8/15/2025, Common Stock2026-03-310001280784Warrant Investments, Application Software, Mixpanel, Inc., Warrant, 9/30/2020, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Mixpanel, Inc., Warrant, 9/30/2020, Common Stock2026-03-310001280784Warrant Investments, Application Software, Pindrop Security, Inc., Warrant, 6/26/2024, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Pindrop Security, Inc., Warrant, 6/26/2024, Common Stock2026-03-310001280784Warrant Investments, Application Software, Reltio, Inc., Warrant, 6/30/2020, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Reltio, Inc., Warrant, 6/30/2020, Common Stock2026-03-310001280784Warrant Investments, Application Software, Simon Data, Inc., Warrant, 3/22/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Simon Data, Inc., Warrant, 3/22/2023, Common Stock2026-03-310001280784Warrant Investments, Application Software, Sisense Ltd., Warrant, 6/8/2023, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, Application Software, Sisense Ltd., Warrant, 6/8/2023, Ordinary Shares2026-03-310001280784Warrant Investments, Application Software, Suzy, Inc., Warrant, 8/24/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Suzy, Inc., Warrant, 8/24/2023, Common Stock2026-03-310001280784Warrant Investments, Application Software, Tipalti Solutions Ltd., Warrant, 3/22/2023, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, Application Software, Tipalti Solutions Ltd., Warrant, 3/22/2023, Ordinary Shares2026-03-310001280784Warrant Investments, Application Software, Tipalti Solutions Ltd., Warrant, 3/27/2025, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, Application Software, Tipalti Solutions Ltd., Warrant, 3/27/2025, Ordinary Shares2026-03-310001280784Warrant Investments, Application Software, Total Tipalti Solutions Ltd.2026-03-310001280784Warrant Investments, Application Software, Ushur, Inc., Warrant, 6/5/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, Ushur, Inc., Warrant, 6/5/2025, Common Stock2026-03-310001280784Warrant Investments, Application Software, VideoAmp, Inc., Warrant, 1/21/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, VideoAmp, Inc., Warrant, 1/21/2022, Common Stock2026-03-310001280784Warrant Investments, Application Software, ZeroEyes, Inc., Warrant, 5/6/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Application Software, ZeroEyes, Inc., Warrant, 5/6/2025, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:ApplicationSoftwareMember2026-03-310001280784Warrant Investments, Biotechnology Tools, Alamar Biosciences, Inc., Warrant, 6/21/2022, Preferred Series C2026-01-012026-03-310001280784Warrant Investments, Biotechnology Tools, Alamar Biosciences, Inc., Warrant, 6/21/2022, Preferred Series C2026-03-310001280784Warrant Investments, Biotechnology Tools, Antheia, Inc., Warrant, 8/29/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Biotechnology Tools, Antheia, Inc., Warrant, 8/29/2025, Common Stock2026-03-310001280784Warrant Investments, Biotechnology Tools, PathAI, Inc., Warrant, 12/23/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Biotechnology Tools, PathAI, Inc., Warrant, 12/23/2022, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:BiotechnologyToolsMember2026-03-310001280784Warrant Investments, Communications & Networking, Aryaka Networks, Inc., Warrant, 6/28/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Communications & Networking, Aryaka Networks, Inc., Warrant, 6/28/2022, Common Stock2026-03-310001280784Warrant Investments, Communications & Networking, Tarana Wireless, Inc.., Warrant, 3/20/2026, Common Stock2026-01-012026-03-310001280784Warrant Investments, Communications & Networking, Tarana Wireless, Inc.., Warrant, 3/20/2026, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:CommunicationsNetworkingMember2026-03-310001280784Warrant Investments, Consumer & Business Products, Gadget Guard, LLC, Warrant, 6/3/2014, Common Stock2026-01-012026-03-310001280784Warrant Investments, Consumer & Business Products, Gadget Guard, LLC, Warrant, 6/3/2014, Common Stock2026-03-310001280784Warrant Investments, Consumer & Business Products, Whoop, Inc., Warrant, 6/27/2018, Preferred Series C2026-01-012026-03-310001280784Warrant Investments, Consumer & Business Products, Whoop, Inc., Warrant, 6/27/2018, Preferred Series C2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:ConsumerBusinessProductsMember2026-03-310001280784Warrant Investment, Consumer & Business Services, Altumint, Inc., Warrant, 10/31/2024, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Altumint, Inc., Warrant, 10/31/2024, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, AppDirect, Inc., Warrant, 9/22/2025, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, AppDirect, Inc., Warrant, 9/22/2025, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Carwow LTD, Warrant, 12/14/2021, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Carwow LTD, Warrant, 12/14/2021, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Carwow LTD, Warrant, 2/13/2024, Preferred Series D-42026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Carwow LTD, Warrant, 2/13/2024, Preferred Series D-42026-03-310001280784Warrant Investment, Consumer & Business Services, Total Carwow LTD2026-03-310001280784Warrant Investment, Consumer & Business Services, CollectiveHealth, Inc., Warrant, 1/26/2026, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, CollectiveHealth, Inc., Warrant, 1/26/2026, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Finix Payments, Inc., Warrant, 12/17/2025, Preferred Series C2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Finix Payments, Inc., Warrant, 12/17/2025, Preferred Series C2026-03-310001280784Warrant Investment, Consumer & Business Services, Houzz, Inc., Warrant, 10/29/2019, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Houzz, Inc., Warrant, 10/29/2019, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Landing Holdings Inc., Warrant, 3/12/2021, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Landing Holdings Inc., Warrant, 3/12/2021, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Lendio, Inc., Warrant, 3/29/2019, Preferred Series D2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Lendio, Inc., Warrant, 3/29/2019, Preferred Series D2026-03-310001280784Warrant Investment, Consumer & Business Services, Peek Travel, Inc., Warrant, 10/28/2025, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Peek Travel, Inc., Warrant, 10/28/2025, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Plentific Ltd, Warrant, 10/3/2023, Ordinary Shares2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Plentific Ltd, Warrant, 10/3/2023, Ordinary Shares2026-03-310001280784Warrant Investment, Consumer & Business Services, Provi, Warrant, 12/22/2022, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Provi, Warrant, 12/22/2022, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Rhino Labs, Inc., Warrant, 3/12/2021, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Rhino Labs, Inc., Warrant, 3/12/2021, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, SeatGeek, Inc., Warrant, 6/12/2019, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, SeatGeek, Inc., Warrant, 6/12/2019, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Skyword, Inc., Warrant, 11/14/2022, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Skyword, Inc., Warrant, 11/14/2022, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Skyword, Inc., Warrant, 8/23/2019, Preferred Series B2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Skyword, Inc., Warrant, 8/23/2019, Preferred Series B2026-03-310001280784Warrant Investment, Consumer & Business Services, Total Skyword, Inc.2026-03-310001280784Warrant Investment, Consumer & Business Services, Snagajob.com, Inc., Warrant, 4/20/2020, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Snagajob.com, Inc., Warrant, 4/20/2020, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Snagajob.com, Inc., Warrant, 6/30/2016, Preferred Series A2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Snagajob.com, Inc., Warrant, 6/30/2016, Preferred Series A2026-03-310001280784Warrant Investment, Consumer & Business Services, Snagajob.com, Inc., Warrant, 8/1/2018, Preferred Series B2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Snagajob.com, Inc., Warrant, 8/1/2018, Preferred Series B2026-03-310001280784Warrant Investment, Consumer & Business Services, Total Snagajob.com, Inc.2026-03-310001280784Warrant Investment, Consumer & Business Services, Thumbtack, Inc., Warrant, 5/1/2018, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Thumbtack, Inc., Warrant, 5/1/2018, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Veem, Inc., Warrant, 3/31/2022, Common Stock2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Veem, Inc., Warrant, 3/31/2022, Common Stock2026-03-310001280784Warrant Investment, Consumer & Business Services, Worldremit Group Limited, Warrant, 2/11/2021, Preferred Series D2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Worldremit Group Limited, Warrant, 2/11/2021, Preferred Series D2026-03-310001280784Warrant Investment, Consumer & Business Services, Worldremit Group Limited, Warrant, 8/27/2021, Preferred Series E2026-01-012026-03-310001280784Warrant Investment, Consumer & Business Services, Worldremit Group Limited, Warrant, 8/27/2021, Preferred Series E2026-03-310001280784Warrant Investment, Consumer & Business Services, Total Worldremit Group Limited2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:ConsumerBusinessServicesMember2026-03-310001280784Warrant Investments, Defense Technologies, Hermeus Corporation, Warrant, 3/20/2026, Common Stock2026-01-012026-03-310001280784Warrant Investments, Defense Technologies, Hermeus Corporation, Warrant, 3/20/2026, Common Stock2026-03-310001280784Warrant Investments, Defense Technologies, Saronic Technologies, Inc, Warrant, 6/9/2025, Preferred Series C2026-01-012026-03-310001280784Warrant Investments, Defense Technologies, Saronic Technologies, Inc, Warrant, 6/9/2025, Preferred Series C2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:DefenseTechnologiesMember2026-03-310001280784Warrant Investments, Drug Discovery & Development, Axsome Therapeutics, Inc., Warrant, 9/25/2020, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Axsome Therapeutics, Inc., Warrant, 9/25/2020, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, Beren Therapeutics P.B.C., Warrant, 10/8/2025, Preferred Series A2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Beren Therapeutics P.B.C., Warrant, 10/8/2025, Preferred Series A2026-03-310001280784Warrant Investments, Drug Discovery & Development, Cellarity, Inc., Warrant, 12/8/2021, Preferred Series B2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Cellarity, Inc., Warrant, 12/8/2021, Preferred Series B2026-03-310001280784Warrant Investments, Drug Discovery & Development, Century Therapeutics, Inc., Warrant, 9/14/2020, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Century Therapeutics, Inc., Warrant, 9/14/2020, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, COMPASS Pathways plc, Warrant, 6/30/2023, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, COMPASS Pathways plc, Warrant, 6/30/2023, Ordinary Shares2026-03-310001280784Warrant Investments, Drug Discovery & Development, Curevo, Inc., Warrant, 6/9/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Curevo, Inc., Warrant, 6/9/2023, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, enGene, Inc., Warrant, 12/22/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, enGene, Inc., Warrant, 12/22/2023, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, Heron Therapeutics, Inc., Warrant, 8/9/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Heron Therapeutics, Inc., Warrant, 8/9/2023, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, Kura Oncology, Inc., Warrant, 11/2/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Kura Oncology, Inc., Warrant, 11/2/2022, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, Madrigal Pharmaceuticals, Inc., Warrant, 5/9/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Madrigal Pharmaceuticals, Inc., Warrant, 5/9/2022, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, Phathom Pharmaceuticals, Inc., Warrant, 9/17/2021, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Phathom Pharmaceuticals, Inc., Warrant, 9/17/2021, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, Redshift Bioanalytics, Inc., Warrant, 3/23/2022, Preferred Series E2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Redshift Bioanalytics, Inc., Warrant, 3/23/2022, Preferred Series E2026-03-310001280784Warrant Investments, Drug Discovery & Development, Scynexis, Inc., Warrant, 5/14/2021, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Scynexis, Inc., Warrant, 5/14/2021, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, SynOx Therapeutics Limited, Warrant, 4/18/2024, Preferred Series B2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, SynOx Therapeutics Limited, Warrant, 4/18/2024, Preferred Series B2026-03-310001280784Warrant Investments, Drug Discovery & Development, TG Therapeutics, Inc., Warrant, 12/30/2021, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, TG Therapeutics, Inc., Warrant, 12/30/2021, Common Stock2026-03-310001280784Warrant Investments, Drug Discovery & Development, Valo Health, LLC, Warrant, 6/15/2020, Common Units2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, Valo Health, LLC, Warrant, 6/15/2020, Common Units2026-03-310001280784Warrant Investments, Drug Discovery & Development, X4 Pharmaceuticals, Inc., Warrant, 3/18/2019, Common Stock2026-01-012026-03-310001280784Warrant Investments, Drug Discovery & Development, X4 Pharmaceuticals, Inc., Warrant, 3/18/2019, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:DrugDiscoveryDevelopmentMember2026-03-310001280784Warrant Investments, Electronics & Computer Hardware, 908 Devices, Inc., Warrant, 3/15/2017, Common Stock2026-01-012026-03-310001280784Warrant Investments, Electronics & Computer Hardware, 908 Devices, Inc., Warrant, 3/15/2017, Common Stock2026-03-310001280784Warrant Investments, Electronics & Computer Hardware, Locus Robotics Corp., Warrant, 6/21/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Electronics & Computer Hardware, Locus Robotics Corp., Warrant, 6/21/2022, Common Stock2026-03-310001280784Warrant Investments, Electronics & Computer Hardware, Skydio, Inc., Warrant, 11/08/2021, Common Stock2026-01-012026-03-310001280784Warrant Investments, Electronics & Computer Hardware, Skydio, Inc., Warrant, 11/08/2021, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:ElectronicsComputerHardwareMember2026-03-310001280784Warrant Investments, Healthcare Services, Other, Belong Health, Inc., Warrant, 11/13/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Healthcare Services, Other, Belong Health, Inc., Warrant, 11/13/2025, Common Stock2026-03-310001280784Warrant Investments, Healthcare Services, Other, Curana Health Holdings, LLC., Warrant, 1/4/2024, Common Units2026-01-012026-03-310001280784Warrant Investments, Healthcare Services, Other, Curana Health Holdings, LLC., Warrant, 1/4/2024, Common Units2026-03-310001280784Warrant Investments, Healthcare Services, Other, Modern Life, Inc., Warrant, 3/30/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Healthcare Services, Other, Modern Life, Inc., Warrant, 3/30/2023, Common Stock2026-03-310001280784Warrant Investments, Healthcare Services, Other, Octave Health Group, Inc. , Warrant, 11/28/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Healthcare Services, Other, Octave Health Group, Inc. , Warrant, 11/28/2025, Common Stock2026-03-310001280784Warrant Investments, Healthcare Services, Other, Strive Health Holdings, LLC., Warrant, 9/28/2023, Common Units2026-01-012026-03-310001280784Warrant Investments, Healthcare Services, Other, Strive Health Holdings, LLC., Warrant, 9/28/2023, Common Units2026-03-310001280784Warrant Investments, Healthcare Services, Other, Recover Together, Inc.., Warrant, 7/3/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Healthcare Services, Other, Recover Together, Inc.., Warrant, 7/3/2023, Common Stock2026-03-310001280784Warrant Investments, Healthcare Services, Other, Vida Health, Inc., Warrant, 3/28/2022, Preferred Series E2026-01-012026-03-310001280784Warrant Investments, Healthcare Services, Other, Vida Health, Inc., Warrant, 3/28/2022, Preferred Series E2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:HealthcareServicesOtherMember2026-03-310001280784Warrant Investments, Information Services, NetBase Quid, Inc., Warrant, 8/22/2017, Preferred Series 12026-01-012026-03-310001280784Warrant Investments, Information Services, NetBase Quid, Inc., Warrant, 8/22/2017, Preferred Series 12026-03-310001280784htgc:WarrantInvestmentMemberhtgc:InformationServicesMember2026-03-310001280784Warrant Investments, Manufacturing Technology, Bright Machines, Inc., Warrant, 3/31/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Manufacturing Technology, Bright Machines, Inc., Warrant, 3/31/2022, Common Stock2026-03-310001280784Warrant Investments, Manufacturing Technology, MacroFab, Inc., Warrant, 3/23/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Manufacturing Technology, MacroFab, Inc., Warrant, 3/23/2022, Common Stock2026-03-310001280784Warrant Investments, Manufacturing Technology, VulcanForms Inc., Warrant, 1/30/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Manufacturing Technology, VulcanForms Inc., Warrant, 1/30/2025, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:ManufacturingTechnologyMember2026-03-310001280784Warrant Investments, Media/Content/Info, Fever Labs, Inc., Warrant, 12/30/2022, Preferred Series E-12026-01-012026-03-310001280784Warrant Investments, Media/Content/Info, Fever Labs, Inc., Warrant, 12/30/2022, Preferred Series E-12026-03-310001280784htgc:WarrantInvestmentMemberhtgc:MediaContentInfoMember2026-03-310001280784Warrant Investments, Medical Devices & Equipment, Cognito Therapeutics Group, Inc., Warrant, 1/23/2026, Common Stock2026-01-012026-03-310001280784Warrant Investments, Medical Devices & Equipment, Cognito Therapeutics Group, Inc., Warrant, 1/23/2026, Common Stock2026-03-310001280784Warrant Investments, Medical Devices & Equipment, Orchestra BioMed Holdings, Inc., Warrant, 11/6/2024, Common Stock2026-01-012026-03-310001280784Warrant Investments, Medical Devices & Equipment, Orchestra BioMed Holdings, Inc., Warrant, 11/6/2024, Common Stock2026-03-310001280784Warrant Investments, Medical Devices & Equipment, Senseonics Holdings, Inc., Warrant, 9/8/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, Medical Devices & Equipment, Senseonics Holdings, Inc., Warrant, 9/8/2023, Common Stock2026-03-310001280784Warrant Investments, Medical Devices & Equipment, Sight Sciences, Inc., Warrant, 1/22/2024, Common Stock2026-01-012026-03-310001280784Warrant Investments, Medical Devices & Equipment, Sight Sciences, Inc., Warrant, 1/22/2024, Common Stock2026-03-310001280784Warrant Investments, Medical Devices & Equipment, Tela Bio, Inc., Warrant, 3/31/2017, Common Stock2026-01-012026-03-310001280784Warrant Investments, Medical Devices & Equipment, Tela Bio, Inc., Warrant, 3/31/2017, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:MedicalDevicesEquipmentMember2026-03-310001280784Warrant Investments, Semiconductors, Achronix Semiconductor Corporation, Warrant, 1/11/2017, Preferred Series D-22026-01-012026-03-310001280784Warrant Investments, Semiconductors, Achronix Semiconductor Corporation, Warrant, 1/11/2017, Preferred Series D-22026-03-310001280784htgc:WarrantInvestmentMemberhtgc:SemiconductorsMember2026-03-310001280784Warrant Investments, Space Technologies, HawkEye 360, Inc., Warrant, 12/18/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Space Technologies, HawkEye 360, Inc., Warrant, 12/18/2025, Common Stock2026-03-310001280784Warrant Investments, Space Technologies, Loft Orbital Solutions Inc.., Warrant, 9/10/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Space Technologies, Loft Orbital Solutions Inc.., Warrant, 9/10/2025, Common Stock2026-03-310001280784Warrant Investments, Space Technologies, Stoke Space Technologies, Inc., Warrant, 6/16/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Space Technologies, Stoke Space Technologies, Inc., Warrant, 6/16/2025, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:SpaceTechnologiesMember2026-03-310001280784Warrant Investments, Sustainable and Renewable Technology, Ampion, PBC, Warrant, 4/15/2022, Common Stock2026-01-012026-03-310001280784Warrant Investments, Sustainable and Renewable Technology, Ampion, PBC, Warrant, 4/15/2022, Common Stock2026-03-310001280784Warrant Investments, Sustainable and Renewable Technology, Electric Hydrogen Co., Warrant, 3/27/2024, Common stock2026-01-012026-03-310001280784Warrant Investments, Sustainable and Renewable Technology, Electric Hydrogen Co., Warrant, 3/27/2024, Common stock2026-03-310001280784Warrant Investments, Sustainable and Renewable Technology, Tidal Vision Products, Inc., Warrant, 10/10/2025, Common Stock2026-01-012026-03-310001280784Warrant Investments, Sustainable and Renewable Technology, Tidal Vision Products, Inc., Warrant, 10/10/2025, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:SustainableAndRenewableTechnologyMember2026-03-310001280784Warrant Investments, System Software, Akeyless Security Ltd., Warrant, 8/4/2025, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, System Software, Akeyless Security Ltd., Warrant, 8/4/2025, Ordinary Shares2026-03-310001280784Warrant Investments, System Software, CloudBolt Software, Inc., Warrant, 9/30/2020, Common Stock2026-01-012026-03-310001280784Warrant Investments, System Software, CloudBolt Software, Inc., Warrant, 9/30/2020, Common Stock2026-03-310001280784Warrant Investments, System Software, Cloudian, Inc., Warrant, 11/6/2018, Common Stock2026-01-012026-03-310001280784Warrant Investments, System Software, Cloudian, Inc., Warrant, 11/6/2018, Common Stock2026-03-310001280784Warrant Investments, System Software, ControlUp Technologies Ltd., Warrant, 1/2/2026, Common stock2026-01-012026-03-310001280784Warrant Investments, System Software, ControlUp Technologies Ltd., Warrant, 1/2/2026, Common stock2026-03-310001280784Warrant Investments, System Software, Coronet Cyber Security Ltd., Warrant, 9/26/2024, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, System Software, Coronet Cyber Security Ltd., Warrant, 9/26/2024, Ordinary Shares2026-03-310001280784Warrant Investments, System Software, Dragos, Inc., Warrant, 6/28/2023, Common Stock2026-01-012026-03-310001280784Warrant Investments, System Software, Dragos, Inc., Warrant, 6/28/2023, Common Stock2026-03-310001280784Warrant Investments, System Software, Harness, Inc., Warrant, 3/12/2024, Common Stock2026-01-012026-03-310001280784Warrant Investments, System Software, Harness, Inc., Warrant, 3/12/2024, Common Stock2026-03-310001280784Warrant Investments, System Software, Lightbend, Inc., Warrant, 2/14/2018, Preferred Series LB-22026-01-012026-03-310001280784Warrant Investments, System Software, Lightbend, Inc., Warrant, 2/14/2018, Preferred Series LB-22026-03-310001280784Warrant Investments, System Software, Morphisec Information Security 2014 Ltd., Warrant, 10/1/2024, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, System Software, Morphisec Information Security 2014 Ltd., Warrant, 10/1/2024, Ordinary Shares2026-03-310001280784Warrant Investments, System Software, Neo4j, Inc., Warrant, 3/31/2026, Common Stock2026-01-012026-03-310001280784Warrant Investments, System Software, Neo4j, Inc., Warrant, 3/31/2026, Common Stock2026-03-310001280784Warrant Investments, System Software, Scylla DB Ltd., Warrant, 7/24/2025, Ordinary Shares2026-01-012026-03-310001280784Warrant Investments, System Software, Scylla DB Ltd., Warrant, 7/24/2025, Ordinary Shares2026-03-310001280784Warrant Investments, System Software, Semperis Technologies Inc., Warrant, 4/23/2024, Common Stock2026-01-012026-03-310001280784Warrant Investments, System Software, Semperis Technologies Inc., Warrant, 4/23/2024, Common Stock2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:SystemSoftwareMember2026-03-310001280784htgc:WarrantInvestmentMember2026-03-310001280784htgc:InvestmentsInSecuritiesMember2026-03-310001280784Investment Funds & Vehicles Investments, Drug Discovery & Development, Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, 11/16/20202026-01-012026-03-310001280784Investment Funds & Vehicles Investments, Drug Discovery & Development, Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, 11/16/20202026-03-310001280784Investment Funds & Vehicles Investments, Drug Discovery & Development, Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, 6/23/20222026-01-012026-03-310001280784Investment Funds & Vehicles Investments, Drug Discovery & Development, Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, 6/23/20222026-03-310001280784htgc:InvestmentFundAndVehicleInvestmentsMemberhtgc:DrugDiscoveryDevelopmentMember2026-03-310001280784Investment Funds & Vehicles Investments, System Software, Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, 7/21/20222026-01-012026-03-310001280784Investment Funds & Vehicles Investments, System Software, Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, 7/21/20222026-03-310001280784htgc:InvestmentFundAndVehicleInvestmentsMemberhtgc:SystemSoftwareMember2026-03-310001280784htgc:InvestmentFundAndVehicleInvestmentsMember2026-03-310001280784Investment Fund, Cash & Cash Equivalent, GS Financial Square Government Fund, FGTXX/38141W2732026-03-310001280784htgc:InvestmentsCashAndCashEquivalentsMember2026-03-310001280784htgc:InvestmentsAfterCashAndCashEquivalentsMember2026-03-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/5/20262026-01-012026-03-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/5/20262026-03-310001280784us-gaap:ForeignExchangeForwardMember2026-03-310001280784htgc:OneMonthSOFRMember2026-03-310001280784htgc:ThreeMonthSOFRMember2026-03-310001280784htgc:SixMonthSOFRMember2026-03-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:WarrantMember2026-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:CommonStockMember2026-03-310001280784htgc:PromissoryNotesMemberhtgc:BlackCrowAIIncMember2026-03-310001280784htgc:RoyaltyContractMemberhtgc:PhathomPharmaceuticalsIncMember2026-03-310001280784Equity Investments, Application Software, Khoros, LLC., Equity, 5/23/2025, Earnout Interest2026-03-310001280784Equity Investments, Application Software, Verge Analytics, Inc., Equity, 7/2/2025, SAFE2026-03-310001280784Debt Investments Application Software and Alchemer LLC, Senior Secured, Maturity Date May 2028, 1-month SOFR + 8.14%, Floor rate 9.14%2025-12-310001280784Debt Investments Application Software and AlphaSense, Inc., Senior Secured, Maturity Date June 2029, 3-month SOFR + 6.25%, Floor rate 8.25%2025-12-310001280784Debt Investments Application Software and Annex Cloud, Senior Secured, Maturity Date June 2028, PIK Interest 3-month SOFR + 9.99%, Floor rate 10.99%2025-12-310001280784Debt Investments Application Software and Annex Cloud, Senior Secured, Maturity Date December 2025, PIK Interest 3-month SOFR + 9.99%, Floor rate 10.99%2025-12-310001280784Debt Investments Application Software and Annex Cloud Senior Secured, Maturity Date June 2028, PIK Interest 3-month SOFR + 5.73%, Floor rate 6.73%2025-12-310001280784Debt Investments Application Software and Annex Cloud2025-12-310001280784Debt Investments Application Software and Babel Street, Senior Secured, December 2027, 3-month SOFR + 8.01%, Floor rate 9.01%2025-12-310001280784Debt Investments Application Software and Behavox Limited, Senior Secured, Maturity Date September 2027, Prime - 0.55%, Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee2025-12-310001280784Debt Investments Application Software and Brain Corporation, Senior Secured, September 2028, Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee2025-12-310001280784Debt Investments Application Software and Carbyne, Inc., Senior Secured, February 2029, Prime + 3.50%, Floor rate 10.00%, 3.50% Exit Fee2025-12-310001280784Debt Investments Application Software and Ceros, Inc., Senior Secured, June 2027, 3-month SOFR + 8.99%, Floor rate 9.89%2025-12-310001280784Debt Investments Application Software and Chainalysis, Inc., Senior Secured, June 2029, Prime + 2.95%, Floor rate 10.45%2025-12-310001280784Debt Investments Application Software and Dashlane, Inc., Senior Secured, December 2027, Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee2025-12-310001280784Debt Investments Application Software and Dispatch Technologies, Inc., Senior Secured, April 2028, 3-month SOFR + 7.86%, Floor rate 8.61%2025-12-310001280784Debt Investments Application Software and Distributed Creation Inc., Senior Secured, April 2029, Prime + 3.00%, Floor rate 10.25%, 4.50% Exit Fee2025-12-310001280784Debt Investments Application Software and DocPlanner., Senior Secured, January 2030, Prime + 2.75%, Floor rate 9.75%, 4.25% Exit Fee2025-12-310001280784Debt Investments Application Software and Earnix, Inc., Senior Secured, June 2029, Prime - 1.15%, Floor rate 5.35%, PIK Interest 4.45%2025-12-310001280784Debt Investments Application Software and Elation Health, Inc., Senior Secured, April 2029, Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.30%, 3.95% Exit Fee2025-12-310001280784Debt Investments Application Software and Funnel Holding AB (publ)., Senior Secured, October 2029, Prime + 0.60%, Floor rate 7.10%, Cap rate 8.60%, PIK Interest 3.00%, 2.25% Exit Fee2025-12-310001280784Debt Investments Application Software and Imagen Technologies, Inc., Senior Secured, November 2028, Prime + 1.55%, Floor rate 9.05%, PIK Interest 1.00%, 3.95% Exit Fee2025-12-310001280784Debt Investments Application Software and iSpot.tv, Inc., Senior Secured, January 2029, Prime + 2.25%, Floor rate 8.75%, PIK Interest 1.00%, 5.70% Exit Fee2025-12-310001280784Debt Investments Application Software and iSpot.tv, Inc., Senior Secured, January 2029, Prime + 1.40%, Floor rate 7.90%, PIK Interest 0.75%, 4.50% Exit Fee2025-12-310001280784Debt Investments Application Software and iSpot.tv, Inc.2025-12-310001280784Debt Investments Application Software and Khoros, LLC, Senior Secured, May 2030, FIXED 10.00%2025-12-310001280784Debt Investments Application Software and LinenMaster, LLC, Senior Secured, August 2029, 1-month SOFR + 8.28%, Floor rate 9.28%2025-12-310001280784Debt Investments Application Software and Loftware, Inc., Senior Secured, March 2028, 3-month SOFR + 7.88%, Floor rate 8.88%2025-12-310001280784Debt Investments Application Software and LogicSource., Senior Secured, July 2027, 3-month SOFR + 8.93%, Floor rate 9.93%2025-12-310001280784Debt Investments Application Software and Mango Technologies, Inc., Senior Secured, August 2030, Prime + 2.25%, Floor rate 8.25%, 2.00% Exit Fee2025-12-310001280784Debt Investments Application Software and Marigold Group, Inc., Senior Secured, April 2028, 6-month SOFR + 4.75%, Floor rate 5.75%, PIK Interest 5.25%2025-12-310001280784Debt Investments Application Software and Omeda Holdings, LLC., Senior Secured, July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%2025-12-310001280784Debt Investments Application Software and Pindrop Security, Inc., Senior Secured, June 2029, Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee2025-12-310001280784Debt Investments Application Software and Proven Optics, LLC, Senior Secured, December 2030, 3-month SOFR + 7.30%, Floor rate 8.30%2025-12-310001280784Debt Investments Application Software and Remodel Health Holdco, LLC, Senior Secured, December 2028, Prime + 2.35%, Floor rate 10.35%, 6.50% Exit Fee2025-12-310001280784Debt Investments Application Software and Reveleer, Senior Secured, February 2027, Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee2025-12-310001280784Debt Investments Application Software and ShadowDragon, LLC, Senior Secured, December 2026, 3-month SOFR + 8.79%, Floor rate 9.69%2025-12-310001280784Debt Investments Application Software and Simon Data, Inc., Senior Secured, March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 3.58% Exit Fee2025-12-310001280784Debt Investments Application Software and Sisense Ltd., Senior Secured, July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee2025-12-310001280784Debt Investments Application Software and Smartsheet Inc., Senior Secured, January 2031, 3-month SOFR + 6.50%, Floor rate 7.25%2025-12-310001280784Debt Investments Application Software and Snappt, Inc., Senior Secured, April 2029, Prime + 2.35%, Floor rate 8.85%, PIK Interest 1.00%, 4.25% Exit Fee2025-12-310001280784Debt Investments Application Software and Streamline Healthcare Solutions, Senior Secured, June 2030, 3-month SOFR + 7.30%, Floor rate 8.30%2025-12-310001280784Debt Investments Application Software and Suzy, Inc., Senior Secured, August 2027, Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee2025-12-310001280784Debt Investments Application Software and TaxCalc, Senior Secured, November 2029, Daily SONIA + 8.17%, Floor rate 8.67%2025-12-310001280784Debt Investments Application Software and Tipalti Solutions Ltd., Senior Secured, April 2029, Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%2025-12-310001280784Debt Investments Application Software and Tipalti Solutions Ltd., Senior Secured, April 2029, Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%, 3.75% Exit Fee2025-12-310001280784Debt Investments Application Software and Tipalti Solutions Ltd.2025-12-310001280784Debt Investments Application Software and Ushur, Inc. Senior Secured, June 2028, Prime + 2.20%, Floor rate 9.20%, 3.95% Exit Fee2025-12-310001280784Debt Investments Application Software and Zappi, Inc. Senior Secured, December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%2025-12-310001280784Debt Investments Application Software and ZeroEyes, Inc. Senior Secured, May 2030, Prime + 2.00%, Floor rate 9.50%, PIK Interest 2.00%, 1.50% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:ApplicationSoftwareMember2025-12-310001280784Debt Investments Biotechnology Tools and Antheia, Inc., Senior Secured, Maturity Date August 2029, Prime + 2.85%, Floor rate 10.35%, 5.55% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:BiotechnologyToolsMember2025-12-310001280784Debt Investments Communications and Networking and Aryaka Networks, Inc., Senior Secured, Maturity Date December 2028, Prime + 1.80%, Floor rate 9.30%, PIK Interest 1.25%, 6.73% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:CommunicationsNetworkingMember2025-12-310001280784Debt Investments Consumer & Business Products Weee! Inc., Senior Secured, April 2028, Prime + 2.25%, Floor rate 9.75%, 2.50% Exit Fee 2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:ConsumerBusinessProductsMember2025-12-310001280784Debt Investments Consumer & Business Services and AppDirect, Inc., Senior Secured, September 2029, Prime + 2.05%, Floor rate 8.55%, PIK Interest 1.00%, 4.70% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Carwow LTD, Senior Secured, December 2027, Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Finix Payments, Inc., Senior Secured, December 2029, Prime + 2.50%, Floor rate 9.25%, 4.95% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and GoEuro Travel GmbH, Senior Secured, November 2029, Prime + 3.45%, Floor rate 10.45%, 4.50% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Houzz, Inc., Convertible Debt, May 2028, PIK Interest 12.00%2025-12-310001280784Debt Investments Consumer & Business Services and Jobandtalent USA, Inc., Senior Secured, October 2028, 1-month SOFR + 3.50%, Floor rate 4.50%, PIK Interest 3.25%, 6.42% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Nerdy Inc., Senior Secured, November 2029, Prime + 3.50%, Floor rate 10.75%, 7.50% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Peek Travel Inc., Senior Secured, October 2028, Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.00%, 4.95% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Plentific Ltd, Senior Secured, October 2026, Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Provi, Senior Secured, December 2027, Prime + 4.40%, Floor rate 10.65%, 1.00% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Riviera Partners LLC, Senior Secured, March 2028, 1-month SOFR + 8.28%, Floor rate 9.28%2025-12-310001280784Debt Investments Consumer & Business Services and RVShare, LLC, Senior Secured, December 2026, 3-month SOFR + 9.50%, Floor rate 10.50%2025-12-310001280784Debt Investments Consumer & Business Services and SeatGeek Inc., Senior Secured, May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.50% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and SeatGeek Inc., Senior Secured, July 2026, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.50% Exit Fee2025-12-310001280784Debt Investment Consumer & Business Services and Total SeatGeek, Inc2025-12-310001280784Debt Investments Consumer & Business Services and Skyword, Inc., Senior Secured, Maturity Date November 2027, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 5.50% Exit Fee2025-12-310001280784Debt Investments Consumer & Business Services and Tectura Corporation, Senior Secured, Maturity Date January 2027, FIXED 8.25%2025-12-310001280784Debt Investments Consumer & Business Services and Thumbtack, Inc., Senior Secured, Maturity Date March 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:ConsumerBusinessServicesMember2025-12-310001280784Debt Investments Defense Technologies and Saronic Technologies, Inc., Senior Secured, June 2030, Prime + 2.50%, Floor rate 9.00%, 2.00% Exit Fee2025-12-310001280784Debt Investments Defense Technologies and Shield AI, Inc., Senior Secured, February 2029, Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:DefenseTechnologiesMember2025-12-310001280784Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC, Unsecured, Maturity Date July 2029, FIXED 3.45%, PIK Interest 8.05%2025-12-310001280784Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC, Unsecured, Maturity Date July 2029, FIXED 11.95%2025-12-310001280784Debt Investment Diversified Financial Services and Total Gibraltar Acquisition, LLC2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:DiversifiedFinancialServicesMember2025-12-310001280784Debt Investments Drug Discovery & Development and Aldeyra Therapeutics, Inc., Senior Secured, Maturity Date April 2026, Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Alector, Inc., Senior Secured, Maturity Date December 2028, Prime + 1.05%, Floor rate 8.05%, 4.75% Exit Fee2025-12-310001280784Debt Investment Drug Discovery & Development and Altimmune, Inc., Senior Secured, Maturity Date June 2029, Prime + 2.45%, Floor rate 9.70%, 6.25% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Arcus Biosciences, Inc., Senior Secured, Maturity Date September 2030, Prime - 0.05%, Floor rate 8.45%, PIK Interest 2.20%, 9.00% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Beren Therapeutics P.B.C., Senior Secured, Maturity Date October 2029, Prime + 2.45%, Floor rate 9.95%, 5.25% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Braeburn, Inc., Senior Secured, Maturity Date October 2028, Prime + 3.00%, Floor rate 10.50%, PIK Interest 0.25%, 5.45% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and COMPASS Pathways plc, Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Corium, Inc., Senior Secured, Maturity Date September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Disc Medicine, Inc., Senior Secured, Maturity Date December 2029, Prime + 1.75%, Floor rate 8.25%, 6.75% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Dyne Therapeutics, Inc., Senior Secured, Maturity Date July 2030, Prime + 2.45%, Floor rate 9.95%, 5.50% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and enGene, Inc., Senior Secured, Maturity Date January 2028, Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Genetix Biotherapeutics Inc. (p.k.a. bluebird bio, Inc.), Senior Secured, Maturity Date April 2029, Prime + 2.45%, Floor rate 9.45%, 6.45% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Heron Therapeutics, Inc., Senior Secured, Maturity Date September 2030, Prime + 1.95%, Floor rate 9.45%, PIK Interest 1.00%, 6.25% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Kura Oncology, Inc., Senior Secured, Maturity Date November 2027, Prime + 2.40%, Floor rate 8.65%, 6.05% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and MoonLake Immunotherapeutics, Senior Secured, Maturity Date April 2030, Prime + 1.45%, Floor rate 8.45%, 6.95% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and NorthSea Therapeutics, Convertible Debt, Maturity Date December 2026, FIXED 6.00%2025-12-310001280784Debt Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Senior Secured, Maturity Date December 2027, Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 7.06% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Senior Secured, Maturity Date December 2027, Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 3.00% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Total Phathom Pharmaceuticals, Inc.2025-12-310001280784Debt Investments Drug Discovery & Development and Replimune Group, Inc., Senior Secured, Maturity Date October 2027, Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Savara, Inc. and Senior Secured and Maturity Date April 2030 and Prime + 1.45%, Floor rate 7.45%, 6.95% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and SynOx Therapeutics Limited, Senior Secured, Maturity Date May 2027, Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and uniQure B.V., Senior Secured, Maturity Date October 2030, Prime + 2.45%, Floor rate 9.45%, 5.50% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Senior Secured, Maturity Date October 2030, Prime + 1.45%, Floor rate 8.95%, Cap rate 9.45%, 6.00% Exit Fee2025-12-310001280784Debt Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Senior Secured, Maturity Date July 2027, Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:DrugDiscoveryDevelopmentMember2025-12-310001280784Debt Investments Electronics & Computer Hardware and Locus Robotics Corp., Senior Secured, Maturity Date December 2028, Prime + 3.00%, Floor rate 9.50%, 4.00% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:ElectronicsComputerHardwareMember2025-12-310001280784Debt Investments Healthcare Services, Other and Belong Health, Inc. and Senior Secured and Maturity Date November 2029 and Prime + 2.25%, Floor rate 9.75%, 5.45% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Blue Sprig Pediatrics, Inc., Senior Secured, Maturity Date November 2026, 1-month SOFR + 5.11%, Floor rate 6.00%, PIK Interest 4.45%2025-12-310001280784Debt Investments Healthcare Services, Other and ChenMed, LLC, Senior Secured, Maturity Date May 2030, Prime + 2.45%, Floor rate 9.45%, 3.75% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Curana Health Holdings, LLC, Senior Secured, Maturity Date January 2028, Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Ennoble Care LLC and Senior Secured and Maturity Date February 2030 and Prime + 2.60%, Floor rate 10.35%, 7.95% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Equality Health, LLC, Senior Secured, Maturity Date February 2028, Prime + 5.85%, Floor rate 9.50%, PIK Interest 1.95%, 1.27% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Main Street Rural, Inc., Senior Secured, Maturity Date July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC, Senior Secured, Maturity Date February 2029, Prime + 0.75%, Floor rate 8.75%, PIK Interest 2.25%, 3.00% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC, Senior Secured, Maturity Date February 2029, Prime + 3.00%, Floor rate 11.00%2025-12-310001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC.2025-12-310001280784Debt Investment Healthcare Services, Other and Modern Life, Inc., Senior Secured, Maturity Date February 2029, Prime + 2.75%, Floor rate 10.25%, 5.00% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and NeueHealth, Inc., Maturity Date June 2028, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Octave Health Group, Inc. and Senior Secured and Maturity Date October 2029, Prime + 2.70%, Floor rate 9.95%, 5.35% Exit Fee2025-12-310001280784Debt Investment Healthcare Services, Other and Recover Together, Inc., Senior Secured, Maturity Date July 2027, Prime + 1.90%, Floor rate 9.90%, 7.50% Exit Fee2025-12-310001280784Debt Investment Healthcare Services, Other and Strive Health Holdings, LLC, Senior Secured, Maturity Date August 2029, Prime + 1.05%, Floor rate 9.55%, 5.95% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Tungsten Health Holdings, LLC and Senior Secured and Maturity Date December 2029 and Prime + 1.00%, Floor rate 8.50%, Cap rate 9.00%, PIK Interest 1.25%, 8.35% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and Vida Health, Inc., Senior Secured, Maturity Date January 2028, Prime - 2.75%, Floor rate 5.75%, PIK Interest 5.35%, 4.95% Exit Fee2025-12-310001280784Debt Investments Healthcare Services, Other and WellBe Senior Medical LLC, Senior Secured, Maturity Date May 2029, Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:HealthcareServicesOtherMember2025-12-310001280784Debt Investments Information Services and Saama Technologies, LLC, Senior Secured, Maturity Date July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 3.45% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:InformationServicesMember2025-12-310001280784Debt Investments Manufacturing Technology and VulcanForms Inc. and Senior Secured, Maturity Date January 2028, Prime + 4.25%, Floor rate 11.25%, 4.25% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:ManufacturingTechnologyMember2025-12-310001280784Debt Investments Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Senior Secured, Maturity Date November 2028, Prime + 2.00%, Floor rate 9.50%, 6.35% Exit Fee2025-12-310001280784Debt Investments Medical Devices & Equipment and Senseonics Holdings, Inc., Senior Secured, Maturity Date August 2029, Prime + 2.40%, Floor rate 9.90%, 13.40% Exit Fee2025-12-310001280784Debt Investments Medical Devices & Equipment and Sight Sciences, Inc., Senior Secured, Maturity Date July 2028, Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:MedicalDevicesEquipmentMember2025-12-310001280784Debt Investments Space Technologies and HawkEye 360, Inc. and Senior Secured and Maturity Date December 2028 and Prime + 2.10%, Floor rate 9.35%, PIK Interest 1.50%, 1.95% Exit Fee2025-12-310001280784Debt Investments Space Technologies and Loft Orbital Solutions Inc. and Senior Secured and Maturity Date December 2029 and Prime + 1.75%, Floor rate 8.75%, PIK Interest 1.00%, 3.45% Exit Fee2025-12-310001280784Debt Investments Space Technologies and Stoke Space Technologies, Inc., Senior Secured, Maturity Date May 2029, Prime + 1.00%, Floor rate 7.50%, PIK Interest 2.00%, 5.25% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:SpaceTechnologiesMember2025-12-310001280784Debt Investments Sustainable and Renewable Technology and Electric Hydrogen Co., Senior Secured, Maturity Date May 2028, Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.25% Exit Fee2025-12-310001280784Debt Investments Sustainable and Renewable Technology and Electric Hydrogen Co., Senior Secured, Maturity Date May 2028, Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 5.95% Exit Fee2025-12-310001280784Debt Investments Sustainable and Renewable Technology Total Electric Hydrogen Co.2025-12-310001280784Debt Investments Sustainable and Renewable Technology and Tidal Vision Products, Inc. and Senior Secured and Maturity Date October 2028 and Prime + 2.45%, Floor rate 9.70%, 3.45% Exit Fee2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:SustainableAndRenewableTechnologyMember2025-12-310001280784Debt Investments System Software and Akeyless Security Ltd. and Senior Secured and Maturity Date August 2028 and Prime + 4.00%, Floor rate 11.00%, 2.95% Exit Fee2025-12-310001280784Debt Investments System Software and Armis, Inc. and Senior Secured and Maturity Date March 2028 and Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee2025-12-310001280784Debt Investments System Software and Armis, Inc. and Senior Secured and Maturity Date March 2028 and Prime + 1.25%, Floor rate 8.75%, PIK Interest 2.00%, 2.25% Exit Fee2025-12-310001280784Debt Investments System Software and Total Armis, Inc.2025-12-310001280784Debt Investments System Software and CoreView USA, Inc. and Senior Secured and Maturity Date January 2029 and Prime + 2.75%, Floor rate 9.25%, 4.95% Exit Fee2025-12-310001280784Debt Investments System Software and Coronet Cyber Security Ltd. and Senior Secured and Maturity Date October 2028 and Prime - 2.95%, Floor rate 3.55%, PIK Interest 5.85%2025-12-310001280784Debt Investments System Software and DNSFilter, Inc. and Senior Secured and Maturity Date October 2028 and Prime + 2.15%, Floor rate 8.65%, PIK Interest 0.75%, 4.95% Exit Fee2025-12-310001280784Debt Investments System Software and Harness, Inc. and Senior Secured and Maturity Date March 2029 and Prime - 2.25%, Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee2025-12-310001280784Debt Investments System Software and LogRhythm, Inc. and Senior Secured and Maturity Date July 2029 and 3-month SOFR + 7.50%, Floor rate 8.50%2025-12-310001280784Debt Investments System Software and Morphisec Information Security 2014 Ltd. and Senior Secured and Maturity Date October 2027 and Prime + 3.45%, Floor rate 11.70%, 5.95% Exit Fee2025-12-310001280784Debt Investments System Software and New Relic, Inc. and Senior Secured and Maturity Date November 2030 and 3-month SOFR + 6.75%, Floor rate 7.75%2025-12-310001280784Debt Investments System Software and PayIt, LLC and Senior Secured and Maturity Date December 2028 and Prime + 1.45%, Floor rate 7.95%, PIK Interest 1.50%, 5.00% Exit Fee2025-12-310001280784Debt Investments System Software and Scylla DB Ltd. and Senior Secured and Maturity Date July 2029 and Prime + 3.00%, Floor rate 10.50%, 0.75% Exit Fee2025-12-310001280784Debt Investments System Software and Semperis Technologies Inc. and Senior Secured and Maturity Date April 2028 and Prime - 1.75%, Floor rate 6.75%, PIK Interest 3.25%2025-12-310001280784Debt Investments System Software and Semperis Technologies Inc. and Senior Secured and Maturity Date April 2028 and Prime - 0.50%, Floor rate 8.00%, PIK Interest 3.85%2025-12-310001280784Debt Investments System Software and Total Semperis Technologies Inc.2025-12-310001280784Debt Investments System Software and Sumo Logic, Inc. and Senior Secured and Maturity Date May 2030 and 3-month SOFR + 6.50%, Floor rate 7.50%2025-12-310001280784Debt Investments System Software and Zimperium, Inc. and Senior Secured and Maturity Date May 2027 and 6-month SOFR + 8.31%, Floor rate 9.31%2025-12-310001280784us-gaap:DebtSecuritiesMemberhtgc:SystemSoftwareMember2025-12-310001280784us-gaap:DebtSecuritiesMember2025-12-310001280784Equity Investments Application Software and Black Crow AI, Inc. affiliates and Equity and Acquisition Date 3/24/2021 and Preferred Note2025-01-012025-12-310001280784Equity Investments Application Software and Black Crow AI, Inc. affiliates and Equity and Acquisition Date 3/24/2021 and Preferred Note2025-12-310001280784Equity Investments Application Software and CapLinked, Inc. and Equity and Acquisition Date 10/26/2012 and Preferred Series A-32025-01-012025-12-310001280784Equity Investments Application Software and CapLinked, Inc. and Equity and Acquisition Date 10/26/2012 and Preferred Series A-32025-12-310001280784Equity Investments Application Software and DNAnexus, Inc. and Equity and Acquisition Date 3/21/2014 and Preferred Series C2025-01-012025-12-310001280784Equity Investments Application Software and DNAnexus, Inc. and Equity and Acquisition Date 3/21/2014 and Preferred Series C2025-12-310001280784Equity Investments Application Software and HighRoads, Inc. and Equity and Acquisition Date 1/18/2013 and Common Stock2025-01-012025-12-310001280784Equity Investments Application Software and HighRoads, Inc. and Equity and Acquisition Date 1/18/2013 and Common Stock2025-12-310001280784Equity Investments Application Software and Khoros, LLC and Equity and Acquisition Date 5/23/2025 and Earnout Interest2025-01-012025-12-310001280784Equity Investments Application Software and Khoros, LLC and Equity and Acquisition Date 5/23/2025 and Earnout Interest2025-12-310001280784Equity Investments Application Software and Leapwork ApS and Equity and Acquisition Date 8/25/2023 and Preferred Series B22025-01-012025-12-310001280784Equity Investments Application Software and Leapwork ApS and Equity and Acquisition Date 8/25/2023 and Preferred Series B22025-12-310001280784Equity Investments Application Software and Nextdoor.com, Inc. and Equity and Acquisition Date 8/1/2018 and Common Stock2025-01-012025-12-310001280784Equity Investments Application Software and Nextdoor.com, Inc. and Equity and Acquisition Date 8/1/2018 and Common Stock2025-12-310001280784Equity Investments Application Software and SirionLabs Pte. Ltd. and Equity and Acquisition Date 6/30/2024 and Preferred Series F12025-01-012025-12-310001280784Equity Investments Application Software and SirionLabs Pte. Ltd. and Equity and Acquisition Date 6/30/2024 and Preferred Series F12025-12-310001280784Equity Investments Application Software and Verana Health, Inc. and Equity and Acquisition Date 7/8/2021 and Common Stock2025-01-012025-12-310001280784Equity Investments Application Software and Verana Health, Inc. and Equity and Acquisition Date 7/8/2021 and Common Stock2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:ApplicationSoftwareMember2025-12-310001280784Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C2025-01-012025-12-310001280784Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:BiotechnologyToolsMember2025-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2025-01-012025-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2025-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc. Equity, Acquisition Date 7/16/2013, Series Preferred Series B2025-01-012025-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc. Equity, Acquisition Date 7/16/2013, Series Preferred Series B2025-12-310001280784Equity Investments Consumer & Business Products and Total Fabletics, Inc.2025-12-310001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock2025-01-012025-12-310001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock2025-12-310001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units2025-01-012025-12-310001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:ConsumerBusinessProductsMember2025-12-310001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42025-12-310001280784Equity Investments Consumer & Business Services and Jobandtalent USA, Inc. and Equity and Acquisition Date 2/11/2025 and Preferred Series F2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Jobandtalent USA, Inc. and Equity and Acquisition Date 2/11/2025 and Preferred Series F2025-12-310001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2025-12-310001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2025-12-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2025-12-310001280784Equity, Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-12025-01-012025-12-310001280784Equity, Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-12025-12-310001280784Equity Investments Consumer & Business Services and Total OfferUp, Inc.2025-12-310001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2025-12-310001280784Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2025-12-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2025-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2025-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2025-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2025-12-310001280784Equity Investments Consumer & Business Services and Total Tectura Corporation2025-12-310001280784Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X2025-01-012025-12-310001280784Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:ConsumerBusinessServicesMember2025-12-310001280784Equity Investments Defense Technologies and Shield AI, Inc., Equity and Acquisition Date 2/7/2025 and Series Preferred Series F12025-01-012025-12-310001280784Equity Investments Defense Technologies and Shield AI, Inc., Equity and Acquisition Date 2/7/2025 and Series Preferred Series F12025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:DefenseTechnologiesMember2025-12-310001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition LLC, Equity, Acquisition Date 3/1/2018, Series Member Units2025-01-012025-12-310001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition LLC, Equity, Acquisition Date 3/1/2018, Series Member Units2025-12-310001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2025-01-012025-12-310001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2025-12-310001280784Equity Investments Diversified Financial Services, Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22025-01-012025-12-310001280784Equity Investments Diversified Financial Services, Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:DiversifiedFinancialServicesMember2025-12-310001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2025-12-310001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2025-01-012025-12-310001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2025-12-310001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2025-12-310001280784Equity Investments Drug Delivery and Talphera, Inc., Equity, Acquisition Date 12/10/2018, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Delivery and Talphera, Inc., Equity, Acquisition Date 12/10/2018, Series Common Stock2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:DrugDeliveryMember2025-12-310001280784Equity Investments Drug Discovery & Development and Arcus Biosciences, Inc., Equity, Acquisition Date 2/19/2025, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Arcus Biosciences, Inc., Equity, Acquisition Date 2/19/2025, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/05/2020, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/05/2020, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Dyne Therapeutics, Inc., Equity, Acquisition Date 7/2/2025, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Dyne Therapeutics, Inc., Equity, Acquisition Date 7/2/2025, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2025-12-310001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and MoonLake Immunotherapeutics, Equity, Acquisition Date 11/6/2025, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and MoonLake Immunotherapeutics, Equity, Acquisition Date 11/6/2025, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2025-12-310001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Rafael Holdings, Inc. (p.k.a. Cyclo Therapeutics, Inc.), Equity, Acquisition Date 4/6/2021, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Rafael Holdings, Inc. (p.k.a. Cyclo Therapeutics, Inc.), Equity, Acquisition Date 4/6/2021, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2025-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2025-12-310001280784Equity Investments Drug Discovery & Development and Total Valo Health, LLC2025-12-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2025-12-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 7/2/2025, Series SAFE2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 7/2/2025, Series SAFE2025-12-310001280784Equity Investments Drug Discovery & Development and Total Verge Analytics, Inc.2025-12-310001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2025-12-310001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2025-01-012025-12-310001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:DrugDiscoveryDevelopmentMember2025-12-310001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2025-01-012025-12-310001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2025-12-310001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2025-01-012025-12-310001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:ElectronicsComputerHardwareMember2025-12-310001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C2025-01-012025-12-310001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C2025-12-310001280784Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock2025-01-012025-12-310001280784Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock2025-12-310001280784Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units2025-01-012025-12-310001280784Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units2025-12-310001280784Equity Investments Healthcare Services, Other and Main Street Rural, Inc., Equity, Acquisition Date 10/28/2024, Series Preferred Series D2025-01-012025-12-310001280784Equity Investments Healthcare Services, Other and Main Street Rural, Inc., Equity, Acquisition Date 10/28/2024, Series Preferred Series D2025-12-310001280784Equity Investments Healthcare Services, Other and NH Holdings 2025 SPV, L.P., Equity, Acquisition Date 6/21/2024, Series Common Units2025-01-012025-12-310001280784Equity Investments Healthcare Services, Other and NH Holdings 2025 SPV, L.P., Equity, Acquisition Date 6/21/2024, Series Common Units2025-12-310001280784Equity Investments Healthcare Services, Other and Strive Health Holdings, LLC, Equity, Acquisition Date 6/27/2025, Series Common Units2025-01-012025-12-310001280784Equity Investments Healthcare Services, Other and Strive Health Holdings, LLC, Equity, Acquisition Date 6/27/2025, Series Common Units2025-12-310001280784Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units2025-01-012025-12-310001280784Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:HealthcareServicesOtherMember2025-12-310001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2025-01-012025-12-310001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:InformationServicesMember2025-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2025-01-012025-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2025-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22025-01-012025-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22025-12-310001280784Equity Investments Medical Devices & Equipment and Total Coronado Aesthetics, LLC2025-12-310001280784Equity Investments Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Equity, Acquisition Date 8/4/2025, Series Common Stock2025-01-012025-12-310001280784Equity Investments Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Equity, Acquisition Date 8/4/2025, Series Common Stock2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:MedicalDevicesEquipmentMember2025-12-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2025-01-012025-12-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2025-12-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 6/26/2015, Series Preferred Series D-22025-01-012025-12-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 6/26/2015, Series Preferred Series D-22025-12-310001280784Equity Investments Semiconductors and Total Achronix Semiconductor Corporation2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:SemiconductorsMember2025-12-310001280784Equity Investments Space Technologies and Stoke Space Technologies, Inc., Equity, Acquisition Date 9/23/2025, Series Preferred Series D2025-01-012025-12-310001280784Equity Investments Space Technologies and Stoke Space Technologies, Inc., Equity, Acquisition Date 9/23/2025, Series Preferred Series D2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:SpaceTechnologiesMember2025-12-310001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12025-01-012025-12-310001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12025-12-310001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2025-01-012025-12-310001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2025-12-310001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2025-01-012025-12-310001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2025-12-310001280784Equity Investments Sustainable and Renewable Technology and SUNation Energy, Inc., Equity, Acquisition Date 12/10/2020, Series Common Stock2025-01-012025-12-310001280784Equity Investments Sustainable and Renewable Technology and SUNation Energy, Inc., Equity, Acquisition Date 12/10/2020, Series Common Stock2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:SustainableAndRenewableTechnologyMember2025-12-310001280784Equity Investments System Software and Armis, Inc., Equity, Acquisition Date 10/18/2024, Series Preferred Series D2025-01-012025-12-310001280784Equity Investments System Software and Armis, Inc., Equity, Acquisition Date 10/18/2024, Series Preferred Series D2025-12-310001280784Equity Investments System Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2025-01-012025-12-310001280784Equity Investments System Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2025-12-310001280784Equity Investments System Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2025-01-012025-12-310001280784Equity Investments System Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2025-12-310001280784Equity Investments System Software and Total Contentful Global, Inc.2025-12-310001280784Equity Investments System Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2025-01-012025-12-310001280784Equity Investments System Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2025-12-310001280784Equity Investments System Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22025-01-012025-12-310001280784Equity Investments System Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22025-12-310001280784Equity Investments System Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32025-01-012025-12-310001280784Equity Investments System Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32025-12-310001280784Equity Investments System Software, Total Druva Holdings, Inc.2025-12-310001280784Equity Investments System Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2025-01-012025-12-310001280784Equity Investments System Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:SystemSoftwareMember2025-12-310001280784us-gaap:EquitySecuritiesMember2025-12-310001280784Warrant Investments and Application Software and Annex Cloud, Warrant, Acquisition Date 6/5/2025, Series Common Units2025-01-012025-12-310001280784Warrant Investments and Application Software and Annex Cloud, Warrant, Acquisition Date 6/5/2025, Series Common Units2025-12-310001280784Warrant Investments and Application Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Carbyne, Inc., Warrant, Acquisition Date 2/24/2025, Series Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and Application Software and Carbyne, Inc., Warrant, Acquisition Date 2/24/2025, Series Ordinary Shares2025-12-310001280784Warrant Investments and Application Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2025-01-012025-12-310001280784Warrant Investments and Application Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2025-12-310001280784Warrant Investments and Application Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Distributed Creation Inc., Warrant, Acquisition Date 4/21/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Distributed Creation Inc., Warrant, Acquisition Date 4/21/2025, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2025-01-012025-12-310001280784Warrant Investments and Application Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2025-12-310001280784Warrant Investments and Application Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Funnel Holding AB (publ), Warrant, Acquisition Date 10/24/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Funnel Holding AB (publ), Warrant, Acquisition Date 10/24/2025, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Imagen Technologies, Inc., Warrant, Acquisition Date 11/26/2025, Series Preferred Series C-3-VI2025-01-012025-12-310001280784Warrant Investments and Application Software and Imagen Technologies, Inc., Warrant, Acquisition Date 11/26/2025, Series Preferred Series C-3-VI2025-12-310001280784Warrant Investments and Application Software and Kore.ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2025-01-012025-12-310001280784Warrant Investments and Application Software and Kore.ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2025-12-310001280784Warrant Investments and Application Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Mango Technologies, Inc., Warrant, Acquisition Date 8/15/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Mango Technologies, Inc., Warrant, Acquisition Date 8/15/2025, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Sisense Ltd., Warrant, Acquisition Date 6/8/2023, Series Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and Application Software and Sisense Ltd., Warrant, Acquisition Date 6/8/2023, Series Ordinary Shares2025-12-310001280784Warrant Investments and Application Software and Suzy, Inc., Warrant, Acquisition Date 8/24/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Suzy, Inc., Warrant, Acquisition Date 8/24/2023, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and Application Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2025-12-310001280784Warrant Investments and Application Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/27/2025, Series Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and Application Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/27/2025, Series Ordinary Shares2025-12-310001280784Warrant Investments and Application Software and Total Tipalti Solutions Ltd.2025-12-310001280784Warrant Investments and Application Software and Ushur, Inc., Warrant, Acquisition Date 6/5/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and Ushur, Inc., Warrant, Acquisition Date 6/5/2025, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2025-12-310001280784Warrant Investments and Application Software and ZeroEyes, Inc., Warrant, Acquisition Date 5/6/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Application Software and ZeroEyes, Inc., Warrant, Acquisition Date 5/6/2025, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:ApplicationSoftwareMember2025-12-310001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C2025-01-012025-12-310001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C2025-12-310001280784Warrant Investments and Biotechnology Tools and Antheia, Inc., Warrant, Acquisition Date 8/29/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Biotechnology Tools and Antheia, Inc., Warrant, Acquisition Date 8/29/2025, Series Common Stock2025-12-310001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:BiotechnologyToolsMember2025-12-310001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:CommunicationsNetworkingMember2025-12-310001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:ConsumerBusinessProductsMember2025-12-310001280784Warrant Investments and Consumer & Business Services and Altumint, Inc., Warrant, Acquisition Date 10/31/2024, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Altumint, Inc., Warrant, Acquisition Date 10/31/2024, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and AppDirect, Inc., Warrant, Acquisition Date 9/22/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and AppDirect, Inc., Warrant, Acquisition Date 9/22/2025, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-42025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-42025-12-310001280784Warrant Investments and Consumer & Business Services and Total Carwow LTD2025-12-310001280784Warrant Investments and Consumer & Business Services and Finix Payment, Inc., Warrant, Acquisition Date 12/17/2025, Series Preferred Series C2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Finix Payment, Inc., Warrant, Acquisition Date 12/17/2025, Series Preferred Series C2025-12-310001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2025-12-310001280784Warrant Investments and Consumer & Business Services and Peek Travel, Inc., Warrant, Acquisition Date 10/28/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Peek Travel, Inc., Warrant, Acquisition Date 10/28/2025, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary Shares2025-12-310001280784Warrant Investments and Consumer & Business Services and Provi., Warrant, Acquisition Date 12/22/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Provi., Warrant, Acquisition Date 12/22/2022, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2025-12-310001280784Warrant Investments and Consumer & Business Services and Total Skyword, Inc.2025-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2025-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2025-12-310001280784Warrant Investments and Consumer & Business Services and Total Snagajob.com, Inc.2025-12-310001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2025-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2025-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2025-01-012025-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2025-12-310001280784Warrant Investments and Consumer & Business Services and Total Worldremit Group Limited2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:ConsumerBusinessServicesMember2025-12-310001280784Warrant Investments and Defense Technologies and Saronic Technologies, Inc., Warrant, Acquisition Date 6/9/2025, Series Preferred Series C2025-01-012025-12-310001280784Warrant Investments and Defense Technologies and Saronic Technologies, Inc., Warrant, Acquisition Date 6/9/2025, Series Preferred Series C2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:DiversifiedFinancialServicesMember2025-12-310001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and Beren Therapeutics P.B.C., Warrant, Acquisition Date 10/8/2025, Series Preferred Series A+2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Beren Therapeutics P.B.C., Warrant, Acquisition Date 10/8/2025, Series Preferred Series A+2025-12-310001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2025-12-310001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2025-12-310001280784Warrant Investments and Drug Discovery & Development and Cuervo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Cuervo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2025-12-310001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B2025-12-310001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 12/30/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 12/30/2021, Series Common Stock2025-12-310001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units2025-12-310001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:DrugDiscoveryDevelopmentMember2025-12-310001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2025-12-310001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2025-12-310001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:ElectronicsComputerHardwareMember2025-12-310001280784Warrant Investments and Healthcare Services, Other and Belong Health, Inc., Warrant, Acquisition Date 11/13/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Healthcare Services, Other and Belong Health, Inc., Warrant, Acquisition Date 11/13/2025, Series Common Stock2025-12-310001280784Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC, Warrant, Acquisition Date 1/4/2024, Series Common Units2025-01-012025-12-310001280784Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC, Warrant, Acquisition Date 1/4/2024, Series Common Units2025-12-310001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc, Warrant, Acquisition Date 3/30/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc, Warrant, Acquisition Date 3/30/2023, Series Common Stock2025-12-310001280784Warrant Investments and Healthcare Services, Other and Octave Health Group, Inc., Warrant, Acquisition Date 11/28/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Healthcare Services, Other and Octave Health Group, Inc., Warrant, Acquisition Date 11/28/2025, Series Common Stock2025-12-310001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc., Warrant, Acquisition Date 7/3/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc., Warrant, Acquisition Date 7/3/2023, Series Common Stock2025-12-310001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC, Warrant, Acquisition Date 9/28/2023, Series Common Units2025-01-012025-12-310001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC, Warrant, Acquisition Date 9/28/2023, Series Common Units2025-12-310001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E2025-01-012025-12-310001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:HealthcareServicesOtherMember2025-12-310001280784Warrant Investments and Information Services and NetBase Quid, Inc., Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12025-01-012025-12-310001280784Warrant Investments and Information Services and NetBase Quid, Inc., Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12025-12-310001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:InformationServicesMember2025-12-310001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2025-12-310001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2025-12-310001280784Warrant Investments and Manufacturing Technology and VulcanForms Inc., Warrant, Acquisition Date 1/30/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Manufacturing Technology and VulcanForms Inc., Warrant, Acquisition Date 1/30/2025, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:ManufacturingTechnologyMember2025-12-310001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12025-01-012025-12-310001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12025-12-310001280784htgc:WarrantInvestmentMemberhtgc:MediaContentInfoMember2025-12-310001280784Warrant Investments and Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Warrant, Acquisition Date 11/6/2024, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Warrant, Acquisition Date 11/6/2024, Series Common Stock2025-12-310001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc, Warrant, Acquisition Date 9/8/2023, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc, Warrant, Acquisition Date 9/8/2023, Series Common Stock2025-12-310001280784Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock2025-12-310001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:MedicalDevicesEquipmentMember2025-12-310001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 1/11/2017, Series Preferred Series D-22025-01-012025-12-310001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 1/11/2017, Series Preferred Series D-22025-12-310001280784htgc:WarrantInvestmentMemberhtgc:SemiconductorsMember2025-12-310001280784Warrant Investments and Space Technologies and HawkEye 360, Inc. and Warrant and 12/18/2025 and Common Stock2025-01-012025-12-310001280784Warrant Investments and Space Technologies and HawkEye 360, Inc. and Warrant and 12/18/2025 and Common Stock2025-12-310001280784Warrant Investments and Space Technologies and Loft Orbital Solutions Inc. and Warrant and 9/10/2025 and Common Stock2025-01-012025-12-310001280784Warrant Investments and Space Technologies and Loft Orbital Solutions Inc. and Warrant and 9/10/2025 and Common Stock2025-12-310001280784Warrant Investments and Space Technologies and Stoke Space Technologies, Inc., Warrant, Acquisition Date 6/16/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Space Technologies and Stoke Space Technologies, Inc., Warrant, Acquisition Date 6/16/2025, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:SpaceTechnologiesMember2025-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2025-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common Stock2025-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Tidal Vision Products, Inc., Warrant, Acquisition Date 10/10/2025, Series Common Stock2025-01-012025-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Tidal Vision Products, Inc., Warrant, Acquisition Date 10/10/2025, Series Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:SustainableAndRenewableTechnologyMember2025-12-310001280784Warrant Investments and System Software and Akeyless Security Ltd. and Warrant, Acquisition Date 8/4/2025 and Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and System Software and Akeyless Security Ltd. and Warrant, Acquisition Date 8/4/2025 and Ordinary Shares2025-12-310001280784Warrant Investments and System Software and CloudBolt Software, Inc. and Warrant, Acquisition Date 9/30/2020 and Common Stock2025-01-012025-12-310001280784Warrant Investments and System Software and CloudBolt Software, Inc. and Warrant, Acquisition Date 9/30/2020 and Common Stock2025-12-310001280784Warrant Investments and System Software and Cloudian, Inc. and Warrant, Acquisition Date 11/6/2018 and Common Stock2025-01-012025-12-310001280784Warrant Investments and System Software and Cloudian, Inc. and Warrant, Acquisition Date 11/6/2018 and Common Stock2025-12-310001280784Warrant Investments and System Software and Coronet Cyber Security Ltd. and Warrant, Acquisition Date 9/26/2024 and Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and System Software and Coronet Cyber Security Ltd. and Warrant, Acquisition Date 9/26/2024 and Ordinary Shares2025-12-310001280784Warrant Investments and System Software and Dragos, Inc. and Warrant, Acquisition Date 6/28/2023 and Common Stock2025-01-012025-12-310001280784Warrant Investments and System Software and Dragos, Inc. and Warrant, Acquisition Date 6/28/2023 and Common Stock2025-12-310001280784Warrant Investments and System Software and Harness, Inc. and Warrant, Acquisition Date 3/12/2024 and Common Stock2025-01-012025-12-310001280784Warrant Investments and System Software and Harness, Inc. and Warrant, Acquisition Date 3/12/2024 and Common Stock2025-12-310001280784Warrant Investments and System Software and Lightbend, Inc. and Warrant, Acquisition Date 2/14/2018 and Preferred Series LB-22025-01-012025-12-310001280784Warrant Investments and System Software and Lightbend, Inc. and Warrant, Acquisition Date 2/14/2018 and Preferred Series LB-22025-12-310001280784Warrant Investments and System Software and Morphisec Information Security 2014 Ltd. and Warrant, Acquisition Date 10/1/2024 and Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and System Software and Morphisec Information Security 2014 Ltd. and Warrant, Acquisition Date 10/1/2024 and Ordinary Shares2025-12-310001280784Warrant Investments and System Software and Scylla DB Ltd. and Warrant, Acquisition Date 7/24/2025 and Ordinary Shares2025-01-012025-12-310001280784Warrant Investments and System Software and Scylla DB Ltd. and Warrant, Acquisition Date 7/24/2025 and Ordinary Shares2025-12-310001280784Warrant Investments and System Software and Semperis Technologies Inc. and Warrant, Acquisition Date 4/23/2024 and Common Stock2025-01-012025-12-310001280784Warrant Investments and System Software and Semperis Technologies Inc. and Warrant, Acquisition Date 4/23/2024 and Common Stock2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:SystemSoftwareMember2025-12-310001280784htgc:WarrantInvestmentMember2025-12-310001280784htgc:InvestmentsInSecuritiesMember2025-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202025-01-012025-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202025-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222025-01-012025-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222025-12-310001280784htgc:InvestmentFundAndVehicleInvestmentsMemberhtgc:DrugDiscoveryDevelopmentMember2025-12-310001280784Investment Funds & Vehicles Investments and System Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222025-01-012025-12-310001280784Investment Funds & Vehicles Investments and System Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222025-12-310001280784htgc:InvestmentFundAndVehicleInvestmentsMemberhtgc:SystemSoftwareMember2025-12-310001280784htgc:InvestmentFundAndVehicleInvestmentsMember2025-12-310001280784htgc:InvestmentsBeforeCashAndCashEquivalentsMember2025-12-310001280784Investment Fund Cash & Cash Equivalent and GS Financial Square Government Fund, Series FGTXX/38141W2732025-12-310001280784htgc:InvestmentsCashAndCashEquivalentsMember2025-12-310001280784htgc:InvestmentsAfterCashAndCashEquivalentsMember2025-12-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/5/20262025-01-012025-12-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/5/20262025-12-310001280784htgc:OneMonthSOFRMember2025-12-310001280784htgc:ThreeMonthSOFRMember2025-12-310001280784htgc:SixMonthSOFRMember2025-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:WarrantMember2025-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:CommonStockMember2025-12-310001280784htgc:PromissoryNotesMemberhtgc:BlackCrowAIIncMember2025-12-310001280784htgc:RoyaltyContractMemberhtgc:PhathomPharmaceuticalsIncMember2025-12-310001280784Equity Investments Application Software and Khoros, LLC., Equity, Acquisition Date 5/23/2025, Series Earnout Interest2025-12-3100012807842025-01-012025-12-310001280784us-gaap:MoneyMarketFundsMember2026-03-310001280784us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001280784us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001280784us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784htgc:EscrowAndOtherInvestmentReceivableMember2026-03-310001280784htgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMember2026-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784htgc:SeniorSecuredDebtMember2026-03-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:UnsecuredDebtMember2026-03-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:PreferredStockMember2026-03-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:CommonStockMember2026-03-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel1Member2026-03-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:WarrantMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Member2026-03-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:FairValueInputsLevel1Member2026-03-310001280784us-gaap:FairValueInputsLevel2Member2026-03-310001280784us-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:PrivateEquityFundsForeignMember2026-03-310001280784htgc:IncludingCashAndCashEquivalentMember2026-03-310001280784htgc:DerivativeInstrumentMember2026-03-310001280784htgc:IncludingCashAndCashEquivalentsAndDerivativeInstrumentsMember2026-03-310001280784us-gaap:MoneyMarketFundsMember2025-12-310001280784us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001280784us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001280784us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784htgc:EscrowAndOtherInvestmentReceivableMember2025-12-310001280784htgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMember2025-12-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784htgc:SeniorSecuredDebtMember2025-12-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:UnsecuredDebtMember2025-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:PreferredStockMember2025-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:CommonStockMember2025-12-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel1Member2025-12-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:WarrantMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Member2025-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:FairValueInputsLevel1Member2025-12-310001280784us-gaap:FairValueInputsLevel2Member2025-12-310001280784us-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:PrivateEquityFundsForeignMember2025-12-310001280784htgc:IncludingCashAndCashEquivalentMember2025-12-310001280784htgc:DerivativeInstrumentMember2025-12-310001280784htgc:IncludingCashAndCashEquivalentsAndDerivativeInstrumentsMember2025-12-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784us-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueInputsLevel3Member2024-12-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784htgc:SeniorSecuredDebtMemberus-gaap:FairValueInputsLevel3Member2025-03-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Member2024-12-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784us-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel3Member2025-03-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Member2024-12-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784us-gaap:PreferredStockMemberus-gaap:FairValueInputsLevel3Member2025-03-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Member2024-12-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784us-gaap:CommonStockMemberus-gaap:FairValueInputsLevel3Member2025-03-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2025-03-310001280784htgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueInputsLevel3Member2024-12-310001280784htgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784htgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueInputsLevel3Member2025-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2024-12-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2025-03-310001280784us-gaap:FairValueInputsLevel3Member2024-12-310001280784us-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Member2025-03-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784htgc:PreferredStockInvestmentMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784htgc:PreferredStockInvestmentMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784htgc:CommonStockInvestmentMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784htgc:CommonStockInvestmentMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784htgc:WarrantInvestmentMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001280784htgc:WarrantInvestmentMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001280784htgc:DebtInvestmentsMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMember2026-03-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsImminentPayoffsMember2026-03-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtMaturingWithinOneYearMember2026-03-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsInWhollyOwnedSubsidiariesMember2026-03-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueExpectedProceedsMember2026-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMember2026-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:MinimumMember2026-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:MaximumMember2026-03-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:WeightedAverageMember2026-03-310001280784htgc:DebtInvestmentsAndOtherInvestmentReceivablesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784htgc:DebtInvestmentsMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:PharmaceuticalsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:IncomeApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:TechnologyMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:MedicalDevicesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784htgc:DebtInvestmentsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberhtgc:LowerMiddleMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMember2025-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsImminentPayoffsMember2025-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtMaturingWithinOneYearMember2025-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsInWhollyOwnedSubsidiariesMember2025-12-310001280784htgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784htgc:EscrowReceivableMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueExpectedProceedsMember2025-12-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMember2025-12-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:MinimumMember2025-12-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:MaximumMember2025-12-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMembersrt:WeightedAverageMember2025-12-310001280784htgc:DebtInvestmentsAndOtherInvestmentReceivablesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMember2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:MinimumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:MaximumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:WeightedAverageMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:WeightedAverageMember2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMember2026-03-310001280784us-gaap:WarrantMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:MinimumMember2026-03-310001280784us-gaap:WarrantMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:MaximumMember2026-03-310001280784us-gaap:WarrantMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:WeightedAverageMember2026-03-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMember2026-03-310001280784htgc:EquityAndWarrantInvestmentsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMember2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:MinimumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:MaximumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:WeightedAverageMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:WeightedAverageMember2025-12-310001280784us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:WeightedAverageMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMember2025-12-310001280784us-gaap:WarrantMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:MinimumMember2025-12-310001280784us-gaap:WarrantMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:MaximumMember2025-12-310001280784us-gaap:WarrantMemberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMembersrt:WeightedAverageMember2025-12-310001280784us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMember2025-12-310001280784htgc:EquityAndWarrantInvestmentsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SBADebenturesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:SBADebenturesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:SBADebenturesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:SBADebenturesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:SBADebenturesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:SeptemberTwoThousandTwentySixNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:SeptemberTwoThousandTwentySixNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:SeptemberTwoThousandTwentySixNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:JanuaryTwoThousandTwentySevenNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:JanuaryTwoThousandTwentySevenNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:JanuaryTwoThousandTwentySevenNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandTwentyEightConvertibleNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandTwentyEightConvertibleNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:TwoThousandTwentyEightConvertibleNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandTwentyEightConvertibleNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:TwoThousandTwentyEightConvertibleNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:TwoThousandTwentyEightConvertibleNotesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyNineNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyNineNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:FebruaryTwoThousandTwentyNineNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:FebruaryTwoThousandTwentyNineNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:FebruaryTwoThousandTwentyNineNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:FebruaryTwoThousandTwentyNineNotesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandAndThirtyNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandAndThirtyNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:JuneTwoThousandAndThirtyNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:JuneTwoThousandAndThirtyNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:JuneTwoThousandAndThirtyNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:JuneTwoThousandAndThirtyNotesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:MUFGBankFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:MUFGBankFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:MUFGBankFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:MUFGBankFacilityMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SMBCFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:SMBCFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:SMBCFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:SMBCFacilityMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberhtgc:SMBCFacilityMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2026-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2026-03-310001280784htgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784htgc:UnderwritingMemberhtgc:TwoThousandThirtyThreeNotesMember2025-12-310001280784htgc:UnderwritingMemberhtgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SBADebenturesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:SBADebenturesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:SBADebenturesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:SBADebenturesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:MarchTwoThousandTwentySixANotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:MarchTwoThousandTwentySixANotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:MarchTwoThousandTwentySixANotesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:MarchTwoThousandTwentySixBNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:MarchTwoThousandTwentySixBNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:MarchTwoThousandTwentySixBNotesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:SeptemberTwoThousandTwentySixNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:SeptemberTwoThousandTwentySixNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:SeptemberTwoThousandTwentySixNotesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:JanuaryTwoThousandTwentySevenNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:JanuaryTwoThousandTwentySevenNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:JanuaryTwoThousandTwentySevenNotesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandTwentyEightConvertibleNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandTwentyEightConvertibleNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:TwoThousandTwentyEightConvertibleNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandTwentyEightConvertibleNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:TwoThousandTwentyEightConvertibleNotesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandAndThirtyNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandAndThirtyNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:JuneTwoThousandAndThirtyNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:JuneTwoThousandAndThirtyNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:JuneTwoThousandAndThirtyNotesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:TwoThousandThirtyThreeNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:TwoThousandThirtyThreeNotesMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:TwoThousandThirtyThreeNotesMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:MUFGBankFacilityMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:MUFGBankFacilityMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:MUFGBankFacilityMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SMBCFacilityMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberhtgc:SMBCFacilityMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberhtgc:SMBCFacilityMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberhtgc:SMBCFacilityMember2025-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2025-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2025-12-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2025-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:GibraltarAcquisitionLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:GibraltarAcquisitionLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:HerculesAdviserLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:HerculesAdviserLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:TecturaCorporationMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:TecturaCorporationMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:GibraltarAcquisitionLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:GibraltarAcquisitionLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:HerculesAdviserLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:HerculesAdviserLLCMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:TecturaCorporationMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:TecturaCorporationMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-03-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-12-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-03-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-01-012026-03-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-12-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-12-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-03-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-01-012026-03-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-12-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-12-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-03-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-01-012026-03-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-12-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-03-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-12-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-03-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-12-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-03-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-12-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-12-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:CHus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:CHus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:CHus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:CHus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:SEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:SEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:SEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:SEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-03-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2026-01-012026-03-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-12-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ApplicationSoftwareMember2026-03-310001280784htgc:ApplicationSoftwareMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ApplicationSoftwareMember2025-12-310001280784htgc:ApplicationSoftwareMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DrugDiscoveryDevelopmentMember2026-03-310001280784htgc:DrugDiscoveryDevelopmentMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DrugDiscoveryDevelopmentMember2025-12-310001280784htgc:DrugDiscoveryDevelopmentMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:HealthcareServicesOtherMember2026-03-310001280784htgc:HealthcareServicesOtherMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:HealthcareServicesOtherMember2025-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:SystemSoftwareMember2026-03-310001280784htgc:SystemSoftwareMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:SystemSoftwareMember2025-12-310001280784htgc:SystemSoftwareMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ConsumerBusinessServicesMember2026-03-310001280784htgc:ConsumerBusinessServicesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ConsumerBusinessServicesMember2025-12-310001280784htgc:ConsumerBusinessServicesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DefenseTechnologiesMember2026-03-310001280784htgc:DefenseTechnologiesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DefenseTechnologiesMember2025-12-310001280784htgc:DefenseTechnologiesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DiversifiedFinancialServicesMember2026-03-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DiversifiedFinancialServicesMember2025-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:MedicalDevicesEquipmentMember2026-03-310001280784htgc:MedicalDevicesEquipmentMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:MedicalDevicesEquipmentMember2025-12-310001280784htgc:MedicalDevicesEquipmentMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ElectronicsComputerHardwareMember2026-03-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ElectronicsComputerHardwareMember2025-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:SpaceTechnologiesMember2026-03-310001280784htgc:SpaceTechnologiesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:SpaceTechnologiesMember2025-12-310001280784htgc:SpaceTechnologiesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ConsumerBusinessProductsMember2026-03-310001280784htgc:ConsumerBusinessProductsMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ConsumerBusinessProductsMember2025-12-310001280784htgc:ConsumerBusinessProductsMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:SustainableAndRenewableTechnologyMember2026-03-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:SustainableAndRenewableTechnologyMember2025-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:CommunicationsNetworkingMember2026-03-310001280784htgc:CommunicationsNetworkingMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:CommunicationsNetworkingMember2025-12-310001280784htgc:CommunicationsNetworkingMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:InformationServicesMember2026-03-310001280784htgc:InformationServicesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:InformationServicesMember2025-12-310001280784htgc:InformationServicesMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:BiotechnologyToolsMember2026-03-310001280784htgc:BiotechnologyToolsMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:BiotechnologyToolsMember2025-12-310001280784htgc:BiotechnologyToolsMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ManufacturingTechnologyMember2026-03-310001280784htgc:ManufacturingTechnologyMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:ManufacturingTechnologyMember2025-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:SemiconductorsMember2026-03-310001280784htgc:SemiconductorsMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:SemiconductorsMember2025-12-310001280784htgc:SemiconductorsMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:MediaContentInfoMember2026-03-310001280784htgc:MediaContentInfoMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:MediaContentInfoMember2025-12-310001280784htgc:MediaContentInfoMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DrugDeliveryMember2026-03-310001280784htgc:DrugDeliveryMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:DrugDeliveryMember2025-12-310001280784htgc:DrugDeliveryMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:TotalIndustrySectorsMember2026-03-310001280784htgc:TotalIndustrySectorsMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:IndustrySubSectorConcentrationRiskMemberhtgc:TotalIndustrySectorsMember2025-12-310001280784htgc:TotalIndustrySectorsMemberhtgc:IndustrySubSectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2025-01-012025-12-310001280784us-gaap:CreditConcentrationRiskMember2026-03-310001280784us-gaap:CreditConcentrationRiskMember2025-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMemberhtgc:AllAssetsIncludingIntellectualPropertyMember2026-01-012026-03-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMemberhtgc:AllAssetsIncludingIntellectualPropertyMember2025-01-012025-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMemberhtgc:AllAssetsWithNegativePledgeOnIntellectualPropertyMember2026-01-012026-03-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMemberhtgc:AllAssetsWithNegativePledgeOnIntellectualPropertyMember2025-01-012025-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMemberhtgc:LastOutWithSecurityInterestInAllOfTheAssetsMember2026-01-012026-03-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMemberhtgc:LastOutWithSecurityInterestInAllOfTheAssetsMember2025-01-012025-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:SecondLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:SecondLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:UnsecuredMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:UnsecuredMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-12-310001280784htgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2026-01-012026-03-310001280784htgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-12-310001280784us-gaap:ForeignExchangeForwardMember2026-03-310001280784us-gaap:ForeignExchangeForwardMember2025-12-310001280784us-gaap:ForeignExchangeForwardMember2026-01-012026-03-310001280784us-gaap:ForeignExchangeForwardMember2025-01-012025-03-310001280784htgc:ContractualInterestIncomeMember2026-01-012026-03-310001280784htgc:ContractualInterestIncomeMember2025-01-012025-03-310001280784htgc:ExitFeeMember2026-01-012026-03-310001280784htgc:ExitFeeMember2025-01-012025-03-310001280784htgc:PIKInterestMember2026-01-012026-03-310001280784htgc:PIKInterestMember2025-01-012025-03-310001280784htgc:DividendIncomeMember2026-01-012026-03-310001280784htgc:DividendIncomeMember2025-01-012025-03-310001280784htgc:OtherInterestIncomeMember2026-01-012026-03-310001280784htgc:OtherInterestIncomeMember2025-01-012025-03-310001280784htgc:RecurringFeeIncomeMember2026-01-012026-03-310001280784htgc:RecurringFeeIncomeMember2025-01-012025-03-310001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2026-01-012026-03-310001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2025-01-012025-03-310001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2026-01-012026-03-310001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2025-01-012025-03-310001280784htgc:IncludedInCostMember2026-03-310001280784htgc:IncludedInCostMember2025-12-310001280784htgc:DeferredFeesMember2026-03-310001280784htgc:DeferredFeesMember2025-12-310001280784htgc:SBADebenturesMember2026-03-310001280784htgc:SBADebenturesMember2025-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2026-03-310001280784htgc:MarchTwoThousandTwentySixANotesMember2025-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2026-03-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2025-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2026-03-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2025-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2026-03-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2025-12-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2026-03-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-12-310001280784htgc:FebruaryTwoThousandTwentyNineNotesMember2026-03-310001280784htgc:FebruaryTwoThousandTwentyNineNotesMember2025-12-310001280784htgc:JuneTwoThousandThirtyNotesMember2026-03-310001280784htgc:JuneTwoThousandThirtyNotesMember2025-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2026-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2025-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2026-03-310001280784htgc:TwoThousandThirtyThreeNotesMember2025-12-310001280784htgc:MUFGBankFacilityMember2026-03-310001280784htgc:MUFGBankFacilityMember2025-12-310001280784htgc:SMBCFacilityMember2026-03-310001280784htgc:SMBCFacilityMember2025-12-310001280784htgc:SmbcLcFacilityMemberhtgc:SMBCFacilityMember2025-12-310001280784htgc:SmbcLcFacilityMemberhtgc:SMBCFacilityMember2026-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2026-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2025-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2025-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2026-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourAndSBICMember2025-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourAndSBICMember2026-03-310001280784htgc:SMBCFacilityMemberhtgc:TermLoanMember2026-03-310001280784htgc:SMBCFacilityMemberhtgc:TermLoanMember2025-12-310001280784htgc:DebtIssuanceCostsNetAndOtherAssetsMember2026-03-310001280784htgc:DebtIssuanceCostsNetAndOtherAssetsMember2025-12-310001280784us-gaap:RevolvingCreditFacilityMemberhtgc:SMBCFacilityMemberus-gaap:LineOfCreditMember2026-03-310001280784us-gaap:RevolvingCreditFacilityMemberhtgc:SMBCFacilityMemberus-gaap:LineOfCreditMember2025-12-310001280784htgc:SBADebenturesMember2026-01-012026-03-310001280784htgc:MarchTwoThousandTwentySixANotesMember2026-01-012026-03-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2026-01-012026-03-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2026-01-012026-03-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2026-01-012026-03-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2026-01-012026-03-310001280784htgc:FebruaryTwoThousandTwentyNineNotesMember2026-01-012026-03-310001280784htgc:JuneTwoThousandThirtyNotesMember2026-01-012026-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2026-01-012026-03-310001280784htgc:TwoThousandThirtyThreeNotesMember2026-01-012026-03-310001280784htgc:MUFGBankFacilityMember2026-01-012026-03-310001280784htgc:SMBCFacilityMember2026-01-012026-03-310001280784htgc:SBADebenturesMember2025-01-012025-03-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2025-01-012025-03-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2025-01-012025-03-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2025-01-012025-03-310001280784htgc:MarchTwoThousandTwentySixANotesMember2025-01-012025-03-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2025-01-012025-03-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2025-01-012025-03-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2025-01-012025-03-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-01-012025-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2025-01-012025-03-310001280784htgc:TwoThousandThirtyThreeNotesMember2025-01-012025-03-310001280784htgc:MUFGBankFacilityMember2025-01-012025-03-310001280784htgc:SMBCFacilityMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2025-12-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2026-03-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2025-12-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2026-03-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2025-12-310001280784htgc:SBADebenturesIssuedOnNovemberEightTwoThousandAndTwentyFourMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnNovemberEightTwoThousandAndTwentyFourMember2026-03-310001280784htgc:SBADebenturesIssuedOnNovemberEightTwoThousandAndTwentyFourMember2025-12-310001280784htgc:SBADebenturesIssuedOnDecemberSixTwoThousandAndTwentyFourMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnDecemberSixTwoThousandAndTwentyFourMember2026-03-310001280784htgc:SBADebenturesIssuedOnDecemberSixTwoThousandAndTwentyFourMember2025-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwelveTwoThousandAndTwentyFourMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwelveTwoThousandAndTwentyFourMember2026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwelveTwoThousandAndTwentyFourMember2025-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyFourMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyFourMember2026-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyFourMember2025-12-310001280784htgc:SBADebenturesIssuedOnFebruaryFiveTwoThousandAndTwentyFiveMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnFebruaryFiveTwoThousandAndTwentyFiveMember2026-03-310001280784htgc:SBADebenturesIssuedOnFebruaryFiveTwoThousandAndTwentyFiveMember2025-12-310001280784htgc:SBADebenturesIssuedOnMarchTwentyEightTwoThousandAndTwentyFiveMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentyEightTwoThousandAndTwentyFiveMember2026-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentyEightTwoThousandAndTwentyFiveMember2025-12-310001280784htgc:SBADebenturesIssuedOnAprilTwentyFiveTwoThousandAndTwentyFiveMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnAprilTwentyFiveTwoThousandAndTwentyFiveMember2026-03-310001280784htgc:SBADebenturesIssuedOnAprilTwentyFiveTwoThousandAndTwentyFiveMember2025-12-310001280784htgc:SBADebenturesIssuedOnMayNineTwoThousandAndTwentyFiveMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnMayNineTwoThousandAndTwentyFiveMember2026-03-310001280784htgc:SBADebenturesIssuedOnMayNineTwoThousandAndTwentyFiveMember2025-12-310001280784htgc:SBADebenturesIssuedOnJuneFiveTwoThousandAndTwentyFiveMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnJuneFiveTwoThousandAndTwentyFiveMember2026-03-310001280784htgc:SBADebenturesIssuedOnJuneFiveTwoThousandAndTwentyFiveMember2025-12-310001280784htgc:SBADebenturesIssuedOnJuneTwelveTwoThousandAndTwentyFiveMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnJuneTwelveTwoThousandAndTwentyFiveMember2026-03-310001280784htgc:SBADebenturesIssuedOnJuneTwelveTwoThousandAndTwentyFiveMember2025-12-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyFiveMember2026-01-012026-03-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyFiveMember2026-03-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyFiveMember2025-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2026-01-012026-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2026-01-012026-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2020-10-272020-10-270001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-07-092024-07-090001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-07-090001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2020-10-270001280784htgc:HerculesCapitalFourLPMember2026-03-310001280784htgc:HerculesSBICVL.P.Member2026-03-310001280784htgc:HerculesCapitalFourLPMember2025-12-310001280784htgc:HerculesSBICVL.P.Member2025-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2026-01-012026-03-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2020-02-050001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2025-02-052025-02-050001280784htgc:JuneTwoThousandTwentyFiveNotesMember2026-01-012026-03-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2020-06-030001280784htgc:JuneTwoThousandTwentyFiveNotesMember2025-06-032025-06-030001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2026-01-012026-03-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2022-06-230001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2025-06-232025-06-230001280784htgc:MarchTwoThousandTwentySixANotesMember2020-11-040001280784htgc:MarchTwoThousandTwentySixANotesMember2026-03-042026-03-040001280784htgc:MarchTwoThousandTwentySixBNotesMember2021-03-040001280784htgc:MarchTwoThousandTwentySixBNotesMember2026-03-042026-03-040001280784htgc:SeptemberTwoThousandTwentySixNotesMember2021-09-160001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2022-01-200001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-100001280784htgc:FebruaryTwoThousandTwentyNineNotesMember2026-02-100001280784htgc:JuneTwoThousandThirtyNotesMember2025-06-160001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2022-06-220001280784htgc:TwoThousandThirtyOneAssetBackedNotesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2026-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2025-01-012025-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2018-09-240001280784us-gaap:RevolvingCreditFacilityMember2026-01-012026-03-310001280784us-gaap:RevolvingCreditFacilityMember2025-01-012025-12-310001280784us-gaap:LineOfCreditMemberhtgc:MUFGBankFacilityMember2025-06-090001280784us-gaap:LineOfCreditMemberhtgc:MUFGBankFacilityMember2025-06-100001280784us-gaap:LineOfCreditMemberhtgc:MUFGBankFacilityMembersrt:MaximumMember2026-03-310001280784us-gaap:LineOfCreditMemberhtgc:MUFGBankFacilityMember2026-01-012026-03-310001280784us-gaap:LineOfCreditMemberhtgc:MUFGBankFacilityMembersrt:MinimumMember2026-01-012026-03-310001280784us-gaap:LineOfCreditMemberhtgc:MUFGBankFacilityMembersrt:MaximumMember2026-01-012026-03-310001280784htgc:MUFGBankFacilityMember2026-01-012026-03-310001280784htgc:SmbcLcFacilityMember2026-03-310001280784htgc:SmbcLcFacilityMemberhtgc:SMBCFacilityMembersrt:MaximumMember2026-03-310001280784htgc:SmbcLcFacilityMemberhtgc:SMBCFacilityMember2026-01-012026-03-310001280784htgc:SmbcLcFacilityMembersrt:MinimumMember2026-01-012026-03-310001280784htgc:SmbcLcFacilityMembersrt:MaximumMember2026-01-012026-03-310001280784htgc:SmbcLcFacilityMember2026-01-012026-03-310001280784htgc:SmbcLcFacilityMemberhtgc:TermLoanMember2026-03-310001280784htgc:SmbcLcFacilityMemberhtgc:TermLoanMember2026-01-012026-03-310001280784htgc:SmbcLcFacilityMemberhtgc:SMBCFacilityMember2025-02-052025-02-050001280784htgc:SmbcLcFacilityMemberhtgc:SMBCFacilityMember2025-02-050001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-102025-03-100001280784htgc:TwoThousandTwentyFourEquityDistributionAgreementMemberus-gaap:CommonStockMember2024-12-120001280784htgc:CommonGrossProceedsMember2026-01-012026-03-310001280784htgc:CommonOfferingExpensesMember2026-01-012026-03-310001280784htgc:CommonGrossProceedsMember2025-01-012025-03-310001280784htgc:CommonOfferingExpensesMember2025-01-012025-03-310001280784htgc:O2025Q1DividendsMember2025-01-012025-03-310001280784htgc:S2025Q1DividendsMember2025-01-012025-03-310001280784htgc:O2025Q2DividendsMember2025-04-012025-06-300001280784htgc:S2025Q2DividendsMember2025-04-012025-06-300001280784htgc:O2025Q3DividendsMember2025-07-012025-09-300001280784htgc:S2025Q3DividendsMember2025-07-012025-09-300001280784htgc:O2025Q4DividendsMember2025-10-012025-12-310001280784htgc:S2025Q4DividendsMember2025-10-012025-12-310001280784htgc:O2026Q1DividendsMember2026-01-012026-03-310001280784htgc:S2026Q1DividendsMember2026-01-012026-03-310001280784htgc:SpilloverAmountPerShareMember2026-03-310001280784htgc:TwoThousandEighteenPlanMemberus-gaap:CommonStockMember2018-06-280001280784htgc:DirectorPlanMemberus-gaap:CommonStockMember2018-06-280001280784htgc:TwoThousandEighteenPlanMemberus-gaap:CommonStockMember2026-03-310001280784htgc:DirectorPlanMemberus-gaap:CommonStockMember2026-03-310001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2026-01-012026-03-310001280784htgc:ServiceVestingAwardsMemberhtgc:ShareBasedPaymentArrangementTrancheTwoAndThreeMember2026-01-012026-03-310001280784srt:MaximumMemberhtgc:ServiceVestingAwardsMember2026-01-012026-03-310001280784htgc:ServiceVestingAwardsMember2026-01-012026-03-310001280784htgc:ServiceVestingAwardsMember2025-01-012025-03-310001280784us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001280784us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2026-01-012026-03-310001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2026-01-012026-03-310001280784us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001280784us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001280784htgc:UnvestedRestrictedStockAwardsMember2026-01-012026-03-310001280784htgc:UnvestedRestrictedStockAwardsMember2025-01-012025-03-310001280784ChenMed, LLC2026-03-310001280784ChenMed, LLC2025-12-310001280784Intercom, Inc.2026-03-310001280784Intercom, Inc.2025-12-310001280784Saronic Technologies, Inc.2026-03-310001280784Saronic Technologies, Inc.2025-12-310001280784Earnix, Inc.2026-03-310001280784Earnix, Inc.2025-12-310001280784ControlUp, Inc.2026-03-310001280784ControlUp, Inc.2025-12-310001280784Maze Therapeutics, Inc.2026-03-310001280784Maze Therapeutics, Inc.2025-12-310001280784Ennoble Care LLC2026-03-310001280784Ennoble Care LLC2025-12-310001280784GoEuro Travel GmbH2026-03-310001280784GoEuro Travel GmbH2025-12-310001280784Disc Medicine, Inc.2026-03-310001280784Disc Medicine, Inc.2025-12-310001280784Viridian Therapeutics, Inc.2026-03-310001280784Viridian Therapeutics, Inc.2025-12-310001280784Expel, Inc.2026-03-310001280784Expel, Inc.2025-12-310001280784Mango Technologies, Inc.2026-03-310001280784Mango Technologies, Inc.2025-12-310001280784Belong Health, Inc.2026-03-310001280784Belong Health, Inc.2025-12-310001280784Alector, Inc.2026-03-310001280784Alector, Inc.2025-12-310001280784CollectiveHealth, Inc.2026-03-310001280784CollectiveHealth, Inc.2025-12-310001280784CoreView USA, Inc.2026-03-310001280784CoreView USA, Inc.2025-12-310001280784DroneDeploy, Inc.2026-03-310001280784DroneDeploy, Inc.2025-12-310001280784Scylla DB Ltd.2026-03-310001280784Scylla DB Ltd.2025-12-310001280784iSpot.tv, Inc.2026-03-310001280784iSpot.tv, Inc.2025-12-310001280784Beren Therapeutics P.B.C.2026-03-310001280784Beren Therapeutics P.B.C.2025-12-310001280784ZeroEyes, Inc.2026-03-310001280784ZeroEyes, Inc.2025-12-310001280784Pindrop Security, Inc.2026-03-310001280784Pindrop Security, Inc.2025-12-310001280784Senseonics Holdings, Inc.2026-03-310001280784Senseonics Holdings, Inc.2025-12-310001280784Imagen Technologies, Inc.2026-03-310001280784Imagen Technologies, Inc.2025-12-310001280784Nerdy Inc.2026-03-310001280784Nerdy Inc.2025-12-310001280784Peek Travel, Inc.2026-03-310001280784Peek Travel, Inc.2025-12-310001280784Loft Orbital Solutions Inc.2026-03-310001280784Loft Orbital Solutions Inc.2025-12-310001280784Marathon Health, LLC2026-03-310001280784Marathon Health, LLC2025-12-310001280784Tipalti Solutions Ltd.2026-03-310001280784Tipalti Solutions Ltd.2025-12-310001280784PayIt, LLC2026-03-310001280784PayIt, LLC2025-12-310001280784Distributed Creation Inc.2026-03-310001280784Distributed Creation Inc.2025-12-310001280784DNSFilter, Inc.2026-03-310001280784DNSFilter, Inc.2025-12-310001280784Smartsheet Inc.2026-03-310001280784Smartsheet Inc.2025-12-310001280784Hermeus Corporation2026-03-310001280784Hermeus Corporation2025-12-310001280784Akeyless Security Ltd.2026-03-310001280784Akeyless Security Ltd.2025-12-310001280784Canary Technologies2026-03-310001280784Canary Technologies2025-12-310001280784Loftware, Inc.2026-03-310001280784Loftware, Inc.2025-12-310001280784Funnel Holding AB (publ)2026-03-310001280784Funnel Holding AB (publ)2025-12-310001280784Zappi, Inc.2026-03-310001280784Zappi, Inc.2025-12-310001280784Tidal Vision Products, Inc.2026-03-310001280784Tidal Vision Products, Inc.2025-12-310001280784Proven Optics, LLC2026-03-310001280784Proven Optics, LLC2025-12-310001280784New Relic, Inc.2026-03-310001280784New Relic, Inc.2025-12-310001280784Streamline Healthcare Solutions2026-03-310001280784Streamline Healthcare Solutions2025-12-310001280784Sumo Logic, Inc.2026-03-310001280784Sumo Logic, Inc.2025-12-310001280784Saama Technologies, LLC2026-03-310001280784Saama Technologies, LLC2025-12-310001280784Babel Street2026-03-310001280784Babel Street2025-12-310001280784DocPlanner2026-03-310001280784DocPlanner2025-12-310001280784Andesa Services, Inc.2026-03-310001280784Andesa Services, Inc.2025-12-310001280784LogicSource2026-03-310001280784LogicSource2025-12-310001280784Zimperium, Inc.2026-03-310001280784Zimperium, Inc.2025-12-310001280784Alchemer LLC2026-03-310001280784Alchemer LLC2025-12-310001280784Dispatch Technologies, Inc.2026-03-310001280784Dispatch Technologies, Inc.2025-12-310001280784LinenMaster, LLC2026-03-310001280784LinenMaster, LLC2025-12-310001280784ShadowDragon, LLC2026-03-310001280784ShadowDragon, LLC2025-12-310001280784TaxCalc2026-03-310001280784TaxCalc2025-12-310001280784Omeda Holdings, LLC2026-03-310001280784Omeda Holdings, LLC2025-12-310001280784Arcus Biosciences, Inc.2026-03-310001280784Arcus Biosciences, Inc.2025-12-310001280784Curana Health Holdings, LLC2026-03-310001280784Curana Health Holdings, LLC2025-12-310001280784Harness, Inc.2026-03-310001280784Harness, Inc.2025-12-310001280784Weee! Inc.2026-03-310001280784Weee! Inc.2025-12-310001280784Finix Payments, Inc.2026-03-310001280784Finix Payments, Inc.2025-12-310001280784Elation Health, Inc.2026-03-310001280784Elation Health, Inc.2025-12-310001280784Octave Health Group, Inc.2026-03-310001280784Octave Health Group, Inc.2025-12-310001280784Carbyne, Inc.2026-03-310001280784Carbyne, Inc.2025-12-310001280784Behavox Limited2026-03-310001280784Behavox Limited2025-12-310001280784htgc:DebtInvestmentsMember2026-03-310001280784htgc:DebtInvestmentsMember2025-12-310001280784Forbion Growth Opportunities Fund I C.V.2026-03-310001280784Forbion Growth Opportunities Fund I C.V.2025-12-310001280784Forbion Growth Opportunities Fund II C.V.2026-03-310001280784Forbion Growth Opportunities Fund II C.V.2025-12-310001280784htgc:InvestmentFundsAndVehiclesMember2026-03-310001280784htgc:InvestmentFundsAndVehiclesMember2025-12-310001280784htgc:AdviserFundsMember2026-03-310001280784htgc:AdviserFundsMember2025-12-310001280784htgc:LeaseAndLicenseObligationsMember2026-03-310001280784htgc:LeaseAndLicenseObligationsMember2025-12-310001280784htgc:AdviserSubsidiaryMemberhtgc:AdviserSubsidiaryMember2026-01-012026-03-310001280784htgc:AdviserSubsidiaryMemberhtgc:AdviserSubsidiaryMember2025-01-012025-03-310001280784htgc:AdviserSubsidiaryMember2026-01-012026-03-310001280784htgc:AdviserSubsidiaryMember2025-01-012025-03-310001280784htgc:AdviserSubsidiaryMember2026-03-310001280784htgc:AdviserSubsidiaryMember2025-12-310001280784htgc:AdviserFundsMember2026-01-012026-03-310001280784htgc:AdviserFundsMember2025-01-012025-03-310001280784htgc:O2026Q1DividendsMemberus-gaap:SubsequentEventMember2026-04-290001280784htgc:S2026ADividendsMembersrt:ScenarioForecastMemberus-gaap:SubsequentEventMember2026-01-012026-12-310001280784htgc:S2026Q1DividendsMembersrt:ScenarioForecastMemberus-gaap:SubsequentEventMember2026-01-012026-12-310001280784htgc:S2026Q4DividendsMembersrt:ScenarioForecastMemberus-gaap:SubsequentEventMember2026-01-012026-12-310001280784htgc:S2026Q3DividendsMembersrt:ScenarioForecastMemberus-gaap:SubsequentEventMember2026-01-012026-12-310001280784htgc:S2026Q2DividendsMembersrt:ScenarioForecastMemberus-gaap:SubsequentEventMember2026-01-012026-12-310001280784htgc:S2026ADividendsMemberus-gaap:SubsequentEventMember2026-04-290001280784htgc:S2026Q1DividendsMember2026-02-042026-02-040001280784us-gaap:SubsequentEventMember2026-04-2900012807842026-02-042026-02-040001280784htgc:SignificantPortfolioInvestmentMember2026-01-012026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-01-012026-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberus-gaap:SeriesAPreferredStockMemberhtgc:MedicalDevicesAndEquipmentMember2026-03-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:GibraltarAcquisitionLLCMemberhtgc:UnsecuredDebtOneMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2026-03-310001280784htgc:GibraltarAcquisitionLLCMemberhtgc:UnsecuredDebtTwoMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2026-03-310001280784htgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2026-03-310001280784htgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2026-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2026-03-310001280784htgc:TecturaCorporationMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2026-03-310001280784htgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMemberhtgc:PreferredSeriesBBMemberhtgc:ConsumerAndBusinessServicesMember2026-03-310001280784htgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMemberus-gaap:SeriesCPreferredStockMemberhtgc:ConsumerAndBusinessServicesMember2026-03-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2026-03-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberus-gaap:SeriesAPreferredStockMemberhtgc:MedicalDevicesAndEquipmentMember2025-12-310001280784htgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:GibraltarAcquisitionLLCMemberhtgc:UnsecuredDebtOneMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2025-12-310001280784htgc:GibraltarAcquisitionLLCMemberhtgc:UnsecuredDebtTwoMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2025-12-310001280784htgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMember2025-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberhtgc:HerculesAdviserLLCMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-310001280784htgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2025-12-310001280784htgc:TecturaCorporationMemberus-gaap:CommonStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMember2025-12-310001280784htgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMemberhtgc:PreferredSeriesBBMemberhtgc:ConsumerAndBusinessServicesMember2025-12-310001280784htgc:TecturaCorporationMemberus-gaap:PreferredStockMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:OtherControlInvestmentsMemberus-gaap:SeriesCPreferredStockMemberhtgc:ConsumerAndBusinessServicesMember2025-12-310001280784htgc:OtherControlInvestmentsMemberhtgc:TecturaCorporationMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-12-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

_________________________________________________

FORM 10-Q

_________________________________________________

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended March 31, 2026

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 814-00702

_________________________________________________

HERCULES CAPITAL, INC.

(Exact Name of Registrant as Specified in its Charter)

_________________________________________________


Maryland						74-3113410
(State or Jurisdiction of Incorporation or Organization)						(IRS Employer Identification Number)

1 North B Street., Suite 2000 San Mateo, California (Address of Principal Executive Offices)						94401 (Zip Code)

(650) 289-3060

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

HTGC

New York Stock Exchange

6.25% Notes due 2033

HCXY

New York Stock Exchange

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

On April 28, 2026, there were 187,118,590 shares outstanding of the Registrant’s common stock, $0.001 par value.

HERCULES CAPITAL, INC.

FORM 10-Q TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION		3

Item 1.	Consolidated Financial Statements	3

	Consolidated Statements of Assets and Liabilities as of March 31, 2026 (unaudited) and December 31, 2025	3

	Consolidated Statements of Operations for the three months ended March 3 1 , 202 6 and 202 5 (unaudited)	4

	Consolidated Statements of Changes in Net Assets for the three months ended March 3 1 , 202 6 and 202 5 (unaudited)	5

	Consolidated Statements of Cash Flows for the three months ended March 3 1 , 202 6 and 202 5 (unaudited)	6

	Consolidated Schedule of Investments as of March 3 1 , 202 6 (unaudited)	7

	Consolidated Schedule of Investments as of December 31, 202 5	22

	Notes to Consolidated Financial Statements (unaudited)	36

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	74

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	90

Item 4.	Controls and Procedures	91

PART II. OTHER INFORMATION		92

Item 1.	Legal Proceedings	92

Item 1A.	Risk Factors	92

Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities	93

Item 3.	Defaults Upon Senior Securities	93

Item 4.	Mine Safety Disclosures	93

Item 5.	Other Information	93

Item 6.	Exhibits and Financial Statement Schedules	94

SIGNATURES		99

Table of Contents

PART I: FINANCIAL INFORMATION

In this Quarterly Report, the “Company,” “Hercules,” “we,” “us” and “our” refer to Hercules Capital, Inc., its wholly owned subsidiaries, and its affiliated securitization trust unless the context otherwise requires.

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES


(in thousands, except per share data)	March 31, 2026 (unaudited)		December 31, 2025

Assets
Investments, at fair value:
Non-control/Non-affiliate investments (cost of $4,662,224 and $4,362,559, respectively)	$	4,605,739	$	4,351,596
Control investments (cost of $108,145 and $105,409, respectively)	116,248		115,051
Total investments, at fair value (cost of $4,770,369 and $4,467,968, respectively; fair value amounts related to a VIE $156,672 and $158,980, respectively)	4,721,987		4,466,647
Cash and cash equivalents (1)	42,365		56,987

Restricted cash (amounts related to a VIE $2,561 and $2,467, respectively)	2,561		2,467
Interest receivable	40,377		37,261
Right of use asset	14,345		14,842
Other assets	4,783		5,822
Total assets	$	4,826,418	$	4,584,026

Liabilities
Debt (net of unamortized debt issuance costs of $30,287 and $26,626, respectively; amounts related to a VIE $64,466 and $64,530, respectively)	$	2,539,032	$	2,286,444
Accounts payable and accrued liabilities	45,189		65,262
Operating lease liability	15,202		16,267
Total liabilities	$	2,599,423	$	2,367,973

Net assets consist of:
Common stock, par value	$	187	$	183
Capital in excess of par value	2,169,888		2,114,719
Total distributable earnings	56,920		101,151
Total net assets	$	2,226,995	$	2,216,053
Total liabilities and net assets	$	4,826,418	$	4,584,026

Shares of common stock outstanding ($0.001 par value and 300,000 authorized)	187,174		182,695
Net asset value per share	$	11.90	$	12.13

(1)Effective March 31, 2026, the former foreign cash category has been consolidated into “Cash and cash equivalents”. Prior year amounts have been reclassified to conform to the current presentation.

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)


(in thousands, except per share data)	Three Months Ended March 31,
	2026		2025
Investment income:
Interest and dividend income:
Excluding payment-in-kind (PIK) interest income
Non-control/Non-affiliate investments	$	120,090	$	98,996
Control investments	3,399		3,103

Total interest and dividend income, excluding PIK interest income	123,489		102,099
PIK interest income
Non-control/Non-affiliate investments	12,914		12,939
Control investments	—		534
Total PIK interest income	12,914		13,473
Total interest and dividend income	136,403		115,572
Fee income:
Non-control/Non-affiliate investments	5,098		3,900
Control investments	35		39
Total fee income	5,133		3,939
Total investment income	141,536		119,511
Operating expenses:
Interest	28,146		19,698
Loan fees	2,677		2,398
General and administrative	4,802		4,812
Tax expenses	990		912
Employee compensation:
Compensation and benefits	17,291		13,914
Stock-based compensation	4,149		3,602
Total employee compensation	21,440		17,516
Total gross operating expenses	58,055		45,336
Expenses allocated to the Adviser Subsidiary	(4,629)		(3,283)
Total net operating expenses	53,426		42,053
Net investment income	88,110		77,458
Net realized gain (loss) and net change in unrealized appreciation (depreciation):
Net realized gain (loss):
Non-control/Non-affiliate investments	(603)		(1,541)

Loss on extinguishment of debt	—		(15)
Total net realized gain (loss)	(603)		(1,556)
Net change in unrealized appreciation (depreciation):
Non-control/Non-affiliate investments	(43,466)		(27,542)
Control investments	(1,539)		1,977

Total net change in unrealized appreciation (depreciation)	(45,005)		(25,565)
Total net realized gain (loss) and net change in unrealized appreciation (depreciation)	(45,608)		(27,121)
Net increase (decrease) in net assets resulting from operations	$	42,502	$	50,337

Net investment income before gains and losses per common share:
Basic	$	0.48	$	0.45
Change in net assets resulting from operations per common share:
Basic	$	0.23	$	0.29
Diluted	$	0.23	$	0.29
Weighted average shares outstanding:
Basic	182,760		171,494
Diluted	196,821		175,383
Distributions paid per common share:
Basic	$	0.47	$	0.47

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

(unaudited)


(in thousands)	Common Stock			Capital in excess of par value		Distributable Earnings (loss)		Net Assets
For the Three Months Ended March 31, 2026	Shares	Par Value
Balance as of December 31, 2025	182,695	$	183	$	2,114,719	$	101,151	$	2,216,053
Net increase (decrease) in net assets resulting from operations	—	—		—		42,502		42,502
Public offering, net of offering expenses	3,541	3		52,033		—		52,036
Issuance of common stock under equity-based award plans	992	1		6		—		7
Shares retired on vesting of equity-based awards	(207)	—		(3,373)		—		(3,373)
Distributions reinvested in common stock	153	—		2,318		—		2,318
Distributions	—	—		—		(86,733)		(86,733)
Stock-based compensation(1)	—	—		4,185		—		4,185
Balance as of March 31, 2026	187,174	$	187	$	2,169,888	$	56,920	$	2,226,995

(1)Stock-based compensation includes $35 thousand of restricted stock and option expense related to director compensation for the three months ended March 31, 2026.


(in thousands)	Common Stock			Capital in excess of par value		Distributable Earnings (loss)		Net Assets
For the Three Months Ended March 31, 2025	Shares	Par Value
Balance as of December 31, 2024	170,575	$	171	$	1,900,490	$	88,920	$	1,989,581
Net increase (decrease) in net assets resulting from operations	—	—		—		50,337		50,337
Public offering, net of offering expenses	2,000	2		39,415		—		39,417
Issuance of common stock under equity-based award plans	789	1		86		—		87
Shares retired on vesting of equity-based awards	(201)	—		(3,556)		—		(3,556)
Distributions reinvested in common stock	122	—		2,511		—		2,511
Distributions	—	—		—		(81,384)		(81,384)
Stock-based compensation(1)	—	—		3,637		—		3,637
Balance as of March 31, 2025	173,285	$	174	$	1,942,583	$	57,873	$	2,000,630

(1)Stock-based compensation includes $35 thousand of restricted stock and option expense related to director compensation for the three months ended March 31, 2025.

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)


(in thousands)	For the Three Months Ended March 31,
	2026		2025
Cash flows provided by (used in) operating activities:
Net increase in net assets resulting from operations	$	42,502	$	50,337
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchases of investments(1)	(529,318)		(415,033)
Fundings assigned to Adviser Funds(1)	2,500		—
Principal and fee repayments received	227,485		144,483
Proceeds from the sale of debt investments	7,500		—
Proceeds from the sale of equity and warrant investments	2,907		329
Net change in unrealized (appreciation) depreciation	45,005		25,565
Net realized (gain) loss	603		1,541

Accretion of paid-in-kind interest	(12,914)		(13,473)
Accretion of loan discounts	(1,771)		(1,109)
Accretion of loan discounts on convertible notes	311		68
Loss on extinguishment of debt	—		15
Accretion of loan exit fees	(10,194)		(7,436)
Change in loan income, net of collections	11,308		4,365
Unearned fees related to unfunded commitments	1,113		1,102
Amortization of debt fees and issuance costs	2,487		1,842
Depreciation and amortization	85		89
Stock-based compensation and amortization of restricted stock grants(2)	4,185		3,637
Change in operating assets and liabilities:
Interest receivable	(3,094)		(1,215)
Other assets	(631)		2,041
Accrued liabilities	(20,702)		(19,345)
Net cash provided by (used in) operating activities	(230,633)		(222,197)

Cash flows provided by (used in) investing activities:
Purchases of capital equipment	(19)		(8)
Net cash provided by (used in) investing activities	(19)		(8)

Cash flows provided by (used in) financing activities:
Issuance of common stock	52,893		40,160
Offering expenses	(857)		(743)
Retirement of employee shares, net	(3,366)		(3,469)
Distributions paid	(84,415)		(78,873)
Issuance of debt	729,816		569,188
Repayment of debt	(474,125)		(360,812)
Debt issuance costs	(3,822)		(4,927)
Fees paid for credit facilities	—		(419)
Net cash provided by (used in) financing activities	216,124		160,105
Net increase (decrease) in cash, cash equivalents and restricted cash	(14,528)		(62,100)
Cash, cash equivalents and restricted cash at beginning of period	59,454		116,421
Cash, cash equivalents and restricted cash at end of period	$	44,926	$	54,321

Supplemental disclosures of cash flow information and non-cash investing and financing activities:
Interest paid	$	32,396	$	25,580
Income tax, including excise tax, paid	$	5,489	$	6,033
Distributions reinvested	$	2,318	$	2,511

(1)Excluded from the amounts presented are certain investment funding allocations of $177.1 million and $124.1 million, which were directly funded by the Adviser Funds (as defined in “Note 1 – Description of Business”) during the three months ended March 31, 2026 and 2025, respectively. Refer to “Note 12 – Related Party Transaction” for additional information.

(2)Stock-based compensation includes $35 thousand and $35 thousand of restricted stock and option expense related to director compensation for the three months ended March 31, 2026 and 2025, respectively.

The following table presents a reconciliation of cash and cash equivalents and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum to the total of the same such amounts in the Consolidated Statements of Cash Flows:



(in thousands)	As of March 31,
	2026		2025
Cash and cash equivalents (1)	$	42,365	$	51,159

Restricted cash	2,561		3,162
Total cash, cash equivalents and restricted cash presented in the Consolidated Statements of Cash Flows	$	44,926	$	54,321

See “Note 2 – Summary of Significant Accounting Policies” for a description of cash and cash equivalents and restricted cash.

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Debt Investments
Application Software
Alchemer LLC	Senior Secured	May 2028	1-month SOFR + 8.14%, Floor rate 9.14%	$	20,105	$	19,883	$	19,560	(13)(17)(18)
AlphaSense, Inc.	Senior Secured	June 2029	3-month SOFR + 6.25%, Floor rate 8.25%	$	20,000	19,858		19,706		(11)
Annex Cloud	Senior Secured	June 2028	PIK Interest 3-month SOFR + 9.99%, Floor rate 10.99%	$	5,642	5,642		282		(8)(13)(18)
	Senior Secured	December 2025	PIK Interest 3-month SOFR + 9.99%, Floor rate 10.99%	$	3,325	3,325		3,325		(8)(18)(26)
	Senior Secured	June 2028	PIK Interest 3-month SOFR + 5.73%, Floor rate 6.73%	$	1,716	1,717		86		(8)(18)
Total Annex Cloud				$	10,683	10,684		3,693
Babel Street	Senior Secured	December 2027	3-month SOFR + 8.01%, Floor rate 9.01%	$	67,465	66,666		65,599		(15)(17)(18)
Behavox Limited	Senior Secured	September 2027	Prime - 0.55%, Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee	$	19,591	19,846		19,518		(5)(10)(11)(14)
Brain Corporation	Senior Secured	September 2028	Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee	$	33,035	33,163		33,077		(13)(14)
Ceros, Inc.	Senior Secured	June 2027	3-month SOFR + 8.99%, Floor rate 9.89%	$	22,656	22,561		22,127		(18)
Chainalysis, Inc.	Senior Secured	June 2029	Prime + 2.95%, Floor rate 10.45%	$	37,372	36,941		36,718
Dashlane, Inc.	Senior Secured	December 2027	Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee	$	46,113	47,149		47,136		(11)(13)(14)(19)
Dispatch Technologies, Inc.	Senior Secured	April 2028	3-month SOFR + 7.86%, Floor rate 8.61%	$	8,231	8,125		7,949		(17)(18)
Distributed Creation Inc.	Senior Secured	April 2029	Prime + 3.00%, Floor rate 10.25%, 4.50% Exit Fee	$	25,000	24,907		24,414		(11)(17)
DocPlanner	Senior Secured	January 2030	Prime + 2.75%, Floor rate 9.75%, 4.25% Exit Fee	€	68,200	70,035		78,210		(5)(10)(17)
Earnix, Inc.	Senior Secured	June 2029	Prime - 1.15%, Floor rate 5.35%, PIK Interest 4.45%	$	20,273	20,028		20,249		(11)(14)(17)
Elation Health, Inc.	Senior Secured	April 2029	Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.30%, 3.95% Exit Fee	$	21,119	20,758		20,692		(11)(14)(19)
Funnel Holding AB (publ)	Senior Secured	October 2029	Prime + 0.60%, Floor rate 7.10%, Cap rate 8.60%, PIK Interest 3.00%, 2.25% Exit Fee	$	18,572	18,368		18,368		(5)(10)(14)(17)(19)
Imagen Technologies, Inc.	Senior Secured	November 2028	Prime + 1.55%, Floor rate 9.05%, PIK Interest 1.00%, 3.95% Exit Fee	$	7,520	7,417		7,417		(6)(14)(17)
Intercom, Inc.	Senior Secured	February 2031	Prime + 2.00%, Floor rate 8.50%, Cap rate 9.25%, PIK Interest 1.00%, 3.95% Exit Fee	$	22,500	22,280		22,280		(17)
iSpot.tv, Inc.	Senior Secured	January 2029	Prime + 2.25%, Floor rate 9.00%, PIK Interest 1.00%, 5.70% Exit Fee	$	3,290	3,305		3,203		(14)(17)
	Senior Secured	January 2029	Prime + 1.40%, Floor rate 8.15%, PIK Interest 0.75%, 4.50% Exit Fee	$	39,213	39,172		38,300		(12)(14)(17)
Total iSpot.tv, Inc.				$	42,503	42,477		41,503
Khoros, LLC	Senior Secured	May 2030	FIXED 10.00%	$	11,704	11,704		11,259
LinenMaster, LLC	Senior Secured	August 2029	1-month SOFR + 8.28%, Floor rate 9.28%	$	11,500	11,197		10,913		(17)(18)
Loftware, Inc.	Senior Secured	March 2028	3-month SOFR + 7.75%, Floor rate 8.75%	$	29,586	29,214		29,000		(17)(18)
LogicSource	Senior Secured	July 2027	3-month SOFR + 8.68%, Floor rate 9.68%	$	11,113	11,033		10,954		(17)(18)
Mango Technologies, Inc.	Senior Secured	August 2030	Prime + 2.25%, Floor rate 8.25%, 2.00% Exit Fee	$	33,500	33,054		32,760		(17)
Marigold Group, Inc.	Senior Secured	April 2028	6-month SOFR + 4.75%, Floor rate 5.75%, PIK Interest 5.25%	$	45,140	44,595		42,883		(13)(14)(19)
Microblink LLC	Senior Secured	August 2027	3-month SOFR + 7.84%, Floor rate 8.84%	$	5,000	4,891		4,891		(18)
Omeda Holdings, LLC	Senior Secured	July 2027	3-month SOFR + 8.05%, Floor rate 9.05%	$	7,284	7,202		7,190		(11)(17)(18)
Pindrop Security, Inc.	Senior Secured	June 2029	Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee	$	31,000	30,811		31,594		(15)(17)
Proven Optics, LLC	Senior Secured	December 2030	3-month SOFR + 7.30%, Floor rate 8.30%	$	15,000	14,737		14,737		(17)(18)
Remodel Health Holdco, LLC	Senior Secured	December 2028	Prime + 2.35%, Floor rate 10.35%, 6.50% Exit Fee	$	25,000	25,233		25,115		(6)(15)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Reveleer	Senior Secured	February 2027	Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee	$	50,303	$	51,663	$	51,663	(6)(14)(15)
ShadowDragon, LLC	Senior Secured	December 2026	3-month SOFR + 8.79%, Floor rate 9.69%	$	6,000	5,969		5,969		(17)(18)
Simon Data, Inc.	Senior Secured	March 2027	Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 3.59% Exit Fee	$	10,802	11,042		10,784		(12)(14)
Sisense Ltd.	Senior Secured	July 2027	Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee	$	29,987	31,140		30,191		(5)(10)(14)
Smartsheet Inc.	Senior Secured	January 2031	3-month SOFR + 5.25%, Floor rate 6.00%	$	46,785	45,989		45,336		(17)
Snappt, Inc.	Senior Secured	April 2029	Prime + 2.35%, Floor rate 8.85%, PIK Interest 1.00%, 4.25% Exit Fee	$	20,189	20,179		19,563		(6)(14)(15)
Streamline Healthcare Solutions	Senior Secured	June 2030	3-month SOFR + 7.30%, Floor rate 8.30%	$	21,000	20,429		20,361		(6)(11)(13)(15)(17) (18)
Suzy, Inc.	Senior Secured	August 2027	Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee	$	23,430	23,599		22,822		(6)(14)(15)
TaxCalc	Senior Secured	November 2029	Daily SONIA + 8.17%, Floor rate 8.67%	£	8,231	10,543		11,199		(5)(10)(17)(18)
Tipalti Solutions Ltd.	Senior Secured	April 2029	Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%	$	72,906	72,580		70,728		(14)(16)(17)
	Senior Secured	April 2029	Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%, 3.75% Exit Fee	$	42,919	43,050		42,776		(14)(16)(17)
Total Tipalti Solutions Ltd.				$	115,825	115,630		113,504
Ushur, Inc.	Senior Secured	June 2028	Prime + 2.20%, Floor rate 9.20%, 3.95% Exit Fee	$	14,150	14,015		13,711		(6)(15)
Zappi, Inc.	Senior Secured	December 2027	3-month SOFR + 8.03%, Floor rate 9.03%	$	12,568	12,440		12,403		(5)(10)(13)(17)(18)
ZeroEyes, Inc.	Senior Secured	May 2030	Prime + 2.00%, Floor rate 9.50%, PIK Interest 2.00%, 1.50% Exit Fee	$	16,497	16,249		15,986		(6)(14)(15)(17)
Subtotal: Application Software (49.53%)*						1,113,704		1,103,004
Biotechnology Tools
Antheia, Inc.	Senior Secured	August 2029	Prime + 2.85%, Floor rate 10.35%, 5.55% Exit Fee	$	21,250	19,886		19,718		(11)
Subtotal: Biotechnology Tools (0.89%)*						19,886		19,718
Communications & Networking
Aryaka Networks, Inc.	Senior Secured	December 2028	Prime + 1.80%, Floor rate 9.30%, PIK Interest 1.25%, 6.73% Exit Fee	$	28,360	28,758		21,196		(12)(14)(19)
Tarana Wireless, Inc.	Senior Secured	March 2030	Prime + 4.00%, Floor rate 10.75%, 3.95% Exit Fee	$	11,000	10,824		10,824		(6)(19)
Subtotal: Communications & Networking (1.44%)*						39,582		32,020
Consumer & Business Products
Tonal Systems, Inc.	Senior Secured	March 2029	Prime + 4.25%, Floor rate 11.00%, 4.25% Exit Fee	$	20,000	19,760		19,760		(19)
Weee! Inc.	Senior Secured	April 2028	Prime + 2.25%, Floor rate 9.75%, 2.50% Exit Fee	$	20,000	19,852		19,937		(11)
Subtotal: Consumer & Business Products (1.78%)*						39,612		39,697
Consumer & Business Services
Andesa Services, Inc.	Senior Secured	March 2031	1-month SOFR + 7.80%, Floor rate 8.80%	$	11,000	10,756		10,756		(17)(18)
AppDirect, Inc.	Senior Secured	September 2029	Prime + 2.05%, Floor rate 8.55%, PIK Interest 1.00%, 4.70% Exit Fee	$	65,696	65,096		63,751		(14)
Carwow LTD	Senior Secured	December 2027	Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee	£	20,737	28,724		27,490		(5)(10)(14)
CollectiveHealth, Inc.	Senior Secured	February 2030	Prime + 3.50%, Floor rate 10.25%, 3.95% Exit Fee	$	10,125	10,013		9,760		(17)
Finix Payments, Inc.	Senior Secured	December 2029	Prime + 2.50%, Floor rate 9.25%, 4.25% Exit Fee	$	24,500	24,133		24,133		(6)


GoEuro Travel GmbH	Senior Secured	November 2029	Prime + 3.45%, Floor rate 10.45%, 4.50% Exit Fee	$	48,750	48,877		48,438		(5)(10)(17)
Houzz, Inc.	Convertible Debt	May 2028	PIK Interest 12.00%	$	29,768	29,768		29,462		(9)(14)
Jobandtalent USA, Inc.	Senior Secured	October 2028	1-month SOFR + 3.50%, Floor rate 4.50%, PIK Interest 3.25%, 6.83% Exit Fee	$	14,386	15,036		14,254		(5)(10)(14)
Nerdy Inc.	Senior Secured	November 2029	Prime + 3.50%, Floor rate 10.75%, 7.50% Exit Fee	$	14,000	13,934		13,934		(17)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Peek Travel, Inc.	Senior Secured	October 2028	Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.00%, 4.95% Exit Fee	$	19,558	$	19,360	$	18,865	(14)(17)
Plentific Ltd	Senior Secured	October 2026	Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee	$	3,035	3,092		3,185		(5)(10)(13)
Provi	Senior Secured	December 2027	Prime + 4.40%, Floor rate 10.65%, 1.00% Exit Fee	$	14,797	14,789		14,580		(15)
Riviera Partners LLC	Senior Secured	March 2028	3-month SOFR + 8.28%, Floor rate 9.28%	$	36,034	35,785		35,237		(18)
RVShare, LLC	Senior Secured	December 2026	3-month SOFR + 9.50%, Floor rate 10.50%	$	25,809	25,752		25,752		(13)(14)(15)
SeatGeek, Inc.	Senior Secured	May 2026	Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.50% Exit Fee	$	25,488	26,526		26,526		(11)(14)(16)
	Senior Secured	July 2026	Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.50% Exit Fee	$	78,532	80,492		80,492		(12)(14)(16)
Total SeatGeek, Inc.				$	104,020	107,018		107,018
Skyword, Inc.	Senior Secured	November 2027	Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 5.50% Exit Fee	$	6,734	6,984		6,764		(13)(14)
Tectura Corporation	Senior Secured	January 2027	FIXED 8.25%	$	8,250	8,250		8,083		(7)
Subtotal: Consumer & Business Services (20.72%)*						467,367		461,462
Defense Technologies
Hermeus Corporation	Senior Secured	March 2030	Prime + 2.75%, Floor rate 10.00%, PIK Interest 1.00%, 4.50% Exit Fee	$	10,739	10,348		10,348		(17)
Saronic Technologies, Inc.	Senior Secured	June 2030	Prime + 2.50%, Floor rate 9.00%, 2.00% Exit Fee	$	21,250	21,005		21,809		(6)(15)(17)
Shield AI, Inc.	Senior Secured	February 2029	Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee	$	117,406	117,460		117,249		(12)(14)(16)
Subtotal: Defense Technologies (6.71%)*						148,813		149,406
Diversified Financial Services
Gibraltar Acquisition LLC	Unsecured	July 2029	FIXED 11.50%	$	28,805	28,439		28,439		(7)(14)(20)
	Unsecured	July 2029	FIXED 11.95%	$	10,000	9,852		9,852		(7)(20)
Total Gibraltar Acquisition LLC				$	38,805	38,291		38,291
Hercules Adviser LLC	Unsecured	March 2027	FIXED 6.75%	$	3,000	3,000		3,000		(7)(23)
Subtotal: Diversified Financial Services (1.85%)*						41,291		41,291
Drug Discovery & Development
Aldeyra Therapeutics, Inc.	Senior Secured	April 2026	Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee	$	15,000	15,299		15,299		(11)
Alector, Inc.	Senior Secured	December 2028	Prime + 1.05%, Floor rate 8.05%, 4.75% Exit Fee	$	7,000	7,074		7,069		(6)(10)(15)(17)
Altimmune, Inc.	Senior Secured	June 2029	Prime + 2.45%, Floor rate 9.70%, 6.25% Exit Fee	$	17,500	17,521		17,357		(6)(10)(15)
Arcus Biosciences, Inc.	Senior Secured	September 2030	Prime - 0.05%, Floor rate 8.45%, PIK Interest 2.20%, 9.00% Exit Fee	$	76,121	76,872		80,548		(6)(10)(11)(14)(15)
Beren Therapeutics P.B.C.	Senior Secured	October 2029	Prime + 2.45%, Floor rate 9.95%, 5.25% Exit Fee	$	8,625	8,513		8,513		(6)(17)
Braeburn, Inc.	Senior Secured	October 2028	Prime + 3.00%, Floor rate 10.50%, PIK Interest 0.25%, 5.45% Exit Fee	$	53,666	54,673		55,682		(14)
COMPASS Pathways plc	Senior Secured	January 2031	Prime + 2.75%, Floor rate 9.75%, 7.75% Exit Fee	$	42,500	42,432		42,432		(5)(10)(11)
Corium, Inc.	Senior Secured	September 2026	Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee	$	86,925	92,785		93,662		(13)
Disc Medicine, Inc.	Senior Secured	December 2029	Prime + 1.75%, Floor rate 8.25%, 6.75% Exit Fee	$	22,500	22,738		23,087		(6)(10)(15)(17)
Dyne Therapeutics, Inc.	Senior Secured	July 2030	Prime + 2.45%, Floor rate 9.95%, 5.50% Exit Fee	$	100,000	99,676		100,946		(6)(10)(12)(15)
enGene, Inc.	Senior Secured	January 2030	Prime + 2.25%, Floor rate 9.25%, Cap rate 10.25%, 5.95% Exit Fee	$	17,500	17,810		18,282		(5)(10)
Genetix Biotherapeutics Inc.	Senior Secured	April 2029	Prime + 2.45%, Floor rate 9.45%, 6.45% Exit Fee	$	67,116	67,163		67,102		(14)
Heron Therapeutics, Inc.	Senior Secured	September 2030	Prime + 1.95%, Floor rate 9.45%, PIK Interest 1.00%, 6.50% Exit Fee	$	80,569	80,315		79,163		(14)(15)
Kura Oncology, Inc.	Senior Secured	November 2027	Prime + 2.40%, Floor rate 8.65%, 6.05% Exit Fee	$	5,500	5,728		5,805		(10)(15)
Maze Therapeutics, Inc.	Senior Secured	February 2031	Prime + 0.95%, Floor rate 7.95%, 6.45% Exit Fee	$	28,000	27,765		27,765		(6)(10)(17)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
MoonLake Immunotherapeutics	Senior Secured	April 2030	Prime + 1.45%, Floor rate 8.45%, 6.95% Exit Fee	$	46,000	$	46,054	$	45,983	(5)(10)
NorthSea Therapeutics	Convertible Debt	December 2026	FIXED 6.00%	$	373	373		373		(5)(9)(10)
Phathom Pharmaceuticals, Inc.	Senior Secured	February 2029	Prime + 3.10%, Floor rate 9.85%, 2.00% Exit Fee	$	133,121	132,012		132,485		(6)(10)(12)(16)(22)
Replimune Group, Inc.	Senior Secured	October 2027	Prime + 1.75%, Floor rate 8.50%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee	$	57,031	57,953		57,961		(10)(12)(13)(14)
Savara, Inc.	Senior Secured	April 2030	Prime + 1.45%, Floor rate 7.45%, 6.95% Exit Fee	$	21,450	21,645		21,555		(6)(10)(15)
SynOx Therapeutics Limited	Senior Secured	May 2027	Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee	$	4,500	4,676		4,672		(5)(10)(11)
Tenpoint Therapeutics Limited	Senior Secured	October 2029	Prime + 2.90%, Floor rate 10.40%, 6.65% Exit Fee	$	18,750	18,619		18,619		(5)(10)
uniQure B.V.	Senior Secured	October 2030	Prime + 2.45%, Floor rate 9.45%, 5.50% Exit Fee	$	27,500	27,511		28,024		(5)(10)(11)
Viridian Therapeutics, Inc.	Senior Secured	October 2030	Prime + 1.45%, Floor rate 8.95%, Cap rate 9.45%, 6.00% Exit Fee	$	24,500	24,438		24,438		(10)(13)(17)
X4 Pharmaceuticals, Inc.	Senior Secured	July 2027	Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee	$	75,000	76,711		76,676		(11)(12)(13)
Subtotal: Drug Discovery & Development (47.31%)*						1,046,356		1,053,498
Electronics & Computer Hardware
Locus Robotics Corp.	Senior Secured	December 2028	Prime + 3.00%, Floor rate 9.50%, 4.00% Exit Fee	$	65,000	65,349		65,068		(6)(11)(12)(15)
Subtotal: Electronics & Computer Hardware (2.92%)*						65,349		65,068
Healthcare Services, Other
Belong Health, Inc.	Senior Secured	November 2029	Prime + 2.25%, Floor rate 9.75%, 5.45% Exit Fee	$	11,250	10,997		10,997		(6)(17)
Blue Sprig Pediatrics, Inc.	Senior Secured	November 2026	1-month SOFR + 5.11%, Floor rate 6.00%, PIK Interest 4.45%	$	76,391	76,183		74,296		(11)(12)(13)(14)
ChenMed, LLC	Senior Secured	May 2030	Prime + 2.45%, Floor rate 9.45%, 3.75% Exit Fee	$	130,000	128,408		128,186		(16)(17)
Curana Health Holdings, LLC	Senior Secured	January 2028	Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee	$	45,000	45,832		46,147		(13)(19)
Ennoble Care LLC	Senior Secured	February 2030	Prime + 2.60%, Floor rate 10.35%, 7.95% Exit Fee	$	31,500	31,373		31,196		(6)(15)(17)
Equality Health, LLC	Senior Secured	February 2028	Prime + 5.85%, Floor rate 9.50%, PIK Interest 1.95%	$	72,294	71,847		70,716		(11)(12)(14)
Main Street Rural, Inc.	Senior Secured	July 2027	Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee	$	73,500	75,542		75,272		(13)(15)
Marathon Health, LLC	Senior Secured	February 2029	Prime + 0.75%, Floor rate 8.75%, PIK Interest 2.25%, 3.00% Exit Fee	$	183,865	184,359		183,062		(14)(16)(17)
	Senior Secured	February 2029	Prime + 3.00%, Floor rate 11.00%	$	4,000	4,000		4,000		(16)(17)
Total Marathon Health, LLC				$	187,865	188,359		187,062
Modern Life, Inc.	Senior Secured	February 2029	Prime + 2.75%, Floor rate 10.25%, 5.00% Exit Fee	$	19,635	19,757		19,521		(13)
NeueHealth, Inc.	Senior Secured	June 2028	Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee	$	54,936	53,204		53,138		(12)(14)
Octave Health Group, Inc.	Senior Secured	October 2029	Prime + 2.70%, Floor rate 9.95%, 5.35% Exit Fee	$	10,000	9,814		9,814		(6)
Strive Health Holdings, LLC	Senior Secured	August 2029	Prime + 1.05%, Floor rate 9.55%, 5.95% Exit Fee	$	36,000	36,007		36,545		(12)(15)
The Recovery Company, Inc. (p.k.a. Recover Together, Inc.)	Senior Secured	July 2027	Prime + 1.90%, Floor rate 9.90%, 7.50% Exit Fee	$	46,500	48,444		50,917		(13)
Tungsten Health Holdings, LLC	Senior Secured	December 2029	Prime + 1.00%, Floor rate 8.50%, Cap rate 9.00%, PIK Interest 1.25%, 8.35% Exit Fee	$	10,146	10,100		10,100		(14)
Vida Health, Inc.	Senior Secured	January 2028	Prime - 2.75%, Floor rate 6.75%, PIK Interest 4.35%	$	39,319	39,213		38,743		(11)(14)
	Senior Secured	January 2028	Prime - 2.75%, Floor rate 6.75%, PIK Interest 4.35%, 10.00% Exit Fee	$	2,000	1,981		1,958		(11)
Total Vida Health, Inc.				$	41,319	41,194		40,701
WellBe Senior Medical, LLC	Senior Secured	May 2029	Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee	$	33,269	33,575		32,988		(14)(15)
Subtotal: Healthcare Services, Other (39.41%)*						880,636		877,596

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Information Services
Saama Technologies, LLC	Senior Secured	July 2027	Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 3.45% Exit Fee	$	22,234	$	22,492	$	22,604	(12)(14)(17)
Subtotal: Information Services (1.02%)*						22,492		22,604
Manufacturing Technology
VulcanForms Inc.	Senior Secured	January 2028	Prime + 4.25%, Floor rate 11.25%, 4.25% Exit Fee	$	20,000	20,134		19,907		(11)(19)
Subtotal: Manufacturing Technology (0.89%)*						20,134		19,907
Medical Devices & Equipment
Cognito Therapeutics Group, Inc.	Senior Secured	January 2030	Prime + 2.70%, Floor rate 9.95%, 5.75% Exit Fee	$	4,500	4,327		4,327		(6)
Orchestra BioMed Holdings, Inc.	Senior Secured	November 2028	Prime + 2.00%, Floor rate 9.50%, 6.35% Exit Fee	$	15,000	15,121		15,141		(6)(15)
Senseonics Holdings, Inc.	Senior Secured	August 2029	Prime + 2.40%, Floor rate 9.90%, 13.40% Exit Fee	$	30,625	31,699		31,336		(11)(17)
Sight Sciences, Inc.	Senior Secured	July 2028	Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee	$	28,000	28,538		28,428		(6)(12)
Subtotal: Medical Devices & Equipment (3.56%)*						79,685		79,232
Space Technologies
HawkEye 360, Inc.	Senior Secured	December 2028	Prime + 2.10%, Floor rate 9.35%, PIK Interest 1.50%, 1.95% Exit Fee	$	8,038	7,767		7,767		(14)(19)
Loft Orbital Solutions Inc.	Senior Secured	December 2029	Prime + 1.75%, Floor rate 8.75%, PIK Interest 1.00%, 3.45% Exit Fee	$	8,842	8,628		8,618		(14)(17)(19)
Stoke Space Technologies, Inc.	Senior Secured	May 2029	Prime + 1.00%, Floor rate 7.50%, PIK Interest 2.00%, 5.25% Exit Fee	$	28,429	27,780		27,795		(6)(14)(15)
Subtotal: Space Technologies (1.98%)*						44,175		44,180
Sustainable and Renewable Technology
Electric Hydrogen Co.	Senior Secured	May 2028	Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.25% Exit Fee	$	12,809	12,825		12,565		(14)(15)(19)
	Senior Secured	May 2028	Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 5.95% Exit Fee	$	17,664	17,752		17,626		(14)(15)(19)
Total Electric Hydrogen Co.				$	30,473	30,577		30,191
Tidal Vision Products, Inc.	Senior Secured	October 2028	Prime + 2.45%, Floor rate 9.70%, 3.45% Exit Fee	$	5,000	4,769		4,769		(6)(17)
Subtotal: Sustainable and Renewable Technology (1.57%)*						35,346		34,960
System Software
Akeyless Security Ltd.	Senior Secured	August 2028	Prime + 4.00%, Floor rate 11.00%, 2.95% Exit Fee	$	10,000	9,893		9,780		(5)(10)(17)
Armis, Inc.	Senior Secured	March 2028	Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee	$	52,030	52,268		53,155		(12)(14)(16)
	Senior Secured	March 2028	Prime + 1.25%, Floor rate 8.75%, PIK Interest 2.00%, 2.25% Exit Fee	$	101,690	101,558		103,940		(11)(14)(16)
Total Armis, Inc.				$	153,720	153,826		157,095
ControlUp, Inc.	Senior Secured	January 2031	Prime + 0.25%, Floor rate 6.75%, PIK Interest 2.00%, 3.00% Exit Fee	$	10,032	9,934		9,934		(14)(17)
CoreView USA, Inc.	Senior Secured	January 2029	Prime + 2.75%, Floor rate 9.25%, 4.95% Exit Fee	$	25,000	25,129		24,558		(6)(17)
Coronet Cyber Security Ltd.	Senior Secured	October 2028	Prime - 2.95%, Floor rate 3.55%, PIK Interest 5.85%	$	7,310	7,226		6,883		(14)
DNSFilter, Inc.	Senior Secured	October 2028	Prime + 2.15%, Floor rate 8.65%, PIK Interest 0.75%, 4.95% Exit Fee	$	5,018	4,999		4,967		(14)(17)(19)
Expel, Inc.	Senior Secured	April 2029	Prime + 3.90%, Floor rate 10.65%, 2.00% Exit Fee	$	12,000	11,875		11,875		(17)
Harness, Inc.	Senior Secured	March 2029	Prime - 2.25%, Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee	$	58,825	58,360		59,115		(14)(19)
LogRhythm, Inc.	Senior Secured	July 2029	3-month SOFR + 7.50%, Floor rate 8.50%	$	25,000	24,461		23,005
Morphisec Information Security 2014 Ltd.	Senior Secured	October 2027	Prime + 3.45%, Floor rate 11.70%, 5.95% Exit Fee	$	11,435	11,664		11,460		(5)(10)
Neo4j, Inc.	Senior Secured	April 2030	Prime + 2.60%, Floor rate 9.10%, 3.50% Exit Fee	$	10,000	9,853		9,853

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
New Relic, Inc.	Senior Secured	November 2030	3-month SOFR + 6.75%, Floor rate 7.75%	$	21,890	$	21,481	$	21,246	(17)
PayIt, LLC	Senior Secured	December 2028	Prime + 1.45%, Floor rate 7.95%, PIK Interest 1.50%, 5.00% Exit Fee	$	26,366	26,398		25,558		(6)(14)(15)(17)(19)
Scylla DB Ltd.	Senior Secured	July 2029	Prime + 3.00%, Floor rate 10.50%, 0.75% Exit Fee	$	15,000	14,817		14,565		(5)(10)(17)
Semperis Technologies Inc.	Senior Secured	April 2028	Prime - 1.75%, Floor rate 6.75%, PIK Interest 3.25%	$	23,703	23,512		23,734		(11)(14)(19)
	Senior Secured	April 2028	Prime - 0.50%, Floor rate 8.00%, PIK Interest 3.85%	$	34,141	33,712		33,487		(14)(19)
	Senior Secured	April 2028	Prime + 2.50%, Floor rate 9.00%, PIK Interest 1.50%	$	8,266	8,199		8,046		(14)(19)
Total Semperis Technologies Inc.				$	66,110	65,423		65,267
Sumo Logic, Inc.	Senior Secured	May 2030	3-month SOFR + 6.50%, Floor rate 7.50%	$	23,063	22,672		22,073		(14)(17)
Zimperium, Inc.	Senior Secured	May 2027	3-month SOFR + 8.84%, Floor rate 9.84%	$	14,790	14,702		14,559		(17)(18)
	Senior Secured	May 2027	6-month SOFR + 8.84%, Floor rate 9.84%	$	2,963	2,939		2,923		(17)(18)
	Senior Secured	May 2027	1-month SOFR + 5.64%, Floor rate 6.64%	$	1,800	1,782		1,786		(17)(18)
Total Zimperium, Inc.				$	19,553	19,423		19,268
Subtotal: System Software (22.29%)*						497,434		496,502
Total: Debt Investments (203.87%)*						$	4,561,862	$	4,540,145


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Equity Investments
Application Software
Black Crow AI, Inc. affiliates	Equity	3/24/2021	Preferred Note	3	$	2,911	$	2,911	(21)
CapLinked, Inc.	Equity	10/26/2012	Preferred Series A-3	53,614	51		—
DNAnexus, Inc.	Equity	3/21/2014	Preferred Series C	51,948	97		8
HighRoads, Inc.	Equity	1/18/2013	Common Stock	190	307		—
Hypercore Inc.	Equity	1/22/2026	Preferred Series A-II	231,938	400		400
Khoros, LLC	Equity	5/23/2025	Earnout Interest	N/A	5,243		748		(24)
Leapwork ApS	Equity	8/25/2023	Preferred Series B2	183,073	250		104		(5)(10)
Nextdoor.com, Inc.	Equity	8/1/2018	Common Stock	1,019,255	4,854		1,427		(4)
Verana Health, Inc.	Equity	7/8/2021	Common Stock	23,814	2,000		—
Subtotal: Application Software (0.25%)*					16,113		5,598
Biotechnology Tools
Alamar Biosciences, Inc.	Equity	2/21/2024	Preferred Series C	503,778	1,500		1,331
Subtotal: Biotechnology Tools (0.06%)*					1,500		1,331
Consumer & Business Products
Fabletics, Inc.	Equity	4/30/2010	Common Stock	42,989	128		46
	Equity	7/16/2013	Preferred Series B	130,191	1,101		265
Total Fabletics, Inc.				173,180	1,229		311
Grove Collaborative, Inc.	Equity	4/30/2021	Common Stock	12,260	433		16		(4)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Savage X Holding, LLC	Equity	4/30/2010	Class A Units	172,328	$	13	$	197
Subtotal: Consumer & Business Products (0.02%)*					1,675		524
Consumer & Business Services
Carwow LTD	Equity	12/15/2021	Preferred Series D-4	216,073	1,151		1,007		(5)(10)
Jobandtalent USA, Inc.	Equity	2/11/2025	Preferred Series F	47,754	563		109		(5)(10)
Lyft, Inc.	Equity	12/26/2018	Common Stock	100,738	5,263		1,340		(4)
Nerdy Inc.	Equity	9/17/2021	Common Stock	100,000	1,000		81		(4)
OfferUp, Inc.	Equity	10/25/2016	Preferred Series A	286,080	1,663		315
	Equity	10/25/2016	Preferred Series A-1	108,710	632		120
Total OfferUp, Inc.				394,790	2,295		435
Oportun	Equity	6/28/2013	Common Stock	48,365	577		223		(4)
Reischling Press, Inc.	Equity	7/31/2020	Common Stock	3,095	39		—
Rhino Labs, Inc.	Equity	1/24/2022	Common Stock	7,063	1,000		—
Tectura Corporation	Equity	5/23/2018	Common Stock	414,994,863	900		—		(7)
	Equity	6/6/2016	Preferred Series BB	1,000,000	—		—		(7)
	Equity	12/29/2023	Preferred Series C	3,235,298	13,263		1,703		(7)
Total Tectura Corporation				419,230,161	14,163		1,703
Worldremit Group Limited	Equity	6/24/2024	Preferred Series X	9,737	922		753		(5)(10)
Subtotal: Consumer & Business Services (0.25%)*					26,973		5,651
Defense Technologies
Saronic Technologies, Inc.	Equity	3/27/2026	Preferred Series D	154,854	4,250		4,305
Shield AI, Inc.	Equity	2/7/2025	Preferred Series F1	28,900	2,250		1,163		(16)
Subtotal: Defense Technologies (0.25%)*					6,500		5,468
Diversified Financial Services
Gibraltar Acquisition LLC	Equity	3/1/2018	Member Units	1	32,156		23,876		(7)(20)
Hercules Adviser LLC	Equity	3/26/2021	Member Units	1	12,035		41,137		(7)(23)
Subtotal: Diversified Financial Services (2.92%)*					44,191		65,013
Drug Delivery
Aytu BioScience, Inc.	Equity	3/28/2014	Common Stock	680	1,500		2		(4)
BioQ Pharma Incorporated	Equity	12/8/2015	Preferred Series D	165,000	500		—
PDS Biotechnology Corporation	Equity	4/6/2015	Common Stock	2,498	309		1		(4)
Talphera, Inc.	Equity	12/10/2018	Common Stock	8,836	1,329		7		(4)
Subtotal: Drug Delivery (0.00%)*					3,638		10
Drug Discovery & Development
Arcus Biosciences, Inc.	Equity	2/19/2025	Common Stock	204,545	2,250		4,418		(4)(10)
Avalo Therapeutics, Inc.	Equity	8/19/2014	Common Stock	42	1,000		1		(4)
Bicycle Therapeutics PLC	Equity	10/5/2020	Common Stock	98,100	1,871		455		(4)(5)(10)
Daré Bioscience, Inc.	Equity	1/8/2015	Common Stock	1,129	1,000		2		(4)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Dyne Therapeutics, Inc.	Equity	7/2/2025	Common Stock	169,697	$	1,400	$	3,077	(4)(10)
Heron Therapeutics, Inc.	Equity	7/25/2023	Common Stock	364,963	500		292		(4)
Hibercell, Inc.	Equity	5/7/2021	Preferred Series B	3,466,840	4,250		240		(15)
Kura Oncology, Inc.	Equity	6/16/2023	Common Stock	47,826	550		389		(4)(10)
MoonLake Immunotherapeutics	Equity	11/6/2025	Common Stock	95,500	1,002		1,780		(4)(5)(10)
NorthSea Therapeutics	Equity	12/15/2021	Preferred Series C	983	2,000		1,260		(5)(10)
Phathom Pharmaceuticals, Inc.	Equity	6/9/2023	Common Stock	147,233	1,730		1,636		(4)(10)(16)
Rafael Holdings, Inc.	Equity	4/6/2021	Common Stock	48	42		—		(4)(10)
Rocket Pharmaceuticals, Ltd.	Equity	8/22/2007	Common Stock	944	1,500		3		(4)
Savara, Inc.	Equity	8/11/2015	Common Stock	11,119	203		61		(4)
uniQure B.V.	Equity	1/31/2019	Common Stock	17,175	332		281		(4)(5)(10)
Valo Health, LLC	Equity	12/11/2020	Preferred Series B	510,308	3,000		1,221
	Equity	10/31/2022	Preferred Series C	170,102	1,000		759
Total Valo Health, LLC				680,410	4,000		1,980
Verge Analytics, Inc.	Equity	9/6/2023	Preferred Series C	208,588	1,500		999
	Equity	7/2/2025	SAFE	N/A	103		103		(25)
Total Verge Analytics, Inc.				208,588	1,603		1,102
Viridian Therapeutics, Inc.	Equity	11/6/2023	Common Stock	32,310	400		632		(4)(10)
X4 Pharmaceuticals, Inc.	Equity	11/26/2019	Common Stock	52,202	2,945		215		(4)
Subtotal: Drug Discovery & Development (0.80%)*					28,578		17,824
Electronics & Computer Hardware
Locus Robotics Corp.	Equity	11/17/2022	Preferred Series F	15,116	650		318
Skydio, Inc.	Equity	3/8/2022	Preferred Series E	248,900	1,500		671
Subtotal: Electronics & Computer Hardware (0.04%)*					2,150		989
Healthcare Services, Other
Click Therapeutics, Inc.	Equity	5/20/2024	Common Stock	560,000	1,662		2,125		(15)
Curana Health Holdings, LLC	Equity	5/13/2024	Class B Voting Common Units	1,114,380	2,500		2,963
	Equity	3/26/2026	Class C Non Voting Common Units	59,697	197		224
Total Curana Health Holdings, LLC				1,174,077	2,697		3,187
Main Street Rural, Inc.	Equity	10/28/2024	Preferred Series D	496	874		1,185
NH Holdings 2025 SPV, L.P.	Equity	6/21/2024	Common Units	401,681	2,234		2,510
Strive Health Holdings, LLC	Equity	6/27/2025	Common Units	82,043	599		802
WellBe Senior Medical, LLC	Equity	6/10/2024	Common Units	181,163	1,600		1,605
Subtotal: Healthcare Services, Other (0.51%)*					9,666		11,414
Information Services
Yipit, LLC	Equity	12/30/2021	Preferred Series E	41,021	3,825		3,030
Subtotal: Information Services (0.14%)*					3,825		3,030

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Medical Devices & Equipment
Coronado Aesthetics, LLC	Equity	10/15/2021	Common Units	180,000	$	—	$	—	(7)
	Equity	10/15/2021	Preferred Series A-2	5,000,000	250		158		(7)
Total Coronado Aesthetics, LLC				5,180,000	250		158
Orchestra BioMed Holdings, Inc.	Equity	8/4/2025	Common Stock	363,636	1,000		1,546		(4)
Subtotal: Medical Devices & Equipment (0.08%)*					1,250		1,704
Semiconductors
Achronix Semiconductor Corporation	Equity	7/1/2011	Preferred Series C	277,995	160		10
	Equity	6/26/2015	Preferred Series D-2	497,767	7		119
Total Achronix Semiconductor Corporation				775,762	167		129
Subtotal: Semiconductors (0.01%)*					167		129
Space Technologies
Planet Labs PBC	Equity	1/13/2026	Common Stock	60,496	1,527		1,691		(4)(10)
Stoke Space Technologies, Inc.	Equity	9/23/2025	Preferred Series D	43,867	1,406		1,880
	Equity	2/6/2026	Preferred Series D-2	28,168	1,407		1,304
Total Stoke Space Technologies, Inc.				72,035	2,813		3,184
Subtotal: Space Technologies (0.22%)*					4,340		4,875
Sustainable and Renewable Technology
Impossible Foods, Inc.	Equity	5/10/2019	Preferred Series E-1	188,611	2,000		105
Modumetal, Inc.	Equity	6/1/2015	Common Stock	1,035	500		—
Pivot Bio, Inc.	Equity	6/28/2021	Preferred Series D	593,080	4,500		358
SUNation Energy, Inc.	Equity	12/10/2020	Common Stock	3	3,153		—		(4)
Subtotal: Sustainable and Renewable Technology (0.02%)*					10,153		463
System Software
Armis, Inc.	Equity	10/18/2024	Preferred Series D	294,213	2,000		3,845		(16)
Contentful Global, Inc.	Equity	12/22/2020	Preferred Series C	41,000	138		255		(5)(10)
	Equity	11/20/2018	Preferred Series D	108,500	500		724		(5)(10)
Total Contentful Global, Inc.				149,500	638		979
Docker, Inc.	Equity	11/29/2018	Common Stock	20,000	4,284		110
Druva Holdings, Inc.	Equity	10/22/2015	Preferred Series 2	458,841	1,000		2,588
	Equity	8/24/2017	Preferred Series 3	93,620	300		554
Total Druva Holdings, Inc.				552,461	1,300		3,142
Lightbend, Inc.	Equity	12/4/2020	Common Stock	38,461	265		9
Subtotal: System Software (0.36%)*					8,487		8,085
Total: Equity Investments (5.93%)*					$	169,206	$	132,108

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Warrant Investments
Application Software
Annex Cloud	Warrant	6/5/2025	Common Units	50,000	$	—	$	—
Automation Anywhere, Inc.	Warrant	9/23/2022	Common Stock	254,778	448		99
Bitsight Technologies, Inc.	Warrant	11/18/2020	Common Stock	29,691	284		230
Brain Corporation	Warrant	10/4/2021	Common Stock	435,396	215		55
Carbyne, Inc.	Warrant	2/24/2025	Ordinary Shares	11,408	24		410
Cloudpay, Inc.	Warrant	4/10/2018	Preferred Series B	6,763	54		542		(5)(10)
Cutover, Inc.	Warrant	9/21/2022	Common Stock	102,898	26		21		(5)(10)
Dashlane, Inc.	Warrant	3/11/2019	Common Stock	770,838	461		562
Demandbase, Inc.	Warrant	8/2/2021	Common Stock	727,047	545		6
Distributed Creation Inc.	Warrant	4/21/2025	Common Stock	104,622	180		252
DroneDeploy, Inc.	Warrant	6/30/2022	Common Stock	95,911	278		305
Earnix, Inc.	Warrant	6/6/2024	Common Stock	20,762	220		213
Elation Health, Inc.	Warrant	9/12/2022	Common Stock	612,166	739		120
First Insight, Inc.	Warrant	5/10/2018	Preferred Series B	75,917	96		—
Fulfil Solutions, Inc.	Warrant	7/29/2022	Common Stock	84,995	325		78
Funnel Holding AB (publ)	Warrant	10/24/2025	Common Stock	485,385	46		27		(5)(10)
Imagen Technologies, Inc.	Warrant	11/26/2025	Preferred Series C-3-VI	311,570	110		173		(6)
Kore.ai, Inc.	Warrant	3/31/2023	Preferred Series C	64,293	208		37
Leapwork ApS	Warrant	1/23/2023	Common Stock	93,211	39		22		(5)(10)(12)
Mango Technologies, Inc.	Warrant	8/15/2025	Common Stock	71,298	377		205
Mixpanel, Inc.	Warrant	9/30/2020	Common Stock	82,362	252		232
Pindrop Security, Inc.	Warrant	6/26/2024	Common Stock	134,542	494		225		(15)
Reltio, Inc.	Warrant	6/30/2020	Common Stock	69,120	215		999
Simon Data, Inc.	Warrant	3/22/2023	Common Stock	77,934	96		—		(12)
Sisense Ltd.	Warrant	6/8/2023	Ordinary Shares	321,956	174		4		(5)(10)
Suzy, Inc.	Warrant	8/24/2023	Common Stock	292,936	367		142		(6)(15)
Tipalti Solutions Ltd.	Warrant	3/22/2023	Ordinary Shares	509,753	360		95		(10)(16)
	Warrant	3/27/2025	Ordinary Shares	473,266	136		12		(16)
Total Tipalti Solutions Ltd.				983,019	496		107
Ushur, Inc.	Warrant	6/5/2025	Common Stock	1,603,911	265		94		(6)(15)
VideoAmp, Inc.	Warrant	1/21/2022	Common Stock	152,048	1,275		—		(15)
ZeroEyes, Inc.	Warrant	5/6/2025	Common Stock	26,422	132		26		(6)(15)
Subtotal: Application Software (0.23%)*					8,441		5,186
Biotechnology Tools
Alamar Biosciences, Inc.	Warrant	6/21/2022	Preferred Series C	75,567	36		71
Antheia, Inc.	Warrant	8/29/2025	Common Stock	2,023,810	1,601		2,885

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
PathAI, Inc.	Warrant	12/23/2022	Common Stock	53,418	$	461	$	55	(12)
Subtotal: Biotechnology Tools (0.14%)*					2,098		3,011
Communications & Networking
Aryaka Networks, Inc.	Warrant	6/28/2022	Common Stock	486,097	242		—		(12)
Tarana Wireless, Inc.	Warrant	3/20/2026	Common Stock	827,622	43		43		(6)
Subtotal: Communications & Networking (0.00%)*					285		43
Consumer & Business Products
Gadget Guard, LLC	Warrant	6/3/2014	Common Stock	1,662,441	228		—
Whoop, Inc.	Warrant	6/27/2018	Preferred Series C	686,270	17		1,966
Subtotal: Consumer & Business Products (0.09%)*					245		1,966
Consumer & Business Services
Altumint, Inc.	Warrant	10/31/2024	Common Stock	1,701	126		88		(15)
AppDirect, Inc.	Warrant	9/22/2025	Common Stock	104,173	254		186
Carwow LTD	Warrant	12/14/2021	Common Stock	174,163	164		201		(5)(10)
	Warrant	2/13/2024	Preferred Series D-4	109,257	20		48		(5)(10)
Total Carwow LTD				283,420	184		249
CollectiveHealth, Inc.	Warrant	1/26/2026	Common Stock	577,252	21		16
Finix Payments, Inc.	Warrant	12/17/2025	Preferred Series C	1,839,547	122		118		(6)
Houzz, Inc.	Warrant	10/29/2019	Common Stock	529,661	20		—
Landing Holdings Inc.	Warrant	3/12/2021	Common Stock	11,806	116		3		(15)
Lendio, Inc.	Warrant	3/29/2019	Preferred Series D	127,032	39		3
Peek Travel, Inc.	Warrant	10/28/2025	Common Stock	60,169	157		60
Plentific Ltd	Warrant	10/3/2023	Ordinary Shares	27,298	60		41		(5)(10)
Provi	Warrant	12/22/2022	Common Stock	117,042	166		—		(15)
Rhino Labs, Inc.	Warrant	3/12/2021	Common Stock	13,106	470		—		(15)
SeatGeek, Inc.	Warrant	6/12/2019	Common Stock	1,604,724	1,242		5,261		(12)(16)
Skyword, Inc.	Warrant	11/14/2022	Common Stock	1,607,143	57		2
	Warrant	8/23/2019	Preferred Series B	444,444	83		—
Total Skyword, Inc.				2,051,587	140		2
Snagajob.com, Inc.	Warrant	4/20/2020	Common Stock	600,000	16		—
	Warrant	6/30/2016	Preferred Series A	1,800,000	782		—
	Warrant	8/1/2018	Preferred Series B	1,211,537	62		—
Total Snagajob.com, Inc.				3,611,537	860		—
Thumbtack, Inc.	Warrant	5/1/2018	Common Stock	343,497	985		1,020
Veem, Inc.	Warrant	3/31/2022	Common Stock	98,428	126		1		(12)
Worldremit Group Limited	Warrant	2/11/2021	Preferred Series D	77,215	129		41		(5)(10)
	Warrant	8/27/2021	Preferred Series E	1,868	26		—		(5)(10)
Total Worldremit Group Limited				79,083	155		41
Subtotal: Consumer & Business Services (0.32%)*					5,243		7,089

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Defense Technologies
Hermeus Corporation	Warrant	3/20/2026	Common Stock	55,973	$	577	$	580
Saronic Technologies, Inc.	Warrant	6/9/2025	Preferred Series C	109,757	726		2,177		(6)(15)
Subtotal: Defense Technologies (0.12%)*					1,303		2,757
Drug Discovery & Development
Axsome Therapeutics, Inc.	Warrant	9/25/2020	Common Stock	61,004	1,290		5,150		(4)(10)(12)
Beren Therapeutics P.B.C.	Warrant	10/8/2025	Preferred Series A+	67,923	102		135		(6)
Cellarity, Inc.	Warrant	12/8/2021	Preferred Series B	100,000	287		72		(15)
Century Therapeutics, Inc.	Warrant	9/14/2020	Common Stock	16,112	37		1		(4)
COMPASS Pathways plc	Warrant	6/30/2023	Ordinary Shares	75,376	278		73		(4)(5)(10)
Curevo, Inc.	Warrant	6/9/2023	Common Stock	95,221	233		282		(15)
enGene, Inc.	Warrant	12/22/2023	Common Stock	72,284	218		151		(4)(5)(10)
Heron Therapeutics, Inc.	Warrant	8/9/2023	Common Stock	238,095	228		17		(4)(15)
Kura Oncology, Inc.	Warrant	11/2/2022	Common Stock	14,342	88		6		(4)(10)(15)
Madrigal Pharmaceuticals, Inc.	Warrant	5/9/2022	Common Stock	13,229	570		4,094		(4)(10)
Phathom Pharmaceuticals, Inc.	Warrant	9/17/2021	Common Stock	64,687	848		67		(4)(10)(12)(15)(16)
Redshift Bioanalytics, Inc.	Warrant	3/23/2022	Preferred Series E	475,510	20		13		(15)
Scynexis, Inc.	Warrant	5/14/2021	Common Stock	106,035	296		—		(4)
SynOx Therapeutics Limited	Warrant	4/18/2024	Preferred Series B	251,195	83		97		(5)(10)
TG Therapeutics, Inc.	Warrant	12/30/2021	Common Stock	117,168	721		1,518		(4)(10)
Valo Health, LLC	Warrant	6/15/2020	Common Units	102,216	256		59
X4 Pharmaceuticals, Inc.	Warrant	3/18/2019	Common Stock	46,424	510		7		(4)
Subtotal: Drug Discovery & Development (0.53%)*					6,065		11,742
Electronics & Computer Hardware
908 Devices, Inc.	Warrant	3/15/2017	Common Stock	49,078	101		46		(4)
Locus Robotics Corp.	Warrant	6/21/2022	Common Stock	8,503	34		67
Skydio, Inc.	Warrant	11/8/2021	Common Stock	622,255	557		565
Subtotal: Electronics & Computer Hardware (0.03%)*					692		678
Healthcare Services, Other
Belong Health, Inc.	Warrant	11/13/2025	Common Stock	1,933,102	400		442		(6)
Curana Health Holdings, LLC	Warrant	1/4/2024	Common Units	447,410	156		532
Modern Life, Inc.	Warrant	3/30/2023	Common Stock	63,202	229		34
Octave Health Group, Inc.	Warrant	11/28/2025	Common Stock	225,310	168		174		(6)
Strive Health Holdings, LLC	Warrant	9/28/2023	Common Units	129,400	278		472		(15)
The Recovery Company, Inc. (p.k.a. Recover Together, Inc.)	Warrant	7/3/2023	Common Stock	194,830	382		22
Vida Health, Inc.	Warrant	3/28/2022	Preferred Series E	192,431	121		34
Subtotal: Healthcare Services, Other (0.08%)*					1,734		1,710

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Information Services
NetBase Quid, Inc.	Warrant	8/22/2017	Preferred Series 1	60,000	$	356	$	—
Subtotal: Information Services (0.00%)*					356		—
Manufacturing Technology
Bright Machines, Inc.	Warrant	3/31/2022	Common Stock	392,308	537		210
MacroFab, Inc.	Warrant	3/23/2022	Common Stock	1,111,111	528		—
VulcanForms Inc.	Warrant	1/30/2025	Common Stock	99,923	74		636
Subtotal: Manufacturing Technology (0.04%)*					1,139		846
Media/Content/Info
Fever Labs, Inc.	Warrant	12/30/2022	Preferred Series E-1	369,370	67		31
Subtotal: Media/Content/Info (0.00%)*					67		31
Medical Devices & Equipment
Cognito Therapeutics Group, Inc.	Warrant	1/23/2026	Common Stock	76,529	149		182		(6)
Orchestra BioMed Holdings, Inc.	Warrant	11/6/2024	Common Stock	167,831	216		295		(4)(6)(15)
Senseonics Holdings, Inc.	Warrant	9/8/2023	Common Stock	51,635	276		96		(4)
Sight Sciences, Inc.	Warrant	1/22/2024	Common Stock	113,247	363		110		(4)(6)(12)
Tela Bio, Inc.	Warrant	3/31/2017	Common Stock	15,712	61		—		(4)
Subtotal: Medical Devices & Equipment (0.03%)*					1,065		683
Semiconductors
Achronix Semiconductor Corporation	Warrant	1/11/2017	Preferred Series D-2	250,000	92		58
Subtotal: Semiconductors (0.00%)*					92		58
Space Technologies
HawkEye 360, Inc.	Warrant	12/18/2025	Common Stock	40,912	227		230
Loft Orbital Solutions Inc.	Warrant	9/10/2025	Common Stock	22,688	185		218
Stoke Space Technologies, Inc.	Warrant	6/16/2025	Common Stock	99,497	990		3,664		(6)(15)
Subtotal: Space Technologies (0.18%)*					1,402		4,112
Sustainable and Renewable Technology
Ampion, PBC	Warrant	4/15/2022	Common Stock	18,472	52		39
Electric Hydrogen Co.	Warrant	3/27/2024	Common Stock	246,618	507		164		(15)
Tidal Vision Products, Inc.	Warrant	10/10/2025	Common Stock	48,491	232		178		(6)
Subtotal: Sustainable and Renewable Technology (0.02%)*					791		381
System Software
Akeyless Security Ltd.	Warrant	8/4/2025	Ordinary Shares	87,917	68		43		(5)(10)
CloudBolt Software, Inc.	Warrant	9/30/2020	Common Stock	211,342	117		—
Cloudian, Inc.	Warrant	11/6/2018	Common Stock	477,454	71		—
ControlUp Technologies Ltd.	Warrant	1/2/2026	Common Stock	62,045	33		31		(5)(10)
Coronet Cyber Security Ltd.	Warrant	9/26/2024	Ordinary Shares	39,183	254		3

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Dragos, Inc.	Warrant	6/28/2023	Common Stock	57,528	$	1,575	$	947
Harness, Inc.	Warrant	3/12/2024	Common Stock	193,618	534		699
Lightbend, Inc.	Warrant	2/14/2018	Preferred Series LB-2	86,984	131		19
Morphisec Information Security 2014 Ltd.	Warrant	10/1/2024	Ordinary Shares	200,115	104		39		(5)(10)
Neo4j, Inc.	Warrant	3/31/2026	Common Stock	18,395	42		42
Scylla DB Ltd.	Warrant	7/24/2025	Ordinary Shares	159,684	52		35		(5)(10)
Semperis Technologies Inc.	Warrant	4/23/2024	Common Stock	193,264	446		356
Subtotal: System Software (0.10%)*					3,427		2,214
Total: Warrant Investments (1.91%)*					$	34,445	$	42,507
Total Investments in Securities (211.71%)*					$	4,765,513	$	4,714,760

Investment Funds & Vehicles Investments
Drug Discovery & Development
Forbion Growth Opportunities Fund I C.V.	Investment Funds & Vehicles	11/16/2020			$	2,906	$	5,384	(5)(10)(17)
Forbion Growth Opportunities Fund II C.V.	Investment Funds & Vehicles	6/23/2022			1,565		1,472		(5)(10)(17)
Subtotal: Drug Discovery & Development (0.31%)*					4,471		6,856
System Software
Liberty Zim Co-Invest L.P.	Investment Funds & Vehicles	7/21/2022			385		371		(5)(10)
Subtotal: System Software (0.02%)*					385		371
Total: Investment Funds & Vehicles Investments (0.32%)*					$	4,856	$	7,227
Total Investments before Cash & Cash Equivalents (212.03%)*					$	4,770,369	$	4,721,987
Cash & Cash Equivalents
GS Financial Square Government Fund	Cash & Cash Equivalents		FGTXX/38141W273		$	8,080	$	8,080
Total: Investments in Cash & Cash Equivalents (0.36%)*					$	8,080	$	8,080
Total: Investments after Cash & Cash Equivalents (212.40%)*					$	4,778,449	$	4,730,067


Foreign Currency Forward Contracts

Foreign Currency	Settlement Date	Counterparty	Amount		Transaction	US $ Value at Settlement Date		Value
Great British Pound (GBP)	6/5/2026	Goldman Sachs Bank USA	£	20,814	Sold	$	28,056	$	522
Total Foreign Currency Forward (0.02%)*						$	28,056	$	522

*Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(1)Prime represents 6.75% as of March 31, 2026. 1-month SOFR, 3-month SOFR and 6-month SOFR represent 3.66%, 3.68%, and 3.70%, respectively, as of March 31, 2026.

(2)Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $90.1 million, $139.7 million and $49.6 million, respectively. The tax cost of investments is $4.8 billion.

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2026 (unaudited)

(dollars in thousands)

(3)Preferred and common stock, warrants, and equity interests are generally non-income producing.

(4)Except for warrants in 16 publicly traded companies and common stock in 26 publicly traded companies, all investments are restricted as of March 31, 2026 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s Valuation Committee (as defined in “Note 2 - Summary of Significant Accounting Policies - Valuation of Investments”) and approved by the board of directors (the “Board”).

(5)Non-U.S. company or the company’s principal place of business is outside the United States.

(6)Denotes that all or a portion of the investment in this portfolio company is held by Hercules SBIC V, L.P., the Company’s wholly owned small business investment company.

(7)Control investment as defined under the Investment Company Act of 1940, as amended (the “1940 Act”) in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.

(8)Debt is on non-accrual status as of March 31, 2026, and is therefore considered non-income producing.

(9)Denotes that all or a portion of the debt investment is convertible debt.

(10)Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(11)Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).

(12)Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”).

(13)Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”).

(14)Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.

(15)Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company.

(16)Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of March 31, 2026.

(17)Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of March 31, 2026 (Refer to “Note 11 - Commitments and Contingencies”).

(18)Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.

(19)Denotes second lien senior secured debt.

(20)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC.

(21)Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of common stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of March 31, 2026, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $2.9 million.

(22)Denotes that a portion of this investment holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $11.5 million and $12.0 million, respectively.

(23)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 – Description of Business” for additional disclosure.

(24)Denotes investment in a non-voting security in the form of an earnout interest. The terms of the security provide the Company with contractual rights to receive approximately 12.48% of contingent earnout payments from the portfolio company to the earnout holders. As of March 31, 2026, the approximate cost and fair value of the earnout interest is $5.2 million and $0.7 million, respectively.

(25)Denotes investment in a SAFE (Simple Agreement for Future Equity). The terms of the SAFE provide the Company with preferred stock in the event of an equity financing before the termination of the SAFE. As of March 31, 2026, the approximate cost and fair value of the SAFE is $0.1 million.

(26)Denotes that the debt investment remains outstanding beyond its stated maturity date as it is subject to an ongoing workout process.

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Debt Investments
Application Software(27)
Alchemer LLC	Senior Secured	May 2028	1-month SOFR + 8.14%, Floor rate 9.14%	$	20,163	$	19,919	$	20,163	(13)(17)(18)
AlphaSense, Inc.	Senior Secured	June 2029	3-month SOFR + 6.25%, Floor rate 8.25%	$	20,000	19,849		19,916		(11)
Annex Cloud	Senior Secured	June 2028	PIK Interest 3-month SOFR + 9.99%, Floor rate 10.99%	$	5,642	5,642		2,257		(8)(13)(18)
	Senior Secured	December 2025	PIK Interest 3-month SOFR + 9.99%, Floor rate 10.99%	$	3,325	3,325		3,325		(8)(18)(26)
	Senior Secured	June 2028	PIK Interest 3-month SOFR + 5.73%, Floor rate 6.73%	$	1,716	1,717		687		(8)(18)
Total Annex Cloud				$	10,683	10,684		6,269
Babel Street	Senior Secured	December 2027	3-month SOFR + 8.01%, Floor rate 9.01%	$	65,937	65,038		64,738		(15)(17)(18)
Behavox Limited	Senior Secured	September 2027	Prime - 0.55%, Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee	$	19,444	19,596		19,598		(5)(10)(11)(14)(17)
Brain Corporation	Senior Secured	September 2028	Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee	$	32,830	32,865		33,410		(13)(14)
Carbyne, Inc.	Senior Secured	February 2029	Prime + 3.50%, Floor rate 10.00%, 3.50% Exit Fee	$	7,450	7,430		7,711		(17)
Ceros, Inc.	Senior Secured	June 2027	3-month SOFR + 8.99%, Floor rate 9.89%	$	22,656	22,543		22,506		(18)
Chainalysis, Inc.	Senior Secured	June 2029	Prime + 2.95%, Floor rate 10.45%	$	36,412	35,954		36,143
Dashlane, Inc.	Senior Secured	December 2027	Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee	$	45,986	46,789		48,034		(11)(13)(14)(19)
Dispatch Technologies, Inc.	Senior Secured	April 2028	3-month SOFR + 7.86%, Floor rate 8.61%	$	8,751	8,634		8,524		(17)(18)
Distributed Creation Inc.	Senior Secured	April 2029	Prime + 3.00%, Floor rate 10.25%, 4.50% Exit Fee	$	25,000	24,825		25,024		(11)(17)
DocPlanner	Senior Secured	January 2030	Prime + 2.75%, Floor rate 9.75%, 4.25% Exit Fee	€	68,200	69,857		80,519		(5)(10)(17)
Earnix, Inc.	Senior Secured	June 2029	Prime - 1.15%, Floor rate 5.35%, PIK Interest 4.45%	$	20,049	19,790		20,126		(11)(14)(17)
Elation Health, Inc.	Senior Secured	April 2029	Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.30%, 3.95% Exit Fee	$	13,575	13,283		13,477		(11)(14)(17)(19)
Funnel Holding AB (publ)	Senior Secured	October 2029	Prime + 0.60%, Floor rate 7.10%, Cap rate 8.60%, PIK Interest 3.00%, 2.25% Exit Fee	$	18,433	18,196		18,196		(5)(10)(14)(17)(19)
Imagen Technologies, Inc.	Senior Secured	November 2028	Prime + 1.55%, Floor rate 9.05%, PIK Interest 1.00%, 3.95% Exit Fee	$	7,501	7,360		7,360		(6)(14)(17)
iSpot.tv, Inc.	Senior Secured	January 2029	Prime + 2.25%, Floor rate 8.75%, PIK Interest 1.00%, 5.70% Exit Fee	$	3,282	3,285		3,265		(14)(17)
	Senior Secured	January 2029	Prime + 1.40%, Floor rate 7.90%, PIK Interest 0.75%, 4.50% Exit Fee	$	39,139	38,980		39,147		(12)(14)(17)
Total iSpot.tv, Inc.				$	42,421	42,265		42,412
Khoros, LLC	Senior Secured	May 2030	FIXED 10.00%	$	11,704	11,704		11,399
LinenMaster, LLC	Senior Secured	August 2029	1-month SOFR + 8.28%, Floor rate 9.28%	$	11,500	11,179		11,096		(17)(18)
Loftware, Inc.	Senior Secured	March 2028	3-month SOFR + 7.88%, Floor rate 8.88%	$	29,660	29,247		29,660		(17)(18)
LogicSource	Senior Secured	July 2027	3-month SOFR + 8.93%, Floor rate 9.93%	$	11,113	11,020		11,113		(17)(18)
Mango Technologies, Inc.	Senior Secured	August 2030	Prime + 2.25%, Floor rate 8.25%, 2.00% Exit Fee	$	16,750	16,528		16,528		(17)
Marigold Group, Inc.	Senior Secured	April 2028	6-month SOFR + 4.75%, Floor rate 5.75%, PIK Interest 5.25%	$	44,555	43,960		40,736		(13)(14)(19)
Omeda Holdings, LLC	Senior Secured	July 2027	3-month SOFR + 8.05%, Floor rate 9.05%	$	7,303	7,207		7,303		(11)(17)(18)
Pindrop Security, Inc.	Senior Secured	June 2029	Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee	$	31,000	30,759		31,338		(15)(17)
Proven Optics, LLC	Senior Secured	December 2030	3-month SOFR + 7.30%, Floor rate 8.30%	$	15,000	14,726		14,726		(17)(18)
Remodel Health Holdco, LLC	Senior Secured	December 2028	Prime + 2.35%, Floor rate 10.35%, 6.50% Exit Fee	$	25,000	25,126		25,334		(6)(15)
Reveleer	Senior Secured	February 2027	Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee	$	50,052	51,052		50,938		(6)(14)(15)
ShadowDragon, LLC	Senior Secured	December 2026	3-month SOFR + 8.79%, Floor rate 9.69%	$	6,000	5,958		5,958		(17)(18)
Simon Data, Inc.	Senior Secured	March 2027	Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 3.58% Exit Fee	$	11,350	11,560		11,343		(12)(14)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Sisense Ltd.	Senior Secured	July 2027	Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee	$	30,613	$	31,624	$	31,029	(5)(10)(14)
Smartsheet Inc.	Senior Secured	January 2031	3-month SOFR + 6.50%, Floor rate 7.25%	$	46,785	45,957		46,204		(17)
Snappt, Inc.	Senior Secured	April 2029	Prime + 2.35%, Floor rate 8.85%, PIK Interest 1.00%, 4.25% Exit Fee	$	20,139	20,071		19,753		(6)(14)(15)
Streamline Healthcare Solutions	Senior Secured	June 2030	3-month SOFR + 7.30%, Floor rate 8.30%	$	21,000	20,403		20,443		(6)(11)(13)(15)(17) (18)
Suzy, Inc.	Senior Secured	August 2027	Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee	$	24,827	24,901		24,378		(6)(14)(15)
TaxCalc	Senior Secured	November 2029	Daily SONIA + 8.17%, Floor rate 8.67%	£	8,250	10,557		10,897		(5)(10)(17)(18)
Tipalti Solutions Ltd.	Senior Secured	April 2029	Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%	$	72,488	72,141		70,507		(14)(16)
	Senior Secured	April 2029	Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%, 3.75% Exit Fee	$	42,673	42,708		42,622		(14)(16)
Total Tipalti Solutions Ltd.				$	115,161	114,849		113,129
Ushur, Inc.	Senior Secured	June 2028	Prime + 2.20%, Floor rate 9.20%, 3.95% Exit Fee	$	14,400	14,191		14,106		(6)(15)
Zappi, Inc.	Senior Secured	December 2027	3-month SOFR + 8.03%, Floor rate 9.03%	$	12,600	12,456		12,614		(5)(10)(13)(17)(18)
ZeroEyes, Inc.	Senior Secured	May 2030	Prime + 2.00%, Floor rate 9.50%, PIK Interest 2.00%, 1.50% Exit Fee	$	16,414	16,146		16,218		(6)(14)(15)(17)
Subtotal: Application Software (48.30%)*						1,066,058		1,070,369
Biotechnology Tools

Antheia, Inc.	Senior Secured	August 2029	Prime + 2.85%, Floor rate 10.35%, 5.55% Exit Fee	$	21,250	19,683		19,683
Subtotal: Biotechnology Tools (0.89%)*						19,683		19,683
Communications & Networking
Aryaka Networks, Inc.	Senior Secured	December 2028	Prime + 1.80%, Floor rate 9.30%, PIK Interest 1.25%, 6.73% Exit Fee	$	28,271	28,536		26,263		(12)(14)(19)


Subtotal: Communications & Networking (1.19%)*						28,536		26,263
Consumer & Business Products
Weee! Inc.	Senior Secured	April 2028	Prime + 2.25%, Floor rate 9.75%, 2.50% Exit Fee	$	7,500	7,472		7,583		(11)(17)
Subtotal: Consumer & Business Products (0.34%)*						7,472		7,583
Consumer & Business Services
AppDirect, Inc.	Senior Secured	September 2029	Prime + 2.05%, Floor rate 8.55%, PIK Interest 1.00%, 4.70% Exit Fee	$	55,357	54,713		54,713		(14)
Carwow LTD	Senior Secured	December 2027	Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee	£	20,662	28,533		27,960		(5)(10)(14)
Finix Payments, Inc.	Senior Secured	December 2029	Prime + 2.50%, Floor rate 9.25%, 4.95% Exit Fee	$	7,000	6,889		6,889		(6)(17)
GoEuro Travel GmbH	Senior Secured	November 2029	Prime + 3.45%, Floor rate 10.45%, 4.50% Exit Fee	$	48,750	48,750		49,137		(5)(10)(17)
Houzz, Inc.	Convertible Debt	May 2028	PIK Interest 12.00%	$	28,901	28,901		30,986		(9)(14)
Jobandtalent USA, Inc.	Senior Secured	October 2028	1-month SOFR + 3.50%, Floor rate 4.50%, PIK Interest 3.25%, 6.42% Exit Fee	$	14,270	14,839		14,082		(5)(10)(14)
Nerdy Inc.	Senior Secured	November 2029	Prime + 3.50%, Floor rate 10.75%, 7.50% Exit Fee	$	14,000	13,867		13,867		(17)
Peek Travel, Inc.	Senior Secured	October 2028	Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.00%, 4.95% Exit Fee	$	16,515	16,280		16,280		(14)(17)
Plentific Ltd	Senior Secured	October 2026	Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee	$	3,035	3,073		3,073		(5)(10)(13)
Provi	Senior Secured	December 2027	Prime + 4.40%, Floor rate 10.65%, 1.00% Exit Fee	$	15,443	15,394		15,389		(15)

Riviera Partners LLC	Senior Secured	March 2028	1-month SOFR + 8.28%, Floor rate 9.28%	$	36,126	35,850		35,546		(18)
RVShare, LLC	Senior Secured	December 2026	3-month SOFR + 9.50%, Floor rate 10.50%	$	25,809	25,719		25,719		(13)(14)(15)
SeatGeek, Inc.	Senior Secured	May 2026	Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.50% Exit Fee	$	25,456	26,250		26,250		(11)(14)(16)
	Senior Secured	July 2026	Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.50% Exit Fee	$	78,434	79,685		79,685		(12)(14)(16)
Total SeatGeek, Inc.				$	103,890	105,935		105,935

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Skyword, Inc.	Senior Secured	November 2027	Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 5.50% Exit Fee	$	6,705	$	6,913	$	6,705	(13)(14)
Tectura Corporation	Senior Secured	January 2027	FIXED 8.25%	$	8,250	8,250		8,091		(7)



Thumbtack, Inc.	Senior Secured	March 2028	Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%	$	21,238	20,976		21,663		(11)(14)







Subtotal: Consumer & Business Services (19.68%)*						434,882		436,035
Defense Technologies
Saronic Technologies, Inc.	Senior Secured	June 2030	Prime + 2.50%, Floor rate 9.00%, 2.00% Exit Fee	$	21,250	20,974		21,237		(6)(15)(17)
Shield AI, Inc.	Senior Secured	February 2029	Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee	$	116,675	116,535		116,843		(12)(14)(16)
Subtotal: Defense Technologies (6.23%)*						137,509		138,080
Diversified Financial Services
Gibraltar Acquisition LLC	Unsecured	July 2029	FIXED 3.45%, PIK Interest 8.05%	$	28,805	28,412		28,412		(7)(14)(20)
	Unsecured	July 2029	FIXED 11.95%	$	10,000	9,843		9,843		(7)(20)
Total Gibraltar Acquisition LLC				$	38,805	38,255		38,255


Subtotal: Diversified Financial Services (1.73%)*						38,255		38,255
Drug Discovery & Development


Aldeyra Therapeutics, Inc.	Senior Secured	April 2026	Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee	$	15,000	15,246		15,246		(11)

Alector, Inc.	Senior Secured	December 2028	Prime + 1.05%, Floor rate 8.05%, 4.75% Exit Fee	$	7,000	7,044		7,055		(6)(10)(15)(17)

Altimmune, Inc.	Senior Secured	June 2029	Prime + 2.45%, Floor rate 9.70%, 6.25% Exit Fee	$	17,500	17,437		17,403		(6)(10)(15)
Arcus Biosciences, Inc.	Senior Secured	September 2030	Prime - 0.05%, Floor rate 8.45%, PIK Interest 2.20%, 9.00% Exit Fee	$	75,704	76,173		79,788		(6)(10)(11)(14)(15) (17)
Beren Therapeutics P.B.C.	Senior Secured	October 2029	Prime + 2.45%, Floor rate 9.95%, 5.25% Exit Fee	$	8,625	8,471		8,471		(6)









Braeburn, Inc.	Senior Secured	October 2028	Prime + 3.00%, Floor rate 10.50%, PIK Interest 0.25%, 5.45% Exit Fee	$	53,633	54,463		55,720		(14)
COMPASS Pathways plc	Senior Secured	July 2027	Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee	$	24,840	25,464		25,543		(5)(10)(11)(14)




Corium, Inc.	Senior Secured	September 2026	Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee	$	86,925	92,296		92,296		(13)
Disc Medicine, Inc.	Senior Secured	December 2029	Prime + 1.75%, Floor rate 8.25%, 6.75% Exit Fee	$	22,500	22,659		23,279		(6)(10)(15)(17)
Dyne Therapeutics, Inc.	Senior Secured	July 2030	Prime + 2.45%, Floor rate 9.95%, 5.50% Exit Fee	$	100,000	99,389		101,148		(6)(10)(15)
enGene, Inc.	Senior Secured	January 2028	Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee	$	16,111	16,510		16,672		(5)(10)(14)
Genetix Biotherapeutics Inc. (p.k.a. bluebird bio, Inc.)	Senior Secured	April 2029	Prime + 2.45%, Floor rate 9.45%, 6.45% Exit Fee	$	67,116	66,811		66,664		(14)



Heron Therapeutics, Inc.	Senior Secured	September 2030	Prime + 1.95%, Floor rate 9.45%, PIK Interest 1.00%, 6.25% Exit Fee	$	80,368	79,892		79,892		(14)(15)



Kura Oncology, Inc.	Senior Secured	November 2027	Prime + 2.40%, Floor rate 8.65%, 6.05% Exit Fee	$	5,500	5,712		5,833		(10)(15)

MoonLake Immunotherapeutics	Senior Secured	April 2030	Prime + 1.45%, Floor rate 8.45%, 6.95% Exit Fee	$	34,500	34,479		34,246		(5)(10)

NorthSea Therapeutics	Convertible Debt	December 2026	FIXED 6.00%	$	373	373		373		(5)(9)(10)
Phathom Pharmaceuticals, Inc.	Senior Secured	December 2027	Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 7.06% Exit Fee	$	140,460	145,207		147,718		(6)(10)(12)(14)(15) (16)(22)
	Senior Secured	December 2027	Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 3.00% Exit Fee	$	31,904	32,005		32,542		(14)(16)
Total Phathom Pharmaceuticals, Inc.				$	172,364	177,212		180,260
Replimune Group, Inc.	Senior Secured	October 2027	Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee	$	32,378	33,205		33,280		(10)(12)(13)(14)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Savara, Inc.	Senior Secured	April 2030	Prime + 1.45%, Floor rate 7.45%, 6.95% Exit Fee	$	21,450	$	21,565	$	21,548	(6)(10)(15)



SynOx Therapeutics Limited	Senior Secured	May 2027	Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee	$	4,500	4,635		4,646		(5)(10)(11)
uniQure B.V.	Senior Secured	October 2030	Prime + 2.45%, Floor rate 9.45%, 5.50% Exit Fee	$	27,500	27,409		28,064		(5)(10)(11)



Viridian Therapeutics, Inc.	Senior Secured	October 2030	Prime + 1.45%, Floor rate 8.95%, Cap rate 9.45%, 6.00% Exit Fee	$	24,500	24,366		24,366		(10)(13)(17)
X4 Pharmaceuticals, Inc.	Senior Secured	July 2027	Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee	$	75,000	76,459		76,524		(11)(12)(13)
Subtotal: Drug Discovery & Development (45.05%)*						987,270		998,317
Electronics & Computer Hardware
Locus Robotics Corp.	Senior Secured	December 2028	Prime + 3.00%, Floor rate 9.50%, 4.00% Exit Fee	$	65,000	65,186		65,543		(6)(11)(15)

Subtotal: Electronics & Computer Hardware (2.96%)*						65,186		65,543
Healthcare Services, Other
Belong Health, Inc.	Senior Secured	November 2029	Prime + 2.25%, Floor rate 9.75%, 5.45% Exit Fee	$	11,250	10,950		10,950		(6)
Blue Sprig Pediatrics, Inc.	Senior Secured	November 2026	1-month SOFR + 5.11%, Floor rate 6.00%, PIK Interest 4.45%	$	75,547	75,265		73,386		(11)(12)(13)(14)
ChenMed, LLC	Senior Secured	May 2030	Prime + 2.45%, Floor rate 9.45%, 3.75% Exit Fee	$	130,000	128,101		128,240		(16)(17)


Curana Health Holdings, LLC	Senior Secured	January 2028	Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee	$	27,500	28,111		28,412		(13)(17)(19)
Ennoble Care LLC	Senior Secured	February 2030	Prime + 2.60%, Floor rate 10.35%, 7.95% Exit Fee	$	13,500	13,473		13,548		(6)(15)
Equality Health, LLC	Senior Secured	February 2028	Prime + 5.85%, Floor rate 9.50%, PIK Interest 1.95%, 1.27% Exit Fee	$	71,943	72,286		72,193		(11)(12)(14)
Main Street Rural, Inc.	Senior Secured	July 2027	Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee	$	73,500	75,009		75,007		(13)(15)
Marathon Health, LLC	Senior Secured	February 2029	Prime + 0.75%, Floor rate 8.75%, PIK Interest 2.25%, 3.00% Exit Fee	$	178,230	178,449		176,337		(14)(16)(17)

	Senior Secured	February 2029	Prime + 3.00%, Floor rate 11.00%	$	5,000	5,000		5,000		(16)(17)
Total Marathon Health, LLC				$	183,230	183,449		181,337
Modern Life, Inc.	Senior Secured	February 2029	Prime + 2.75%, Floor rate 10.25%, 5.00% Exit Fee	$	20,238	20,281		20,281		(13)
NeueHealth, Inc.	Senior Secured	June 2028	Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee	$	46,393	44,817		45,469		(12)(14)
Octave Health Group, Inc.	Senior Secured	October 2029	Prime + 2.70%, Floor rate 9.95%, 5.35% Exit Fee	$	10,000	9,768		9,768		(6)(17)
Recover Together, Inc.	Senior Secured	July 2027	Prime + 1.90%, Floor rate 9.90%, 7.50% Exit Fee	$	46,500	48,117		47,862		(13)
Strive Health Holdings, LLC	Senior Secured	August 2029	Prime + 1.05%, Floor rate 9.55%, 5.95% Exit Fee	$	36,000	35,899		35,899		(12)(15)
Tungsten Health Holdings, LLC	Senior Secured	December 2029	Prime + 1.00%, Floor rate 8.50%, Cap rate 9.00%, PIK Interest 1.25%, 8.35% Exit Fee	$	10,125	10,033		10,033
Vida Health, Inc.	Senior Secured	January 2028	Prime - 2.75%, Floor rate 5.75%, PIK Interest 5.35%, 4.95% Exit Fee	$	38,798	40,005		39,714		(11)(14)
WellBe Senior Medical, LLC	Senior Secured	May 2029	Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee	$	33,050	33,239		32,690		(14)(15)

Subtotal: Healthcare Services, Other (37.22%)*						828,803		824,789
Information Services



Saama Technologies, LLC	Senior Secured	July 2027	Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 3.45% Exit Fee	$	22,123	22,297		22,689		(12)(14)(17)



Subtotal: Information Services (1.02%)*						22,297		22,689













Manufacturing Technology
VulcanForms Inc.	Senior Secured	January 2028	Prime + 4.25%, Floor rate 11.25%, 4.25% Exit Fee	$	20,000	20,088		19,941		(11)(19)
Subtotal: Manufacturing Technology (0.90%)*						20,088		19,941
Medical Devices & Equipment
Orchestra BioMed Holdings, Inc.	Senior Secured	November 2028	Prime + 2.00%, Floor rate 9.50%, 6.35% Exit Fee	$	15,000	15,036		15,132		(6)(15)
Senseonics Holdings, Inc.	Senior Secured	August 2029	Prime + 2.40%, Floor rate 9.90%, 13.40% Exit Fee	$	30,625	31,441		31,252		(11)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Maturity Date	Interest Rate and Floor(1)	Principal Amount		Cost(2)		Value		Footnotes
Sight Sciences, Inc.	Senior Secured	July 2028	Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee	$	28,000	$	28,398	$	28,387	(6)(12)
Subtotal: Medical Devices & Equipment (3.37%)*						74,875		74,771

























































































Space Technologies
HawkEye 360, Inc.	Senior Secured	December 2028	Prime + 2.10%, Floor rate 9.35%, PIK Interest 1.50%, 1.95% Exit Fee	$	8,013	7,674		7,674		(19)
Loft Orbital Solutions Inc.	Senior Secured	December 2029	Prime + 1.75%, Floor rate 8.75%, PIK Interest 1.00%, 3.45% Exit Fee	$	8,820	8,579		8,579		(14)(17)(19)
Stoke Space Technologies, Inc.	Senior Secured	May 2029	Prime + 1.00%, Floor rate 7.50%, PIK Interest 2.00%, 5.25% Exit Fee	$	28,294	27,440		27,539		(6)(14)(15)
Subtotal: Space Technologies (1.98%)*						43,693		43,792
Sustainable and Renewable Technology

Electric Hydrogen Co.	Senior Secured	May 2028	Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.25% Exit Fee	$	12,769	12,718		12,559		(14)(15)(19)
	Senior Secured	May 2028	Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 5.95% Exit Fee	$	17,615	17,578		17,642		(14)(15)(19)
Total Electric Hydrogen Co.				$	30,384	30,296		30,201
Tidal Vision Products, Inc.	Senior Secured	October 2028	Prime + 2.45%, Floor rate 9.70%, 3.45% Exit Fee	$	5,000	4,736		4,736		(6)(17)

Subtotal: Sustainable and Renewable Technology (1.58%)*						35,032		34,937
System Software(27)
Akeyless Security Ltd.	Senior Secured	August 2028	Prime + 4.00%, Floor rate 11.00%, 2.95% Exit Fee	$	10,000	9,848		9,848		(5)(10)(17)
Armis, Inc.	Senior Secured	March 2028	Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee	$	51,771	51,909		52,896		(12)(14)(16)
	Senior Secured	March 2028	Prime + 1.25%, Floor rate 8.75%, PIK Interest 2.00%, 2.25% Exit Fee	$	101,183	100,789		102,916		(11)(14)(16)
Total Armis, Inc.				$	152,954	152,698		155,812
CoreView USA, Inc.	Senior Secured	January 2029	Prime + 2.75%, Floor rate 9.25%, 4.95% Exit Fee	$	25,000	25,045		24,978		(6)(17)
Coronet Cyber Security Ltd.	Senior Secured	October 2028	Prime - 2.95%, Floor rate 3.55%, PIK Interest 5.85%	$	9,115	8,999		8,759		(14)
DNSFilter, Inc.	Senior Secured	October 2028	Prime + 2.15%, Floor rate 8.65%, PIK Interest 0.75%, 4.95% Exit Fee	$	5,009	4,968		4,968		(14)(17)(19)
Harness, Inc.	Senior Secured	March 2029	Prime - 2.25%, Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee	$	57,906	57,378		58,967		(14)(17)(19)
LogRhythm, Inc.	Senior Secured	July 2029	3-month SOFR + 7.50%, Floor rate 8.50%	$	25,000	24,428		23,977
Morphisec Information Security 2014 Ltd.	Senior Secured	October 2027	Prime + 3.45%, Floor rate 11.70%, 5.95% Exit Fee	$	11,435	11,574		11,496		(5)(10)
New Relic, Inc.	Senior Secured	November 2030	3-month SOFR + 6.75%, Floor rate 7.75%	$	21,890	21,465		21,491		(17)
PayIt, LLC	Senior Secured	December 2028	Prime + 1.45%, Floor rate 7.95%, PIK Interest 1.50%, 5.00% Exit Fee	$	26,271	26,218		25,868		(6)(14)(15)(17)(19)
Scylla DB Ltd.	Senior Secured	July 2029	Prime + 3.00%, Floor rate 10.50%, 0.75% Exit Fee	$	15,000	14,798		14,700		(5)(10)
Semperis Technologies Inc.	Senior Secured	April 2028	Prime - 1.75%, Floor rate 6.75%, PIK Interest 3.25%	$	23,511	23,300		23,736		(11)(14)(19)
	Senior Secured	April 2028	Prime - 0.50%, Floor rate 8.00%, PIK Interest 3.85%	$	33,815	33,363		33,350		(14)(19)
Total Semperis Technologies Inc.				$	57,326	56,663		57,086
Sumo Logic, Inc.	Senior Secured	May 2030	3-month SOFR + 6.50%, Floor rate 7.50%	$	23,000	22,591		22,796		(17)
Zimperium, Inc.	Senior Secured	May 2027	6-month SOFR + 8.31%, Floor rate 9.31%	$	17,771	17,638		17,619		(17)(18)
Subtotal: System Software (20.68%)*						454,311		458,365
Total: Debt Investments (193.11%)*						$	4,263,950	$	4,279,412

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Equity Investments
Application Software(27)
Black Crow AI, Inc. affiliates	Equity	3/24/2021	Preferred Note	3	$	2,846	$	2,846	(21)
CapLinked, Inc.	Equity	10/26/2012	Preferred Series A-3	53,614	51		—
DNAnexus, Inc.	Equity	3/21/2014	Preferred Series C	51,948	97		8
HighRoads, Inc.	Equity	1/18/2013	Common Stock	190	307		—
Khoros, LLC	Equity	5/23/2025	Earnout Interest	N/A	5,242		3,651		(24)
Leapwork ApS	Equity	8/25/2023	Preferred Series B2	183,073	250		135		(5)(10)
Nextdoor.com, Inc.	Equity	8/1/2018	Common Stock	1,019,255	4,854		2,140		(4)
SirionLabs Pte. Ltd.	Equity	6/30/2024	Preferred Series F1	152,250	1,792		1,827		(5)(10)
Verana Health, Inc.	Equity	7/8/2021	Common Stock	23,814	2,000		—
Subtotal: Application Software (0.48%)*					17,439		10,607
Biotechnology Tools
Alamar Biosciences, Inc.	Equity	2/21/2024	Preferred Series C	503,778	1,500		841
Subtotal: Biotechnology Tools (0.04%)*					1,500		841
Consumer & Business Products
Fabletics, Inc.	Equity	4/30/2010	Common Stock	42,989	128		42
	Equity	7/16/2013	Preferred Series B	130,191	1,101		275
Total Fabletics, Inc.				173,180	1,229		317
Grove Collaborative, Inc.	Equity	4/30/2021	Common Stock	12,260	433		14		(4)
Savage X Holding, LLC	Equity	4/30/2010	Class A Units	172,328	13		183


Subtotal: Consumer & Business Products (0.02%)*					1,675		514
Consumer & Business Services
Carwow LTD	Equity	12/15/2021	Preferred Series D-4	216,073	1,151		1,036		(5)(10)
Jobandtalent USA, Inc.	Equity	2/11/2025	Preferred Series F	47,754	563		225		(5)(10)
Lyft, Inc.	Equity	12/26/2018	Common Stock	100,738	5,263		1,951		(4)
Nerdy Inc.	Equity	9/17/2021	Common Stock	100,000	1,000		104		(4)
OfferUp, Inc.	Equity	10/25/2016	Preferred Series A	286,080	1,663		427
	Equity	10/25/2016	Preferred Series A-1	108,710	632		162
Total OfferUp, Inc.				394,790	2,295		589
Oportun	Equity	6/28/2013	Common Stock	48,365	577		256		(4)
Reischling Press, Inc.	Equity	7/31/2020	Common Stock	3,095	39		—
Rhino Labs, Inc.	Equity	1/24/2022	Common Stock	7,063	1,000		—
Tectura Corporation	Equity	5/23/2018	Common Stock	414,994,863	900		—		(7)
	Equity	6/6/2016	Preferred Series BB	1,000,000	—		—		(7)
	Equity	12/29/2023	Preferred Series C	3,235,298	13,263		1,250		(7)
Total Tectura Corporation				419,230,161	14,163		1,250
Worldremit Group Limited	Equity	6/24/2024	Preferred Series X	9,737	922		922		(5)(10)

Subtotal: Consumer & Business Services (0.29%)*					26,973		6,333

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Defense Technologies
Shield AI, Inc.	Equity	2/7/2025	Preferred Series F1	28,900	$	2,250	$	1,284	(16)
Subtotal: Defense Technologies (0.06%)*					2,250		1,284
Diversified Financial Services
Gibraltar Acquisition LLC	Equity	3/1/2018	Member Units	1	32,456		23,963		(7)(20)


Hercules Adviser LLC	Equity	3/26/2021	Member Units	1	12,035		43,274		(7)(23)
Newfront Insurance Holdings, Inc.	Equity	9/30/2021	Preferred Series D-2	210,282	403		404
Subtotal: Diversified Financial Services (3.05%)*					44,894		67,641
Drug Delivery
Aytu BioScience, Inc.	Equity	3/28/2014	Common Stock	680	1,500		2		(4)
BioQ Pharma Incorporated	Equity	12/8/2015	Preferred Series D	165,000	500		—
PDS Biotechnology Corporation	Equity	4/6/2015	Common Stock	2,498	309		2		(4)
Talphera, Inc.	Equity	12/10/2018	Common Stock	8,836	1,329		10		(4)
Subtotal: Drug Delivery (0.00%)*					3,638		14
Drug Discovery & Development
Arcus Biosciences, Inc.	Equity	2/19/2025	Common Stock	204,545	2,250		4,874		(4)(10)
Avalo Therapeutics, Inc.	Equity	8/19/2014	Common Stock	42	1,000		1		(4)

Bicycle Therapeutics PLC	Equity	10/5/2020	Common Stock	98,100	1,871		695		(4)(5)(10)


Daré Bioscience, Inc.	Equity	1/8/2015	Common Stock	1,129	1,000		2		(4)
Dynavax Technologies	Equity	7/22/2015	Common Stock	20,000	550		308		(4)(10)
Dyne Therapeutics, Inc.	Equity	7/2/2025	Common Stock	169,697	1,400		3,319		(4)(10)
Heron Therapeutics, Inc.	Equity	7/25/2023	Common Stock	364,963	500		474		(4)
Hibercell, Inc.	Equity	5/7/2021	Preferred Series B	3,466,840	4,250		222		(15)


Kura Oncology, Inc.	Equity	6/16/2023	Common Stock	47,826	550		497		(4)(10)
MoonLake Immunotherapeutics	Equity	11/6/2025	Common Stock	95,500	1,002		1,259		(4)(5)(10)
NorthSea Therapeutics	Equity	12/15/2021	Preferred Series C	983	2,000		1,278		(5)(10)
Phathom Pharmaceuticals, Inc.	Equity	6/9/2023	Common Stock	147,233	1,730		2,443		(4)(10)(16)
Rafael Holdings, Inc. (p.k.a. Cyclo Therapeutics, Inc.)	Equity	4/6/2021	Common Stock	48	42		—		(4)(10)
Rocket Pharmaceuticals, Ltd.	Equity	8/22/2007	Common Stock	944	1,500		3		(4)
Savara, Inc.	Equity	8/11/2015	Common Stock	11,119	203		67		(4)


uniQure B.V.	Equity	1/31/2019	Common Stock	17,175	332		411		(4)(5)(10)
Valo Health, LLC	Equity	12/11/2020	Preferred Series B	510,308	3,000		1,395

	Equity	10/31/2022	Preferred Series C	170,102	1,000		827
Total Valo Health, LLC				680,410	4,000		2,222
Verge Analytics, Inc.	Equity	9/6/2023	Preferred Series C	208,588	1,500		2,382
	Equity	7/2/2025	SAFE	N/A	103		103		(25)
Total Verge Analytics, Inc.				208,588	1,603		2,485

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Viridian Therapeutics, Inc.	Equity	11/6/2023	Common Stock	32,310	$	400	$	1,005	(4)(10)
X4 Pharmaceuticals, Inc.	Equity	11/26/2019	Common Stock	52,202	2,945		209		(4)
Subtotal: Drug Discovery & Development (0.98%)*					29,128		21,774
Electronics & Computer Hardware
Locus Robotics Corp.	Equity	11/17/2022	Preferred Series F	15,116	650		348
Skydio, Inc.	Equity	3/8/2022	Preferred Series E	248,900	1,500		624
Subtotal: Electronics & Computer Hardware (0.04%)*					2,150		972
Healthcare Services, Other

Carbon Health Technologies, Inc.	Equity	3/30/2021	Common Stock	390,809	1,910		—
Click Therapeutics, Inc.	Equity	5/20/2024	Common Stock	560,000	1,662		2,074		(15)
Curana Health Holdings, LLC	Equity	5/13/2024	Common Units	1,114,380	2,500		3,664
Main Street Rural, Inc.	Equity	10/28/2024	Preferred Series D	496	874		1,166
NH Holdings 2025 SPV, L.P.	Equity	6/21/2024	Common Units	339,806	1,848		2,439
Strive Health Holdings, LLC	Equity	6/27/2025	Common Units	82,043	599		814
WellBe Senior Medical, LLC	Equity	6/10/2024	Common Units	181,163	1,600		1,762
Subtotal: Healthcare Services, Other (0.54%)*					10,993		11,919
Information Services

Yipit, LLC	Equity	12/30/2021	Preferred Series E	41,021	3,825		3,200

Subtotal: Information Services (0.14%)*					3,825		3,200
Medical Devices & Equipment
Coronado Aesthetics, LLC	Equity	10/15/2021	Common Units	180,000	—		—		(7)

	Equity	10/15/2021	Preferred Series A-2	5,000,000	250		218		(7)
Total Coronado Aesthetics, LLC				5,180,000	250		218
Orchestra BioMed Holdings, Inc.	Equity	8/4/2025	Common Stock	363,636	1,000		1,509		(4)


Subtotal: Medical Devices & Equipment (0.08%)*					1,250		1,727
Semiconductors
Achronix Semiconductor Corporation	Equity	7/1/2011	Preferred Series C	277,995	160		7
	Equity	6/26/2015	Preferred Series D-2	497,767	7		102
Total Achronix Semiconductor Corporation				775,762	167		109
Subtotal: Semiconductors (0.00%)*					167		109























Space Technologies
Stoke Space Technologies, Inc.	Equity	9/23/2025	Preferred Series D	43,867	1,406		1,256
Subtotal: Space Technologies (0.06%)*					1,406		1,256











Sustainable and Renewable Technology

Impossible Foods, Inc.	Equity	5/10/2019	Preferred Series E-1	188,611	2,000		106
Modumetal, Inc.	Equity	6/1/2015	Common Stock	1,035	500		—
Pivot Bio, Inc.	Equity	6/28/2021	Preferred Series D	593,080	4,500		397

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
SUNation Energy, Inc.	Equity	12/10/2020	Common Stock	3	$	3,153	$	—	(4)







Subtotal: Sustainable and Renewable Technology (0.02%)*					10,153		503
System Software(27)
Armis, Inc.	Equity	10/18/2024	Preferred Series D	294,213	2,000		3,860		(16)
Contentful Global, Inc.	Equity	12/22/2020	Preferred Series C	41,000	138		330		(5)(10)
	Equity	11/20/2018	Preferred Series D	108,500	500		919		(5)(10)
Total Contentful Global, Inc.				149,500	638		1,249
Docker, Inc.	Equity	11/29/2018	Common Stock	20,000	4,284		125
Druva Holdings, Inc.	Equity	10/22/2015	Preferred Series 2	458,841	1,000		4,190
	Equity	8/24/2017	Preferred Series 3	93,620	300		873
Total Druva Holdings, Inc.				552,461	1,300		5,063
Lightbend, Inc.	Equity	12/4/2020	Common Stock	38,461	265		19
Subtotal: System Software (0.47%)*					8,487		10,316
Total: Equity Investments (6.27%)*					$	165,928	$	139,010
Warrant Investments
Application Software(27)
Annex Cloud	Warrant	6/5/2025	Common Units	50,000	$	—	$	—
Automation Anywhere, Inc.	Warrant	9/23/2022	Common Stock	254,778	448		207
Bitsight Technologies, Inc.	Warrant	11/18/2020	Common Stock	29,691	284		401
Brain Corporation	Warrant	10/4/2021	Common Stock	435,396	215		81
Carbyne, Inc.	Warrant	2/24/2025	Ordinary Shares	11,408	24		460
Cloudpay, Inc.	Warrant	4/10/2018	Preferred Series B	6,763	54		811		(5)(10)
Cutover, Inc.	Warrant	9/21/2022	Common Stock	102,898	26		75		(5)(10)
Dashlane, Inc.	Warrant	3/11/2019	Common Stock	770,838	461		864
Demandbase, Inc.	Warrant	8/2/2021	Common Stock	727,047	545		41
Distributed Creation Inc.	Warrant	4/21/2025	Common Stock	104,622	180		248
DroneDeploy, Inc.	Warrant	6/30/2022	Common Stock	95,911	278		440
Earnix, Inc.	Warrant	6/6/2024	Common Stock	20,762	220		283
Elation Health, Inc.	Warrant	9/12/2022	Common Stock	612,166	739		220
First Insight, Inc.	Warrant	5/10/2018	Preferred Series B	75,917	96		1
Fulfil Solutions, Inc.	Warrant	7/29/2022	Common Stock	84,995	325		110
Funnel Holding AB (publ)	Warrant	10/24/2025	Common Stock	485,385	46		47		(5)(10)
Imagen Technologies, Inc.	Warrant	11/26/2025	Preferred Series C-3-VI	311,570	110		92		(6)
Kore.ai, Inc.	Warrant	3/31/2023	Preferred Series C	64,293	208		104
Leapwork ApS	Warrant	1/23/2023	Common Stock	93,211	39		33		(5)(10)(12)
Mango Technologies, Inc.	Warrant	8/15/2025	Common Stock	75,825	401		410
Mixpanel, Inc.	Warrant	9/30/2020	Common Stock	82,362	252		331
Pindrop Security, Inc.	Warrant	6/26/2024	Common Stock	134,542	494		320		(15)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Reltio, Inc.	Warrant	6/30/2020	Common Stock	69,120	$	215	$	609
Simon Data, Inc.	Warrant	3/22/2023	Common Stock	77,934	96		7		(12)
Sisense Ltd.	Warrant	6/8/2023	Ordinary Shares	321,956	174		44		(5)(10)
Suzy, Inc.	Warrant	8/24/2023	Common Stock	292,936	367		182		(6)(15)
Tipalti Solutions Ltd.	Warrant	3/22/2023	Ordinary Shares	509,753	360		255		(10)(16)
	Warrant	3/27/2025	Ordinary Shares	473,266	136		83		(16)
Total Tipalti Solutions Ltd.				983,019	496		338
Ushur, Inc.	Warrant	6/5/2025	Common Stock	1,603,911	265		183		(6)(15)
VideoAmp, Inc.	Warrant	1/21/2022	Common Stock	152,048	1,275		2		(15)
ZeroEyes, Inc.	Warrant	5/6/2025	Common Stock	26,422	132		34		(6)(15)
Subtotal: Application Software (0.31%)*					8,465		6,978
Biotechnology Tools
Alamar Biosciences, Inc.	Warrant	6/21/2022	Preferred Series C	75,567	36		31
Antheia, Inc.	Warrant	8/29/2025	Common Stock	2,023,810	1,601		2,547
PathAI, Inc.	Warrant	12/23/2022	Common Stock	53,418	461		62		(12)
Subtotal: Biotechnology Tools (0.12%)*					2,098		2,640
Communications & Networking
Aryaka Networks, Inc.	Warrant	6/28/2022	Common Stock	486,097	242		—		(12)

Subtotal: Communications & Networking (0.00%)*					242		—
Consumer & Business Products
Gadget Guard, LLC	Warrant	6/3/2014	Common Stock	1,662,441	228		—





Whoop, Inc.	Warrant	6/27/2018	Preferred Series C	686,270	17		713
Subtotal: Consumer & Business Products (0.03%)*					245		713
Consumer & Business Services
Altumint, Inc.	Warrant	10/31/2024	Common Stock	1,701	126		155		(15)
AppDirect, Inc.	Warrant	9/22/2025	Common Stock	87,938	228		188
Carwow LTD	Warrant	12/14/2021	Common Stock	174,163	164		232		(5)(10)

	Warrant	2/13/2024	Preferred Series D-4	109,257	20		62		(5)(10)
Total Carwow LTD				283,420	184		294
Finix Payments, Inc.	Warrant	12/17/2025	Preferred Series C	525,583	38		38		(6)
Houzz, Inc.	Warrant	10/29/2019	Common Stock	529,661	20		—
Landing Holdings Inc.	Warrant	3/12/2021	Common Stock	11,806	116		11		(15)
Lendio, Inc.	Warrant	3/29/2019	Preferred Series D	127,032	39		7
Peek Travel, Inc.	Warrant	10/28/2025	Common Stock	60,169	157		163
Plentific Ltd	Warrant	10/3/2023	Ordinary Shares	27,298	60		24		(5)(10)
Provi	Warrant	12/22/2022	Common Stock	117,042	166		12		(15)
Rhino Labs, Inc.	Warrant	3/12/2021	Common Stock	13,106	470		—		(15)
SeatGeek, Inc.	Warrant	6/12/2019	Common Stock	1,604,724	1,242		5,096		(12)(16)

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Skyword, Inc.	Warrant	11/14/2022	Common Stock	1,607,143	$	57	$	2
	Warrant	8/23/2019	Preferred Series B	444,444	83		—
Total Skyword, Inc.				2,051,587	140		2
Snagajob.com, Inc.	Warrant	4/20/2020	Common Stock	600,000	16		—
	Warrant	6/30/2016	Preferred Series A	1,800,000	782		—
	Warrant	8/1/2018	Preferred Series B	1,211,537	62		—
Total Snagajob.com, Inc.				3,611,537	860		—
Thumbtack, Inc.	Warrant	5/1/2018	Common Stock	343,497	985		1,214

Veem, Inc.	Warrant	3/31/2022	Common Stock	98,428	126		4		(12)
Worldremit Group Limited	Warrant	2/11/2021	Preferred Series D	77,215	129		55		(5)(10)



	Warrant	8/27/2021	Preferred Series E	1,868	26		—		(5)(10)
Total Worldremit Group Limited				79,083	155		55
Subtotal: Consumer & Business Services (0.33%)*					5,112		7,263
Defense Technologies
Saronic Technologies, Inc.	Warrant	6/9/2025	Preferred Series C	109,757	726		1,094		(6)(15)
Subtotal: Defense Technologies (0.05%)*					726		1,094





Drug Discovery & Development



Axsome Therapeutics, Inc.	Warrant	9/25/2020	Common Stock	61,004	1,290		5,765		(4)(10)(12)
Beren Therapeutics P.B.C.	Warrant	10/8/2025	Preferred Series A+	67,923	102		117		(6)
Cellarity, Inc.	Warrant	12/8/2021	Preferred Series B	100,000	287		65		(15)
Century Therapeutics, Inc.	Warrant	9/14/2020	Common Stock	16,112	37		—		(4)
COMPASS Pathways plc	Warrant	6/30/2023	Ordinary Shares	75,376	278		127		(4)(5)(10)
Curevo, Inc.	Warrant	6/9/2023	Common Stock	95,221	233		272		(15)

enGene, Inc.	Warrant	12/22/2023	Common Stock	43,689	118		170		(4)(5)(10)


Heron Therapeutics, Inc.	Warrant	8/9/2023	Common Stock	238,095	228		67		(4)(15)

Kura Oncology, Inc.	Warrant	11/2/2022	Common Stock	14,342	88		16		(4)(10)(15)
Madrigal Pharmaceuticals, Inc.	Warrant	5/9/2022	Common Stock	13,229	570		4,669		(4)(10)

Phathom Pharmaceuticals, Inc.	Warrant	9/17/2021	Common Stock	64,687	848		180		(4)(10)(12)(15)(16)
Redshift Bioanalytics, Inc.	Warrant	3/23/2022	Preferred Series E	475,510	20		10		(15)
Scynexis, Inc.	Warrant	5/14/2021	Common Stock	106,035	296		—		(4)
SynOx Therapeutics Limited	Warrant	4/18/2024	Preferred Series B	251,195	83		84		(5)(10)
TG Therapeutics, Inc.	Warrant	12/30/2021	Common Stock	117,168	721		1,311		(4)(10)
Valo Health, LLC	Warrant	6/15/2020	Common Units	102,216	256		61
X4 Pharmaceuticals, Inc.	Warrant	3/18/2019	Common Stock	46,424	510		8		(4)


Subtotal: Drug Discovery & Development (0.58%)*					5,965		12,922

Electronics & Computer Hardware
908 Devices, Inc.	Warrant	3/15/2017	Common Stock	49,078	101		30		(4)
Locus Robotics Corp.	Warrant	6/21/2022	Common Stock	8,503	34		61

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Skydio, Inc.	Warrant	11/8/2021	Common Stock	622,255	$	557	$	386
Subtotal: Electronics & Computer Hardware (0.02%)*					692		477
Healthcare Services, Other
Belong Health, Inc.	Warrant	11/13/2025	Common Stock	1,933,102	400		238		(6)
Curana Health Holdings, LLC	Warrant	1/4/2024	Common Units	447,410	156		718
Modern Life, Inc.	Warrant	3/30/2023	Common Stock	63,202	229		70
Octave Health Group, Inc.	Warrant	11/28/2025	Common Stock	225,310	168		175		(6)
Recover Together, Inc.	Warrant	7/3/2023	Common Stock	194,830	382		50
Strive Health Holdings, LLC	Warrant	9/28/2023	Common Units	129,400	278		501		(15)


Vida Health, Inc.	Warrant	3/28/2022	Preferred Series E	192,431	121		48
Subtotal: Healthcare Services, Other (0.08%)*					1,734		1,800
Information Services


NetBase Quid, Inc.	Warrant	8/22/2017	Preferred Series 1	60,000	356		—
Signal Media Limited	Warrant	6/29/2022	Common Stock	129,638	57		—		(5)(10)
Subtotal: Information Services (0.00%)*					413		—
Manufacturing Technology
Bright Machines, Inc.	Warrant	3/31/2022	Common Stock	392,308	537		185
MacroFab, Inc.	Warrant	3/23/2022	Common Stock	1,111,111	528		—
VulcanForms Inc.	Warrant	1/30/2025	Common Stock	83,262	37		64
Subtotal: Manufacturing Technology (0.01%)*					1,102		249
Media/Content/Info
Fever Labs, Inc.	Warrant	12/30/2022	Preferred Series E-1	369,370	67		32
Subtotal: Media/Content/Info (0.00%)*					67		32
Medical Devices & Equipment

Orchestra BioMed Holdings, Inc.	Warrant	11/6/2024	Common Stock	167,831	216		299		(4)(6)(15)

Senseonics Holdings, Inc.	Warrant	9/8/2023	Common Stock	51,635	276		75		(4)




Sight Sciences, Inc.	Warrant	1/22/2024	Common Stock	113,247	363		385		(4)(6)(12)

Tela Bio, Inc.	Warrant	3/31/2017	Common Stock	15,712	61		—		(4)
Subtotal: Medical Devices & Equipment (0.03%)*					916		759
Semiconductors
Achronix Semiconductor Corporation	Warrant	1/11/2017	Preferred Series D-2	250,000	92		49

Subtotal: Semiconductors (0.00%)*					92		49














































Space Technologies
HawkEye 360, Inc.	Warrant	12/18/2025	Common Stock	40,912	263		283
Loft Orbital Solutions Inc.	Warrant	9/10/2025	Common Stock	22,688	185		184
Stoke Space Technologies, Inc.	Warrant	6/16/2025	Common Stock	99,497	990		2,301		(6)(15)
Subtotal: Space Technologies (0.12%)*					1,438		2,768
Sustainable and Renewable Technology

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Portfolio Company	Type of Investment	Acquisition Date(4)	Series (3)	Shares	Cost (2)		Value		Footnotes
Ampion, PBC	Warrant	4/15/2022	Common Stock	18,472	$	52	$	45
Electric Hydrogen Co.	Warrant	3/27/2024	Common Stock	246,618	507		100		(15)
Tidal Vision Products, Inc.	Warrant	10/10/2025	Common Stock	48,491	232		174		(6)






Subtotal: Sustainable and Renewable Technology (0.01%)*					791		319
System Software(27)
Akeyless Security Ltd.	Warrant	8/4/2025	Ordinary Shares	87,917	68		47		(5)(10)
CloudBolt Software, Inc.	Warrant	9/30/2020	Common Stock	211,342	117		1
Cloudian, Inc.	Warrant	11/6/2018	Common Stock	477,454	71		—
Coronet Cyber Security Ltd.	Warrant	9/26/2024	Ordinary Shares	39,183	254		25
Dragos, Inc.	Warrant	6/28/2023	Common Stock	57,528	1,575		970
Harness, Inc.	Warrant	3/12/2024	Common Stock	193,618	534		1,446
Lightbend, Inc.	Warrant	2/14/2018	Preferred Series LB-2	86,984	131		38
Morphisec Information Security 2014 Ltd.	Warrant	10/1/2024	Ordinary Shares	200,115	104		58		(5)(10)
Scylla DB Ltd.	Warrant	7/24/2025	Ordinary Shares	159,684	52		59		(5)(10)
Semperis Technologies Inc.	Warrant	4/23/2024	Common Stock	193,264	446		455
Subtotal: System Software (0.14%)*					3,352		3,099
Total: Warrant Investments (1.86%)*					$	33,450	$	41,162
Total Investments in Securities (201.24%)*					$	4,463,328	$	4,459,584

Investment Funds & Vehicles Investments
Drug Discovery & Development
Forbion Growth Opportunities Fund I C.V.	Investment Funds & Vehicles	11/16/2020			$	2,906	$	5,408	(5)(10)(17)
Forbion Growth Opportunities Fund II C.V.	Investment Funds & Vehicles	6/23/2022			1,349		1,291		(5)(10)(17)
Subtotal: Drug Discovery & Development (0.30%)*					4,255		6,699
System Software(27)
Liberty Zim Co-Invest L.P.	Investment Funds & Vehicles	7/21/2022			385		364		(5)(10)
Subtotal: System Software (0.02%)*					385		364
Total: Investment Funds & Vehicles Investments (0.32%)*					$	4,640	$	7,063
Total Investments before Cash & Cash Equivalents (201.56%)*					$	4,467,968	$	4,466,647

Cash & Cash Equivalents
GS Financial Square Government Fund	Cash & Cash Equivalents		FGTXX/38141W273		$	10,250	$	10,250
Total: Investments in Cash & Cash Equivalents (0.46%)*					$	10,250	$	10,250
Total: Investments after Cash & Cash Equivalents (202.02%)*					$	4,478,218	$	4,476,897

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2025

(dollars in thousands)


Foreign Currency Forward Contracts

Foreign Currency	Settlement Date	Counterparty	Amount		Transaction	US $ Notional Value at Settlement Date		Value
Great British Pound (GBP)	6/5/2026	Goldman Sachs Bank USA	£	20,814	Sold	$	28,056	$	50
Total Foreign Currency Forward (0.00%)*						$	28,056	$	50

(1)Prime represents 6.75% as of December 31, 2025. 1-month SOFR, 3-month SOFR, and 6-month SOFR represent 3.69%, 3.65%, and 3.57%, respectively, as of December 31, 2025.

(2)Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $107.0 million, $109.4 million, and $2.4 million, respectively. The tax cost of investments is $4.5 billion.

(3)Preferred and common stock, warrants, and equity interests are generally non-income producing.

(4)Except for warrants in 16 publicly traded companies and common stock in 26 publicly traded companies, all investments are restricted as of December 31, 2025 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s Valuation Committee (as defined in “Note 2 - Summary of Significant Accounting Policies - Valuation of Investments”) and approved by the board of directors (the “Board”).

(5)Non-U.S. company or the company’s principal place of business is outside the United States.

(6)Denotes that all or a portion of the investment in this portfolio company is held by Hercules SBIC V, L.P., the Company's wholly owned small business investment company.

(7)Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.

(8)Debt is on non-accrual status as of December 31, 2025, and is therefore considered non-income producing.

(9)Denotes that all or a portion of the debt investment is convertible debt.

(11)Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).

(12)Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”).

(13)Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”).

(14)Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.

(15)Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company.

(16)Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of December 31, 2025.

(17)Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2025 (Refer to “Note 11 — Commitments and Contingencies”).

(19)Denotes second lien senior secured debt.

(21)Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of December 31, 2025, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $2.8 million.

(22)Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $11.6 million and $11.9 million, respectively.

(23)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 — Description of Business” for additional disclosure.

(24)Denotes investment in a non-voting security in the form of an earnout interest. The terms of the security provide the Company with contractual rights to receive approximately 12.48% of contingent earnout payments from the portfolio company to the earnout holders. As of December 31, 2025, the approximate cost and fair value of the earnout interest is $5.2 million and $3.7 million, respectively.

(25)Denotes investment in a SAFE (Simple Agreement for Future Equity). The terms of the SAFE provide the Company with preferred stock in the event of an equity financing before the termination of the SAFE. As of December 31, 2025, the approximate cost and fair value of the SAFE is $0.1 million.

(26)Denotes that the debt investment remains outstanding beyond its stated maturity date as it is subject to an ongoing workout process.

(27)Effective December 31, 2025, the former “Software” category has been separated into “Application Software” and “System Software”.

See notes to consolidated financial statements

Table of Contents

HERCULES CAPITAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business

Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. The Company sources its investments through its principal office located in San Mateo, CA, as well as through its additional offices in Boston, MA, New York, NY, San Diego, CA, Denver, CO, and London, United Kingdom. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the 1940 Act. Effective January 1, 2006, the Company elected to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M Part I of the Internal Revenue Code of 1986, as amended (the “Code”) (see “Note 6 – Income Taxes”).

The Company is not registered with the Commodity Futures Trading Commission (“CFTC”). The Company has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. Therefore, the Company is not subject to registration or regulation as a “commodity pool operator” under the CEA.

Hercules Capital IV, L.P. (“HC IV”) and Hercules SBIC V, L.P. (“SBIC V”) are our wholly owned Delaware limited partnerships that were formed in December 2010 and September 2023, respectively. HC IV and SBIC V have each received licenses to operate as a Small Business Investment Company (“SBIC”) under the authority of the Small Business Administration (“SBA”) on October 27, 2020 and July 9, 2024, respectively. Our SBICs are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. Hercules Technology SBIC Management, LLC (“HTM”), is a wholly owned limited liability company subsidiary of the Company, which was formed in November 2003 and serves as the general partner of HC IV and SBIC V.

The Company has also established certain wholly owned subsidiaries, all of which are structured as Delaware corporations or limited liability companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Certain of the subsidiaries are taxable and not consolidated with Hercules for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.

The Company formed Hercules Capital Management LLC and Hercules Adviser LLC (the “Adviser Subsidiary”) in 2020 as wholly owned Delaware limited liability company subsidiaries. The Company was granted no-action relief by the staff of the Securities and Exchange Commission (“SEC”) to allow the Adviser Subsidiary to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”). The Adviser Subsidiary provides investment advisory and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser Subsidiary is owned by Hercules Capital Management LLC and collectively held and presented with Hercules Partner Holdings, LLC, which separately wholly owns the general partnership interests to each of the Adviser Funds.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated interim financial statements have been prepared in accordance with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair presentation of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2025. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency.

Table of Contents

As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946, Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such, pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated.

Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE.

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.

The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.

The Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in 2022 in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The assets of the Company's consolidated securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit.

Table of Contents

Fair Value Measurements

The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value.

The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

Valuation of Investments

The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

Pursuant to Rule 2a-5 under the 1940 Act, the Board has designated a group of the Company’s executive officers and senior employees to serve as the Board’s “valuation designee” (such group of executive officers and senior employees are referred to herein as the “Valuation Committee”). As of March 31, 2026, approximately 97.8% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Fair value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Valuation Committee, as valuation designee of the Board. The Company’s investments are carried at fair value in accordance with Rule 2a-5 under the 1940 Act and ASC Topic 946. Given the Company's investment strategy, nature of investments, and types of businesses in which it invests, substantially all of the Company’s investments are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to the valuation guidelines approved by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market values, the fair value of the Company’s investments may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

In accordance with procedures approved by its Board, the Company values investments on a quarterly basis following a multistep valuation process. The quarterly Board approved multi-step valuation process is described below:

(1)The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment;

Table of Contents

(2)Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary;

(3)The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board;

(4)The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and

(5)The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio.

Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee subject to oversight and approval of the Board.

As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where it believes collection of a debt investment is doubtful or, if under the in-exchange premise, when it believes the value of a debt investment is less than the amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if it believes, under the in-exchange premise, the value of an investment is greater than its amortized cost.

Debt Investments

The Company’s debt investments are substantially considered Level 3 assets under ASC Topic 820 with fair value as

determined in good faith pursuant to the process described above. In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below.

The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to

Table of Contents

estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date.

The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. The Company values syndicated debt investments, for which sufficient liquidity and market data are available, using broker quotes and bond indices amongst other factors. Debt investments with market quotations are generally considered Level 1 or 2 assets in line with ASC Topic 820. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recording warrant or other equity instruments is accreted into interest income over the life of the debt investment.

Equity Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes Option Pricing Model (“OPM”). For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors.

Investment Funds & Vehicles

The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate net asset value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820.

Derivative Instruments

The Company's derivative instruments include foreign currency forward contracts. The Company recognizes all derivative instruments as assets or liabilities at fair value in its consolidated financial statements. Derivative contracts entered into by the Company are not designated as hedging instruments, and as a result, the Company presents changes in fair value through net change in unrealized appreciation (depreciation) on non-control/non-affiliate investments in the Consolidated Statements of Operations. Realized gains and losses of the derivative instruments are included in net realized gains (losses) on non-control/non-affiliate investments in the Consolidated Statements of Operations. The net cash flows realized on settlement of derivatives are included in realized (gain) loss in the Consolidated Statements of Cash Flows.

Cash and Cash Equivalents and Restricted Cash

Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair

Table of Contents

value. As of March 31, 2026, the Company held $87 thousand (Cost basis $88 thousand) of foreign cash. As of December 31, 2025, the Company held $113 thousand (Cost basis $113 thousand) of foreign cash. Foreign cash includes the value of foreign currencies held and translated using the prevailing foreign exchange rates on the reporting date. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to its 2031 Asset-Backed Notes (refer to “Note 5 – Debt”).

Foreign Currency Translation

The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.

Other Assets

Other assets generally consist of prepaid expenses, debt issuance costs related to our Credit Facilities (as defined below) net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow and other investment related receivables.

Escrow Receivables

Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. The Company uses the implicit rate when readily determinable. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”.

Investment Income Recognition

The Company’s investment portfolio generates interest, fee, and dividend income. The Company records interest income on an accrual basis, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. The Company’s Structured Debt investments may generate OID related income. “Structured Debt” refers to a debt investment that is structured with an equity, warrant, option, or other right to purchase or convert into common or preferred equity investments. The OID recorded upfront typically represents the value of detachable equity, warrants, or another asset obtained in conjunction with the acquisition of debt securities. The OID value is accreted into interest income over the term of the loan as a yield enhancement following the effective interest method. Additionally, certain debt investments in the Company’s portfolio earn PIK interest. The Company records PIK interest in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. Contractual PIK interest represents contractually deferred interest that is added to the loan balance as principal and is generally due at the end of the loan term.

Table of Contents

Additionally, the Company’s loan origination activities generate fee income, which is generally collected in advance and includes loan commitment, facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are capitalized and then amortized into income over the contractual life of the loan using the effective interest method. One-off fees for transaction and management services are generally recognized as income in the period when the services are rendered. The Company may also earn loan exit fees, which are contractual fees that are generally received upon the earlier of maturity or prepayment. The Company accretes loan exit fees into interest income following the effective interest method, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected.

From time to time, additional fees may be earned by the Company relating to specific loan modifications, prepayments, or other one-off events. These non-recurring fees are either amortized into fee income over the remaining term of the loan commencing in the quarter for loan modifications, or recognized currently as one-time fee income for items such as prepayment penalties, fees related to select covenant default waiver fees, and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding.

Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may determine to continue to accrue interest on a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.

Dividend income is recorded on the record date for private portfolio companies or on the ex-dividend date for publicly traded portfolio companies to the extent that such amounts are payable by the portfolio company and are expected to be collected.

Realized Gains or Losses

Realized gains or losses are measured by the difference between the net proceeds from the sale or other realization event and the cost basis of the investment using the specific identification method without regard to unrealized appreciation or depreciation previously recognized, and includes investments charged off during the period, net of recoveries.

Secured Borrowings

The Company follows the guidance in ASC Topic 860, Transfers and Servicing (“ASC Topic 860”), when accounting for participation and other partial loan sales. Certain loan sales do not qualify for sale accounting under ASC Topic 860 because these sales do not meet the definition of a “participating interest”, as defined in the guidance, in order for sale accounting treatment to be allowed. Participations or other partial loan sales which do not meet the definition of a participating interest, or which are not eligible for sale accounting treatment remain as an investment on the consolidated balance sheet as required under U.S. GAAP and the proceeds are recorded as a secured borrowing. Secured borrowings are carried at fair value.

Equity Offering Expenses

The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities.

Debt

The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss in the Consolidated Statements of Operations within net realized gains (losses) as a “Loss on extinguishment of debt”.

Debt Issuance Costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30, Interest – Imputation of Interest, debt issuance costs are presented as a reduction to the associated

Table of Contents

liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements which are included within Other Assets as permitted under GAAP.

Stock-Based Compensation

The Company has issued and may, from time to time, issue stock options, restricted stock, and other stock-based compensation awards to employees and directors. Management follows the guidance set forth under ASC Topic 718, to account for stock-based compensation awards granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment. This includes certain assumptions such as stock price volatility, forfeiture rate, expected outcome probability, and expected option life, as applicable to each award.

Income Taxes

The Company accounts for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized.

Because taxable income as determined in accordance with U.S. federal tax regulations differ from U.S. GAAP, taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gains or losses are recognized at some time in the future for tax or U.S. GAAP purposes.

The Company has elected to be treated as a RIC under Subchapter M Part I of the Code. To qualify as a RIC, the Company is required to meet certain income and asset tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. See “Item 1. Business - Certain United States Federal Income Tax Considerations” included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 12, 2026 for additional information.

As a RIC, the Company is subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of its ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of its capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal income tax (such as the tax imposed on a RIC’s retained net capital gains).

The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company's earnings fall below the amount of the dividend distributions declared, however, a portion of the total amount of the Company's distributions for the fiscal year may be deemed a return of capital.

Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital. The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, it may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

Table of Contents

Earnings Per Share (“EPS”)

Basic EPS is calculated by dividing net earnings applicable to common stockholders by the weighted average number of common shares outstanding. Common shares outstanding includes common stock and restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which future service is required as a condition to the delivery of the underlying common stock. Diluted EPS is computed using the if-converted method for convertible debt, which reflects the potential dilution that would occur if all of the notes were converted as of the beginning of the reporting period (or the date of issuance, if later). The if-converted method is computed by dividing the net increase (decrease) in net assets resulting from operations (adjusted to reverse any recognized interest expense), by the weighted average number of shares of common stock assuming all potential shares had been converted, and the additional shares of common stock were dilutive. In accordance with ASC 260-10-45-60A, the Company uses the two-class method in the computation of basic EPS and diluted EPS, if applicable.

Comprehensive Income

The Company reports all changes in comprehensive income in the Consolidated Statements of Operations. The Company did not have other comprehensive income for the three months ended March 31, 2026 or 2025. The Company’s comprehensive income is equal to its net increase in net assets resulting from operations.

Distributions

Distributions to common stockholders are approved by the Board on a quarterly basis and the distribution payable is recorded on the ex-dividend date. The Company maintains an “opt out” dividend reinvestment plan that provides for reinvestment of the Company’s distribution on behalf of the Company’s stockholders, unless a stockholder elects to receive cash. As a result, if the Company declares a distribution, cash distributions (net of applicable withholding tax) will be automatically reinvested in additional shares of its common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash distributions.

Segments

The Company has determined that it has a single operating segment in accordance with Topic 280, Segment Reporting (“ASC 280”). Our Chief Executive Officer is the Company’s Chief Operating Decision Maker (“CODM”). While the Company lends to and separately evaluates the performance of each portfolio company in which it invests across various technology-related industries including application software, drug discovery and development, other healthcare services, system software, and consumer & business services, the Company and the CODM evaluate and monitor performance of the business on an aggregated basis. Further, each investment is evaluated and managed using similar processes and shared operations support functions such as deal origination, underwriting, documentation, loan and compliance administration in addition to administrative functions of human resources, legal, finance and information technology.

The CODM uses our consolidated net investment income and net increase (decrease) in net assets resulting from operations as reported in the Consolidated Statements of Operations to assess the Company’s performance and when allocating resources. Net investment income is comprised of consolidated total investment income (“segment revenues”) and consolidated total net operating expenses (“significant segment expenses”), which are considered the key segment measures of profit or loss received by the CODM. The information and operating expense categories included in the Company’s Consolidated Statement of Operations are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.

Table of Contents

3. Fair Value of Financial Instruments

The Company values financial instruments in accordance with ASC 820, using the techniques and approaches outlined in the Company's valuation guidelines, which are approved by the Board. During the periods ended March 31, 2026 and December 31, 2025, there were no changes to the Company’s valuation techniques or approaches as described herein.

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2026 and December 31, 2025.


(in thousands)	Balance as of March 31, 2026		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Description
Cash and cash equivalents
Money Market Fund(1)	$	8,080	$	8,080	$	—	$	—

Other assets and liabilities
Escrow Receivables	$	114	$	—	$	—	$	114
Accounts Payable and Accrued Liabilities	(86)		—		—		(86)

Investments
Senior Secured Debt	$	4,469,019	$	—	$	—	$	4,469,019
Unsecured Debt	71,126		—		—		71,126
Preferred Stock	53,449		—		—		53,449
Common Stock(2)	78,659		19,575		—		59,084
Warrants	42,507		—		11,631		30,876
	$	4,714,760	$	19,575	$	11,631	$	4,683,554
Investment Funds & Vehicles measured at Net Asset Value(3)	7,227
Total Investments, at fair value	$	4,721,987
Derivative Instruments(4)	522
Total Investments including cash and cash equivalents and derivative instruments	$	4,730,589


(in thousands)	Balance as of December 31, 2025		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Description
Cash and cash equivalents
Money Market Fund(1)	$	10,250	$	10,250	$	—	$	—

Other assets and liabilities
Escrow Receivables	$	168	$	—	$	—	$	168
Accounts Payable and Accrued Liabilities	(87)		$	—	$	—	(87)

Investments
Senior Secured Debt	$	4,209,798	$	—	$	—	$	4,209,798
Unsecured Debt	69,614		—		—		69,614
Preferred Stock	52,735		—		—		52,735
Common Stock(2)	86,275		21,555		—		64,720
Warrants	41,162		—		13,101		28,061
	$	4,459,584	$	21,555	$	13,101	$	4,424,928
Investment Funds & Vehicles measured at Net Asset Value(3)	7,063
Total Investments, at fair value	$	4,466,647
Derivative Instruments(4)	50
Total Investments including cash and cash equivalents and derivative instruments	$	4,476,947

(1)This investment is included in Cash and cash equivalents in the accompanying Consolidated Statements of Assets and Liabilities.

(2)Common stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's common stock.

Table of Contents

(3)In accordance with U.S. GAAP, certain investments are measured at fair value using the NAV per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statements of Assets and Liabilities.

(4)Derivative Instruments are carried at fair value and are a Level 2 security within the Company's fair value hierarchy.

The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the three months ended March 31, 2026 and 2025.


(in thousands)	Balance as of January 1, 2026		Net Realized Gains (Losses)(1)		Net Change in Unrealized Appreciation (Depreciation)(2)		Purchases(5)		Capitalized PIK Interest		Sales		Repayments(6)		Gross Transfers into Level 3(3)*		Gross Transfers out of Level 3(3)*		Balance as of March 31, 2026

Investments
Senior Secured Debt	$	4,209,798	$	—	$	(34,788)	$	524,980	$	11,879	$	(7,500)	$	(235,350)	$	—	$	—	$	4,469,019
Unsecured Debt	69,614		—		(2,391)		3,036		867		—		—		—		—		71,126
Preferred Stock	52,735		77		(3,148)		6,056		—		(2,271)		—		—		—		53,449
Common Stock	64,720		(1,910)		(4,074)		648		—		(300)		—		—		—		59,084
Warrants	28,061		(68)		1,920		1,012		—		(49)		—		—		—		30,876
Other Assets and Liabilities
Escrow Receivables	168		(33)		—		22		—		(43)		—		—		—		114
Accounts Payable and Accrued Liabilities	(87)		—		—		1		—		—		—		—		—		(86)
Total	$	4,425,009	$	(1,934)	$	(42,481)	$	535,755	$	12,746	$	(10,163)	$	(235,350)	$	—	$	—	$	4,683,582


(in thousands)	Balance as of January 1, 2025		Net Realized Gains (Losses)(1)		Net Change in Unrealized Appreciation (Depreciation)(2)		Purchases(5)		Capitalized PIK Interest		Sales		Repayments(6)		Gross Transfers into Level 3(4)*		Gross Transfers out of Level 3(4)*		Balance as of March 31, 2025
Investments
Senior Secured Debt	$	3,419,044	$	(48)	$	(25,181)	$	416,157	$	12,673	$	—	$	(148,147)	$	—	$	—	$	3,674,498
Unsecured Debt	75,557		—		65		63		1,273		—		—		—		(12,222)		64,736
Preferred Stock	53,802		—		(3,953)		2,813		—		—		—		—		—		52,662
Common Stock	44,593		(670)		(2,014)		—		—		(331)		—		17,316		—		58,894
Warrants	21,823		(63)		(1,527)		352		—		—		—		—		—		20,585
Other Assets and Liabilities
Escrow and Other Investment Receivables	152		56		—		1,814		—		(56)		—		—		—		1,966
Accounts Payable and Accrued Liabilities	(1,012)		—		358		44		—		(362)		—		—		—		(972)
Total	$	3,613,959	$	(725)	$	(32,252)	$	421,243	$	13,946	$	(749)	$	(148,147)	$	17,316	$	(12,222)	$	3,872,369

* The Company recognizes transfers as of the transaction date.

(1)Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations.

(2)Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations.

(3)There were no transfers into or out of Level 3 during the three months ended March 31, 2026.

(4)Transfers out of Level 3 during the three months ended March 31, 2025 related to the conversion of the Company's Level 3 debt investments in the Adviser Subsidiary and Carbon Health Technologies, Inc., into common stock Level 3 investments. Transfers into Level 3 during the three months ended March 31, 2025 included the conversion of 23andMe, Inc. Level 1 common stock into Level 3 common stock due to bankruptcy and delisting.

(5)Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of Level 3 investments. Amounts are net of purchases assigned to the Adviser Funds.

(6)Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.

Table of Contents

The following table presents the net unrealized appreciation (depreciation) recorded for debt, preferred stock, common stock and warrant Level 3 investments relating to assets still held at the reporting date.


(in millions)	Three Months Ended March 31,
	2026		2025
Debt investments	$	(33.4)	$	(23.4)
Preferred stock	(3.1)		(4.0)
Common stock	(6.0)		(2.3)
Warrant investments	1.9		(1.6)

Table of Contents

The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of March 31, 2026 and December 31, 2025. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation guidelines, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.


Investment Type - Level 3 Debt Investments	Fair Value as of March 31, 2026 (in thousands)		Valuation Techniques/ Methodologies	Unobservable Input(1)	Range	Weighted Average(2)
Pharmaceuticals	$	721,599	Market Comparable Companies	Hypothetical Market Yield	9.40% - 17.06%	11.90%
				Premium/(Discount)	(2.00%) - 2.00%	(0.81%)


Technology	1,719,485		Market Comparable Companies	Hypothetical Market Yield	9.39% - 18.84%	12.96%
				Premium/(Discount)	(2.75%) - 6.00%	0.04%
	29,462		Convertible Note Analysis	Probability weighting of alternative outcomes	5.00% - 95.00%	90.46%
	24,889		Liquidation(3)	Probability weighting of alternative outcomes	5.00% - 95.00%	61.59%




Medical Devices	74,905		Market Comparable Companies	Hypothetical Market Yield	12.45% - 13.98%	13.42%
				Premium/(Discount)	(0.25%) - 0.50%	0.11%

Lower Middle Market	894,810		Market Comparable Companies	Hypothetical Market Yield	10.89% - 20.07%	13.91%
				Premium/(Discount)	(1.50%) - 4.50%	0.21%


Debt Investments for which Cost Approximates Fair Value
	479,165		Debt Investments originated within 6 months
	348,464		Imminent Payoffs(4)
	206,075		Debt Investments Maturing in Less than One Year
	41,291		Debt Investments in Wholly-Owned Subsidiaries
	$	4,540,145	Total Level 3 Debt Investments
Escrow Receivables	114		Expected Proceeds
Accounts Payable and Accrued Liabilities	(86)		Liquidation(3)	Probability weighting of alternative outcomes	10.00% - 50.00%	44.84%
	$	4,540,173	Total Level 3 Debt Investments and Other Assets (Liabilities)

(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment.

Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:

•Pharmaceuticals, above, is comprised of debt investments in the “Biotechnology Tools” and “Drug Discovery & Development” industries.

•Technology, above, is comprised of debt investments in the “Application Software”, “Communications & Networking”, “Consumer & Business Services”, “Defense Technologies”, “Electronics & Computer Hardware”, “Healthcare Services, Other”, “Information Services”, “Manufacturing Technology”, “Space Technologies”, and “System Software” industries.

•Medical Devices, above, is comprised of debt investments in the “Medical Devices & Equipment” industry.

•Lower Middle Market, above, is comprised of debt investments in the “Application Software”, “Consumer & Business Products”, “Consumer & Business Services”, “Diversified Financial Services”, “Healthcare Services, Other”, and “Sustainable and Renewable Technology” industries.

(2)The weighted averages are calculated based on the fair market value of each investment.

(3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables (payables) is the probability weighting of alternative outcomes.

(4)Imminent Payoffs represent debt investments that the Company expects to be repaid within the next three months, prior to their scheduled maturity date.

Table of Contents


Investment Type - Level 3 Debt Investments	Fair Value as of December 31, 2025 (in thousands)		Valuation Techniques/ Methodologies	Unobservable Input(1)	Range	Weighted Average(2)
Pharmaceuticals	$	777,671	Market Comparable Companies	Hypothetical Market Yield	9.01% - 15.39%	11.97%
				Premium/(Discount)	(2.50%) - 2.00%	(0.34%)


Technology	1,779,826		Market Comparable Companies	Hypothetical Market Yield	9.58% - 17.46%	12.30%
				Premium/(Discount)	(1.50%) - 4.50%	0.22%
	30,986		Convertible Note Analysis	Probability weighting of alternative outcomes	1.00% - 70.00%	51.23%
	73,268		Liquidation(3)	Probability weighting of alternative outcomes	10.00% - 90.00%	76.29%

Sustainable and Renewable Technology	30,201		Market Comparable Companies	Hypothetical Market Yield	15.89% - 16.25%	16.04%
				Premium/(Discount)	0.75% - 0.75%	0.75%

Medical Devices	74,771		Market Comparable Companies	Hypothetical Market Yield	12.18% - 14.21%	13.36%
				Premium/(Discount)	(0.25%) - 0.50%	0.11%

Lower Middle Market	814,412		Market Comparable Companies	Hypothetical Market Yield	10.30% - 18.73%	13.60%
				Premium/(Discount)	(0.50%) - 4.00%	0.60%

Debt Investments for which Cost Approximates Fair Value
	403,710		Debt Investments originated within 6 months
	7,711		Imminent Payoffs(4)
	248,601		Debt Investments Maturing in Less than One Year
	38,255		Debt Investments in Wholly-Owned Subsidiaries
	$	4,279,412	Total Level 3 Debt Investments
Escrow Receivables	168		Expected Proceeds
Accounts Payable and Accrued Liabilities	(87)		Liquidation(3)	Probability weighting of alternative outcomes	10.00% - 50.00%	44.84%
	$	4,279,493	Total Level 3 Debt Investments and Other Assets (Liabilities)

Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:

•Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development”, “Biotechnology Tools”, and “Healthcare Services, Other” industries.

•Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, “Space Technologies”, “Defense Technologies”, “Manufacturing Technology”, “Electronics & Computer Hardware”, “Application Software”, and “System Software” industries.

•Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry.

•Medical Devices, above, is comprised of debt investments in the “Medical Devices & Equipment” industry.

•Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, “Consumer & Business Products”, and “Application Software” industries.

(2)The weighted averages are calculated based on the fair market value of each investment.

(3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables (payables) is the probability weighting of alternative outcomes.

(4)Imminent payoffs represent debt investments that the Company expects to be repaid within the next three months, prior to their scheduled maturity date.

Table of Contents


Investment Type - Level 3 Equity and Warrant Investments	Fair Value as of March 31, 2026 (in thousands)		Valuation Techniques/ Methodologies	Unobservable Input(1)	Range	Weighted Average(5)
Equity Investments	$	46,476	Market Comparable Companies	Revenue Multiple(2)	0.1x - 9.2x	3.1x

				Tangible Book Value Multiple(2)	1.6x - 1.6x	1.6x
				Discount for Lack of Marketability(3)	14.80% - 91.85%	27.83%
	12,236		Market Adjusted OPM Backsolve	Market Equity Adjustment(4)	(92.01%) - 1.35%	(22.88%)
	46,127		Discounted Cash Flow	Discount Rate(7)	11.29% - 35.31%	32.99%


	7,694		Other(6)
Warrant Investments	17,501		Market Comparable Companies	Revenue Multiple(2)	0.5x - 12.7x	3.7x

				Discount for Lack of Marketability(3)	14.80% - 35.70%	25.15%
	11,967		Market Adjusted OPM Backsolve	Market Equity Adjustment(4)	(65.94%) - 102.93%	18.43%
	1,408		Other(6)
Total Level 3 Equity and Warrant Investments	$	143,409

(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, discount rate, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes.

(2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

(3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event.

(5)Weighted averages are calculated based on the fair market value of each investment.

(6)The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices.

(7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.


Investment Type - Level 3 Equity and Warrant Investments	Fair Value as of December 31, 2025 (in thousands)		Valuation Techniques/ Methodologies	Unobservable Input(1)	Range	Weighted Average(5)

Equity Investments	$	48,874	Market Comparable Companies	Revenue Multiple(2)	0.1x - 12.3x	4.5x
				Tangible Book Value Multiple(2)	1.7x - 1.7x	1.7x
				Discount for Lack of Marketability(3)	9.44% - 92.30%	26.25%
	7,702		Market Adjusted OPM Backsolve	Market Equity Adjustment(4)	(89.31%) - 70.57%	(7.13%)
	51,250		Discounted Cash Flow	Discount Rate(7)	11.14% - 33.18%	30.09%


	9,629		Other(6)

Warrant Investments	19,318		Market Comparable Companies	Revenue Multiple(2)	0.3x - 13.0x	5.5x
				Discount for Lack of Marketability(3)	13.28% - 36.40%	26.90%
	8,283		Market Adjusted OPM Backsolve	Market Equity Adjustment(4)	(60.90%) - 87.40%	26.66%
	460		Other(6)


Total Level 3 Equity and Warrant Investments	$	145,516

(2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

Table of Contents

(3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event.

(5)Weighted averages are calculated based on the fair market value of each investment.

(6)The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices.

(7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.

The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt obligations of the Company are recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument.

The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of March 31, 2026 and December 31, 2025:


(in thousands)	March 31, 2026
Description	Carrying Value		Approximate Fair Value		Identical Assets (Level 1)		Observable Inputs (Level 2)		Unobservable Inputs (Level 3)		Market Quotations (Level 2)*
SBA Debentures (1)	$	341,301	$	333,445	$	—	$	—	$	333,445	$	—






September 2026 Notes	324,548		321,090		—		321,090		—		0.988
January 2027 Notes	348,928		344,127		—		344,127		—		0.983
2028 Convertible Notes	281,076		280,152		—		280,152		—		0.974
February 2029 Notes	294,267		294,756		—		294,756		—		0.983
June 2030 Notes	343,104		344,617		—		344,617		—		0.985
2031 Asset-Backed Notes	64,466		63,325		—		63,325		—		0.982
2033 Notes (2)	39,178		39,648		—		39,648		—		0.991

MUFG Bank Facility (3)	220,000		220,000		—		—		220,000		—
SMBC Facility (3)	282,164		282,307		—		—		282,307		—
Total	$	2,539,032	$	2,523,467	$	—	$	1,687,715	$	835,752

* Level 2 market quotations are the observable market quotations per dollar at par value on the last trading day of the quarter ended March 31, 2026.

(1)The fair values of the SBA debentures (as defined in "Note 5 - Debt") are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms.

(2)As of March 31, 2026, the 2033 Notes (as defined in “Note 5 - Debt”) were trading on the New York Stock Exchange (“NYSE”) at $24.78 per unit at par value. The par value at underwriting for the 2033 Notes was $25.00 per unit.

(3)The fair values of the outstanding debt under the MUFG Bank Facility and the SMBC Facility (each as defined in “Note 5 - Debt”) are equal to their outstanding principal balances as of March 31, 2026.


(in thousands)	December 31, 2025
Description	Carrying Value		Approximate Fair Value		Identical Assets (Level 1)		Observable Inputs (Level 2) (1)		Unobservable Inputs (Level 3) (2)
SBA Debentures	$	341,012	$	335,905	$	—	$	—	$	335,905




March 2026 A Notes	49,984		50,615		—		—		50,615
March 2026 B Notes	49,983		50,627		—		—		50,627
September 2026 Notes	324,302		320,186		—		—		320,186
January 2027 Notes	348,596		346,365		—		—		346,365
2028 Convertible Notes	280,412		286,870		—		286,870		—
June 2030 Notes	342,694		352,274		—		—		352,274
2031 Asset-Backed Notes	64,530		63,486		—		63,486		—
2033 Notes	39,151		40,784		—		40,784		—
MUFG Bank Facility (3)	168,000		168,000		—		—		168,000
SMBC Facility (3)	277,780		277,934		—		—		277,934
Total	$	2,286,444	$	2,293,046	$	—	$	391,140	$	1,901,906

(1)The Company estimated the fair value of its debt instruments classified within Level 2 using observable market quotations on the last trading day of the quarter ended December 31, 2025. Based on such market quotations, the 2031 Asset-Backed Notes were quoted for 0.982 and the

Table of Contents

2028 Convertible Notes were quoted for 0.998 per dollar at par value. As of December 31, 2025, the 2033 Notes were trading on the NYSE at $25.49 per unit at par value. The par value at underwriting for the 2033 Notes was $25.00 per unit.

(2)As of December 31, 2025, the fair values of the SBA debentures, March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, and June 2030 Notes (each as defined in “Note 5 - Debt”) are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms.

(3)The fair values of the outstanding debt under the MUFG Bank Facility and the SMBC Facility are equal to their outstanding principal balances as of December 31, 2025.

4. Investments

Control and Affiliate Investments

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting securities or board appointment rights held by the Adviser Funds.

The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three months ended March 31, 2026 and 2025.


(in thousands)				Three Months Ended March 31, 2026
Portfolio Company(1)	Type	Fair Value as of March 31, 2026		Interest & Dividend Income		Fee Income		Net Change in Unrealized Appreciation (Depreciation)		Realized Gain (Loss)
Control Investments
Coronado Aesthetics, LLC	Control	$	158	$	—	$	—	$	(60)	$	—
Gibraltar Acquisition LLC(2)	Control	62,167		1,128		35		213		—
Hercules Adviser LLC(3)	Control	44,137		2,101		—		(2,137)		—
Tectura Corporation	Control	9,786		170		—		445		—
Total Control Investments		$	116,248	$	3,399	$	35	$	(1,539)	$	—


(in thousands)				Three Months Ended March 31, 2025
Portfolio Company(1)	Type	Fair Value as of March 31, 2025		Interest & Dividend Income		Fee Income		Net Change in Unrealized Appreciation (Depreciation)		Realized Gain (Loss)
Control Investments
Coronado Aesthetics, LLC	Control	$	47	$	—	$	—	$	(22)	$	—
Gibraltar Acquisition LLC(2)	Control	58,900		1,567		39		(941)		—
Hercules Adviser LLC(3)	Control	45,017		1,900		—		2,827		—
Tectura Corporation	Control	11,770		170		—		113		—
Total Control Investments		$	115,734	$	3,637	$	39	$	1,977	$	—

(1)In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of March 31, 2026 and March 31, 2025, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”.

(2)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.

(3)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.

Table of Contents

Portfolio Composition

The following table shows the fair value of the Company’s portfolio of investments by asset class as of March 31, 2026 and December 31, 2025:


(in thousands)	March 31, 2026				December 31, 2025

	Investments at Fair Value		Percentage of Total Portfolio		Investments at Fair Value		Percentage of Total Portfolio
Senior Secured Debt	$	4,469,019	94.6	%	$	4,209,798	94.2	%
Unsecured Debt	71,126		1.5	%	69,614		1.6	%
Preferred Stock	53,449		1.1	%	52,735		1.2	%
Common Stock	78,659		1.7	%	86,275		1.9	%
Warrants	42,507		0.9	%	41,162		0.9	%
Investment Funds & Vehicles	7,227		0.2	%	7,063		0.2	%
Total	$	4,721,987	100.0	%	$	4,466,647	100.0	%

A summary of the Company’s investment portfolio, at value, by geographic location as of March 31, 2026 and December 31, 2025 is shown as follows:


(in thousands)	March 31, 2026				December 31, 2025
	Investments at Fair Value		Percentage of Total Portfolio		Investments at Fair Value		Percentage of Total Portfolio
United States	$	4,249,172	90.0	%	$	4,035,927	90.4	%
United Kingdom	152,389		3.2	%	118,031		2.7	%
Netherlands	115,004		2.4	%	117,344		2.6	%
Israel	66,148		1.4	%	67,280		1.5	%
Germany	49,417		1.1	%	50,386		1.1	%
Switzerland	47,763		1.0	%	35,504		0.8	%
Canada	18,432		0.4	%	16,841		0.4	%
Sweden	18,395		0.4	%	18,244		0.4	%
Ireland	4,770		0.1	%	4,729		0.1	%
Singapore	—		0.0	%	1,827		0.0	%
Other(1)	497		0.0	%	534		0.0	%
Total	$	4,721,987	100.0	%	$	4,466,647	100.0	%

(1)Effective March 31, 2026, the Company’s investment portfolio based in Denmark has been consolidated with “Other”. Prior year amounts have been reclassified to conform to the current presentation.

Table of Contents

The following table shows the fair value of the Company’s portfolio by industry sector as of March 31, 2026 and December 31, 2025:


(in thousands)	March 31, 2026				December 31, 2025
	Investments at Fair Value		Percentage of Total Portfolio		Investments at Fair Value		Percentage of Total Portfolio
Application Software	$	1,113,788	23.6	%	$	1,087,954	24.3	%
Drug Discovery & Development	1,089,920		23.1	%	1,039,712		23.3	%
Healthcare Services, Other	890,720		18.9	%	838,508		18.8	%
System Software	507,172		10.7	%	472,144		10.6	%
Consumer & Business Services	474,202		10.0	%	449,631		10.1	%
Defense Technologies	157,631		3.3	%	140,458		3.1	%
Diversified Financial Services	106,304		2.3	%	105,896		2.4	%
Medical Devices & Equipment	81,619		1.7	%	77,257		1.7	%
Electronics & Computer Hardware	66,735		1.4	%	66,992		1.5	%
Space Technologies	53,167		1.1	%	47,816		1.1	%
Consumer & Business Products	42,187		0.9	%	8,810		0.2	%
Sustainable and Renewable Technology	35,804		0.8	%	35,759		0.8	%
Communications & Networking	32,063		0.7	%	26,263		0.6	%
Information Services	25,634		0.6	%	25,889		0.6	%
Biotechnology Tools	24,060		0.5	%	23,164		0.5	%
Manufacturing Technology	20,753		0.4	%	20,190		0.4	%
Semiconductors	187		0.0	%	158		0.0	%
Media/Content/Info	31		0.0	%	32		0.0	%
Drug Delivery	10		0.0	%	14		0.0	%
Total	$	4,721,987	100.0	%	$	4,466,647	100.0	%

No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of March 31, 2026 or December 31, 2025.

Concentrations of Credit Risk

The Company’s customers are primarily privately held companies and public companies which are active in the “Application Software”, “Drug Discovery & Development”, “Healthcare Services, Other”, “System Software”, and “Consumer & Business Services” sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property.

Industry and sector concentrations vary as new loans are recorded and loans are paid off. Investment income, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Investment income recognized in any given year can be highly concentrated among several portfolio companies.

As of March 31, 2026 and December 31, 2025, the Company’s ten largest portfolio companies represented approximately 26.2% and 28.6%, respectively, of the total fair value of the Company’s investments in portfolio companies. As of March 31, 2026 and December 31, 2025, the Company had seven portfolio companies each, respectively, that represented 5% or more of the Company’s net assets. As of March 31, 2026, the Company had two equity investments which represented approximately 49.2% of the total fair value of the Company's equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments. As of December 31, 2025, the Company had two equity investments which represented approximately 48.4% of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments.

Investment Collateral

In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative

Table of Contents

pledge covering a company’s intellectual property. The Company's investments were collateralized as follows as of March 31, 2026 and December 31, 2025:


	Percentage of debt investments (at fair value), as of
	March 31, 2026		December 31, 2025
Senior Secured First Lien
All assets including intellectual property	72.6	%	72.8	%
All assets with negative pledge on intellectual property	9.1	%	9.5	%
“Last-out” with security interest in all of the assets	6.9	%	7.0	%

Total senior secured first lien position	88.6	%	89.3	%
Second lien	9.8	%	9.1	%
Unsecured	1.6	%	1.6	%
Total debt investments at fair value	100.0	%	100.0	%

Derivative Instruments

The Company enters into forward currency contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of March 31, 2026 and December 31, 2025:


(in thousands)		Fair Value
Derivative Instrument	Statement Location	March 31, 2026		December 31, 2025
Foreign currency forward contract	Other assets	$	522	$	50

	Total	$	522	$	50

Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three months ended March 31, 2026 and 2025 are in the following locations in the Consolidated Statements of Operations:


(in thousands)		Three Months Ended March 31,
Derivative Instrument	Statement Location	2026		2025

Foreign currency forward contract	Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments	$	472	$	(840)
	Total	$	472	$	(840)

Investment Income

The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows:


(in thousands)	Three Months Ended March 31,
	2026		2025
Contractual interest income	$	104,082	$	87,817
Exit fee interest income	14,698		10,228
PIK interest income	12,914		13,473
Dividend income	2,100		2,400
Other investment income(1)	2,609		1,654
Total interest and dividend income	$	136,403	$	115,572

Recurring fee income	$	2,912	$	2,680
Fee income - expired commitments	563		317
Accelerated fee income - early repayments	1,658		942
Total fee income	$	5,133	$	3,939

(1)Other investment income includes OID interest income and interest recorded on other assets.

Table of Contents

As of March 31, 2026 and December 31, 2025, unamortized capitalized fee income was recorded as follows:


(in millions)	March 31, 2026		December 31, 2025
Offset against debt investment cost	$	43.6	$	42.5
Deferred obligation contingent on funding or other milestone	11.5		9.8
Total Unamortized Fee Income	$	55.1	$	52.3

As of March 31, 2026 and December 31, 2025, loan exit fees receivable were recorded as follows:


(in millions)	March 31, 2026		December 31, 2025
Included within debt investment cost	$	49.5	$	48.6
Deferred receivable related to expired commitments	5.9		4.5
Total Exit Fees Receivable	$	55.4	$	53.1

5. Debt

As of March 31, 2026 and December 31, 2025, the Company had the following available and outstanding debt:


(in thousands)	March 31, 2026						December 31, 2025
	Total Available		Principal Outstanding		Carrying Value(1)		Total Available		Principal Outstanding		Carrying Value(1)
SBA Debentures(2)(4)	$	350,000	$	350,000	$	341,301	$	350,000	$	350,000	$	341,012



March 2026 A Notes	—		—		—		50,000		50,000		49,984
March 2026 B Notes	—		—		—		50,000		50,000		49,983
September 2026 Notes	325,000		325,000		324,548		325,000		325,000		324,302
January 2027 Notes	350,000		350,000		348,928		350,000		350,000		348,596
2028 Convertible Notes	287,500		287,500		281,076		287,500		287,500		280,412
February 2029 Notes	300,000		300,000		294,267		—		—		—
June 2030 Notes	350,000		350,000		343,104		350,000		350,000		342,694
2031 Asset-Backed Notes	64,512		64,512		64,466		64,636		64,636		64,530
2033 Notes	40,000		40,000		39,178		40,000		40,000		39,151
MUFG Bank Facility(2)	440,000		220,000		220,000		440,000		168,000		168,000
SMBC Facility(2)(3)(5)	475,000		282,307		282,164		475,000		277,934		277,780
Total	$	2,982,012	$	2,569,319	$	2,539,032	$	2,782,136	$	2,313,070	$	2,286,444

(1)Except for the SMBC Facility and MUFG Bank Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date.

(2)Availability subject to the Company meeting the borrowing base and/or capital commitment requirements.

(3)“Total Available” includes $175.0 million of available commitment through the letter of credit facility as of March 31, 2026 and December 31, 2025.

(4)As of March 31, 2026 and December 31, 2025, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V. HC IV and SBIC V have each issued the entire $175.0 million in SBIC Debentures.

(5)In November 2024, the Company amended its SMBC Facility and converted a portion of the existing revolver facility into a term loan facility in connection therewith. As of March 31, 2026, the term loan portion of the SMBC Facility for total available, outstanding principal, and carrying value was $25.0 million, $25.0 million, and $24.9 million respectively. As of December 31, 2025, the term loan portion of the SMBC Facility for total available, outstanding principal, and carrying value was $25.0 million, $25.0 million, and $24.8 million, respectively.

Table of Contents

Debt issuance costs, net of accumulated amortization, were as follows as of March 31, 2026 and December 31, 2025:


(in thousands)	March 31, 2026		December 31, 2025
SBA Debentures	$	8,699	$	8,988




March 2026 A Notes	—		16
March 2026 B Notes	—		17
September 2026 Notes	452		698
January 2027 Notes	1,072		1,404
2028 Convertible Notes	6,424		7,088
February 2029 Notes	5,733		—
June 2030 Notes	6,896		7,306
2031 Asset-Backed Notes	46		106
2033 Notes	822		849

MUFG Bank Facility(1)	3,278		3,537
SMBC Facility(1)(2)	2,010		2,214
Total	$	35,432	$	32,223

(1)The MUFG Bank Facility and SMBC Facility are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30.

(2)As part of the November 2024 amendment of the SMBC Facility, the existing revolver facility was split into a revolver facility and a term loan facility. As of March 31, 2026, the debt issuance costs, net of accumulated amortization of the revolver facility is $1.9 million and the term loan is $0.1 million. As of December 31, 2025, the debt issuance costs, net of accumulated amortization of the revolver facility is $2.0 million and the term loan is $0.2 million.

For the three months ended March 31, 2026, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were as follows:


(in thousands)	Three Months Ended March 31, 2026
Description	Interest expense(1)		Amortization of debt issuance cost (loan fees)		Unused facility and other fees (loan fees)		Total interest expense and fees		Cash paid for interest expense
SBA Debentures	$	3,253	$	289	$	—	$	3,542	$	6,343
March 2026 A Notes	393		16		—		409		1,125
March 2026 B Notes	398		17		—		415		1,138
September 2026 Notes	2,175		203		—		2,378		4,266
January 2027 Notes	3,079		207		—		3,286		5,906
2028 Convertible Notes	3,725		354		—		4,079		6,828
February 2029 Notes	2,284		174		—		2,458		—
June 2030 Notes	5,441		219		—		5,660		—
2031 Asset-Backed Notes(2)	818		42		—		860		799
2033 Notes	625		27		—		652		625
MUFG Bank Facility	2,663		259		455		3,377		2,316
SMBC Facility	3,292		203		212		3,707		3,050
Total	$	28,146	$	2,010	$	667	$	30,823	$	32,396

(1)Interest expense includes amortization of OID for the three months ended March 31, 2026, of $42 thousand, $126 thousand, $311 thousand, $99 thousand, $191 thousand, and $19 thousand related to the September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, February 2029 Notes, June 2030 Notes, and 2031 Asset-Backed Notes, respectively.

(2)During the three months ended March 31, 2026, we did not have any loss on debt extinguishment for 2031 Asset-Backed Notes.

Table of Contents

For the three months ended March 31, 2025, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were as follows:


(in thousands)	Three Months Ended March 31, 2025
Description	Interest expense(1)		Amortization of debt issuance cost (loan fees)		Unused facility and other fees (loan fees)		Total interest expense and fees		Cash paid for interest expense
SBA Debentures	$	2,499	$	227	$	—	$	2,726	$	3,971


February 2025 Notes	202		19		—		221		1,070
June 2025 Notes	754		40		—		794		—
June 2025 3-Year Notes	750		39		—		789		—
March 2026 A Notes	562		24		—		586		1,125
March 2026 B Notes	568		26		—		594		1,138
September 2026 Notes	2,175		203		—		2,378		4,266
January 2027 Notes	3,079		207		—		3,286		5,906
2028 Convertible Notes	827		77		—		904		—
2031 Asset-Backed Notes(2)	1,492		80		—		1,572		1,457
2033 Notes	625		27		—		652		625

MUFG Bank Facility	2,570		442		560		3,572		2,179
SMBC Facility	3,595		208		219		4,022		3,843
Total	$	19,698	$	1,619	$	779	$	22,096	$	25,580

(1)Interest expense includes amortization of OID for the three months ended March 31, 2025 of $42 thousand, $126 thousand, $68 thousand, and $38 thousand related to the September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, and 2031 Asset-Backed Notes, respectively.

(2)During the three months ended March 31, 2025, the Company has recognized $15 thousand of loss on debt extinguishment for 2031 Asset-Backed Notes.

The overall weighted average interest cost, cost of debt and debt outstanding for the Company for the three months ended March 31, 2026 and 2025 were as follows:


	Three Months Ended March 31,
(in thousands)	2026			2025
Weighted average interest cost	4.5		%	4.3		%
Weighted average cost of debt(1)	5.1		%	4.9		%
Weighted average debt outstanding	$	2,420,380		$	1,815,224

(1)Cost of debt includes interest and fees.

As of March 31, 2026 and December 31, 2025, the Company was in compliance with the terms of all borrowing arrangements. There are no sinking fund requirements for any of the Company's debt.

Table of Contents

SBA Debentures

The Company held the following SBA debentures outstanding principal balances as of March 31, 2026 and December 31, 2025:



(in thousands) Issuance/Pooling Date	Maturity Date	Interest Rate(1)	March 31, 2026		December 31, 2025
March 26, 2021	September 1, 2031	1.58%	$	37,500	$	37,500
June 25, 2021	September 1, 2031	1.58%	16,200		16,200
July 28, 2021	September 1, 2031	1.58%	5,400		5,400
August 20, 2021	September 1, 2031	1.58%	5,400		5,400
October 21, 2021	March 1, 2032	3.21%	14,000		14,000
November 1, 2021	March 1, 2032	3.21%	21,000		21,000
November 15, 2021	March 1, 2032	3.21%	5,200		5,200
November 30, 2021	March 1, 2032	3.21%	20,800		20,800
December 20, 2021	March 1, 2032	3.21%	10,000		10,000
December 23, 2021	March 1, 2032	3.21%	10,000		10,000
December 28, 2021	March 1, 2032	3.21%	5,000		5,000
January 14, 2022	March 1, 2032	3.21%	4,500		4,500
January 21, 2022	March 1, 2032	3.21%	20,000		20,000
November 8, 2024	March 1, 2035	5.09%	30,000		30,000
December 6, 2024	March 1, 2035	5.09%	33,600		33,600
December 12, 2024	March 1, 2035	5.09%	8,400		8,400
December 20, 2024	March 1, 2035	5.09%	32,000		32,000
February 5, 2025	March 1, 2035	5.09%	6,000		6,000
March 28, 2025	September 1, 2035	4.66%	10,000		10,000
April 25, 2025	September 1, 2035	4.66%	15,000		15,000
May 9, 2025	September 1, 2035	4.66%	5,000		5,000
June 5, 2025	September 1, 2035	4.66%	17,000		17,000
June 12, 2025	September 1, 2035	4.66%	3,000		3,000
June 25, 2025	September 1, 2035	4.66%	15,000		15,000
Total SBA Debentures			$	350,000	$	350,000

(1) Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges.

SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments. The SBA as part of its oversight periodically examines and audits to determine SBICs' compliance with SBA regulations.

HC IV and SBIC V each received their licenses to operate as an SBIC on October 27, 2020 and July 9, 2024, respectively, and each license has a 10 year term. Each license provides the Company access to up to $175.0 million of capital through the SBA debenture program, subject to maintaining certain capital commitments. HC IV and SBIC V have each issued the entire $175.0 million in SBIC guaranteed debentures. SBA debentures bear fixed interest based on the treasury rate plus a spread applicable for the period the debentures are drawn. HC IV’s investment period concluded on October 27, 2025 and therefore, it will no longer make any future commitments to new portfolio companies. HC IV will only satisfy contractually agreed upon follow-on fundings to existing portfolio companies and may seek to pay-off a portion or all of the outstanding debentures early depending on the available liquidity in HC IV.

Table of Contents

The Company's SBICs were in compliance with all SBIC terms, including those pertaining to the SBA debentures as of March 31, 2026 and December 31, 2025. The following table summarizes information related to our SBICs as of March 31, 2026 and December 31, 2025.


	March 31, 2026						December 31, 2025
Description	HC IV			SBIC V			HC IV			SBIC V
Number of investments held	39			31			39			28
Fair value of investments (in millions)	$	386.7		$	281.8		$	404.8		$	277.6
Percentage of fair value of investments based on the Company's total investment portfolio	8.2		%	6.0		%	9.1		%	6.2		%
Tangible assets (in millions)	$	396.2		$	285.2		$	421.2		$	283.1
Percentage of tangible assets based on the Company's total assets	8.2		%	5.9		%	9.2		%	6.2		%

February 2025 Notes

On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.280% interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the February 2025 Notes was due semiannually. The February 2025 Notes were the general unsecured obligations of the Company that ranked pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. On February 5, 2025, the Company fully repaid the aggregate outstanding $50.0 million principal and $1.1 million of accrued interest pursuant to the terms of the February 2025 Notes.

June 2025 Notes

On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.310% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 Notes was due semiannually. The June 2025 Notes were the general unsecured obligations of the Company that ranked pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. On June 3, 2025, the Company fully repaid the aggregate outstanding $70.0 million principal and $1.5 million of accrued interest pursuant to the terms of the June 2025 Notes.

June 2025 3-Year Notes

On June 23, 2022, the Company issued $50.0 million in aggregate principal amount of 6.000% interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 3-Year Notes was due semiannually. The June 2025 3-Year Notes were the general unsecured obligations of the Company that ranked pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. On June 23, 2025, the Company fully repaid the aggregate outstanding $50.0 million principal and $1.5 million of accrued interest pursuant to the terms of the June 2025 3-Year Notes.

March 2026 A Notes

On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.500% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the March 2026 A Notes was due semiannually. The March 2026 A Notes were the general unsecured obligations of the Company that ranked pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. On March 4, 2026, the Company fully repaid the aggregate outstanding $50.0 million principal and $1.1 million of accrued interest pursuant to the terms of the March 2026 A Notes.

March 2026 B Notes

On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.550% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering. Interest on the March 2026 B Notes was due semiannually. The March 2026 B Notes were the general unsecured obligations of the Company that ranked pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. On March 4, 2026, the Company fully repaid the aggregate outstanding $50.0 million principal and $1.1 million of accrued interest pursuant to the terms of the March 2026 B Notes.

Table of Contents

September 2026 Notes

On September 16, 2021, the Company issued $325.0 million in aggregate principal amount of 2.625% interest-bearing unsecured notes due September 16, 2026 (the “September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021 (the “Seventh Supplemental Indenture”). Interest on the September 2026 Notes is payable semiannually in arrears on March 16 and September 16 of each year. The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the September 2026 Notes at any time, or from time to time, at the redemption price set forth under the terms of the Seventh Supplemental Indenture.

January 2027 Notes

On January 20, 2022, the Company issued $350.0 million in aggregate principal amount of 3.375% interest-bearing unsecured notes due January 20, 2027 (the “January 2027 Notes”), unless repurchased in accordance with the terms of the Eight Supplemental Indenture, dated January 20, 2022 (the “Eighth Supplemental Indenture”). Interest on the January 2027 Notes is payable semiannually in arrears on January 20 and July 20 of each year. The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the Eighth Supplemental Indenture.

2028 Convertible Notes

On March 10, 2025, the Company issued $287.5 million in aggregate principal amount of 4.750% interest-bearing convertible unsecured notes due on September 1, 2028 (the “2028 Convertible Notes”), unless previously converted or caused to repurchase the notes in accordance with their terms by the holders of the 2028 Convertible Notes. The Company may not redeem the 2028 Convertible Notes at its option prior to maturity. Interest on the 2028 Convertible Notes is due semiannually. The 2028 Convertible Notes are unsecured obligations of the Company and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

Prior to the close of business on the business day immediately preceding March 1, 2028, holders may convert their 2028 Convertible Notes only under certain circumstances set forth in the 2028 Convertible Notes Indenture, dated March 10, 2025, between the Company and U.S. Bank Trust Company, National Association, as trustee. On or after March 1, 2028 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their 2028 Convertible Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at its election, cash, shares of its common stock or a combination of cash and shares of its common stock, subject to an irrevocable settlement method election that may be made by the Company. The conversion rate is initially 46.5631 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of $21.48 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its 2028 Convertible Notes in connection with such a corporate event in certain circumstances. As of March 31, 2026, the conversion rate was 46.5631 shares of common stock per $1,000 principal amount of 2028 Convertible Notes or conversion price of $21.48 per share of common stock.

February 2029 Notes

On February 10, 2026, the Company issued $300.0 million in aggregate principal amount of 5.350% interest-bearing unsecured notes due February 10, 2029 (the “February 2029 Notes”), unless repurchased in accordance with the terms of the Tenth Supplemental Indenture, dated February 10, 2026 (the “Tenth Supplemental Indenture”). Interest on the February 2029 Notes is payable semianually in arrears on February 10 and August 10 of each year, commencing August 10, 2026. The February 2029 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the February 2029 Notes at any time, or from time to time, at the redemption price set forth under the terms of the Tenth Supplemental Indenture.

June 2030 Notes

On June 16, 2025, the Company issued $350.0 million in aggregate principal amount of 6.000% interest-bearing unsecured notes due June 16, 2030 (the “June 2030 Notes”), unless repurchased in accordance with the terms of the Ninth Supplemental Indenture, dated June 16, 2025 (the “Ninth Supplemental Indenture”). Interest on the June 2030 Notes is payable semiannually in arrears on June 16 and December 16 of each year, commencing December 16, 2025. The June 2030 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the June

Table of Contents

2030 Notes at any time, or from time to time, at the redemption price set forth under the terms of the Ninth Supplemental Indenture.

2031 Asset-Backed Notes

On June 22, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company issued $150.0 million in aggregate principal amount of 4.950% interest-bearing asset-backed notes due on July 20, 2031 (the “2031 Asset-Backed Notes”). The 2031 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2022-1 LLC (the “2022 Securitization Issuer”) pursuant to a note purchase agreement, dated as of June 22, 2022, by and among the Company, Hercules Capital Funding 2022-1 LLC, as trust depositor, the 2022 Securitization Issuer, and U.S. Bank Trust Company, N. A., as trustee, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available.

Under the terms of the 2031 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2031 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2031 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. As of March 31, 2026 and December 31, 2025, there was approximately $2.6 million and $2.5 million, respectively, of funds segregated as restricted cash related to the 2031 Asset-Backed Notes. The reinvestment period for 2031 Asset-Backed Notes ended on July 20, 2024, and as a result all principal payments received from portfolio companies are no longer eligible for reinvestment and are utilized to pay down the outstanding principal amount. During the three months ended March 31, 2026, the Company repaid $0.1 million of principal and did not recognize any accelerated debt issuance costs associated with extinguishment of the debt. During the three months ended March 31, 2025 and the year ended December 31, 2025, the Company repaid $2.6 million and $54.8 million of principal, respectively, and accelerated recognition of $15 thousand and $0.2 million, respectively, of debt issuance costs associated with extinguishment of the debt. During the three months ended March 31, 2026 and 2025, this accelerated recognition, if any, is disclosed as “Loss on extinguishment of debt” in the Consolidated Statements of Operations.

2033 Notes

On September 24, 2018, the Company issued $40.0 million in aggregate principal amount of 6.250% interest-bearing unsecured notes due October 30, 2033 (the “2033 Notes”), unless repurchased in accordance with the terms of the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018 (the “Sixth Supplemental Indenture”). Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year. The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the Sixth Supplemental Indenture after October 30, 2023.

Credit Facilities

As of March 31, 2026 and December 31, 2025, the Company has two available credit facilities, the MUFG Bank Facility and the SMBC Facility (together, the “Credit Facilities”). For the three months ended March 31, 2026 and the year ended December 31, 2025, the weighted average interest rate was 5.70% and 6.14%, respectively, and the average debt outstanding under the Credit Facilities was $417.8 million and $328.3 million, respectively.

MUFG Bank Facility

On June 10, 2025, the Company entered into a fourth amended credit facility agreement (the “Fourth Amendment”), which amends the agreement initially dated as of February 20, 2020. The Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “MUFG Bank Facility”) with MUFG Bank Ltd. as the arranger and administrative agent, and the lenders party to the MUFG Bank Facility from time to time.

The Fourth Amendment increased the lenders' commitments from $400.0 million to $440.0 million, which may be further increased via an accordion feature up to an aggregate $600.0 million, funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the MUFG Bank Facility to increase available borrowings. The Fourth Amendment adjusted the interest rate per annum from SOFR plus 2.75% to SOFR plus an applicable margin adjustment which can range from 2.50% to 2.75% subject to certain conditions. The maturity date was amended from January 13, 2026, plus a twelve-month amortization period to June 10, 2029, unless sooner terminated in accordance with its terms. The MUFG Bank Facility is

Table of Contents

secured by all of the assets of Hercules Funding IV. The MUFG Bank Facility requires payment of a non-use fee at a rate based on average utilization rate during its term.

The MUFG Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio and a minimum tangible net worth with respect to Hercules Funding IV. The MUFG Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy.

SMBC Facility

On November 26, 2024, the Company entered into a fifth amendment (the “Fifth Amendment”) to its revolving credit agreement, which amends the revolving credit agreement, dated as of November 9, 2021, with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”), as administrative agent, and the lenders and issuing banks to the SMBC Facility. As of March 31, 2026, the SMBC Facility provides for borrowings in U.S. dollars and certain agreed upon foreign currencies of up to $300.0 million, from which the Company may access subject to certain conditions. The SMBC Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $500.0 million, funded by existing or additional lenders and with the agreement of SMBC Bank and subject to other customary conditions. Availability under the revolving SMBC Facility will terminate on November 24, 2028, and the outstanding loans under the SMBC Facility will mature on November 26, 2029. Borrowings under the SMBC Facility are subject to compliance with a borrowing base and an aggregate portfolio balance. The Company’s obligations under the SMBC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and the subsidiary guarantors thereunder.

Interest under the revolving portion of the SMBC Facility is determined by the nature and denomination of the borrowing. Interest rates are determined by the appropriate benchmark rate (SOFR, EURIBOR, Prime, CORRA, SONIA or TIBOR) as applicable for the type of borrowing plus an applicable margin adjustment which can range from 1.0% to 2.0% per annum subject to certain conditions. In addition to interest, the SMBC Facility is subject to a non-usage fee of 0.375% per annum (based on the immediately preceding period’s average usage) on the unused portion of the commitment under the SMBC Facility during the revolving period. The Company is required to pay letter of credit participation fees and a fronting fee on the average daily amount of any lender’s exposure with respect to any letters of credit issued under the SMBC Facility.

In connection with the Fifth Amendment, $25.0 million of the total available commitment under the revolver facility was converted into a term loan (the “SMBC Term Loan”). The SMBC Term loan is a SOFR based interest-bearing plus 2.0% spread loan and will mature on November 26, 2029, unless repurchased in accordance with the terms of the SMBC Facility. Interest on the SMBC Term Loan is payable monthly or quarterly based on the SOFR tenor.

On February 5, 2025, the Company entered into the Third Amendment to the SMBC Letter of Credit Facility Agreement (the “SMBC LC Facility”), which amends the SMBC LC Facility with Sumitomo Mitsui Banking Corporation, dated as of January 13, 2023. The SMBC LC Facility provides for a letter of credit facility with a final maturity date ending on February 5, 2028 and a commitment amount of $175.0 million as amended. Further, the SMBC LC Facility includes an accordion provision to increase the commitment up to $400.0 million, subject to certain conditions. The Company’s obligations under the SMBC LC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and is primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and any subsidiary guarantors thereunder.

The SMBC Facility contains customary events of default with customary cure and notice provisions, including, without limitation, nonpayment, misrepresentation of representations and warranties in a material respect, breach of covenant, cross-default and cross-acceleration to other indebtedness and bankruptcy. The SMBC Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, including covenants relating to minimum stockholders' equity, asset coverage ratios, and our status as a RIC.

6. Income Taxes

The determination of taxable income pursuant to U.S. federal income tax regulations differs from U.S. GAAP. As a result, permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character.

Table of Contents

Taxable income and taxable net realized gains (losses) for the three months ended March 31, 2026 and 2025 appears as follows:


(in millions, except per share data)	Three Months Ended March 31,
	2026		2025
Taxable income	$	85.1	$	73.2
Taxable income per share	$	0.47	$	0.43
Taxable net realized gains (losses)	$	(1.9)	$	3.5
Taxable net realized gains (losses) per share	$	(0.01)	$	0.02
Weighted average shares outstanding	182.8		171.5

The aggregate gross unrealized appreciation (depreciation) of the Company’s investment over cost for U.S. federal income tax purposes appears as follows:



(in millions)	March 31, 2026		December 31, 2025
Aggregate gross unrealized appreciation	$	90.1	$	107.0
Aggregate gross unrealized depreciation	139.7		109.4
Net unrealized appreciation (depreciation) over cost for U.S. federal income tax purposes	(49.6)		(2.4)
Aggregate cost of securities for U.S. federal income tax purposes (in billions)	4.8		4.5

For the three months ended March 31, 2026, the Company paid approximately $5.5 million of income tax, including excise tax, and had $1.6 million of accrued, but unpaid tax expense as of March 31, 2026. For the three months ended March 31, 2025, the Company paid approximately $6.0 million of income tax, including excise tax, and had $1.5 million of accrued, but unpaid tax expense as of March 31, 2025.

Additionally, the Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal U.S. federal tax rates based on its taxable income.

In accordance with ASC 740, the Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties, if any, related to unrecognized tax benefits as a component of provision for income taxes. Based on an analysis of the Company’s tax position, there are no uncertain tax positions that meet the recognition or measurement criteria. The Company is currently not undergoing any tax examinations. The Company does not anticipate any significant increase or decrease in unrecognized tax benefits for the next twelve months. The 2022 – 2024 federal tax years for the Company remain subject to examination by the Internal Revenue Service. The 2020 – 2024 state tax years for the Company remain subject to examination by the state taxing authorities.

7. Stockholders’ Equity and Distributions

The Company has issued and outstanding 187,174 thousand and 182,695 thousand shares of common stock as of March 31, 2026 and December 31, 2025, respectively. The Company currently sells shares through its equity distribution agreements (the “2024 Equity Distribution Agreements”) with Citizens JMP Securities LLC and Jefferies LLC (the “Sales Agents”) entered into on December 12, 2024. The 2024 Equity Distribution Agreements provide that the Company may offer and sell up to 30.0 million shares of its common stock from time to time through the Sales Agents. Sales of the Company's common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

Table of Contents

The Company issued and sold the following shares of common stock during the three months ended March 31, 2026 and 2025:


(in millions, except per share data)
Three Months Ended March 31,	Number of Shares Issued	Gross Proceeds		Underwriting Fees/Offering Expenses		Net Proceeds		Average Price/Share
2026	3.5	$	52.9	$	0.9	$	52.0	$	14.70
2025	2.0	$	40.1	$	0.7	$	39.4	$	19.71

The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of March 31, 2026, approximately 15.3 million shares remain available for issuance and sale under the 2024 Equity Distribution Agreements.

The Company currently pays quarterly distributions to its stockholders. The following table summarizes the Company’s distributions declared during the three months ended March 31, 2026 and year ended December 31, 2025:

(in thousands, except per share data)

Distribution Type

Declared Date

Record Date

Payment Date

Per Share Amount

Total Amount

Base

February 6, 2025

February 26, 2025

March 5, 2025

0.40

69,263

Supplemental

February 6, 2025

February 26, 2025

March 5, 2025

0.07

12,121

Base

April 23, 2025

May 13, 2025

May 20, 2025

0.40

70,709

Supplemental

April 23, 2025

May 13, 2025

May 20, 2025

0.07

12,374

Base

July 24, 2025

August 12, 2025

August 19, 2025

0.40

72,671

Supplemental

July 24, 2025

August 12, 2025

August 19, 2025

0.07

12,717

Base

October 23, 2025

November 12, 2025

November 19, 2025

0.40

72,688

Supplemental

October 23, 2025

November 12, 2025

November 19, 2025

0.07

12,720

Total distributions declared during the year ended December 31, 2025

1.88

335,263

Base

February 4, 2026

February 25, 2026

March 4, 2026

0.40

73,815

Supplemental

February 4, 2026

February 25, 2026

March 4, 2026

0.07

12,918

Total distributions declared during the three months ended March 31, 2026

0.47

86,733

During the three months ended March 31, 2026, for income tax purposes, the distributions paid of $0.47 per share were from ordinary spillover earnings from 2025. As of March 31, 2026, the Company estimates that it has generated undistributed taxable earnings “spillover” of $0.80 per share. The undistributed taxable earnings spillover will be carried forward toward distributions to be paid in accordance with RIC requirements.

The Company has a distribution reinvestment plan, whereby the Company may buy shares of its common stock in the open market or issue new shares in order to satisfy dividend reinvestment requests. When the Company issues new shares in connection with the dividend reinvestment plan, the issue price is equal to the closing price of its common stock on the dividend record date. During the three months ended March 31, 2026 and 2025, the Company issued 153,423 and 121,743 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan.

8. Equity Incentive Plans

The Company grants equity-based awards to employees and non-employee directors for the purpose of attracting and retaining the services of its executive officers, key employees, and members of the Board. The Company’s equity-based awards are granted under the 2018 Equity Incentive Plan (the “2018 Plan”) for employees and 2018 Non-Employee Director Plan (the “Director Plan”) for non-employee directors. The 2018 Plan and the Director Plan were approved by stockholders on June 28, 2018 and unless earlier terminated by the Board, terminate on May 12, 2028. Subject to certain adjustments and permitted reversions of shares, the maximum aggregate number of shares that may be authorized for issuance under awards granted under the 2018 Plan and Director Plan is 9,261,229 shares and 300,000 shares, respectively. In connection with the issuance of shares under the 2018 Plan and Director Plan, the Company has registered, in aggregate, 18.7 million and 300,000 shares of common stock, respectively. For additional information regarding the 2018 Plan and Director Plan, please refer to the Company’s definitive proxy statement filed with the SEC on April 23, 2026.

The Company has received exemptive relief from the SEC that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Plan. The exemptive order also allows participants in the Director Plan and the 2018 Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock.

Table of Contents

All of the Company’s equity-based awards require future service, and are expensed over the relevant service period. The Company does not estimate forfeitures, and reverses all unvested costs associated with equity-awards in the period they are forfeited. For the three months ended March 31, 2026 and 2025, the Company recognized $4.1 million and $3.6 million of stock-based compensation expense in the Consolidated Statements of Operations, respectively. As of March 31, 2026 and March 31, 2025, approximately $34.5 million and $30.1 million of total unrecognized compensation costs are expected to be recognized over the next 2.7 and 2.7 years, respectively.

Service Vesting Awards

The Company grants equity-based awards which have service conditions, which generally begin to vest one-third after one year after the date of grant and ratably over the succeeding two years in accordance with the individual award terms. Certain awards have service conditions of longer duration and may begin to vest up to seven years after the date of grant. These equity-based awards which vest upon achievement of service conditions are collectively referred to as the “Service Vesting Awards”. The grant date fair value of Service Vesting Awards granted during the three months ended March 31, 2026 and 2025, were approximately $18.1 million, and $15.6 million, respectively.

The Company has granted restricted stock equity awards in the form of restricted stock awards and restricted stock units. The Company determines the grant date fair values of restricted stock equity awards using the grant date stock close price. The activities for the Company's unvested restricted stock equity awards for each of the three months ended March 31, 2026 and 2025, are summarized below:


	Three Months Ended March 31,
	2026			2025
	Shares	Weighted Average Grant Date Fair Value per Share		Shares	Weighted Average Grant Date Fair Value per Share
Unvested Shares Beginning of Period	2,180,593	$	13.35	2,060,432	$	12.24
Granted	991,156	$	18.23	780,295	$	19.96
Vested	(396,326)	$	18.33	(389,553)	$	16.63
Forfeited	(24,459)	$	18.75	(35,458)	$	12.96
Unvested Shares End of Period	2,750,964	$	14.34	2,415,716	$	14.02

In addition to the restricted stock equity-based awards, the Company has also issued stock options to certain employees. The fair value of options granted during the three months ended March 31, 2026 and 2025, was approximately $9 thousand and $29 thousand, respectively. During the three months ended March 31, 2026 and 2025, approximately $31 thousand, and $36 thousand of share-based cost due to stock option grants was expensed, respectively.

Table of Contents

9. Earnings Per Share

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:


(in thousands, except per share data)	Three Months Ended March 31,
	2026		2025
Numerator
Net increase (decrease) in net assets resulting from operations	$	42,502	$	50,337
Less: Total distributions declared	(86,733)		(81,384)
Total Earnings (loss), net of total distributions	(44,231)		(31,047)

Earnings (loss), net of distributions attributable to common shares	(44,230)		(31,048)
Add: Distributions declared attributable to common shares	85,885		80,616
Numerator for basic change in net assets per common share	41,655		49,568
Add: Income impact of assumed conversion of 2028 Convertible Notes	4,079		904
Numerator for diluted change in net assets per common share	$	45,734	$	50,472

Denominator
Basic weighted average common shares outstanding	182,760		171,494
Incremental shares from assumed conversion of 2028 Convertible Notes	13,387		3,272
Common shares issuable	674		617
Weighted average common shares outstanding assuming dilution	196,821		175,383

Change in net assets per common share:
Basic	$	0.23	$	0.29
Diluted	$	0.23	$	0.29

In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share.

The issuance of the 2028 Convertible Notes is considered part of the if-converted method for calculation of diluted earnings per share. In applying the if-converted method, conversion is not assumed for purposes of computing diluted earnings per share if the effect would be anti-dilutive. For the three months ended March 31, 2026, there was no anti-dilution when applying the if-converted method for the 2028 Convertible Notes.

The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three months ended March 31, 2026 and 2025, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows:


	Three Months Ended March 31,
Anti-dilutive Securities	2026	2025
Unvested common stock options	326	1,974

Unvested restricted stock awards	125,767	23

As of March 31, 2026 and December 31, 2025, the Company was authorized to issue 300.0 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.

Table of Contents

10. Financial Highlights

Following is a schedule of financial highlights for the three months ended March 31, 2026 and 2025:


(in thousands, except per share data and ratios)	Three Months Ended March 31,
	2026			2025
Per share data: (1)
Net asset value at beginning of period	$	12.13		$	11.66
Net investment income	0.48			0.45
Net realized gain (loss)	—			(0.01)
Net unrealized appreciation (depreciation)	(0.25)			(0.15)
Total from investment operations	0.23			0.29
Net increase (decrease) in net assets from capital share transactions(1)	(0.02)			0.04
Distributions of net investment income(6)	(0.47)			(0.47)
Distributions of capital gains (6)	—			—
Stock-based compensation expense included in net investment income and other movements(2)	0.03			0.03
Net asset value at end of period	$	11.90		$	11.55

Ratios and supplemental data:
Per share market value at end of period	$	14.77		$	19.21
Total return(3)	(19.06		%)	(2.03		%)
Shares outstanding at end of period	187,174			173,285
Weighted average number of common shares outstanding	182,760			171,494
Net assets at end of period	$	2,226,995		$	2,000,630
Ratio of total expense to average net assets(4)	9.60		%	8.33		%
Ratio of net investment income before investment gains and losses to average net assets(4)	15.84		%	15.35		%
Portfolio turnover rate(5)	4.89		%	3.40		%
Weighted average debt outstanding	$	2,420,380		$	1,815,224
Weighted average debt per common share	$	13.24		$	10.58

(1)All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date.

(2)Adjusts for the impact of stock-based compensation expense, which is a non-cash expense and has no net impact to NAV. Pursuant to ASC Topic 718, the expense is offset by a corresponding increase in paid-in capital. Additionally, adjusts for other items attributed to the difference between certain per share data based on the weighted-average basic shares outstanding and those calculated using the shares outstanding as of a period end or transaction date.

(3)The total return for the three months ended March 31, 2026 and 2025 equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors.

(4)The ratios are calculated based on weighted average net assets for the relevant period and are annualized.

(5)The portfolio turnover rate for the three months ended March 31, 2026 and 2025 equals to the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized.

(6)Includes distributions on unvested restricted stock awards.

11. Commitments and Contingencies

The Company’s commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company’s portfolio companies. As of March 31, 2026, a portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow the Company relief from funding obligations for previously made unfunded commitments in instances where the underlying portfolio company experiences materially adverse events that affect the financial condition or business outlook for the portfolio company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by future or unachieved milestones, taking into consideration relevant funding provisions such as any notice provisions in the credit agreements with the portfolio company.

As of March 31, 2026 and December 31, 2025, the Company had approximately $397.4 million and $385.6 million, respectively, of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones. In order to draw a portion of the Company's available unfunded commitments, a portfolio company must submit to the Company a formal funding request

Table of Contents

that complies with the applicable advance notice and other operational requirements. The amounts disclosed exclude unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) related to the portion of portfolio company investments assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations embedded in the borrowing agreements.

As of March 31, 2026 and December 31, 2025, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows:


(in thousands)	Unfunded Commitments (1) as of
Portfolio Company	March 31, 2026		December 31, 2025
Debt Investments:
ChenMed, LLC	$	25,000	$	25,000
Intercom, Inc.	22,500		—
Saronic Technologies, Inc.	21,250		21,250
Earnix, Inc.	16,250		26,250
ControlUp, Inc.	15,000		—
Maze Therapeutics, Inc.	14,000		—
Ennoble Care LLC	13,500		—
GoEuro Travel GmbH	13,496		18,750
Disc Medicine, Inc.	12,500		22,500
Viridian Therapeutics, Inc.	12,250		12,250
Expel, Inc.	12,000		—
Mango Technologies, Inc.	11,750		16,750
Belong Health, Inc.	11,250		—
Alector, Inc.	10,500		10,500
CollectiveHealth, Inc.	10,125		—
CoreView USA, Inc.	10,000		10,000
DroneDeploy, Inc.	10,000		10,000
Scylla DB Ltd.	10,000		—
iSpot.tv, Inc.	9,750		5,980
Beren Therapeutics P.B.C.	8,625		—
ZeroEyes, Inc.	8,000		8,000
Pindrop Security, Inc.	7,750		7,750
Senseonics Holdings, Inc.	7,750		—
Imagen Technologies, Inc.	7,500		7,500
Nerdy Inc.	7,000		7,000
Peek Travel, Inc.	6,750		9,750
Loft Orbital Solutions Inc.	6,600		6,600
Marathon Health, LLC	6,000		9,620
Tipalti Solutions Ltd.	6,000		—
PayIt, LLC	5,698		4,800
Distributed Creation Inc.	5,000		5,000
DNSFilter, Inc.	5,000		5,000
Smartsheet Inc.	4,840		4,840
Hermeus Corporation	3,580		—
Akeyless Security Ltd.	3,500		2,000
Canary Technologies	3,375		—
Loftware, Inc.	2,846		2,846
Funnel Holding AB (publ)	2,625		2,625
Zappi, Inc.	2,571		2,571
Tidal Vision Products, Inc.	2,500		2,500
Proven Optics, LLC	2,250		2,250

Table of Contents


(in thousands)	Unfunded Commitments (1) as of
Portfolio Company	March 31, 2026		December 31, 2025
Debt Investments:
New Relic, Inc.	$	2,176	$	2,176
Streamline Healthcare Solutions	2,100		2,100
Sumo Logic, Inc.	2,000		2,000
Saama Technologies, LLC	1,938		1,938
Babel Street	1,747		3,275
DocPlanner	1,499		9,538
Andesa Services, Inc.	1,222		—
LogicSource	1,209		1,209
Zimperium, Inc.	1,088		1,087
Alchemer LLC	890		890
Dispatch Technologies, Inc.	500		625
LinenMaster, LLC	338		338
ShadowDragon, LLC	333		333
TaxCalc	311		311
Omeda Holdings, LLC	61		160
Arcus Biosciences, Inc.	—		18,750
Curana Health Holdings, LLC	—		17,500
Harness, Inc.	—		14,438
Weee! Inc.	—		12,500
Finix Payments, Inc.	—		8,750
Elation Health, Inc.	—		7,500
Octave Health Group, Inc.	—		2,500
Carbyne, Inc.	—		2,334
Behavox Limited	—		2,100



















Total Unfunded Debt Commitments:	394,293		382,234

Investment Funds & Vehicles:(2)
Forbion Growth Opportunities Fund I C.V.	1,740		1,771
Forbion Growth Opportunities Fund II C.V.	1,413		1,618
Total Unfunded Commitments in Investment Funds & Vehicles:	3,153		3,389

Total Unfunded Commitments	$	397,446	$	385,623

(1)For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $160.6 million and $96.2 million of unfunded commitments as of March 31, 2026 and December 31, 2025, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note 12 - Related Party Transactions”.

(2)For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

Table of Contents

The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type:


(in thousands) Unfunded Commitments
	March 31, 2026		December 31, 2025
Expiring during:



2026	$	234,980	$	281,807
2027	97,901		41,112
2028	4,236		4,361
2029	17,588		16,588
2030	33,526		33,526
2031	6,062		4,840
Total Unfunded Debt Commitments	394,293		382,234

Unfunded Commitments in Investment Funds & Vehicles:
Expiring during:
2030	1,740		1,771
2032	1,413		1,618
Total Unfunded Commitments in Investment Funds & Vehicles	3,153		3,389
Total Unfunded Commitments	$	397,446	$	385,623

The following tables provide the Company’s contractual obligations as of March 31, 2026 and December 31, 2025:


As of March 31, 2026:	Payments due by period (in thousands)
Contractual Obligations(1)	Total		Less than 1 year		1 - 3 years		3 - 5 years		After 5 years
Debt(2)(3)	$	2,569,319	$	675,000	$	587,500	$	852,307	$	454,512
Lease and License Obligations(4)	20,291		3,387		6,281		5,495		5,128
Total	$	2,589,610	$	678,387	$	593,781	$	857,802	$	459,640

As of December 31, 2025:	Payments due by period (in thousands)
Contractual Obligations(1)	Total		Less than 1 year		1 - 3 years		3 - 5 years		After 5 years
Debt(3)(5)	$	2,313,070	$	425,000	$	637,500	$	795,934	$	454,636
Lease and License Obligations(4)	20,892		3,339		6,228		5,586		5,739
Total	$	2,333,962	$	428,339	$	643,728	$	801,520	$	460,375

(1)Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds.

(2)Includes $350.0 million in principal outstanding under the SBA Debentures, $325.0 million of the September 2026 Notes, $350.0 million of the January 2027 Notes, $287.5 million of the 2028 Convertible Notes, $300.0 million of the February 2029 Notes, $350.0 million of the June 2030 Notes, $64.5 million of the 2031 Asset-Backed Notes and $40.0 million of the 2033 Notes as of March 31, 2026. There was also $282.3 million outstanding under the SMBC Facility and $220.0 million outstanding under the MUFG Bank Facility as of March 31, 2026.

(3)Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”.

(4)Leases and license obligations includes contractual amounts related to short-term leases.

(5)Includes $350.0 million in principal outstanding under the SBA Debentures, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $325.0 million of the September 2026 Notes, $350.0 million of the January 2027 Notes, $287.5 million of the 2028 Convertible Notes, $350.0 million of the June 2030 Notes, $64.6 million of the 2031 Asset-Backed Notes and $40.0 million of the 2033 Notes as of December 31, 2025. There was also $277.9 million outstanding under the SMBC Facility and $168.0 million outstanding under the MUFG Bank Facility as of December 31, 2025.

Certain premises are leased or licensed under agreements which expire at various dates through July 2034. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset. During the three months ended March 31, 2026 and 2025, total rent expense, including short-term leases, amounted to approximately $0.8 million and $0.8 million in each period, respectively.

Table of Contents

The following tables set forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases for the three months ended March 31, 2026 and 2025:


(in thousands)	Three Months Ended March 31,
	2026		2025
Total operating lease cost	$	774	$	774
Cash paid for amounts included in the measurement of lease liabilities	$	608	$	595


	As of
	March 31, 2026		December 31, 2025
Weighted-average remaining lease term (in years)	6.69		6.94
Weighted-average discount rate	6.91	%	6.91	%

The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of March 31, 2026:


(in thousands)	As of March 31, 2026
2026	$	2,571
2027	3,452
2028	2,766
2029	2,823
Thereafter	8,501
Total lease payments	20,113
Less: imputed interest & other items	(4,911)
Total operating lease liability	$	15,202

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

12. Related Party Transactions

As disclosed in “Note 1 - Description of Business”, the Adviser Subsidiary is the Company's wholly owned registered investment adviser business, comprised of the collectively held and presented entities Hercules Adviser LLC, Hercules Capital Management, LLC, and Hercules Partner Holdings, LLC entities. The Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value. The Adviser Subsidiary has entered into investment management agreements with its privately offered Adviser Funds, and it receives management fees based on the assets under management of the Adviser Funds. In addition, the general partner interests (the “GP Interests”) held by Hercules Partner Holdings, LLC may receive incentive fees based on the performance of the Adviser Funds. Both the Adviser Subsidiary and Hercules Partner Holdings, LLC are owned by Hercules Capital Management LLC. The following table summarized the total income from the Adviser Subsidiary for the three months ended March 31, 2026 and 2025:


(in millions)	Three Months Ended March 31,
	2026		2025

Interest and Dividend Income	$	2.1	$	1.9

Refer to “Note 4 – Investments” for additional information related to income, gains and losses recognized related to the Company’s investment.

The Company has a shared services agreement (“Sharing Agreement”) with the Adviser Subsidiary, through which the Adviser Subsidiary has access to the Company's human capital resources (including administrative functions) and other resources and infrastructure (including office space and technology). Under the terms of the Sharing Agreement, the Company allocates the related expenses of shared services to the Adviser Subsidiary based on direct time spent, investment activity, and proportion of assets under management depending on the nature of the expense. The Company’s total expenses for the three months ended March 31, 2026 and 2025, are net of expenses allocated to the Adviser Subsidiary of $4.6 million and $3.3 million, respectively. As of March 31, 2026 and December 31, 2025, there was approximately $0.9 million and $1.7 million receivable, respectively, from the Adviser Subsidiary.

Table of Contents

In addition, the Company may from time-to-time make investments alongside the Adviser Funds or assign a portion of investments to the Adviser Funds in accordance with the Company’s allocation policy. The assigned investment activities for the three months ended March 31, 2026 and 2025, are summarized below:


(in millions)	Three Months Ended March 31,
	2026		2025
Investment commitments assigned to or directly committed by the Adviser Funds	$	444.3	$	235.8
Investment commitments sold to Adviser Funds	44.2		—
Investment fundings assigned to, directly originated or funded by the Adviser Funds	179.6		124.1
Amounts received by the Company from the Adviser Funds relating to assigned investments	2.5		—

13. Subsequent Events

Dividend Distribution Declaration

On April 29, 2026, the Board declared a cash distribution of $0.40 per share to be paid on May 21, 2026 to stockholders of record as of May 14, 2026. In addition to the cash distribution, and as part of the supplemental cash distribution of $0.28 per share to be paid in four quarterly distributions of $0.07 per share, the Board declared a supplemental cash distribution of $0.07 per share to be paid on May 21, 2026 to stockholders of record as of May 14, 2026. Including the $0.07 per share supplemental cash distributions paid to stockholders of record as of February 25, 2026, the Board has declared a total of $0.14 per share of the $0.28 per share of supplemental cash distribution declared on February 4, 2026.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

The matters discussed in this Quarterly Report, as well as in future oral and written statements by management of Hercules Capital, Inc., that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties, including those discussed under “Item 1A. Risk Factors”, which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:

•our current and future management structure;

•our future operating results;

•our business prospects and the prospects of our prospective portfolio companies;

•the impact of investments that we expect to make;

•our informal relationships with third parties including in the venture capital industry;

•the expected market for venture capital investments and our addressable market;

•the dependence of our future success on the general economy and its impact on the industries in which we invest;

•our ability to access debt markets and equity markets;

•the occurrence and impact of macro-economic developments (for example, tariffs and other trade or sanction issues, government shutdown, global pandemics, natural disasters, terrorism, international conflicts and war) on us and our portfolio companies;

•the ability of our portfolio companies to achieve their objectives;

•our expected financings and investments;

•our regulatory structure and tax status as a RIC;

•our ability to operate as a BDC and our subsidiaries ability to operate as SBICs;

•the impact of information technology system failures, data security breaches, data privacy compliance, network disruptions, and cybersecurity attacks;

•the adequacy of our cash resources and working capital;

•the timing of cash flows, if any, from the operations of our portfolio companies;

•the timing, form and amount of any distributions;

•the impact of fluctuations in interest rates on our business;

•the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and

•our ability to recover unrealized depreciation on investments.

You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this Quarterly Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this Quarterly Report.

Use of Non-GAAP Measures

We present our financial condition and results of operations in the way we believe will be most meaningful and representative of our business results. Some of the measurements we use are “Non-GAAP financial measures” under SEC rules and regulations. GAAP is the acronym for “generally accepted accounting principles” in the United States. The Non-GAAP financial measures we present may not be comparable to similarly-named measures reported by other companies.

Table of Contents

Overview

We are a leading specialty finance company with a focus on providing financing solutions to high-growth and innovative venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. Our primary business objectives are to increase our net income, net investment income, and net asset value through our investments. We principally invest in debt securities and, to a lesser extent, warrant and equity securities, with a particular emphasis on Structured Debt. We aim to achieve our business objectives by maximizing our portfolio total return through generation of current income from our debt investments and capital appreciation from our warrant and equity investments. We expect that our investments will generally range from $25.0 million to $100.0 million, although we may make investments in amounts above or below this range. Through generation of current income from our debt investments and capital appreciation from our warrant and equity investments, we aim to maximize our portfolio total return.

Since inception through March 31, 2026, we have originated more than $27.0 billion in commitments in over 700 companies. We, through the Adviser Subsidiary, may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we, through the Adviser Subsidiary may earn management or other fees for our services. As of March 31, 2026, we, including through our Adviser Subsidiary, actively manage approximately $6.1 billion of assets.

We are structured as an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a BDC under the 1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents, and high-quality debt investments that mature in one year or less. Consistent with requirements under the 1940 Act, we invest primarily in United States based companies and to a lesser extent in foreign companies. We source our investments through our principal office located in San Mateo, CA, as well as through our additional offices in Boston, MA, New York, NY, San Diego, CA, Denver, CO, and London, United Kingdom.

We have elected to be treated for tax purposes as a RIC under the Code and operate in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC, among other requirements, we must maintain certain income, asset, and distribution requirements. As a RIC, we generally will not be subject to U.S. federal income tax on the income that we distribute (or are deemed to distribute) to our stockholders provided that we maintain our RIC status for a given year. See “Certain United States Federal Income Tax Considerations” included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 12, 2026 for additional information.

Portfolio and Investment Activity

The total fair value of our investment portfolio as of March 31, 2026 and December 31, 2025 was as follows:


(in millions)	Fair Value
	March 31, 2026		December 31, 2025
Debt	$	4,540.1	$	4,279.4
Equity	132.1		139.0
Warrants	42.5		41.1
Investment Funds & Vehicles	7.3		7.1
Total Investment Portfolio	$	4,722.0	$	4,466.6

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. Not all debt commitments represent future cash requirements. Unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the year following the underwriting of such debt commitment. From time to time, unfunded contractual commitments may expire without being drawn and thus do not represent future cash requirements.

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing and some portion may be assigned or allocated to or directly originated by the Adviser Funds prior to or after closing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

Table of Contents

Our portfolio activity for the three months ended March 31, 2026 and 2025 was comprised of the following:


(in millions)	March 31, 2026		March 31, 2025
Investment Commitments(1)
Investment Commitments Originated by Hercules Capital and the Adviser Funds	$	1,812.2	$	1,019.4
Less: Commitments assigned to or directly committed by the Adviser Funds (2)	(444.3)		(235.8)
Net Total Investment Commitments	$	1,367.9	$	783.6

Gross Debt Commitments Originated by Hercules Capital and the Adviser Funds
New portfolio company	$	1,062.2	$	775.2
Existing portfolio company	742.5		236.9
Sub-total	1,804.7		1,012.1
Less: Debt commitments assigned to or directly committed by the Adviser Funds	(443.1)		(233.6)
Net Total Debt Commitments	$	1,361.6	$	778.5

Investment Fundings (3)
Gross Debt Fundings by Hercules Capital and the Adviser Funds
New portfolio company	$	238.8	$	337.0
Existing portfolio company	459.9		194.8
Sub-total	698.7		531.8
Less: Debt fundings assigned to or directly funded by the Adviser Funds	(178.4)		(121.9)
Net Total Debt Fundings	$	520.3	$	409.9
Equity Investments and Investment Funds and Vehicles Fundings by Hercules Capital and the Adviser Funds
New portfolio company	$	0.4	$	—
Existing portfolio company	7.3		7.3
Sub-total	$	7.7	$	7.3
Less: Equity fundings assigned to or directly funded by the Adviser Funds	(1.2)		(2.2)
Net Total Equity and Investment Funds and Vehicle Fundings	$	6.5	$	5.1

Total Unfunded Contractual Commitments (4)	$	397.4	$	455.7

Non-Binding Term Sheets
New portfolio company	$	90.0	$	428.3
Existing portfolio company	28.8		78.5
Total	$	118.8	$	506.8

(1)Includes restructured loans and renewals in addition to new commitments.

(2)Excludes $44.2 million investment commitments sold to Adviser funds during the three months ended March 31, 2026.

(3)Funded amounts include borrowings on revolving facilities.

(4)Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. This excludes $160.6 million and $136.0 million of unfunded commitments as of March 31, 2026 and March 31, 2025, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds.

We receive principal payments on our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the three months ended March 31, 2026, we received approximately $227.5 million in aggregate principal repayments. Approximately $1.7 million of the aggregate principal repayments related to scheduled principal payments and approximately $225.8 million were early principal repayments related to 12 portfolio companies. Additionally, during the three months ended March 31, 2026, we received $7.5 million from the partial sale of one debt investment to external parties.

Table of Contents

Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable and escrow receivables) as of and for the three months ended March 31, 2026 and 2025 was as follows:


(in millions)	March 31, 2026		March 31, 2025
Beginning Portfolio	$	4,466.6	$	3,660.0
New fundings and restructures	706.4		539.1
Fundings assigned to or directly funded by the Adviser Funds	(179.6)		(124.1)
Equity and warrants not related to current period fundings	0.2		—
Principal repayments received on investments	(1.7)		(12.7)
Early payoffs	(225.8)		(131.8)
Proceeds from the sale of debt investments	(7.5)		—
Proceeds from sale of equity and warrant investments	(2.9)		(0.3)
Paid-in-kind interest	12.8		13.9
Accretion of loan discounts	14.0		10.5
Net acceleration of loan discounts and loan fees due to early payoffs or restructures	(7.8)		(3.6)
New loan fees	(4.9)		(3.9)
Gain (loss) on investments due to sales or write offs	(0.6)		(0.9)
Net change in unrealized appreciation (depreciation)	(47.2)		(21.7)
Ending Portfolio	$	4,722.0	$	3,924.5

Additionally, we may hold investments in debt, warrant, or equity positions of portfolio companies that have filed a registration statement with the SEC in contemplation of a potential initial public offering. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely manner or at all.

The following table presents certain additional selected information regarding our debt investment portfolio as of March 31, 2026, December 31, 2025, and March 31, 2025. This includes information on benchmark index rate floors which we have in place on all of our floating rate debt investments.


	March 31, 2026		December 31, 2025		March 31, 2025
Number of portfolio companies with debt outstanding	139		127		119
Percentage of debt bearing a floating rate	98.0	%	97.9	%	98.0	%
Percentage of debt bearing a fixed rate	2.0	%	2.1	%	2.0	%
Weighted average core yield on debt investments(1)(3)	12.2	%	12.5	%	12.6	%
Weighted average effective yield on debt investments(2)(3)	12.8	%	12.9	%	13.0	%
Prime rate at the end of the period	6.75	%	6.75	%	7.50	%
Percentage of Prime rate linked debt investments	84.6	%	84.0	%	79.0	%
Weighted average floor rate bearing a Prime rate	7.1	%	7.2	%	7.1	%
Percentage of SOFR and SONIA rate linked debt investments	13.4	%	13.9	%	19.0	%
Weighted average floor rate bearing a SOFR or SONIA rate	1.0	%	1.0	%	1.0	%

(1)The core yield is a Non-GAAP financial measure. The core yield on our debt investments excludes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, other one-time events, and includes income from expired commitments. Please refer to the “Portfolio Yield” section below for further discussion of this measure.

(2)The effective yield on our debt investments includes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events. The effective yield is derived by dividing total investment income from debt investments by the weighted average earning investment portfolio assets outstanding during the year, excluding non-interest earning assets such as warrants and equity investments. Please refer to the “Portfolio Yield” section below for further discussion of this measure.

(3)The core and effective yields represent the weighted average yields for the three-month periods ended March 31, 2026, December 31, 2025 and March 31, 2025. Please refer to the “Portfolio Yield” section below for further discussion of these measures.

Macroeconomic Market Developments

The capital markets are subject to fluctuations caused by various external factors such as changes in the inflationary environment, interest rate movements, concerns over slowing economic growth and possible global recession, changes to U.S. tariff and import/export regulations, uncertainty and disruption caused by geopolitical tensions, government shutdowns, and rapid advances in technology, including artificial intelligence, among other factors. These macroeconomic developments are outside our control and could require us to adjust our plan of operations, and impact our financial position, results of operations or cash flows in the future. We monitor macroeconomic market developments and their related impact to our business, including impacts to our portfolio companies, employees, due diligence and underwriting processes, and the broader financial markets.

Table of Contents

Our investment portfolio continues to be focused on industries and sectors that are generally expected to be more resilient to U.S. and global economic cycles. This includes being partially insulated from declining interest rates as all of our floating rate debt investments, which represent 98.0% and 97.9% of our debt portfolio as of March 31, 2026 and December 31, 2025, respectively, are subject to interest rate floors. While our portfolio is not immune to the impact of macroeconomic events, we believe we and our portfolio are well positioned to manage the current environment. Given the unpredictability and fluidity of the macroeconomic market, neither our management nor our Board is able to predict the full impact of the macroeconomic events on our business, future results of operations, financial position, or cash flows. For additional information, see “Part I - Item 1A. Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 12, 2026.

Income from Portfolio

We primarily generate revenue in the form of interest income, from our investments in debt securities, and fee income, which is primarily comprised of commitment and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate income from dividends on either direct equity investments or equity interests obtained in connection with originating loans, such as options, warrants or conversion rights. We also generate revenue in the form of capital gains, if any, on warrants or other equity securities that we acquire from our portfolio companies.

As of March 31, 2026, our debt investments generally have a term of between two and five years and typically bear interest at a rate ranging from approximately 7% to approximately 14%. In addition to the cash yields received on our debt investments, in some instances, our debt investments may also include any of the following: exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.

Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.

Loan origination and commitment fees are generally received in full at the inception of a loan, are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. As of March 31, 2026 and December 31, 2025, unamortized capitalized fee income was recorded as follows:


(in millions)	March 31, 2026		December 31, 2025
Offset against debt investment cost	$	43.6	$	42.5
Deferred obligation contingent on funding or other milestone	11.5		9.8
Total Unamortized Fee Income	$	55.1	$	52.3

Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of March 31, 2026 and December 31, 2025, loan exit fees receivable were recorded as follows:


(in millions)	March 31, 2026		December 31, 2025
Included within debt investment cost	$	49.5	$	48.6
Deferred receivable related to expired commitments	5.9		4.5
Total Exit Fees Receivable	$	55.4	$	53.1

Additionally, we have debt investments in our portfolio that earn PIK interest. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our status as a RIC, the non-cash PIK income must be distributed to stockholders with other sources of income in the form of dividend distributions even though we have not yet collected any cash from the borrower. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. During the three months ended March 31, 2026 and 2025, we recorded approximately $12.9 million and $13.5 million of PIK income, respectively.

Portfolio Yield

We report our financial results on a GAAP basis. We monitor the performance of our total investment portfolio and total debt portfolio using both GAAP and Non-GAAP financial measures. In particular, we evaluate performance through

Table of Contents

monitoring the portfolio yields as we consider them to be effective indicators, for both management and stockholders, of the financial performance of our total investment portfolio and total debt portfolio. The key metrics that we monitor with respect to yields are as described below:

•“Total Yield” - The total yield is derived by dividing GAAP basis “Total investment income” by the weighted average GAAP basis value of investment portfolio assets outstanding during the year, including non-interest earning assets such as warrants and equity investments at amortized cost.

•“Effective Yield” on total debt investments - The effective yield is derived by dividing GAAP basis “Total investment income” from debt investments(1) by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year.

•“Core Yield” on total debt investments – The core yield is a Non-GAAP financial measure. The core yield is derived by dividing “Core investment income” from debt investments by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year. “Core investment income” adjusts GAAP basis “Total investment income” from debt investments(1) to exclude fee and other income accelerations attributed to early payoffs, deal restructuring, loan modifications, and other one-time income events, but includes income from expired commitments.


	Three Months Ended March 31,
	2026		2025
Total Yield	12.4	%	12.6	%
Effective Yield(1)	12.8	%	13.0	%
Core Yield (Non-GAAP)(1)	12.2	%	12.6	%

(1)Yield calculated using “Total investment income” excluding bank interest, dividend income, and investment income from other assets for the three months ended March 31, 2026 and 2025.

We believe that these measures are useful for our stockholders as it provides further insight into the yield of our portfolio to allow a more meaningful comparison with our competitors. The reconciliation to calculate “Core investment income” from GAAP basis “Total investment income” are as follows:


(in thousands)	Three Months Ended March 31,
	2026		2025
GAAP Basis: Total investment income	$	141,536	$	119,511
Less: fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events except income from expired commitments	(6,592)		(4,009)
Non-GAAP Basis: Core investment income	$	134,944	$	115,502
Less: bank interest income, dividend income, and other investment income from other assets	(2,939)		(2,945)
Core investment income from debt portfolio	$	132,005	$	112,557

We believe the Core Yield is useful for our investors as it provides the yield at which our debt investments are originated and eliminates one-off items that can fluctuate significantly from period to period, thereby allowing for a more meaningful comparison over time.

Although the Core Yield, a Non-GAAP financial measure, is intended to enhance our stockholders’ understanding of our performance, the Core Yield should not be considered in isolation from or as an alternative to the GAAP financial metrics presented. The aforementioned Non-GAAP financial measure may not be comparable to similar Non-GAAP financial measures used by other companies.

Another financial measure that we monitor is the total return for our investors, which was approximately (19.1)% and (2.0%) during the three months ended March 31, 2026 and 2025, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. The total return does not reflect any sales load that may be paid by investors. See “Note 10 – Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this report.

Table of Contents

Portfolio Composition

Our portfolio companies are primarily privately held companies which are active in sectors characterized by high margins, high growth rates, consolidation, and product and market extension opportunities and, to a lesser extent, public companies active in those sectors.

The following table presents the fair value of our portfolio by industry sector as of March 31, 2026 and December 31, 2025:


	March 31, 2026				December 31, 2025
(in thousands)	Investments at Fair Value		Percentage of Total Portfolio		Investments at Fair Value		Percentage of Total Portfolio
Application Software	$	1,113,788	23.6	%	$	1,087,954	24.3	%
Drug Discovery & Development	1,089,920		23.1	%	1,039,712		23.3	%
Healthcare Services, Other	890,720		18.9	%	838,508		18.8	%
System Software	507,172		10.7	%	472,144		10.6	%
Consumer & Business Services	474,202		10.0	%	449,631		10.1	%
All other industries(1)	646,185		13.7	%	578,698		12.9	%
Total	$	4,721,987	100.0	%	$	4,466,647	100.0	%

(1)See “Note 4 – Investments” for complete list of industry sectors and corresponding amounts of investments at fair value as a percentage of the total portfolio. As of March 31, 2026, the fair value as a percentage of total portfolio does not exceed 5.0% for any individual industry sector other than “Application Software", “Drug Discovery & Development”, “Healthcare Services, Other”, “System Software”, and “Consumer & Business Services”.

Industry and sector concentrations vary as new loans are recorded and loans are paid off. Investment income, consisting of interest, fees, and recognition of gains on equity and warrants or other equity interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Investment income recognized in any given year can be highly concentrated in several portfolio companies.

As of March 31, 2026 and December 31, 2025, our ten largest portfolio companies represented approximately 26.2% and 28.6%, respectively, of the total fair value of our investments in portfolio companies. As of March 31, 2026 and December 31, 2025, we had seven investments, respectively, that represented 5% or more of our net assets. As of March 31, 2026 and December 31, 2025, we had two equity investments, respectively, that represented 5% or more of the total fair value of our equity investments. These equity investments represented approximately 49.2% and 48.4% of the total fair value of our equity investments as of March 31, 2026 and December 31, 2025, respectively.

As of March 31, 2026 and December 31, 2025, approximately 98.0% and 97.9%, respectively, of the debt investment portfolio was priced at floating interest rates with a floor. Our interest rates use Prime, SOFR, or SONIA as benchmark index rates. Changes in these benchmark index rates may affect the interest income and the value of our investment portfolio for portfolio investments with floating rates.

Our investments in Structured Debt generally have detachable equity enhancement features in the form of warrants or other equity securities designed to provide us with an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of March 31, 2026, we held warrants in 113 portfolio companies, with a fair value of approximately $42.5 million. The fair value of our warrant portfolio increased by approximately $1.4 million, as compared to a fair value of $41.1 million as of December 31, 2025, primarily driven by new warrants received in connection with debt originations.

Our existing warrant holdings would require us to invest approximately $65.7 million to exercise such warrants as of March 31, 2026. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. As attractive investment opportunities arise, we may exercise certain of our warrants to purchase stock, and could ultimately monetize our investments. Of the warrants that we have monetized since inception, we have realized multiples in the range of approximately 1.00x to 42.71x based on the historical rate of return on our investments. We may also experience losses from our warrant portfolio in the event that warrants are terminated or expire unexercised.

Table of Contents

Portfolio Grading

We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of March 31, 2026 and December 31, 2025, respectively:


(in thousands)	March 31, 2026					December 31, 2025
Investment Grading	Number of Companies	Debt Investments at Fair Value		Percentage of Total Portfolio		Number of Companies	Debt Investments at Fair Value		Percentage of Total Portfolio
1	20	$	944,499	20.8	%	16	$	681,631	15.9	%
2	76	2,256,528		49.7	%	69	2,168,985		50.7	%
3	40	1,299,975		28.6	%	39	1,355,528		31.7	%
4	2	35,450		0.8	%	3	73,268		1.7	%
5	1	3,693		0.1	%	—	—		0.0	%
Total	139	$	4,540,145	100.0	%	127	$	4,279,412	100.0	%

As of March 31, 2026 and December 31, 2025, our debt investments had a weighted average investment grading of 2.11 and 2.20 on a cost basis, respectively. Changes in a portfolio company's investment grading may be a result of changes in portfolio company's performance and/or timing of expected liquidity events. For instance, we may downgrade a portfolio company if it is not meeting our financing criteria or is underperforming relative to its respective business plan. We may also downgrade a portfolio company as it approaches a point in time when it will require additional equity capital to continue operations. Conversely, we may upgrade a portfolio company's investment grading when it is exceeding our financial performance expectations and/or is expected to mature/repay in full due to a liquidity event.

If macroeconomic events evolve and cause disruption in the capital markets and to businesses, we monitor and work with the management teams and stakeholders of our portfolio companies to navigate any significant market, operational, and economic challenges created by these events. This includes remaining proactive in our assessments of credit performance to manage potential risks across our investment portfolio.

Performing and Non-accrual Investments

The following table shows the amortized cost of our performing and non-accrual investments as of March 31, 2026 and December 31, 2025:


(in millions)	March 31, 2026				December 31, 2025
	Amortized Cost		Percentage of Total Portfolio at Amortized Cost		Amortized Cost		Percentage of Total Portfolio at Amortized Cost
Performing	$	4,759.7	99.8	%	$	4,457.1	99.8	%
Non-accrual	10.7		0.2	%	10.7		0.2	%
Total Investments	$	4,770.4	100.0	%	$	4,467.8	100.0	%

Debt investments are placed on non-accrual status when it is probable that principal, interest, or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, we cease to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay our current and future contractual obligations. We may choose not to apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.

Table of Contents

Results of Operations

Our condensed consolidated operating results for the three months ended March 31, 2026 and 2025, were as follows:


(in thousands, except per share data)	Three Months Ended March 31,
	2026		2025
Total investment income	$	141,536	$	119,511
Total expenses	53,426		42,053
Net investment income	88,110		77,458
Net realized gain (loss):	(603)		(1,556)
Net change in unrealized appreciation (depreciation):	(45,005)		(25,565)
Net increase (decrease) in net assets resulting from operations	$	42,502	$	50,337

Net investment income before gains and losses per common share:
Basic	$	0.48	$	0.45

Change in net assets resulting from operations per common share:
Basic	$	0.23	$	0.29
Diluted	$	0.23	$	0.29

Our operating results can vary substantially from period to period due to various factors, including changes in the level of investments held, changes in our investment yields, recognition of realized gains and losses, and changes in net unrealized appreciation and depreciation, among other factors. As a result, comparison of the net increase (decrease) in net assets resulting from operations may not be meaningful.

Investment Income

Total investment income for the three months ended March 31, 2026 was approximately $141.5 million as compared to approximately $119.5 million for the three months ended March 31, 2025. Investment income is primarily composed of interest income earned on our debt investments, fee income from commitments, facilities, and other loan related fees and dividend income.

Interest and Dividend Income

The following table summarizes the components of interest and dividend income for the three months ended March 31, 2026 and 2025:


(in thousands)	Three Months Ended March 31,
	2026		2025
Contractual interest income	$	104,082	$	87,817
Exit fee interest income	14,698		10,228
PIK interest income	12,914		13,473
Dividend income	2,100		2,400
Other investment income(1)	2,609		1,654
Total interest and dividend income	$	136,403	$	115,572

(1)Other investment income includes OID interest income and interest recorded on other assets.

Interest and dividend income for the three months ended March 31, 2026 totaled approximately $136.4 million as compared to approximately $115.6 million for the three months ended March 31, 2025. The increase in interest income for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 was primarily attributable to an increase in the weighted average principal outstanding, partially offset by lower core yield.

Table of Contents

Interest income is comprised of recurring interest income from the contractual servicing of loans and non-recurring interest income that is related to the acceleration of income due to early loan repayments and other one-time events during the period.

The following table summarizes recurring and non-recurring interest income and dividend income for the three months ended March 31, 2026 and 2025:


(in thousands)	Three Months Ended March 31,
	2026		2025
Recurring interest income	$	129,368	$	110,105
Non-recurring interest income	4,935		3,067
Dividend income	2,100		2,400
Total interest and dividend income	$	136,403	$	115,572

A portion of interest income is earned in the form of PIK interest. The following table shows the PIK-related activity for the three months ended March 31, 2026 and 2025, at cost:


(in thousands)	Three Months Ended March 31,
	2026		2025
Beginning PIK interest receivable balance	$	109,135	$	67,656
PIK interest income during the period	12,914		13,473
PIK capitalized as principal or converted to equity or other assets	(387)		(1,407)
Payments received from PIK loans	(15,334)		(991)

Ending PIK interest receivable balance	$	106,328	$	78,731

The decrease in PIK interest income during the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 was due to a decrease in the weighted average principal outstanding for debt investments which earn PIK interest. Payments on PIK loans are normally received only in the event of payoffs. The PIK receivable for March 31, 2026 and March 31, 2025 was approximately 2% and 2% of total debt investments, respectively.

Fee Income

Fee income is comprised of recurring fee income from commitment, facility, and loan related fees, fee income due to expired commitments, and acceleration of fee income due to early loan repayments during the period. The following table summarizes the components of fee income for the three months ended March 31, 2026 and 2025:


(in thousands)	Three Months Ended March 31,
	2026		2025
Recurring fee income	$	2,912	$	2,680
Fee income - expired commitments	563		317
Accelerated fee income - early repayments	1,658		942
Total fee income	$	5,133	$	3,939

The fee income for the three months ended March 31, 2026 totaled approximately $5.1 million as compared to approximately $3.9 million for the three months ended March 31, 2025. The increase in fee income for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 was primarily attributable to higher prepayment penalty from early repayments, higher fees recognized on expired commitments and higher recurring fee income resulting from an increase in the weighted average principal outstanding.

Operating Expenses

Our operating expenses are comprised of interest and fees on our debt borrowings, general and administrative expenses, taxes, and employee compensation and benefits. During the three months ended March 31, 2026 and 2025, our net operating expenses totaled approximately $53.4 million and $42.1 million, respectively.

Interest and Fees on our Debt

Interest and fees on our debt totaled approximately $30.8 million and $22.1 million for the three months ended March 31, 2026 and 2025, respectively. Interest and fee expense during the three months ended March 31, 2026 as compared to the three months ended March 31, 2025, increased due to higher weighted average debt outstanding.

Our weighted average cost of debt was approximately 5.1% and 4.9% for the three months ended March 31, 2026 and 2025, respectively. The weighted average cost of debt includes interest and fees on our debt, but excludes the impact of fee accelerations due to the extinguishment of debt, as applicable.

Table of Contents

General and Administrative Expenses and Tax Expenses

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, rent, expenses associated with the workout of underperforming investments, and various other expenses. Our general and administrative expenses were unchanged at $4.8 million for the three months ended March 31, 2026 and 2025. Tax expenses were $1.0 million and $0.9 million during the three months ended March 31, 2026 and 2025, respectively. Our tax expenses primarily relate to excise tax accruals.

Employee Compensation

Employee compensation and benefits totaled approximately $17.3 million and $13.9 million for the three months ended March 31, 2026 and 2025. The movement between the three months ended March 31, 2026 and 2025 was primarily due to fluctuations in variable compensation.

Employee stock-based compensation totaled approximately $4.1 million and $3.6 million, for the three months ended March 31, 2026 and 2025, respectively. The increase between the three months ended March 31, 2026 and 2025 was primarily attributable to higher overall grant size associated with Service Vesting Awards.

Expenses allocated to the Adviser Subsidiary

The Sharing Agreement provides the Adviser Subsidiary access to our human capital resources, including deal professionals, finance, and administrative functions, as well as other resources including infrastructure assets such as office space and technology. Under the terms of the Sharing Agreement, we allocate the related expenses of shared services to the Adviser Subsidiary. Our total net operating expenses for the three months ended March 31, 2026 and 2025, are net of expenses allocated to the Adviser Subsidiary of $4.6 million and $3.3 million, respectively. The increase in expenses allocated to the Adviser Subsidiary for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was due to an increase in time spent on the Adviser Funds and an increase in investments allocated to the Adviser Funds. As of March 31, 2026 and December 31, 2025, there was approximately $0.9 million and $1.7 million due from the Adviser Subsidiary, respectively.

Net Realized Gains and Losses and Net Change in Unrealized Appreciation and Depreciation

Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Realized loss on debt extinguishment relates to additional fees, costs, and accelerated recognition of remaining debt issuance costs, which are recognized in the event our debt is extinguished before its stated maturity. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

A summary of net realized gains and losses for the three months ended March 31, 2026 and 2025 is as follows:


(in thousands)	Three Months Ended March 31,
	2026		2025
Realized gains	$	1,623	$	57
Realized losses	(2,253)		(934)
Realized foreign exchange gains (losses)	27		(664)
Realized loss on debt extinguishment	—		(15)
Net realized gains (losses)	$	(603)	$	(1,556)

During the three months ended March 31, 2026, we recognized a net realized loss of $0.6 million. The net realized gains (losses) were generated from gross realized gains of $1.6 million, primarily attributable to contingent consideration received in the form of earnout equity shares of Planet Labs PBC. Our gains were offset by gross realized losses of $2.2 million, primarily from the write-off of our equity investments in Carbon Health Technologies, Inc and Dynavax Technologies.

During the three months ended March 31, 2025, we recognized a net realized loss of $1.6 million. The net realized losses were generated from gross realized losses of $0.9 million from the write-off of equity and warrant investments in 3GTMS, LLC, Fresh Tracks Therapeutics, Inc. and others. Additionally, we realized $0.7 million of foreign exchange losses primarily from our investments in foreign denominated debt investments.

Table of Contents

The net change in unrealized appreciation and depreciation of our investments is derived from the changes in fair value of each investment determined in good faith by our Valuation Committee (as defined in “Note 2 - Summary of Significant Accounting Policies - Valuation of Investments”) and approved by the Board. The following table summarizes the change in net unrealized appreciation or depreciation of investments for the three months ended March 31, 2026 and 2025:


	Three Months Ended March 31,
(in thousands)	2026		2025
Gross unrealized appreciation on portfolio investments	$	19,211	$	30,237
Gross unrealized depreciation on portfolio investments	(62,207)		(55,842)
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event	(1,793)		(1,213)
Net change in unrealized appreciation (depreciation) on portfolio investments	(44,789)		(26,818)
Other net changes in unrealized appreciation (depreciation)(1)	(216)		1,253
Total net change in unrealized appreciation (depreciation) on investments	$	(45,005)	$	(25,565)

(1)Includes the net change in unrealized appreciation (depreciation) related to foreign exchange movements, derivative instruments and other assets and liabilities.

During the three months ended March 31, 2026 and 2025, we recorded approximately $45.0 million and $25.6 million of net unrealized depreciation, respectively, on our investments. The increase in unrealized depreciation during the three months ended March 31, 2026 was primarily related to the depreciation on our debt investments due to widening of spreads, depreciation of our private equity holdings due to compression of market multiples, depreciation of public equity and warrant holdings and reversal of previously recorded net unrealized appreciation of our debt investments as realization events occurred.

The following table summarizes the key drivers of change in net unrealized appreciation (depreciation) of investments for the three months ended March 31, 2026 and 2025:


	For the Three Months Ended March 31, 2026

(in thousands)	Debt		Equity, Warrants and Investment Funds(1)		Total
Investment valuation appreciation (depreciation)	$	(31,052)	$	(11,944)	$	(42,996)
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event	(3,966)		2,173		(1,793)
Other net changes in unrealized appreciation (depreciation)(1)	(2,161)		1,945		(216)
Net change in unrealized appreciation (depreciation)	$	(37,179)	$	(7,826)	$	(45,005)


	For the Three Months Ended March 31, 2025

(in thousands)	Debt		Equity, Warrants and Investment Funds(1)		Total
Investment valuation appreciation (depreciation)	$	(28,263)	$	2,658	$	(25,605)
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event	(1,729)		516		(1,213)
Other net changes in unrealized appreciation (depreciation)(1)	4,876		(3,623)		1,253
Net change in unrealized appreciation (depreciation)	$	(25,116)	$	(449)	$	(25,565)

(1)Includes the net change in unrealized appreciation (depreciation) related to foreign exchange movements, derivative instruments and other assets and liabilities.

Income and Excise Taxes

We account for income taxes in accordance with the provisions of ASC Topic 740, Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

Table of Contents

Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

The Adviser Subsidiary

The Adviser Subsidiary has entered into investment management agreements (the “IMAs”) with the Adviser Funds. Pursuant to the IMAs, the Adviser Subsidiary provides investment advisory and management services to the Adviser Funds in exchange for an asset-based fee. In addition, Hercules Capital Management LLC through its control of the general partner interests of each of the Adviser Funds may receive incentive fees based on the performance of the Adviser Funds. The Adviser Funds are privately offered investment funds exempt from registration under the 1940 Act that invest in debt and equity investments in venture or institutionally backed technology related and life sciences companies.


(in thousands)	As of
Assets Under Management *	March 31, 2026		December 31, 2025		Growth %

by the Company	$	4,766,913	$	4,526,101	5.3	%
by the Adviser Funds	1,330,547		1,214,631		9.5	%
Total	$	6,097,460	$	5,740,732	6.2	%

* Assets under management includes investments, at fair value, cash and cash equivalents and restricted cash.

The Adviser Subsidiary’s contribution to our net investment income is primarily derived from expenses allocated to the Adviser Subsidiary, dividend income declared by the Adviser Subsidiary, and interest income earned on loans to the Adviser Subsidiary. A summary of the Adviser Subsidiary’s contribution to our net investment income for the three months ended March 31, 2026 and 2025 is as follows:


(in millions)	Three Months Ended March 31,
	2026		2025
Expenses allocated	$	4.6	$	3.3
Interest and Dividend income	2.1		1.9

Financial Condition, Liquidity, Capital Resources and Obligations

Our liquidity and capital resources are derived from our debt borrowings and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our debt and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We may also raise additional equity or debt capital through registered offerings off a shelf registration, At-the-Market (“ATM”) offerings, and private offerings of securities, by securitizing a portion of our investments, or by borrowing from the SBA through our SBIC subsidiaries. This “Financial Condition, Liquidity, Capital Resources and Obligations” section should be read in conjunction with the “Macroeconomic Market Developments” section above.

During the three months ended March 31, 2026, we principally funded our operations from (i) cash receipts from interest, dividend, and fee income from our investment portfolio, (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments, (iii) debt borrowings on our Credit Facilities and February 2029 Notes, and (iv) equity offerings.

During the three months ended March 31, 2026, our operating activities used $230.6 million of cash and cash equivalents, compared to $222.2 million used during the three months ended March 31, 2025. The $8.4 million increase in cash used in operating activities was primarily due to a $111.8 million increase in net purchases of investments, which was partially offset by an increase of $90.5 million in principal, fee repayments, and proceeds from the sale of debt investments.

During the three months ended March 31, 2026, our investing activities used approximately $19 thousand of cash, compared to $8 thousand used during the three months ended March 31, 2025. The $11 thousand increase in cash used in investing activities was due to an increase in purchases of capital equipment.

During the three months ended March 31, 2026, our financing activities provided $216.1 million of cash, compared to $160.1 million provided during the three months ended March 31, 2025. The $56.0 million increase in cash flows from financing activities was primarily due to a $48.8 million increase in net borrowing activity and a $12.6 million increase in equity issued. During the three months ended March 31, 2026, we issued $300.0 million in aggregate principal amount of

Table of Contents

February 2029 Notes. Additionally, during the three months ended March 31, 2026, we fully repaid the aggregate outstanding $50.0 million each in principal of the March 2026 A Notes and March 2026 B Notes, respectively. During the three months ended March 31, 2026, our ATM program provided (net of offering costs) approximately $52.0 million, compared to $39.4 million net proceeds received during the three months ended March 31, 2025. During the three months ended March 31, 2026, we distributed dividends of $84.4 million compared to $78.9 million during the three months ended March 31, 2025.

As of March 31, 2026, our net assets totaled $2.2 billion, with a NAV per share of $11.90. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.

Available liquidity and capital resources as of March 31, 2026

As of March 31, 2026, we had $454.5 million in available liquidity, including $42.4 million in cash and cash equivalents and available borrowing capacity of approximately $17.1 million (net of $0.5 million of outstanding letter of credits) under the SMBC Facility, $175.0 million under our SMBC letter of credit facility, and $220.0 million under the MUFG Bank Facility, subject to certain conditions. Additional liquidity is available through accordion provisions within the terms of our Credit Facilities, through which the available borrowing capacity can be increased by an aggregate $360.0 million, subject to certain conditions. Further, the SMBC letter of credit facility may also be increased by an additional $225.0 million (up to $400.0 million), subject to certain conditions. Total amounts outstanding as of March 31, 2026, were $502.3 million outstanding under our Credit Facilities, which are floating interest rate obligations, and the remaining $2,067.0 million of term debt outstanding, which are all fixed interest rate debt obligations.

Not considered above, as of March 31, 2026, we held $2.6 million of cash classified as restricted cash. Our restricted cash relates to amounts that are held as collateral securing certain of our financing transactions, including collections of interest and principal payments on assets that are securitized related to the 2031 Asset-Backed Notes. Based on current characteristics of the securitized debt investment portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt with any excess distributed to us or available for our general operations. Refer to “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our debt obligations.

The 1940 Act permits BDCs to incur borrowings, issue debt securities, or issue preferred stock unless immediately after the borrowings or issuance the ratio of total assets (less total liabilities other than indebtedness) to total indebtedness plus preferred stock is less than 200% (or 150% if certain requirements are met). On September 4, 2018 and December 6, 2018, our Board, including a “required majority” (as such term is defined in Section 57(o) of the 1940 Act) and our stockholders, respectively, approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As of March 31, 2026, our asset coverage ratio under our regulatory requirements as a BDC was 199.6% excluding our SBA debentures. We received an exemptive order from the SEC that allows us to exclude all SBA leverage as senior securities from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 150%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total asset coverage when including our SBA debentures as senior securities was 186.3% as of March 31, 2026.

The 1940 Act prohibits us from selling shares of our common stock at a price below the current NAV per share of such stock, with certain exceptions. One such exception is prior stockholder approval of issuances below NAV provided that our Board makes certain determinations. We do not currently have the authorization from our stockholders to issue common stock at a price below the then-current NAV per share and there is no guarantee that we will obtain such authorization from our stockholders in the future.

As detailed above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have ample liquidity to support our near-term capital requirements. As the impact of the macro-economic events, potential global recession, acts of terrorism, war, geopolitical events, and the related disruption to markets and business continues to impact the economy, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current circumstances.

Equity Offerings

We may from time-to-time issue and sell shares of our common stock through public or ATM offerings. We currently sell shares through the 2024 Equity Distribution Agreements with Citizens JMP Securities LLC and Jefferies LLC, as Sales Agents, entered into on December 12, 2024. The 2024 Equity Distribution Agreements provide that we may offer and sell up to 30.0 million shares of our common stock from time to time through the Sales Agents. Sales of our common stock, if

Table of Contents

any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. We generally use net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of March 31, 2026, approximately 15.3 million shares remain available for issuance and sale under the 2024 Equity Distribution Agreements.

During the three months ended March 31, 2026, we issued and sold 3.5 million shares of our common stock receiving total accumulated net proceeds of $52.0 million. This represents an increase from the approximately $39.4 million of accumulated net proceeds received from the issuance and sale of 2.0 million shares during the three months ended March 31, 2025.

Stock Repurchase

We may from time to time seek to retire or repurchase our common stock through cash purchases, as well as retire, cancel or purchase our outstanding debt through cash purchases and/or exchanges, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual and regulatory restrictions and other factors. The amounts involved may be material. We had no common stock repurchases during the three months ended March 31, 2026 and 2025.

Commitments and Obligations

Our significant cash requirements generally relate to our debt obligations. As of March 31, 2026, we had $2,569.3 million of debt outstanding, $675.0 million due within the next year, $587.5 million due within 1 to 3 years, and $1,306.8 million due beyond 3 years.

In addition to our debt obligations, in the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet.

Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made unfunded commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. As such, our disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones. Refer to “Note 11 – Commitments and Contingencies” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our unfunded commitments.

As of March 31, 2026, we had approximately $397.4 million of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones, as well as uncalled capital commitments to make investments in private equity funds. In order to draw a portion of the our available unfunded commitments, a portfolio company must submit to us a formal funding request that complies with the applicable advance notice and other operational requirements. The available unfunded commitments excludes unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) $160.6 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.

Additionally, we had approximately $118.8 million of non-binding term sheets outstanding to three new companies and three existing companies, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations embedded in the borrowing agreements.

Table of Contents

Critical Accounting Policies and Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.

For a description of our critical accounting policies, refer to “Note 2 – Summary of Significant Accounting Policies” included in the notes to our consolidated financial statements appearing elsewhere in this Quarterly Report. We consider the most significant accounting policies to be those related to our Valuation of Investments, Fair Valuation Measurements, Income Recognition, and Income Taxes. The Valuation of Investments is our most significant critical estimate. The most significant input to this estimate is the yield interest rate, which includes the hypothetical market yield plus premium or discount adjustment, used in determining the fair value of our debt investments. The following table shows the approximate increase (decrease) to the fair value of our debt investments from hypothetical change to the yield interest rates used for each valuation, assuming no other changes:


(in thousands)	Change in unrealized appreciation (depreciation)
Basis Point Change
(100)	$	69,541
(50)	$	34,872
50	$	(34,332)
100	$	(68,078)

For a further discussion and disclosure of key inputs and considerations related to this estimate, refer to “Note 3 – Fair Value of Financial Instruments” included in the notes to our consolidated financial statements appearing elsewhere in this report.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our investment income will be affected by changes in various interest rates, including Prime, SOFR, and SONIA rates, to the extent our debt investments include variable interest rates. As of March 31, 2026, approximately 98.0% of the loans in our portfolio had floating rates with a floor, indexed to Prime, SOFR, or SONIA. The majority of our loans are linked to the Prime rate and comprise 84.6% of the loan portfolio as of March 31, 2026. Our debt borrowings under the Credit Facilities bear interest at a floating rate, all other outstanding debt borrowings bear interest at a fixed rate. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.

Based on our Consolidated Statements of Assets and Liabilities as of March 31, 2026, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and debt:


(in thousands)	Interest Income		Interest Expense		Net Income		EPS
Basis Point Change
(200)	$	(19,600)	$	(8,355)	$	(11,245)	$	(0.06)
(100)	$	(11,446)	$	(4,178)	$	(7,268)	$	(0.04)
(75)	$	(9,393)	$	(3,133)	$	(6,260)	$	(0.03)
(50)	$	(6,637)	$	(2,089)	$	(4,548)	$	(0.02)
(25)	$	(3,831)	$	(1,044)	$	(2,787)	$	(0.02)
25	$	5,015	$	1,044	$	3,971	$	0.02
50	$	11,452	$	2,089	$	9,363	$	0.05
75	$	17,931	$	3,133	$	14,798	$	0.08

From time-to-time, we may hedge against interest rate fluctuations and foreign currency by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates and foreign currency, they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the three months ended March 31, 2026, we have an outstanding foreign currency forward contract to limit our foreign currency exposure with respect to the British Pound. For additional information refer to “Note 4 – Investments”, included in the notes to our consolidated financial statements appearing elsewhere in this report.

Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including our debt borrowings and use of our Credit Facilities that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from our portfolio companies. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of declining interest rates, our interest income and our net investment income could be reduced as the interest income earned on our floating rate debt investments declines and any new fixed rate debt may be issued at lower coupon rates. For additional information regarding the interest rate associated with each of our debt borrowings, refer to Part I, Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Financial Condition, Liquidity and Capital Resources” in this report and “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company’s chief executive and chief financial officers, under the supervision and with the participation of the Company’s management, conducted an evaluation of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d- 15(e) under the Exchange Act. As of the end of the period covered by this quarterly report on Form 10-Q, the Company’s chief executive and chief financial officers have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in reports that the Company files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.

ITEM 1A. RISK FACTORS

In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 12, 2026.

Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies as of March 31, 2026 that represent greater than 5% of our net assets:


(in thousands)	March 31, 2026
	Fair Value		Percentage of Net Assets
Marathon Health, LLC	$	187,062	8.4	%
Armis, Inc.	160,940		7.2	%
Phathom Pharmaceuticals, Inc.	134,188		6.0	%
ChenMed, LLC	128,186		5.8	%
Shield AI, Inc.	118,412		5.3	%
Tipalti Solutions Ltd.	113,611		5.1	%
SeatGeek, Inc.	112,279		5.0	%

•Marathon Health, LLC is a provider of employer-sponsored healthcare platform intended to provide convenient and unhurried patient-centered care services.

•Armis, Inc. is the leading agentless, enterprise-class device security platform designed to address the new threat landscape of unmanaged and IoT devices.

•Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

•ChenMed, LLC is a healthcare company that delivers value-based, primary care to seniors, focusing on prevention and personalized treatment.

•Shield AI, Inc. is an aerospace and defense technology company that designs and builds AI-powered, autonomous Unmanned Aerial Vehicles (UAVs) for national defense operations and military organizations.

•Tipalti Solutions Ltd. is a provider of an end-to-end accounts payable automation software platform for mid-market businesses and enterprises.

•SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and theater events.

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

Dividend Reinvestment Plan

During the three months ended March 31, 2026, we issued 153,423 shares of common stock to stockholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act. The aggregate value of the shares of our common stock issued under our dividend reinvestment plan was approximately $2.3 million.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

During the first quarter ended March 31, 2026, no directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

Table of Contents

ITEM 6. EXHIBITS


Exhibit Number			Description
3(a)			Articles of Amendment and Restatement.(1)
3(b)			Articles of Amendment, dated March 6, 2007.(2)
3(c)			Articles of Amendment, dated April 5, 2011.(3)
3(d)			Articles of Amendment, dated April 3, 2015.(4)
3(e)			Articles of Amendment, dated February 23, 2016.(9)
3(f)			Articles of Amendment, dated October 28, 2024.(6)
3(g)			Amended and Restated Bylaws of Hercules Capital, Inc.(5)






4(a)			Tenth Supplemental Indenture, dated as of February 10, 2026, between the Registrant and U.S. Bank Trust Company, National Association.(10)
4(b)			Form of 5.350% Note due 2029 (included as part of Exhibit 4(a)).
31.1*			Chief Executive Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*			Chief Financial Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*			Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*			Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*			Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*			Inline XBRL Taxonomy Extension Schema Document.
101.CAL*			Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*			Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*			Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*			Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104			The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, has been formatted in Inline XBRL

_____________________________________

*Filed herewith.

(1)Previously filed as part of Pre-Effective Amendment No. 1, as filed on May 17, 2005 (File No. 333-122950) to the Registration Statement on Form N-2 of the Company.

(2)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 9, 2007.

(3)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 11, 2011.

(4)Previously filed as part of the Registration Statement on Form N-2 of the Company, as filed on April 20, 2015 (File No. 333-203511).

(5)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 20, 2020.

(6)Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on October 30, 2024.

(7)Reserved.

(8)Reserved.

(9)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on February 25, 2016.

(10)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on February 10, 2026.

Table of Contents

Schedule 12 – 14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

For the Three Months Ended March 31, 2026 (unaudited)


(in thousands)
Portfolio Company	Investment(1)	Amount of Interest, Dividends, and Fees Credited to Income(2)		Realized Gain (Loss)		Fair Value as of December 31, 2025		Gross Additions(3)		Gross Reductions(4)		Net Change in Unrealized Appreciation/ (Depreciation)		Fair Value as of March 31, 2026
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC(8)	Preferred Units	$	—	$	—	$	218	$	—	$	—	$	(60)	$	158
	Common Units	—		—		—		—		—		—		—
Gibraltar Acquisition LLC(5)	Unsecured Debt	1,163		—		38,255		36		—		—		38,291
	Member Units	—		—		23,963		—		(300)		213		23,876
Hercules Adviser LLC(6)	Unsecured Debt	2,101		—		—		3,000		—		—		3,000
	Member Units	—		—		43,274		—		—		(2,137)		41,137
Total Majority Owned Control Investments		$	3,264	$	—	$	105,710	$	3,036	$	(300)	$	(1,984)	$	106,462
Other Control Investments
Tectura Corporation(7)	Senior Debt	$	170	$	—	$	8,091	$	—	$	—	$	(8)	$	8,083
	Preferred Stock	—		—		1,250		—		—		453		1,703
	Common Stock	—		—		—		—		—		—		—
Total Other Control Investments		$	170	$	—	$	9,341	$	—	$	—	$	445	$	9,786
Total Control Investments		$	3,434	$	—	$	115,051	$	3,036	$	(300)	$	(1,539)	$	116,248

(1)Stock and warrants are generally non-income producing and restricted.

(2)Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.

(3)Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities.

(4)Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period.

(5)As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.

(6)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.

(7)As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018.

(8)As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company.

Table of Contents

Schedule 12 – 14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

For the Three Months Ended March 31, 2025 (unaudited)


(in thousands)
Portfolio Company	Investment(1)	Amount of Interest, Dividends and Fees Credited to Income(2)		Realized Gain (Loss)		Fair Value as of December 31, 2024		Gross Additions(3)		Gross Reductions(4)		Net Change in Unrealized Appreciation/ (Depreciation)		Fair Value as of March 31, 2025
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC(8)	Preferred Units	$	—	$	—	$	69	$	—	$	—	$	(22)	$	47
	Common Units	—		—		—		—		—		—		—
Gibraltar Acquisition LLC(5)	Unsecured Debt	1,606		—		36,212		578		—		—		36,790
	Member Units	—		—		23,051		—		—		(941)		22,110

Hercules Adviser LLC(6)	Unsecured Debt	1,900		—		12,000		—		(12,000)		—		—
	Member Units	—		—		30,190		12,000		—		2,827		45,017
Total Majority Owned Control Investments		$	3,506	$	—	$	101,522	$	12,578	$	(12,000)	$	1,864	$	103,964
Other Control Investments
Tectura Corporation(7)	Senior Debt	$	170	$	—	$	8,027	$	—	$	—	$	5	$	8,032
	Preferred Stock	—		—		3,623		—		—		113		3,736
	Common Stock	—		—		7		—		—		(5)		2
Total Other Control Investments		$	170	$	—	$	11,657	$	—	$	—	$	113	$	11,770
Total Control Investments		$	3,676	$	—	$	113,179	$	12,578	$	(12,000)	$	1,977	$	115,734

(1)Stock and warrants are generally non-income producing and restricted.

(2)Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.

Table of Contents

Schedule 12 – 14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

As of March 31, 2026 (unaudited)


(in thousands)
Portfolio Company	Industry	Type of Investment(1)	Maturity Date	Interest Rate and Floor	Principal or Shares		Cost		Value(2)
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC	Medical Devices & Equipment	Preferred Series A-2			5,000,000		$	250	$	158
	Medical Devices & Equipment	Common Units			180,000		—		—
Total Coronado Aesthetics, LLC							$	250	$	158
Gibraltar Acquisition LLC(3)	Diversified Financial Services	Unsecured Debt	July 2029	FIXED 11.50%	$	28,805	28,439		28,439
	Diversified Financial Services	Unsecured Debt	July 2029	FIXED 11.95%	$	10,000	9,852		9,852
	Diversified Financial Services	Member Units			1		32,156		23,876
Total Gibraltar Acquisition LLC							$	70,447	$	62,167
Hercules Adviser LLC(4)	Diversified Financial Services	Unsecured Debt	March 2027	FIXED 6.75%	$	3,000	3,000		3,000
	Diversified Financial Services	Member Units			1		12,035		41,137
Total Hercules Adviser LLC							$	15,035	$	44,137
Total Majority Owned Control Investments (4.78%)*							$	85,732	$	106,462
Other Control Investments
Tectura Corporation	Consumer & Business Services	Senior Secured Debt	January 2027	FIXED 8.25%	$	8,250	$	8,250	$	8,083
	Consumer & Business Services	Common Stock			414,994,863		900		—
	Consumer & Business Services	Preferred Series BB Equity			1,000,000		—		—
	Consumer & Business Services	Preferred Series C Equity			3,235,298		13,263		1,703
Total Tectura Corporation							$	22,413	$	9,786
Total Other Control Investments (0.44%)*							$	22,413	$	9,786
Total Control Investments (5.22%)*							$	108,145	$	116,248

*Value as a percent of net assets

(1)Stock and warrants are generally non-income producing and restricted.

(2)All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

(3)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.

(4)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.

Table of Contents

Schedule 12 – 14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

As of and for the year ended December 31, 2025


(in thousands)
Portfolio Company	Industry	Type of Investment(1)	Maturity Date	Interest Rate and Floor	Principal or Shares		Cost		Value(2)
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC	Medical Devices & Equipment	Preferred Series A-2			5,000,000		$	250	$	218
	Medical Devices & Equipment	Common Units			180,000		—		—
Total Coronado Aesthetics, LLC							$	250	$	218

Gibraltar Acquisition LLC(3)	Diversified Financial Services	Unsecured Debt	July 2029	FIXED 3.45%, PIK Interest 8.05%	$	28,805	28,412		28,412
	Diversified Financial Services	Unsecured Debt	July 2029	FIXED 11.95%	$	10,000	9,843		9,843
	Diversified Financial Services	Member Units			1		32,456		23,963
Total Gibraltar Acquisition LLC							$	70,711	$	62,218

Hercules Adviser LLC(4)	Diversified Financial Services	Member Units			1		12,035		43,274
Total Hercules Adviser LLC							$	12,035	$	43,274
Total Majority Owned Control Investments (4.77%)*							$	82,996	$	105,710
Other Control Investments
Tectura Corporation	Consumer & Business Services	Senior Secured Debt	January 2027	FIXED 8.25%	$	8,250	$	8,250	$	8,091
	Consumer & Business Services	Common Stock			414,994,863		900		—

	Consumer & Business Services	Preferred Series BB Equity			1,000,000		—		—
	Consumer & Business Services	Preferred Series C Equity			3,235,298		13,263		1,250
Total Tectura Corporation							$	22,413	$	9,341
Total Other Control Investments (0.42%)*							$	22,413	$	9,341
Total Control Investments (5.19%)*							$	105,409	$	115,051

*Value as a percent of net assets

(1)Stock and warrants are generally non-income producing and restricted.

(2)All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


						HERCULES CAPITAL, INC. (Registrant)

Dated: May 5, 2026						/S/ SCOTT BLUESTEIN
						Scott Bluestein
						President, Chief Executive Officer, and Chief Investment Officer

Dated: May 5, 2026						/S/ SETH H. MEYER
						Seth H. Meyer
						Chief Financial Officer, and Chief Accounting Officer

Hercules Capital - 10-Q quarterly report FY

What is the market capitalization of a company?

DISCLAIMER

Contact

Links